DDI-MedLine.d161.s0;;
Metabotropic;O;O
glutamate;O;O
receptor;O;O
5;O;O
antagonist;O;O
protects;O;O
dopaminergic;O;O
and;O;O
noradrenergic;O;O
neurons;O;O
from;O;O
degeneration;O;O
in;O;O
MPTP;B-drug_n;B-DDI-MedLine.d161.s0.e0
-;O;O
treated;O;O
monkeys;O;O
.;O;O
DDI-MedLine.d161.s1;;
Degeneration;O;O
of;O;O
the;O;O
dopaminergic;O;O
nigrostriatal;O;O
system;O;O
and;O;O
of;O;O
noradrenergic;O;O
neurons;O;O
in;O;O
the;O;O
locus;O;O
coeruleus;O;O
are;O;O
important;O;O
pathological;O;O
features;O;O
of;O;O
Parkinson;O;O
's;O;O
disease;O;O
.;O;O
DDI-MedLine.d161.s2;;
There;O;O
is;O;O
an;O;O
urgent;O;O
need;O;O
to;O;O
develop;O;O
therapies;O;O
that;O;O
slow;O;O
down;O;O
the;O;O
progression;O;O
of;O;O
neurodegeneration;O;O
in;O;O
Parkinson;O;O
's;O;O
disease;O;O
.;O;O
DDI-MedLine.d161.s3;;
In;O;O
the;O;O
present;O;O
study;O;O
,;O;O
we;O;O
tested;O;O
whether;O;O
the;O;O
highly;O;O
specific;O;O
metabotropic;O;O
glutamate;O;O
receptor;O;O
5;O;O
antagonist;O;O
,;O;O
3;B-drug_n;B-DDI-MedLine.d161.s3.e0
-;I-drug_n;I-DDI-MedLine.d161.s3.e0
[(2;I-drug_n;I-DDI-MedLine.d161.s3.e0
-;I-drug_n;I-DDI-MedLine.d161.s3.e0
methyl;I-drug_n;I-DDI-MedLine.d161.s3.e0
-;I-drug_n;I-DDI-MedLine.d161.s3.e0
1,3;I-drug_n;I-DDI-MedLine.d161.s3.e0
-;I-drug_n;I-DDI-MedLine.d161.s3.e0
thiazol;I-drug_n;I-DDI-MedLine.d161.s3.e0
-;I-drug_n;I-DDI-MedLine.d161.s3.e0
4;I-drug_n;I-DDI-MedLine.d161.s3.e0
-;I-drug_n;I-DDI-MedLine.d161.s3.e0
yl;I-drug_n;I-DDI-MedLine.d161.s3.e0
);I-drug_n;I-DDI-MedLine.d161.s3.e0
ethynyl;I-drug_n;I-DDI-MedLine.d161.s3.e0
];I-drug_n;I-DDI-MedLine.d161.s3.e0
pyridine;I-drug_n;I-DDI-MedLine.d161.s3.e0
,;O;O
reduces;O;O
dopaminergic;O;O
and;O;O
noradrenergic;O;O
neuronal;O;O
loss;O;O
in;O;O
monkeys;O;O
rendered;O;O
parkinsonian;O;O
by;O;O
chronic;O;O
treatment;O;O
with;O;O
low;O;O
doses;O;O
of;O;O
1;B-drug_n;B-DDI-MedLine.d161.s3.e1
-;I-drug_n;I-DDI-MedLine.d161.s3.e1
methyl;I-drug_n;I-DDI-MedLine.d161.s3.e1
-;I-drug_n;I-DDI-MedLine.d161.s3.e1
4;I-drug_n;I-DDI-MedLine.d161.s3.e1
-;I-drug_n;I-DDI-MedLine.d161.s3.e1
phenyl;I-drug_n;I-DDI-MedLine.d161.s3.e1
-;I-drug_n;I-DDI-MedLine.d161.s3.e1
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s3.e1
-;I-drug_n;I-DDI-MedLine.d161.s3.e1
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s3.e1
.;O;O
DDI-MedLine.d161.s4;;
Weekly;O;O
intramuscular;O;O
1;B-drug_n;B-DDI-MedLine.d161.s4.e0
-;I-drug_n;I-DDI-MedLine.d161.s4.e0
methyl;I-drug_n;I-DDI-MedLine.d161.s4.e0
-;I-drug_n;I-DDI-MedLine.d161.s4.e0
4;I-drug_n;I-DDI-MedLine.d161.s4.e0
-;I-drug_n;I-DDI-MedLine.d161.s4.e0
phenyl;I-drug_n;I-DDI-MedLine.d161.s4.e0
-;I-drug_n;I-DDI-MedLine.d161.s4.e0
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s4.e0
-;I-drug_n;I-DDI-MedLine.d161.s4.e0
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s4.e0
injections;O;O
(;O;O
0.2;O;O
-;O;O
0.5;O;O
mg;O;O
/;O;O
kg;O;O
body;O;O
weight;O;O
);O;O
,;O;O
in;O;O
combination;O;O
with;O;O
daily;O;O
administration;O;O
of;O;O
3;B-drug_n;B-DDI-MedLine.d161.s4.e1
-;I-drug_n;I-DDI-MedLine.d161.s4.e1
[(2;I-drug_n;I-DDI-MedLine.d161.s4.e1
-;I-drug_n;I-DDI-MedLine.d161.s4.e1
methyl;I-drug_n;I-DDI-MedLine.d161.s4.e1
-;I-drug_n;I-DDI-MedLine.d161.s4.e1
1,3;I-drug_n;I-DDI-MedLine.d161.s4.e1
-;I-drug_n;I-DDI-MedLine.d161.s4.e1
thiazol;I-drug_n;I-DDI-MedLine.d161.s4.e1
-;I-drug_n;I-DDI-MedLine.d161.s4.e1
4;I-drug_n;I-DDI-MedLine.d161.s4.e1
-;I-drug_n;I-DDI-MedLine.d161.s4.e1
yl;I-drug_n;I-DDI-MedLine.d161.s4.e1
);I-drug_n;I-DDI-MedLine.d161.s4.e1
ethynyl;I-drug_n;I-DDI-MedLine.d161.s4.e1
];I-drug_n;I-DDI-MedLine.d161.s4.e1
pyridine;I-drug_n;I-DDI-MedLine.d161.s4.e1
or;O;O
vehicle;O;O
,;O;O
were;O;O
performed;O;O
until;O;O
the;O;O
development;O;O
of;O;O
parkinsonian;O;O
motor;O;O
symptoms;O;O
in;O;O
either;O;O
of;O;O
the;O;O
two;O;O
experimental;O;O
groups;O;O
(;O;O
1;B-drug_n;B-DDI-MedLine.d161.s4.e2
-;I-drug_n;I-DDI-MedLine.d161.s4.e2
methyl;I-drug_n;I-DDI-MedLine.d161.s4.e2
-;I-drug_n;I-DDI-MedLine.d161.s4.e2
4;I-drug_n;I-DDI-MedLine.d161.s4.e2
-;I-drug_n;I-DDI-MedLine.d161.s4.e2
phenyl;I-drug_n;I-DDI-MedLine.d161.s4.e2
-;I-drug_n;I-DDI-MedLine.d161.s4.e2
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s4.e2
-;I-drug_n;I-DDI-MedLine.d161.s4.e2
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s4.e2
/;O;O
3;B-drug_n;B-DDI-MedLine.d161.s4.e3
-;I-drug_n;I-DDI-MedLine.d161.s4.e3
[(2;I-drug_n;I-DDI-MedLine.d161.s4.e3
-;I-drug_n;I-DDI-MedLine.d161.s4.e3
methyl;I-drug_n;I-DDI-MedLine.d161.s4.e3
-;I-drug_n;I-DDI-MedLine.d161.s4.e3
1,3;I-drug_n;I-DDI-MedLine.d161.s4.e3
-;I-drug_n;I-DDI-MedLine.d161.s4.e3
thiazol;I-drug_n;I-DDI-MedLine.d161.s4.e3
-;I-drug_n;I-DDI-MedLine.d161.s4.e3
4;I-drug_n;I-DDI-MedLine.d161.s4.e3
-;I-drug_n;I-DDI-MedLine.d161.s4.e3
yl;I-drug_n;I-DDI-MedLine.d161.s4.e3
);I-drug_n;I-DDI-MedLine.d161.s4.e3
ethynyl;I-drug_n;I-DDI-MedLine.d161.s4.e3
];I-drug_n;I-DDI-MedLine.d161.s4.e3
pyridine;I-drug_n;I-DDI-MedLine.d161.s4.e3
versus;O;O
1;B-drug_n;B-DDI-MedLine.d161.s4.e4
-;I-drug_n;I-DDI-MedLine.d161.s4.e4
methyl;I-drug_n;I-DDI-MedLine.d161.s4.e4
-;I-drug_n;I-DDI-MedLine.d161.s4.e4
4;I-drug_n;I-DDI-MedLine.d161.s4.e4
-;I-drug_n;I-DDI-MedLine.d161.s4.e4
phenyl;I-drug_n;I-DDI-MedLine.d161.s4.e4
-;I-drug_n;I-DDI-MedLine.d161.s4.e4
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s4.e4
-;I-drug_n;I-DDI-MedLine.d161.s4.e4
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s4.e4
/;O;O
vehicle;O;O
);O;O
.;O;O
DDI-MedLine.d161.s5;;
After;O;O
21;O;O
weeks;O;O
of;O;O
1;B-drug_n;B-DDI-MedLine.d161.s5.e0
-;I-drug_n;I-DDI-MedLine.d161.s5.e0
methyl;I-drug_n;I-DDI-MedLine.d161.s5.e0
-;I-drug_n;I-DDI-MedLine.d161.s5.e0
4;I-drug_n;I-DDI-MedLine.d161.s5.e0
-;I-drug_n;I-DDI-MedLine.d161.s5.e0
phenyl;I-drug_n;I-DDI-MedLine.d161.s5.e0
-;I-drug_n;I-DDI-MedLine.d161.s5.e0
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s5.e0
-;I-drug_n;I-DDI-MedLine.d161.s5.e0
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s5.e0
treatment;O;O
,;O;O
all;O;O
1;B-drug_n;B-DDI-MedLine.d161.s5.e1
-;I-drug_n;I-DDI-MedLine.d161.s5.e1
methyl;I-drug_n;I-DDI-MedLine.d161.s5.e1
-;I-drug_n;I-DDI-MedLine.d161.s5.e1
4;I-drug_n;I-DDI-MedLine.d161.s5.e1
-;I-drug_n;I-DDI-MedLine.d161.s5.e1
phenyl;I-drug_n;I-DDI-MedLine.d161.s5.e1
-;I-drug_n;I-DDI-MedLine.d161.s5.e1
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s5.e1
-;I-drug_n;I-DDI-MedLine.d161.s5.e1
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s5.e1
/;O;O
vehicle;O;O
-;O;O
treated;O;O
animals;O;O
displayed;O;O
parkinsonian;O;O
symptoms;O;O
,;O;O
whereas;O;O
none;O;O
of;O;O
the;O;O
1;B-drug_n;B-DDI-MedLine.d161.s5.e2
-;I-drug_n;I-DDI-MedLine.d161.s5.e2
methyl;I-drug_n;I-DDI-MedLine.d161.s5.e2
-;I-drug_n;I-DDI-MedLine.d161.s5.e2
4;I-drug_n;I-DDI-MedLine.d161.s5.e2
-;I-drug_n;I-DDI-MedLine.d161.s5.e2
phenyl;I-drug_n;I-DDI-MedLine.d161.s5.e2
-;I-drug_n;I-DDI-MedLine.d161.s5.e2
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s5.e2
-;I-drug_n;I-DDI-MedLine.d161.s5.e2
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s5.e2
/;O;O
3;B-drug_n;B-DDI-MedLine.d161.s5.e3
-;I-drug_n;I-DDI-MedLine.d161.s5.e3
[(2;I-drug_n;I-DDI-MedLine.d161.s5.e3
-;I-drug_n;I-DDI-MedLine.d161.s5.e3
methyl;I-drug_n;I-DDI-MedLine.d161.s5.e3
-;I-drug_n;I-DDI-MedLine.d161.s5.e3
1,3;I-drug_n;I-DDI-MedLine.d161.s5.e3
-;I-drug_n;I-DDI-MedLine.d161.s5.e3
thiazol;I-drug_n;I-DDI-MedLine.d161.s5.e3
-;I-drug_n;I-DDI-MedLine.d161.s5.e3
4;I-drug_n;I-DDI-MedLine.d161.s5.e3
-;I-drug_n;I-DDI-MedLine.d161.s5.e3
yl;I-drug_n;I-DDI-MedLine.d161.s5.e3
);I-drug_n;I-DDI-MedLine.d161.s5.e3
ethynyl;I-drug_n;I-DDI-MedLine.d161.s5.e3
];I-drug_n;I-DDI-MedLine.d161.s5.e3
pyridine;I-drug_n;I-DDI-MedLine.d161.s5.e3
-;O;O
treated;O;O
monkeys;O;O
were;O;O
significantly;O;O
affected;O;O
.;O;O
DDI-MedLine.d161.s6;;
These;O;O
behavioural;O;O
observations;O;O
were;O;O
consistent;O;O
with;O;O
in;O;O
vivo;O;O
positron;O;O
emission;O;O
tomography;O;O
dopamine;O;O
transporter;O;O
imaging;O;O
data;O;O
,;O;O
and;O;O
with;O;O
post;O;O
-;O;O
mortem;O;O
stereological;O;O
counts;O;O
of;O;O
midbrain;O;O
dopaminergic;O;O
neurons;O;O
,;O;O
as;O;O
well;O;O
as;O;O
striatal;O;O
intensity;O;O
measurements;O;O
of;O;O
dopamine;O;O
transporter;O;O
and;O;O
tyrosine;O;O
hydroxylase;O;O
immunoreactivity;O;O
,;O;O
which;O;O
were;O;O
all;O;O
significantly;O;O
higher;O;O
in;O;O
1;B-drug_n;B-DDI-MedLine.d161.s6.e0
-;I-drug_n;I-DDI-MedLine.d161.s6.e0
methyl;I-drug_n;I-DDI-MedLine.d161.s6.e0
-;I-drug_n;I-DDI-MedLine.d161.s6.e0
4;I-drug_n;I-DDI-MedLine.d161.s6.e0
-;I-drug_n;I-DDI-MedLine.d161.s6.e0
phenyl;I-drug_n;I-DDI-MedLine.d161.s6.e0
-;I-drug_n;I-DDI-MedLine.d161.s6.e0
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s6.e0
-;I-drug_n;I-DDI-MedLine.d161.s6.e0
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s6.e0
/;O;O
3;B-drug_n;B-DDI-MedLine.d161.s6.e1
-;I-drug_n;I-DDI-MedLine.d161.s6.e1
[(2;I-drug_n;I-DDI-MedLine.d161.s6.e1
-;I-drug_n;I-DDI-MedLine.d161.s6.e1
methyl;I-drug_n;I-DDI-MedLine.d161.s6.e1
-;I-drug_n;I-DDI-MedLine.d161.s6.e1
1,3;I-drug_n;I-DDI-MedLine.d161.s6.e1
-;I-drug_n;I-DDI-MedLine.d161.s6.e1
thiazol;I-drug_n;I-DDI-MedLine.d161.s6.e1
-;I-drug_n;I-DDI-MedLine.d161.s6.e1
4;I-drug_n;I-DDI-MedLine.d161.s6.e1
-;I-drug_n;I-DDI-MedLine.d161.s6.e1
yl;I-drug_n;I-DDI-MedLine.d161.s6.e1
);I-drug_n;I-DDI-MedLine.d161.s6.e1
ethynyl;I-drug_n;I-DDI-MedLine.d161.s6.e1
];I-drug_n;I-DDI-MedLine.d161.s6.e1
pyridine;I-drug_n;I-DDI-MedLine.d161.s6.e1
-;O;O
treated;O;O
animals;O;O
than;O;O
in;O;O
1;B-drug_n;B-DDI-MedLine.d161.s6.e2
-;I-drug_n;I-DDI-MedLine.d161.s6.e2
methyl;I-drug_n;I-DDI-MedLine.d161.s6.e2
-;I-drug_n;I-DDI-MedLine.d161.s6.e2
4;I-drug_n;I-DDI-MedLine.d161.s6.e2
-;I-drug_n;I-DDI-MedLine.d161.s6.e2
phenyl;I-drug_n;I-DDI-MedLine.d161.s6.e2
-;I-drug_n;I-DDI-MedLine.d161.s6.e2
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s6.e2
-;I-drug_n;I-DDI-MedLine.d161.s6.e2
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s6.e2
/;O;O
vehicle;O;O
-;O;O
treated;O;O
monkeys;O;O
.;O;O
DDI-MedLine.d161.s7;;
The;O;O
3;B-drug_n;B-DDI-MedLine.d161.s7.e0
-;I-drug_n;I-DDI-MedLine.d161.s7.e0
[(2;I-drug_n;I-DDI-MedLine.d161.s7.e0
-;I-drug_n;I-DDI-MedLine.d161.s7.e0
methyl;I-drug_n;I-DDI-MedLine.d161.s7.e0
-;I-drug_n;I-DDI-MedLine.d161.s7.e0
1,3;I-drug_n;I-DDI-MedLine.d161.s7.e0
-;I-drug_n;I-DDI-MedLine.d161.s7.e0
thiazol;I-drug_n;I-DDI-MedLine.d161.s7.e0
-;I-drug_n;I-DDI-MedLine.d161.s7.e0
4;I-drug_n;I-DDI-MedLine.d161.s7.e0
-;I-drug_n;I-DDI-MedLine.d161.s7.e0
yl;I-drug_n;I-DDI-MedLine.d161.s7.e0
);I-drug_n;I-DDI-MedLine.d161.s7.e0
ethynyl;I-drug_n;I-DDI-MedLine.d161.s7.e0
];I-drug_n;I-DDI-MedLine.d161.s7.e0
pyridine;I-drug_n;I-DDI-MedLine.d161.s7.e0
treatment;O;O
also;O;O
had;O;O
a;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
1;B-drug_n;B-DDI-MedLine.d161.s7.e1
-;I-drug_n;I-DDI-MedLine.d161.s7.e1
methyl;I-drug_n;I-DDI-MedLine.d161.s7.e1
-;I-drug_n;I-DDI-MedLine.d161.s7.e1
4;I-drug_n;I-DDI-MedLine.d161.s7.e1
-;I-drug_n;I-DDI-MedLine.d161.s7.e1
phenyl;I-drug_n;I-DDI-MedLine.d161.s7.e1
-;I-drug_n;I-DDI-MedLine.d161.s7.e1
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s7.e1
-;I-drug_n;I-DDI-MedLine.d161.s7.e1
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s7.e1
-;O;O
induced;O;O
loss;O;O
of;O;O
norepinephrine;O;O
neurons;O;O
in;O;O
the;O;O
locus;O;O
coeruleus;O;O
and;O;O
adjoining;O;O
A5;O;O
and;O;O
A7;O;O
noradrenaline;O;O
cell;O;O
groups;O;O
.;O;O
DDI-MedLine.d161.s8;;
In;O;O
1;B-drug_n;B-DDI-MedLine.d161.s8.e0
-;I-drug_n;I-DDI-MedLine.d161.s8.e0
methyl;I-drug_n;I-DDI-MedLine.d161.s8.e0
-;I-drug_n;I-DDI-MedLine.d161.s8.e0
4;I-drug_n;I-DDI-MedLine.d161.s8.e0
-;I-drug_n;I-DDI-MedLine.d161.s8.e0
phenyl;I-drug_n;I-DDI-MedLine.d161.s8.e0
-;I-drug_n;I-DDI-MedLine.d161.s8.e0
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s8.e0
-;I-drug_n;I-DDI-MedLine.d161.s8.e0
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s8.e0
/;O;O
vehicle;O;O
-;O;O
treated;O;O
animals;O;O
,;O;O
almost;O;O
40;O;O
%;O;O
loss;O;O
of;O;O
tyrosine;O;O
hydroxylase;O;O
-;O;O
positive;O;O
norepinephrine;O;O
neurons;O;O
was;O;O
found;O;O
in;O;O
locus;O;O
coeruleus;O;O
/;O;O
A5;O;O
/;O;O
A7;O;O
noradrenaline;O;O
cell;O;O
groups;O;O
,;O;O
whereas;O;O
the;O;O
extent;O;O
of;O;O
neuronal;O;O
loss;O;O
was;O;O
lower;O;O
than;O;O
15;O;O
%;O;O
of;O;O
control;O;O
values;O;O
in;O;O
1;B-drug_n;B-DDI-MedLine.d161.s8.e1
-;I-drug_n;I-DDI-MedLine.d161.s8.e1
methyl;I-drug_n;I-DDI-MedLine.d161.s8.e1
-;I-drug_n;I-DDI-MedLine.d161.s8.e1
4;I-drug_n;I-DDI-MedLine.d161.s8.e1
-;I-drug_n;I-DDI-MedLine.d161.s8.e1
phenyl;I-drug_n;I-DDI-MedLine.d161.s8.e1
-;I-drug_n;I-DDI-MedLine.d161.s8.e1
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s8.e1
-;I-drug_n;I-DDI-MedLine.d161.s8.e1
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s8.e1
/;O;O
3;B-drug_n;B-DDI-MedLine.d161.s8.e2
-;I-drug_n;I-DDI-MedLine.d161.s8.e2
[(2;I-drug_n;I-DDI-MedLine.d161.s8.e2
-;I-drug_n;I-DDI-MedLine.d161.s8.e2
methyl;I-drug_n;I-DDI-MedLine.d161.s8.e2
-;I-drug_n;I-DDI-MedLine.d161.s8.e2
1,3;I-drug_n;I-DDI-MedLine.d161.s8.e2
-;I-drug_n;I-DDI-MedLine.d161.s8.e2
thiazol;I-drug_n;I-DDI-MedLine.d161.s8.e2
-;I-drug_n;I-DDI-MedLine.d161.s8.e2
4;I-drug_n;I-DDI-MedLine.d161.s8.e2
-;I-drug_n;I-DDI-MedLine.d161.s8.e2
yl;I-drug_n;I-DDI-MedLine.d161.s8.e2
);I-drug_n;I-DDI-MedLine.d161.s8.e2
ethynyl;I-drug_n;I-DDI-MedLine.d161.s8.e2
];I-drug_n;I-DDI-MedLine.d161.s8.e2
pyridine;I-drug_n;I-DDI-MedLine.d161.s8.e2
-;O;O
treated;O;O
monkeys;O;O
.;O;O
DDI-MedLine.d161.s9;;
Our;O;O
data;O;O
demonstrate;O;O
that;O;O
chronic;O;O
treatment;O;O
with;O;O
the;O;O
metabotropic;O;O
glutamate;O;O
receptor;O;O
5;O;O
antagonist;O;O
,;O;O
3;B-drug_n;B-DDI-MedLine.d161.s9.e0
-;I-drug_n;I-DDI-MedLine.d161.s9.e0
[(2;I-drug_n;I-DDI-MedLine.d161.s9.e0
-;I-drug_n;I-DDI-MedLine.d161.s9.e0
methyl;I-drug_n;I-DDI-MedLine.d161.s9.e0
-;I-drug_n;I-DDI-MedLine.d161.s9.e0
1,3;I-drug_n;I-DDI-MedLine.d161.s9.e0
-;I-drug_n;I-DDI-MedLine.d161.s9.e0
thiazol;I-drug_n;I-DDI-MedLine.d161.s9.e0
-;I-drug_n;I-DDI-MedLine.d161.s9.e0
4;I-drug_n;I-DDI-MedLine.d161.s9.e0
-;I-drug_n;I-DDI-MedLine.d161.s9.e0
yl;I-drug_n;I-DDI-MedLine.d161.s9.e0
);I-drug_n;I-DDI-MedLine.d161.s9.e0
ethynyl;I-drug_n;I-DDI-MedLine.d161.s9.e0
];I-drug_n;I-DDI-MedLine.d161.s9.e0
pyridine;I-drug_n;I-DDI-MedLine.d161.s9.e0
,;O;O
significantly;O;O
reduces;O;O
1;B-drug_n;B-DDI-MedLine.d161.s9.e1
-;I-drug_n;I-DDI-MedLine.d161.s9.e1
methyl;I-drug_n;I-DDI-MedLine.d161.s9.e1
-;I-drug_n;I-DDI-MedLine.d161.s9.e1
4;I-drug_n;I-DDI-MedLine.d161.s9.e1
-;I-drug_n;I-DDI-MedLine.d161.s9.e1
phenyl;I-drug_n;I-DDI-MedLine.d161.s9.e1
-;I-drug_n;I-DDI-MedLine.d161.s9.e1
1,2,3,6;I-drug_n;I-DDI-MedLine.d161.s9.e1
-;I-drug_n;I-DDI-MedLine.d161.s9.e1
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d161.s9.e1
toxicity;O;O
towards;O;O
dopaminergic;O;O
and;O;O
noradrenergic;O;O
cell;O;O
groups;O;O
in;O;O
non;O;O
-;O;O
human;O;O
primates;O;O
.;O;O
DDI-MedLine.d161.s10;;
This;O;O
suggests;O;O
that;O;O
the;O;O
use;O;O
of;O;O
metabotropic;O;O
glutamate;O;O
receptor;O;O
5;O;O
antagonists;O;O
may;O;O
be;O;O
a;O;O
useful;O;O
strategy;O;O
to;O;O
reduce;O;O
degeneration;O;O
of;O;O
catecholaminergic;O;O
neurons;O;O
in;O;O
Parkinson;O;O
's;O;O
disease;O;O
.;O;O
DDI-MedLine.d185.s0;;
Effect;O;O
of;O;O
ketoconazole;B-drug;B-DDI-MedLine.d185.s0.e0
-;O;O
mediated;O;O
CYP3A4;O;O
inhibition;O;O
on;O;O
clinical;O;O
pharmacokinetics;O;O
of;O;O
panobinostat;B-drug;B-DDI-MedLine.d185.s0.e1
(;O;O
LBH589;B-drug;B-DDI-MedLine.d185.s0.e2
);O;O
,;O;O
an;O;O
orally;O;O
active;O;O
histone;B-group;B-DDI-MedLine.d185.s0.e3
deacetylase;I-group;I-DDI-MedLine.d185.s0.e3
inhibitor;I-group;I-DDI-MedLine.d185.s0.e3
.;O;O
DDI-MedLine.d185.s1;;
Panobinostat;B-drug;B-DDI-MedLine.d185.s1.e0
is;O;O
partly;O;O
metabolized;O;O
by;O;O
CYP3A4;O;O
in;O;O
vitro;O;O
.;O;O
DDI-MedLine.d185.s2;;
This;O;O
study;O;O
evaluated;O;O
the;O;O
effect;O;O
of;O;O
a;O;O
potent;O;O
CYP3A;O;O
inhibitor;O;O
,;O;O
ketoconazole;B-drug;B-DDI-MedLine.d185.s2.e0
,;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
and;O;O
safety;O;O
of;O;O
panobinostat;B-drug;B-DDI-MedLine.d185.s2.e1
.;O;O
DDI-MedLine.d185.s3;;
Patients;O;O
received;O;O
a;O;O
single;O;O
panobinostat;B-drug;B-DDI-MedLine.d185.s3.e0
oral;O;O
dose;O;O
on;O;O
day;O;O
1;O;O
,;O;O
followed;O;O
by;O;O
4;O;O
days;O;O
wash;O;O
-;O;O
out;O;O
period;O;O
.;O;O
DDI-MedLine.d185.s4;;
On;O;O
days;O;O
5;O;O
-;O;O
9;O;O
,;O;O
ketoconazole;B-drug;B-DDI-MedLine.d185.s4.e0
was;O;O
administered;O;O
.;O;O
DDI-MedLine.d185.s5;;
On;O;O
day;O;O
8;O;O
,;O;O
a;O;O
single;O;O
panobinostat;B-drug;B-DDI-MedLine.d185.s5.e0
dose;O;O
was;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
ketoconazole;B-drug;B-DDI-MedLine.d185.s5.e1
.;O;O
DDI-MedLine.d185.s6;;
Panobinostat;B-drug;B-DDI-MedLine.d185.s6.e0
was;O;O
administered;O;O
as;O;O
single;O;O
agent;O;O
three;O;O
times;O;O
a;O;O
week;O;O
on;O;O
day;O;O
15;O;O
and;O;O
onward;O;O
.;O;O
DDI-MedLine.d185.s7;;
In;O;O
the;O;O
presence;O;O
of;O;O
ketoconazole;B-drug;B-DDI-MedLine.d185.s7.e0
,;O;O
there;O;O
was;O;O
1.6;O;O
-;O;O
and;O;O
1.8;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
C;O;O
(;O;O
max;O;O
);O;O
and;O;O
AUC;O;O
of;O;O
panobinostat;B-drug;B-DDI-MedLine.d185.s7.e1
,;O;O
respectively;O;O
.;O;O
DDI-MedLine.d185.s8;;
No;O;O
substantial;O;O
change;O;O
in;O;O
T;O;O
(;O;O
max;O;O
);O;O
or;O;O
half;O;O
-;O;O
life;O;O
was;O;O
observed;O;O
.;O;O
DDI-MedLine.d185.s9;;
No;O;O
difference;O;O
in;O;O
panobinostat;B-drug;B-DDI-MedLine.d185.s9.e0
-;O;O
pharmacokinetics;O;O
between;O;O
patients;O;O
carrying;O;O
CYP3A5;O;O
*;O;O
1;O;O
/;O;O
*;O;O
3;O;O
and;O;O
CYP3A5;O;O
*;O;O
3;O;O
/;O;O
*;O;O
3;O;O
alleles;O;O
was;O;O
observed;O;O
.;O;O
DDI-MedLine.d185.s10;;
Most;O;O
frequently;O;O
reported;O;O
adverse;O;O
events;O;O
were;O;O
gastrointestinal;O;O
related;O;O
.;O;O
DDI-MedLine.d185.s11;;
Patients;O;O
had;O;O
asymptomatic;O;O
hypophosphatemia;O;O
(;O;O
64;O;O
%;O;O
);O;O
,;O;O
and;O;O
urine;O;O
analysis;O;O
suggested;O;O
renal;O;O
phosphate;O;O
wasting;O;O
.;O;O
DDI-MedLine.d185.s12;;
Co;O;O
-;O;O
administration;O;O
of;O;O
panobinostat;B-drug;B-DDI-MedLine.d185.s12.e0
with;O;O
CYP3A;O;O
inhibitors;O;O
is;O;O
feasible;O;O
as;O;O
the;O;O
observed;O;O
increase;O;O
in;O;O
panobinostat;B-drug;B-DDI-MedLine.d185.s12.e1
PK;O;O
parameters;O;O
was;O;O
not;O;O
considered;O;O
clinically;O;O
relevant;O;O
.;O;O
DDI-MedLine.d185.s13;;
Considering;O;O
the;O;O
variability;O;O
in;O;O
exposure;O;O
following;O;O
enzyme;O;O
inhibition;O;O
and;O;O
the;O;O
fact;O;O
that;O;O
chronic;O;O
dosing;O;O
of;O;O
panobinostat;B-drug;B-DDI-MedLine.d185.s13.e0
was;O;O
not;O;O
studied;O;O
with;O;O
CYP3A;O;O
inhibitors;O;O
,;O;O
close;O;O
monitoring;O;O
of;O;O
panobinostat;B-drug;B-DDI-MedLine.d185.s13.e1
-;O;O
related;O;O
adverse;O;O
events;O;O
is;O;O
necessary;O;O
.;O;O
DDI-MedLine.d231.s0;;
Interaction;O;O
study;O;O
of;O;O
moxifloxacin;B-drug;B-DDI-MedLine.d231.s0.e0
and;O;O
lomefloxacin;B-drug;B-DDI-MedLine.d231.s0.e1
with;O;O
co;O;O
-;O;O
administered;O;O
drugs;O;O
.;O;O

;O;O
DDI-MedLine.d231.s1;;
Moxifloxacin;B-drug;B-DDI-MedLine.d231.s1.e0
and;O;O
lomefloxacin;B-drug;B-DDI-MedLine.d231.s1.e1
are;O;O
fluoroquinolone;B-group;B-DDI-MedLine.d231.s1.e2
antibiotics;I-group;I-DDI-MedLine.d231.s1.e2
used;O;O
in;O;O
treating;O;O
urinary;O;O
and;O;O
respiratory;O;O
tract;O;O
infections;O;O
.;O;O
DDI-MedLine.d231.s2;;
Fluoroquinolones;B-group;B-DDI-MedLine.d231.s2.e0
are;O;O
known;O;O
to;O;O
have;O;O
interactions;O;O
with;O;O
drugs;O;O
that;O;O
are;O;O
active;O;O
in;O;O
gastro;O;O
intestinal;O;O
tract;O;O
.;O;O
DDI-MedLine.d231.s3;;
Being;O;O
moxifloxacin;B-drug;B-DDI-MedLine.d231.s3.e0
and;O;O
lomefloxacin;O;O
fluoroquinolones;B-group;B-DDI-MedLine.d231.s3.e1
the;O;O
interaction;O;O
study;O;O
of;O;O
was;O;O
carried;O;O
out;O;O
with;O;O
sucralfate;B-drug;B-DDI-MedLine.d231.s3.e2
,;O;O
gelusil;B-brand;B-DDI-MedLine.d231.s3.e3
,;O;O
erythromycin;B-drug;B-DDI-MedLine.d231.s3.e4
and;O;O
multi;B-group;B-DDI-MedLine.d231.s3.e5
minerals;I-group;I-DDI-MedLine.d231.s3.e5
.;O;O
DDI-MedLine.d231.s4;;
The;O;O
interaction;O;O
was;O;O
studied;O;O
at;O;O
neutral;O;O
,;O;O
acidic;O;O
and;O;O
basic;O;O
conditions;O;O
both;O;O
at;O;O
room;O;O
temperature;O;O
and;O;O
37;O;O
C.;O;O
DDI-MedLine.d231.s5;;
The;O;O
effect;O;O
of;O;O
dissolution;O;O
medium;O;O
simulating;O;O
various;O;O
body;O;O
environments;O;O
with;O;O
response;O;O
to;O;O
pH;O;O
has;O;O
been;O;O
examined;O;O
in;O;O
order;O;O
to;O;O
elucidate;O;O
the;O;O
interactions;O;O
.;O;O
DDI-MedLine.d231.s6;;
The;O;O
response;O;O
of;O;O
moxifloxacin;B-drug;B-DDI-MedLine.d231.s6.e0
and;O;O
lomefloxacin;B-drug;B-DDI-MedLine.d231.s6.e1
after;O;O
interaction;O;O
with;O;O
co;O;O
-;O;O
administered;O;O
drugs;O;O
at;O;O
different;O;O
conditions;O;O
and;O;O
temperature;O;O
were;O;O
noted;O;O
using;O;O
a;O;O
Shimadzu;O;O
HPLC;O;O
system;O;O
with;O;O
PDA;O;O
detector;O;O
.;O;O
DDI-MedLine.d231.s7;;
It;O;O
was;O;O
seen;O;O
that;O;O
interaction;O;O
of;O;O
these;O;O
fluoroquinolones;B-group;B-DDI-MedLine.d231.s7.e0
was;O;O
more;O;O
at;O;O
37;O;O
C;O;O
than;O;O
at;O;O
room;O;O
temperature;O;O
.;O;O
DDI-MedLine.d231.s8;;
Moxifloxacin;B-drug;B-DDI-MedLine.d231.s8.e0
and;O;O
Lomefloxacin;B-drug;B-DDI-MedLine.d231.s8.e1
reacts;O;O
faster;O;O
with;O;O
sucralfate;B-drug;B-DDI-MedLine.d231.s8.e2
and;O;O
gelusil;B-brand;B-DDI-MedLine.d231.s8.e3
in;O;O
acidic;O;O
media;O;O
whereas;O;O
with;O;O
erythromycin;B-drug;B-DDI-MedLine.d231.s8.e4
in;O;O
basic;O;O
media;O;O
and;O;O
multi;B-group;B-DDI-MedLine.d231.s8.e5
-;I-group;I-DDI-MedLine.d231.s8.e5
minerals;I-group;I-DDI-MedLine.d231.s8.e5
in;O;O
neutral;O;O
media;O;O
.;O;O
DDI-MedLine.d231.s9;;
The;O;O
study;O;O
ensures;O;O
the;O;O
interaction;O;O
of;O;O
fluoroquinolones;B-group;B-DDI-MedLine.d231.s9.e0
with;O;O
selected;O;O
class;O;O
of;O;O
drugs;O;O
.;O;O
DDI-MedLine.d231.s10;;
In;O;O
order;O;O
to;O;O
achieve;O;O
the;O;O
effective;O;O
therapeutic;O;O
effect;O;O
appropriate;O;O
time;O;O
intervals;O;O
between;O;O
administrations;O;O
of;O;O
drugs;O;O
is;O;O
essential;O;O
.;O;O
DDI-MedLine.d216.s0;;
Exposure;O;O
to;O;O
oral;O;O
S;B-drug;B-DDI-MedLine.d216.s0.e0
-;I-drug;I-DDI-MedLine.d216.s0.e0
ketamine;I-drug;I-DDI-MedLine.d216.s0.e0
is;O;O
unaffected;O;O
by;O;O
itraconazole;B-drug;B-DDI-MedLine.d216.s0.e1
but;O;O
greatly;O;O
increased;O;O
by;O;O
ticlopidine;B-drug;B-DDI-MedLine.d216.s0.e2
.;O;O
DDI-MedLine.d216.s1;;
This;O;O
study;O;O
examined;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
of;O;O
oral;O;O
S;B-drug;B-DDI-MedLine.d216.s1.e0
-;I-drug;I-DDI-MedLine.d216.s1.e0
ketamine;I-drug;I-DDI-MedLine.d216.s1.e0
with;O;O
the;O;O
cytochrome;O;O
P450;O;O
(;O;O
CYP;O;O
);O;O
2B6;O;O
inhibitor;O;O
ticlopidine;B-drug;B-DDI-MedLine.d216.s1.e1
and;O;O
the;O;O
CYP3A;O;O
inhibitor;O;O
itraconazole;B-drug;B-DDI-MedLine.d216.s1.e2
.;O;O
DDI-MedLine.d216.s2;;
In;O;O
this;O;O
randomized;O;O
,;O;O
blinded;O;O
,;O;O
crossover;O;O
study;O;O
,;O;O
11;O;O
healthy;O;O
volunteers;O;O
ingested;O;O
0.2;O;O
mg;O;O
/;O;O
kg;O;O
S;B-drug;B-DDI-MedLine.d216.s2.e0
-;I-drug;I-DDI-MedLine.d216.s2.e0
ketamine;I-drug;I-DDI-MedLine.d216.s2.e0
after;O;O
pretreatments;O;O
with;O;O
oral;O;O
ticlopidine;B-drug;B-DDI-MedLine.d216.s2.e1
(;O;O
250;O;O
mg;O;O
twice;O;O
daily;O;O
);O;O
,;O;O
itraconazole;B-drug;B-DDI-MedLine.d216.s2.e2
(;O;O
200;O;O
mg;O;O
once;O;O
daily;O;O
);O;O
,;O;O
or;O;O
placebo;O;O
in;O;O
6;O;O
-;O;O
day;O;O
treatment;O;O
periods;O;O
at;O;O
intervals;O;O
of;O;O
4;O;O
weeks;O;O
.;O;O
DDI-MedLine.d216.s3;;
Ticlopidine;B-drug;B-DDI-MedLine.d216.s3.e0
treatment;O;O
increased;O;O
the;O;O
mean;O;O
area;O;O
under;O;O
the;O;O
plasma;O;O
concentration;O;O
-;O;O
time;O;O
curve;O;O
extrapolated;O;O
to;O;O
infinity;O;O
(;O;O
AUC(0;O;O
-;O;O
);O;O
);O;O
of;O;O
oral;O;O
ketamine;B-drug;B-DDI-MedLine.d216.s3.e1
by;O;O
2.4;O;O
-;O;O
fold;O;O
,;O;O
whereas;O;O
itraconazole;B-drug;B-DDI-MedLine.d216.s3.e2
treatment;O;O
did;O;O
not;O;O
increase;O;O
the;O;O
exposure;O;O
to;O;O
S;B-drug;B-DDI-MedLine.d216.s3.e3
-;I-drug;I-DDI-MedLine.d216.s3.e3
ketamine;I-drug;I-DDI-MedLine.d216.s3.e3
.;O;O
DDI-MedLine.d216.s4;;
The;O;O
ratio;O;O
of;O;O
norketamine;B-drug_n;B-DDI-MedLine.d216.s4.e0
AUC(0;O;O
-;O;O
);O;O
to;O;O
ketamine;B-drug;B-DDI-MedLine.d216.s4.e1
AUC(0;O;O
-;O;O
);O;O
was;O;O
significantly;O;O
decreased;O;O
in;O;O
the;O;O
ticlopidine;B-drug;B-DDI-MedLine.d216.s4.e2
(;O;O
P;O;O
&;O;O
lt;O;O
;;O;O
0.001;O;O
);O;O
and;O;O
itraconazole;B-drug;B-DDI-MedLine.d216.s4.e3
phases;O;O
(;O;O
P;O;O
=;O;O
0.006;O;O
);O;O
as;O;O
compared;O;O
to;O;O
placebo;O;O
.;O;O
DDI-MedLine.d216.s5;;
In;O;O
the;O;O
ticlopidine;B-drug;B-DDI-MedLine.d216.s5.e0
and;O;O
itraconazole;B-drug;B-DDI-MedLine.d216.s5.e1
phases;O;O
,;O;O
the;O;O
areas;O;O
under;O;O
the;O;O
effect;O;O
-;O;O
time;O;O
curves;O;O
(;O;O
self;O;O
-;O;O
reported;O;O
drowsiness;O;O
and;O;O
performance;O;O
);O;O
were;O;O
significantly;O;O
higher;O;O
than;O;O
those;O;O
in;O;O
the;O;O
placebo;O;O
phase;O;O
(;O;O
P;O;O
<;O;O
0.05;O;O
);O;O
.;O;O
DDI-MedLine.d216.s6;;
The;O;O
findings;O;O
suggest;O;O
that;O;O
the;O;O
dosage;O;O
of;O;O
S;B-drug;B-DDI-MedLine.d216.s6.e0
-;I-drug;I-DDI-MedLine.d216.s6.e0
ketamine;I-drug;I-DDI-MedLine.d216.s6.e0
should;O;O
be;O;O
reduced;O;O
in;O;O
patients;O;O
receiving;O;O
ticlopidine;B-drug;B-DDI-MedLine.d216.s6.e1
.;O;O
DDI-MedLine.d180.s0;;
Determinants;O;O
of;O;O
sensitivity;O;O
to;O;O
DZNep;B-drug_n;B-DDI-MedLine.d180.s0.e0
induced;O;O
apoptosis;O;O
in;O;O
multiple;O;O
myeloma;O;O
cells;O;O
.;O;O
DDI-MedLine.d180.s1;;
The;O;O
3;B-drug_n;B-DDI-MedLine.d180.s1.e0
-;I-drug_n;I-DDI-MedLine.d180.s1.e0
Deazaneplanocin;I-drug_n;I-DDI-MedLine.d180.s1.e0
A;I-drug_n;I-DDI-MedLine.d180.s1.e0
(;O;O
DZNep;B-drug_n;B-DDI-MedLine.d180.s1.e1
);O;O
,;O;O
one;O;O
of;O;O
S;O;O
-;O;O
adenosylhomocysteine;O;O
(;O;O
AdoHcy;O;O
);O;O
hydrolase;O;O
inhibitors;O;O
,;O;O
has;O;O
shown;O;O
antitumor;O;O
activities;O;O
in;O;O
a;O;O
broad;O;O
range;O;O
of;O;O
solid;O;O
tumors;O;O
and;O;O
acute;O;O
myeloid;O;O
leukemia;O;O
.;O;O
DDI-MedLine.d180.s2;;
Here;O;O
,;O;O
we;O;O
examined;O;O
its;O;O
effects;O;O
on;O;O
multiple;O;O
myeloma;O;O
(;O;O
MM;O;O
);O;O
cells;O;O
and;O;O
found;O;O
that;O;O
,;O;O
at;O;O
500;O;O
nM;O;O
,;O;O
it;O;O
potently;O;O
inhibited;O;O
growth;O;O
and;O;O
induced;O;O
apoptosis;O;O
in;O;O
2;O;O
of;O;O
8;O;O
MM;O;O
cell;O;O
lines;O;O
.;O;O
DDI-MedLine.d180.s3;;
RNA;O;O
from;O;O
un;O;O
-;O;O
treated;O;O
and;O;O
DZNep;B-drug_n;B-DDI-MedLine.d180.s3.e0
treated;O;O
cells;O;O
was;O;O
profiled;O;O
by;O;O
Affymetrix;O;O
HG;O;O
-;O;O
U133;O;O
Plus;O;O
2.0;O;O
microarray;O;O
and;O;O
genes;O;O
with;O;O
a;O;O
significant;O;O
change;O;O
in;O;O
gene;O;O
expression;O;O
were;O;O
determined;O;O
by;O;O
significance;O;O
analysis;O;O
of;O;O
microarray;O;O
(;O;O
SAM;O;O
);O;O
testing;O;O
.;O;O
DDI-MedLine.d180.s4;;
ALOX5;O;O
was;O;O
the;O;O
most;O;O
down;O;O
-;O;O
regulated;O;O
gene;O;O
(;O;O
5.8;O;O
-;O;O
fold;O;O
);O;O
in;O;O
sensitive;O;O
cells;O;O
and;O;O
was;O;O
expressed;O;O
at;O;O
low;O;O
level;O;O
in;O;O
resistant;O;O
cells;O;O
.;O;O
DDI-MedLine.d180.s5;;
The;O;O
results;O;O
were;O;O
corroborated;O;O
by;O;O
quantitative;O;O
RT;O;O
-;O;O
PCR;O;O
.;O;O
DDI-MedLine.d180.s6;;
Western;O;O
-;O;O
blot;O;O
analysis;O;O
indicated;O;O
ALOX5;O;O
was;O;O
highly;O;O
expressed;O;O
only;O;O
in;O;O
sensitive;O;O
cell;O;O
line;O;O
H929;O;O
and;O;O
greatly;O;O
decreased;O;O
upon;O;O
DZNep;B-drug_n;B-DDI-MedLine.d180.s6.e0
treatment;O;O
.;O;O
DDI-MedLine.d180.s7;;
Ectopic;O;O
expression;O;O
of;O;O
ALOX5;O;O
reduced;O;O
sensitivity;O;O
to;O;O
DZNep;B-drug_n;B-DDI-MedLine.d180.s7.e0
in;O;O
H929;O;O
cells;O;O
.;O;O
DDI-MedLine.d180.s8;;
Furthermore;O;O
,;O;O
down;O;O
-;O;O
regulation;O;O
of;O;O
ALOX5;O;O
by;O;O
RNA;O;O
interference;O;O
could;O;O
also;O;O
induce;O;O
apoptosis;O;O
in;O;O
H929;O;O
.;O;O
DDI-MedLine.d180.s9;;
Gene;O;O
expression;O;O
analysis;O;O
on;O;O
MM;O;O
patient;O;O
dataset;O;O
indicated;O;O
ALOX5;O;O
expression;O;O
was;O;O
significantly;O;O
higher;O;O
in;O;O
MM;O;O
patients;O;O
compared;O;O
to;O;O
normal;O;O
plasma;O;O
cells;O;O
.;O;O
DDI-MedLine.d180.s10;;
We;O;O
also;O;O
found;O;O
that;O;O
Bcl;O;O
-;O;O
2;O;O
was;O;O
overexpressed;O;O
in;O;O
DZNep;B-drug_n;B-DDI-MedLine.d180.s10.e0
insensitive;O;O
cells;O;O
,;O;O
and;O;O
cotreatment;O;O
with;O;O
DZNep;B-drug_n;B-DDI-MedLine.d180.s10.e1
and;O;O
ABT;B-drug_n;B-DDI-MedLine.d180.s10.e2
-;I-drug_n;I-DDI-MedLine.d180.s10.e2
737;I-drug_n;I-DDI-MedLine.d180.s10.e2
,;O;O
a;O;O
Bcl;O;O
-;O;O
2;O;O
family;O;O
inhibitor;O;O
,;O;O
synergistically;O;O
inhibited;O;O
growth;O;O
and;O;O
induced;O;O
apoptosis;O;O
of;O;O
DZNep;B-drug_n;B-DDI-MedLine.d180.s10.e3
insensitive;O;O
MM;O;O
cells;O;O
.;O;O
DDI-MedLine.d180.s11;;
Taken;O;O
together;O;O
,;O;O
this;O;O
study;O;O
shows;O;O
one;O;O
of;O;O
mechanisms;O;O
of;O;O
the;O;O
DZNep;B-drug_n;B-DDI-MedLine.d180.s11.e0
efficacy;O;O
on;O;O
MM;O;O
correlates;O;O
with;O;O
its;O;O
ability;O;O
to;O;O
down;O;O
-;O;O
regulate;O;O
the;O;O
ALOX5;O;O
levels;O;O
.;O;O
DDI-MedLine.d180.s12;;
In;O;O
addition;O;O
,;O;O
DZNep;B-drug_n;B-DDI-MedLine.d180.s12.e0
insensitivity;O;O
might;O;O
be;O;O
associated;O;O
with;O;O
overexpression;O;O
of;O;O
Bcl;O;O
-;O;O
2;O;O
,;O;O
and;O;O
the;O;O
combination;O;O
of;O;O
ABT;B-drug_n;B-DDI-MedLine.d180.s12.e1
-;I-drug_n;I-DDI-MedLine.d180.s12.e1
737;I-drug_n;I-DDI-MedLine.d180.s12.e1
and;O;O
DZNep;B-drug_n;B-DDI-MedLine.d180.s12.e2
could;O;O
synergistically;O;O
induced;O;O
apoptosis;O;O
.;O;O
DDI-MedLine.d180.s13;;
These;O;O
results;O;O
suggest;O;O
that;O;O
DZNep;B-drug_n;B-DDI-MedLine.d180.s13.e0
may;O;O
be;O;O
exploited;O;O
therapeutically;O;O
for;O;O
a;O;O
subset;O;O
of;O;O
MM;O;O
.;O;O
DDI-MedLine.d208.s0;;
Implanon;B-brand;B-DDI-MedLine.d208.s0.e0
failure;O;O
in;O;O
an;O;O
HIV;O;O
-;O;O
positive;O;O
woman;O;O
on;O;O
antiretroviral;B-group;B-DDI-MedLine.d208.s0.e1
therapy;O;O
resulting;O;O
in;O;O
two;O;O
ectopic;O;O
pregnancies;O;O
.;O;O
DDI-MedLine.d208.s1;;
Since;O;O
its;O;O
introduction;O;O
in;O;O
1999;O;O
,;O;O
Implanon;B-brand;B-DDI-MedLine.d208.s1.e0
remains;O;O
one;O;O
of;O;O
the;O;O
preferred;O;O
contraceptive;O;O
choices;O;O
for;O;O
many;O;O
women;O;O
as;O;O
it;O;O
offers;O;O
a;O;O
highly;O;O
effective;O;O
means;O;O
of;O;O
long;O;O
-;O;O
term;O;O
contraception;O;O
for;O;O
three;O;O
years;O;O
that;O;O
does;O;O
not;O;O
rely;O;O
on;O;O
adherence;O;O
.;O;O
DDI-MedLine.d208.s2;;
Like;O;O
all;O;O
hormonal;B-group;B-DDI-MedLine.d208.s2.e0
contraceptives;I-group;I-DDI-MedLine.d208.s2.e0
,;O;O
certain;O;O
hepatic;O;O
enzyme;O;O
-;O;O
inducing;O;O
drugs;O;O
may;O;O
reduce;O;O
its;O;O
efficacy;O;O
.;O;O
DDI-MedLine.d208.s3;;
We;O;O
present;O;O
an;O;O
interesting;O;O
case;O;O
of;O;O
an;O;O
HIV;O;O
-;O;O
positive;O;O
woman;O;O
on;O;O
antiretroviral;B-group;B-DDI-MedLine.d208.s3.e0
therapy;O;O
having;O;O
tubal;O;O
pregnancies;O;O
on;O;O
two;O;O
separate;O;O
occasions;O;O
with;O;O
Implanon;B-brand;B-DDI-MedLine.d208.s3.e1
in;O;O
place;O;O
.;O;O
DDI-MedLine.d218.s0;;
Antidepressant;B-group;B-DDI-MedLine.d218.s0.e0
-;O;O
warfarin;B-drug;B-DDI-MedLine.d218.s0.e1
interaction;O;O
and;O;O
associated;O;O
gastrointestinal;O;O
bleeding;O;O
risk;O;O
in;O;O
a;O;O
case;O;O
-;O;O
control;O;O
study;O;O
.;O;O
DDI-MedLine.d218.s1;;
Bleeding;O;O
is;O;O
the;O;O
most;O;O
common;O;O
and;O;O
worrisome;O;O
adverse;O;O
effect;O;O
of;O;O
warfarin;B-drug;B-DDI-MedLine.d218.s1.e0
therapy;O;O
.;O;O
DDI-MedLine.d218.s2;;
One;O;O
of;O;O
the;O;O
factors;O;O
that;O;O
might;O;O
increase;O;O
bleeding;O;O
risk;O;O
is;O;O
initiation;O;O
of;O;O
interacting;O;O
drugs;O;O
that;O;O
potentiate;O;O
warfarin;B-drug;B-DDI-MedLine.d218.s2.e0
.;O;O
DDI-MedLine.d218.s3;;
We;O;O
sought;O;O
to;O;O
evaluate;O;O
whether;O;O
initiation;O;O
of;O;O
an;O;O
antidepressant;B-group;B-DDI-MedLine.d218.s3.e0
increases;O;O
the;O;O
risk;O;O
of;O;O
hospitalization;O;O
for;O;O
gastrointestinal;O;O
bleeding;O;O
in;O;O
warfarin;B-drug;B-DDI-MedLine.d218.s3.e1
users;O;O
.;O;O
DDI-MedLine.d218.s4;;
Medicaid;O;O
claims;O;O
data;O;O
(;O;O
1999;O;O
-;O;O
2005;O;O
);O;O
were;O;O
used;O;O
to;O;O
perform;O;O
an;O;O
observational;O;O
case;O;O
-;O;O
control;O;O
study;O;O
nested;O;O
within;O;O
person;O;O
-;O;O
time;O;O
exposed;O;O
to;O;O
warfarin;B-drug;B-DDI-MedLine.d218.s4.e0
in;O;O
those;O;O
18;O;O
years;O;O
.;O;O
DDI-MedLine.d218.s5;;
In;O;O
total;O;O
,;O;O
430,455;O;O
warfarin;B-drug;B-DDI-MedLine.d218.s5.e0
users;O;O
contributed;O;O
407,370;O;O
person;O;O
-;O;O
years;O;O
of;O;O
warfarin;B-drug;B-DDI-MedLine.d218.s5.e1
use;O;O
.;O;O
DDI-MedLine.d218.s6;;
The;O;O
incidence;O;O
rate;O;O
of;O;O
hospitalization;O;O
for;O;O
GI;O;O
bleeding;O;O
among;O;O
warfarin;B-drug;B-DDI-MedLine.d218.s6.e0
users;O;O
was;O;O
4.48;O;O
per;O;O
100;O;O
person;O;O
-;O;O
years;O;O
(;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
4.42;O;O
-;O;O
4.55;O;O
);O;O
.;O;O
DDI-MedLine.d218.s7;;
Each;O;O
gastrointestinal;O;O
bleeding;O;O
cases;O;O
was;O;O
matched;O;O
to;O;O
50;O;O
controls;O;O
based;O;O
on;O;O
index;O;O
date;O;O
and;O;O
state;O;O
.;O;O
DDI-MedLine.d218.s8;;
Warfarin;B-drug;B-DDI-MedLine.d218.s8.e0
users;O;O
had;O;O
an;O;O
increased;O;O
odds;O;O
ratio;O;O
of;O;O
gastrointestinal;O;O
bleeding;O;O
upon;O;O
initiation;O;O
of;O;O
citalopram;B-drug;B-DDI-MedLine.d218.s8.e1
(;O;O
OR;O;O
=;O;O
1.73;O;O
[;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
1.25;O;O
-;O;O
2.38;O;O
];O;O
);O;O
,;O;O
fluoxetine;B-drug;B-DDI-MedLine.d218.s8.e2
(;O;O
OR;O;O
=;O;O
1.63;O;O
[;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
1.11;O;O
-;O;O
2.38;O;O
];O;O
);O;O
,;O;O
paroxetine;B-drug;B-DDI-MedLine.d218.s8.e3
(;O;O
OR;O;O
=;O;O
1.64;O;O
[;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
1.27;O;O
-;O;O
2.12;O;O
];O;O
);O;O
,;O;O
amitriptyline;B-drug;B-DDI-MedLine.d218.s8.e4
(;O;O
OR;O;O
=;O;O
1.47;O;O
[;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
1.02;O;O
-;O;O
2.11;O;O
];O;O
);O;O
.;O;O
DDI-MedLine.d218.s9;;
Also;O;O
mirtazapine;B-drug;B-DDI-MedLine.d218.s9.e0
,;O;O
which;O;O
is;O;O
not;O;O
believed;O;O
to;O;O
interact;O;O
with;O;O
warfarin;B-drug;B-DDI-MedLine.d218.s9.e1
,;O;O
increased;O;O
the;O;O
risk;O;O
of;O;O
GI;O;O
bleeding;O;O
(;O;O
OR;O;O
=;O;O
1.75;O;O
[;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
1.30;O;O
-;O;O
2.35;O;O
];O;O
);O;O
.;O;O
DDI-MedLine.d218.s10;;
Warfarin;B-drug;B-DDI-MedLine.d218.s10.e0
users;O;O
who;O;O
initiated;O;O
citalopram;B-drug;B-DDI-MedLine.d218.s10.e1
,;O;O
fluoxetine;B-drug;B-DDI-MedLine.d218.s10.e2
,;O;O
paroxetine;B-drug;B-DDI-MedLine.d218.s10.e3
,;O;O
amitriptyline;B-drug;B-DDI-MedLine.d218.s10.e4
,;O;O
or;O;O
mirtazapine;B-drug;B-DDI-MedLine.d218.s10.e5
had;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
hospitalization;O;O
for;O;O
gastrointestinal;O;O
bleeding;O;O
.;O;O
DDI-MedLine.d218.s11;;
However;O;O
,;O;O
the;O;O
elevated;O;O
risk;O;O
with;O;O
mirtazapine;B-drug;B-DDI-MedLine.d218.s11.e0
suggests;O;O
that;O;O
a;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
may;O;O
not;O;O
have;O;O
been;O;O
responsible;O;O
for;O;O
all;O;O
of;O;O
the;O;O
observed;O;O
increased;O;O
risk;O;O
.;O;O
DDI-MedLine.d189.s0;;
Effects;O;O
of;O;O
CYP;O;O
inhibitors;O;O
on;O;O
precocene;B-drug_n;B-DDI-MedLine.d189.s0.e0
I;I-drug_n;I-DDI-MedLine.d189.s0.e0
metabolism;O;O
and;O;O
toxicity;O;O
in;O;O
rat;O;O
liver;O;O
slices;O;O
.;O;O
DDI-MedLine.d189.s1;;
We;O;O
present;O;O
a;O;O
comprehensive;O;O
in;O;O
vitro;O;O
approach;O;O
to;O;O
assessing;O;O
metabolism;O;O
-;O;O
mediated;O;O
hepatotoxicity;O;O
using;O;O
male;O;O
Sprague;O;O
-;O;O
Dawley;O;O
rat;O;O
liver;O;O
slices;O;O
incubated;O;O
with;O;O
the;O;O
well;O;O
characterized;O;O
hepatotoxicant;O;O
,;O;O
precocene;B-drug_n;B-DDI-MedLine.d189.s1.e0
I;I-drug_n;I-DDI-MedLine.d189.s1.e0
,;O;O
and;O;O
inhibitors;O;O
of;O;O
cytochrome;O;O
P450;O;O
(;O;O
CYP;O;O
);O;O
enzymes;O;O
.;O;O
DDI-MedLine.d189.s2;;
This;O;O
approach;O;O
combines;O;O
liquid;O;O
chromatography;O;O
mass;O;O
spectrometry;O;O
(;O;O
LC;O;O
MS;O;O
);O;O
detection;O;O
methods;O;O
with;O;O
multiple;O;O
toxicity;O;O
endpoints;O;O
to;O;O
enable;O;O
identification;O;O
of;O;O
critical;O;O
metabolic;O;O
pathways;O;O
for;O;O
hepatotoxicity;O;O
.;O;O
DDI-MedLine.d189.s3;;
The;O;O
incubations;O;O
were;O;O
performed;O;O
in;O;O
the;O;O
absence;O;O
and;O;O
presence;O;O
of;O;O
the;O;O
non;O;O
-;O;O
specific;O;O
CYP;O;O
inhibitor;O;O
,;O;O
1;B-drug_n;B-DDI-MedLine.d189.s3.e0
-;I-drug_n;I-DDI-MedLine.d189.s3.e0
aminobenzotriazole;I-drug_n;I-DDI-MedLine.d189.s3.e0
(;O;O
ABT;B-drug_n;B-DDI-MedLine.d189.s3.e1
);O;O
and;O;O
isoform;O;O
-;O;O
specific;O;O
inhibitors;O;O
.;O;O
DDI-MedLine.d189.s4;;
The;O;O
metabolite;O;O
profile;O;O
of;O;O
precocene;B-drug_n;B-DDI-MedLine.d189.s4.e0
I;I-drug_n;I-DDI-MedLine.d189.s4.e0
in;O;O
rat;O;O
liver;O;O
slices;O;O
shares;O;O
some;O;O
features;O;O
of;O;O
the;O;O
in;O;O
vivo;O;O
profile;O;O
,;O;O
but;O;O
also;O;O
had;O;O
a;O;O
major;O;O
difference;O;O
in;O;O
that;O;O
epoxide;O;O
dihydrodiol;O;O
hydrolysis;O;O
products;O;O
were;O;O
not;O;O
observed;O;O
to;O;O
a;O;O
measurable;O;O
extent;O;O
.;O;O
DDI-MedLine.d189.s5;;
As;O;O
examples;O;O
of;O;O
our;O;O
liver;O;O
slice;O;O
metabolite;O;O
identification;O;O
procedure;O;O
,;O;O
a;O;O
minor;O;O
glutathione;O;O
adduct;O;O
and;O;O
previously;O;O
unreported;O;O
7;O;O
-;O;O
O;O;O
-;O;O
desmethyl;O;O
and;O;O
glucuronidated;O;O
metabolites;O;O
of;O;O
precocene;B-drug_n;B-DDI-MedLine.d189.s5.e0
I;I-drug_n;I-DDI-MedLine.d189.s5.e0
are;O;O
reported;O;O
.;O;O
DDI-MedLine.d189.s6;;
Precocene;B-drug_n;B-DDI-MedLine.d189.s6.e0
I;I-drug_n;I-DDI-MedLine.d189.s6.e0
induced;O;O
hepatocellular;O;O
necrosis;O;O
in;O;O
a;O;O
dose;O;O
-;O;O
and;O;O
time;O;O
-;O;O
dependent;O;O
manner;O;O
.;O;O
DDI-MedLine.d189.s7;;
ABT;B-drug_n;B-DDI-MedLine.d189.s7.e0
decreased;O;O
the;O;O
toxicity;O;O
of;O;O
precocene;B-drug_n;B-DDI-MedLine.d189.s7.e1
I;I-drug_n;I-DDI-MedLine.d189.s7.e1
,;O;O
increased;O;O
exposure;O;O
to;O;O
parent;O;O
compound;O;O
,;O;O
and;O;O
decreased;O;O
metabolite;O;O
levels;O;O
in;O;O
a;O;O
dose;O;O
-;O;O
dependent;O;O
manner;O;O
.;O;O
DDI-MedLine.d189.s8;;
Of;O;O
the;O;O
isoform;O;O
-;O;O
specific;O;O
CYP;O;O
inhibitors;O;O
tested;O;O
for;O;O
an;O;O
effect;O;O
on;O;O
the;O;O
precocene;B-drug_n;B-DDI-MedLine.d189.s8.e0
I;I-drug_n;I-DDI-MedLine.d189.s8.e0
metabolite;O;O
profile;O;O
,;O;O
only;O;O
tranylcypromine;B-drug;B-DDI-MedLine.d189.s8.e1
was;O;O
noticeably;O;O
effective;O;O
,;O;O
indicating;O;O
a;O;O
role;O;O
of;O;O
CYPs;O;O
2A6;O;O
,;O;O
2C9;O;O
,;O;O
2Cl9;O;O
,;O;O
and;O;O
2E1;O;O
.;O;O
DDI-MedLine.d189.s9;;
With;O;O
respect;O;O
to;O;O
toxicity;O;O
,;O;O
the;O;O
order;O;O
of;O;O
CYP;O;O
inhibitor;O;O
effectiveness;O;O
was;O;O
ABT;B-drug_n;B-DDI-MedLine.d189.s9.e0
>;O;O
diethyldithiocarbamate;B-drug_n;B-DDI-MedLine.d189.s9.e1
~;O;O
tranylcypromine;B-drug;B-DDI-MedLine.d189.s9.e2
>;O;O
ketoconazole;B-drug;B-DDI-MedLine.d189.s9.e3
.;O;O
DDI-MedLine.d189.s10;;
Furafylline;B-drug_n;B-DDI-MedLine.d189.s10.e0
and;O;O
sulfaphenazole;B-drug_n;B-DDI-MedLine.d189.s10.e1
had;O;O
no;O;O
effect;O;O
,;O;O
while;O;O
quinidine;B-drug;B-DDI-MedLine.d189.s10.e2
appeared;O;O
to;O;O
augment;O;O
precocene;B-drug_n;B-DDI-MedLine.d189.s10.e3
I;I-drug_n;I-DDI-MedLine.d189.s10.e3
toxicity;O;O
.;O;O
DDI-MedLine.d189.s11;;
These;O;O
results;O;O
suggest;O;O
that;O;O
rat;O;O
liver;O;O
slices;O;O
do;O;O
not;O;O
reproduce;O;O
the;O;O
reported;O;O
in;O;O
vivo;O;O
biotransformation;O;O
of;O;O
precocene;B-drug_n;B-DDI-MedLine.d189.s11.e0
I;I-drug_n;I-DDI-MedLine.d189.s11.e0
and;O;O
therefore;O;O
may;O;O
not;O;O
be;O;O
an;O;O
appropriate;O;O
model;O;O
for;O;O
precocene;B-drug_n;B-DDI-MedLine.d189.s11.e1
I;I-drug_n;I-DDI-MedLine.d189.s11.e1
metabolism;O;O
.;O;O
DDI-MedLine.d189.s12;;
However;O;O
,;O;O
these;O;O
results;O;O
provide;O;O
an;O;O
example;O;O
of;O;O
how;O;O
small;O;O
molecule;O;O
manipulation;O;O
of;O;O
CYP;O;O
activity;O;O
in;O;O
an;O;O
in;O;O
vitro;O;O
model;O;O
can;O;O
be;O;O
used;O;O
to;O;O
confirm;O;O
metabolism;O;O
-;O;O
mediated;O;O
toxicity;O;O
.;O;O
DDI-MedLine.d190.s0;;
Glycosidic;O;O
enzymes;O;O
enhance;O;O
retinal;O;O
transduction;O;O
following;O;O
intravitreal;O;O
delivery;O;O
of;O;O
AAV2;B-drug_n;B-DDI-MedLine.d190.s0.e0
.;O;O
DDI-MedLine.d190.s1;;
To;O;O
determine;O;O
whether;O;O
the;O;O
co;O;O
-;O;O
injection;O;O
of;O;O
extracellular;O;O
matrix;O;O
degrading;O;O
enzymes;O;O
improves;O;O
retinal;O;O
transduction;O;O
following;O;O
intravitreal;O;O
delivery;O;O
of;O;O
adeno;O;O
-;O;O
associated;O;O
virus;O;O
-;O;O
2;O;O
(;O;O
AAV2;B-drug_n;B-DDI-MedLine.d190.s1.e1
);O;O
.;O;O
DDI-MedLine.d190.s2;;
AAV2;B-drug_n;B-DDI-MedLine.d190.s2.e0
containing;O;O
cDNA;O;O
encoding;O;O
enhanced;O;O
green;O;O
fluorescent;O;O
protein;O;O
(;O;O
GFP;O;O
);O;O
,;O;O
under;O;O
the;O;O
control;O;O
of;O;O
a;O;O
chicken;O;O
-actin;O;O
promoter;O;O
,;O;O
was;O;O
delivered;O;O
by;O;O
intravitreal;O;O
injection;O;O
to;O;O
adult;O;O
mice;O;O
in;O;O
conjunction;O;O
with;O;O
enzymes;O;O
including;O;O
collagenase;B-drug_n;B-DDI-MedLine.d190.s2.e1
,;O;O
hyaluronan;B-drug_n;B-DDI-MedLine.d190.s2.e2
lyase;I-drug_n;I-DDI-MedLine.d190.s2.e2
,;O;O
heparinase;B-drug_n;B-DDI-MedLine.d190.s2.e3
III;I-drug_n;I-DDI-MedLine.d190.s2.e3
,;O;O
or;O;O
chondroitin;B-drug_n;B-DDI-MedLine.d190.s2.e4
ABC;I-drug_n;I-DDI-MedLine.d190.s2.e4
lyase;I-drug_n;I-DDI-MedLine.d190.s2.e4
.;O;O
DDI-MedLine.d190.s3;;
Two;O;O
weeks;O;O
later;O;O
,;O;O
retinal;O;O
flatmounts;O;O
were;O;O
examined;O;O
for;O;O
GFP;O;O
expression;O;O
using;O;O
confocal;O;O
microscopy;O;O
.;O;O
DDI-MedLine.d190.s4;;
Without;O;O
the;O;O
addition;O;O
of;O;O
enzymes;O;O
,;O;O
transduction;O;O
was;O;O
limited;O;O
to;O;O
occasional;O;O
cells;O;O
in;O;O
the;O;O
retinal;O;O
ganglion;O;O
cell;O;O
layer;O;O
.;O;O
DDI-MedLine.d190.s5;;
The;O;O
addition;O;O
of;O;O
heparinase;B-drug_n;B-DDI-MedLine.d190.s5.e0
III;I-drug_n;I-DDI-MedLine.d190.s5.e0
or;O;O
chondroitin;B-drug_n;B-DDI-MedLine.d190.s5.e1
ABC;I-drug_n;I-DDI-MedLine.d190.s5.e1
lyase;I-drug_n;I-DDI-MedLine.d190.s5.e1
greatly;O;O
enhanced;O;O
transduction;O;O
of;O;O
the;O;O
retinal;O;O
ganglion;O;O
cell;O;O
layer;O;O
and;O;O
increased;O;O
the;O;O
depth;O;O
of;O;O
transduction;O;O
into;O;O
the;O;O
outer;O;O
retina;O;O
.;O;O
DDI-MedLine.d190.s6;;
Hyaluronan;B-drug_n;B-DDI-MedLine.d190.s6.e0
lyase;I-drug_n;I-DDI-MedLine.d190.s6.e0
had;O;O
a;O;O
limited;O;O
effect;O;O
and;O;O
collagenase;B-drug_n;B-DDI-MedLine.d190.s6.e1
was;O;O
ineffective;O;O
.;O;O
DDI-MedLine.d190.s7;;
Electroretinograms;O;O
survived;O;O
with;O;O
higher;O;O
concentrations;O;O
of;O;O
heparinase;B-drug_n;B-DDI-MedLine.d190.s7.e0
III;I-drug_n;I-DDI-MedLine.d190.s7.e0
and;O;O
chondroitin;B-drug_n;B-DDI-MedLine.d190.s7.e1
ABC;I-drug_n;I-DDI-MedLine.d190.s7.e1
lyase;I-drug_n;I-DDI-MedLine.d190.s7.e1
than;O;O
were;O;O
required;O;O
for;O;O
optimal;O;O
retinal;O;O
transduction;O;O
.;O;O
DDI-MedLine.d190.s8;;
AAV2;B-drug_n;B-DDI-MedLine.d190.s8.e0
-;O;O
mediated;O;O
retinal;O;O
transduction;O;O
is;O;O
improved;O;O
by;O;O
co;O;O
-;O;O
injection;O;O
of;O;O
heparinase;B-drug_n;B-DDI-MedLine.d190.s8.e1
III;I-drug_n;I-DDI-MedLine.d190.s8.e1
or;O;O
chondroitin;B-drug_n;B-DDI-MedLine.d190.s8.e2
ABC;I-drug_n;I-DDI-MedLine.d190.s8.e2
lyase;I-drug_n;I-DDI-MedLine.d190.s8.e2
.;O;O
DDI-MedLine.d190.s9;;
Improved;O;O
transduction;O;O
efficiency;O;O
may;O;O
allow;O;O
intravitreal;O;O
injection;O;O
to;O;O
become;O;O
the;O;O
preferred;O;O
route;O;O
for;O;O
delivering;O;O
gene;O;O
therapy;O;O
to;O;O
both;O;O
the;O;O
inner;O;O
and;O;O
outer;O;O
retina;O;O
.;O;O
DDI-MedLine.d199.s0;;
Prevention;O;O
of;O;O
emergence;O;O
agitation;O;O
in;O;O
seven;O;O
children;O;O
receiving;O;O
low;O;O
-;O;O
dose;O;O
ketamine;B-drug;B-DDI-MedLine.d199.s0.e0
and;O;O
propofol;B-drug;B-DDI-MedLine.d199.s0.e1
total;O;O
intravenous;O;O
anesthesia;O;O
.;O;O
DDI-MedLine.d199.s1;;
Emergence;O;O
agitation;O;O
(;O;O
EA;O;O
);O;O
can;O;O
be;O;O
a;O;O
distressing;O;O
side;O;O
effect;O;O
of;O;O
pediatric;O;O
anesthesia;O;O
.;O;O
DDI-MedLine.d199.s2;;
We;O;O
retrospectively;O;O
reviewed;O;O
the;O;O
records;O;O
of;O;O
7;O;O
pediatric;O;O
oncology;O;O
patients;O;O
who;O;O
received;O;O
low;O;O
-;O;O
dose;O;O
ketamine;B-drug;B-DDI-MedLine.d199.s2.e0
in;O;O
conjunction;O;O
with;O;O
propofol;B-drug;B-DDI-MedLine.d199.s2.e1
for;O;O
total;O;O
intravenous;O;O
anesthesia;O;O
(;O;O
TIVA;O;O
);O;O
repeatedly;O;O
for;O;O
radiation;O;O
therapy;O;O
.;O;O
DDI-MedLine.d199.s3;;
EA;O;O
signs;O;O
were;O;O
observed;O;O
in;O;O
all;O;O
7;O;O
patients;O;O
in;O;O
association;O;O
with;O;O
propofol;B-drug;B-DDI-MedLine.d199.s3.e0
TIVA;O;O
but;O;O
did;O;O
not;O;O
recur;O;O
in;O;O
any;O;O
of;O;O
123;O;O
subsequent;O;O
anesthetics;O;O
sessions;O;O
during;O;O
which;O;O
low;O;O
-;O;O
dose;O;O
ketamine;B-drug;B-DDI-MedLine.d199.s3.e1
was;O;O
added;O;O
to;O;O
propofol;B-drug;B-DDI-MedLine.d199.s3.e2
.;O;O
DDI-MedLine.d199.s4;;
Based;O;O
on;O;O
this;O;O
experience;O;O
,;O;O
we;O;O
suggest;O;O
that;O;O
low;O;O
-;O;O
dose;O;O
ketamine;B-drug;B-DDI-MedLine.d199.s4.e0
added;O;O
to;O;O
propofol;B-drug;B-DDI-MedLine.d199.s4.e1
may;O;O
be;O;O
associated;O;O
with;O;O
prevention;O;O
of;O;O
EA;O;O
in;O;O
children;O;O
with;O;O
a;O;O
history;O;O
of;O;O
EA;O;O
with;O;O
propofol;B-drug;B-DDI-MedLine.d199.s4.e2
TIVA;O;O
.;O;O
DDI-MedLine.d209.s0;;
Tamoxifen;B-drug;B-DDI-MedLine.d209.s0.e0
and;O;O
CYP;O;O
2D6;O;O
inhibitors;O;O
:;O;O
caution;O;O
.;O;O
DDI-MedLine.d209.s1;;
Tamoxifen;B-drug;B-DDI-MedLine.d209.s1.e0
,;O;O
an;O;O
estrogen;B-group;B-DDI-MedLine.d209.s1.e1
antagonist;I-group;I-DDI-MedLine.d209.s1.e1
,;O;O
is;O;O
the;O;O
standard;O;O
hormone;O;O
treatment;O;O
for;O;O
breast;O;O
cancer;O;O
.;O;O
DDI-MedLine.d209.s2;;
It;O;O
is;O;O
extensively;O;O
transformed;O;O
into;O;O
its;O;O
active;O;O
metabolites;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
enzyme;O;O
system;O;O
,;O;O
especially;O;O
into;O;O
endoxifen;B-drug_n;B-DDI-MedLine.d209.s2.e0
by;O;O
isoenzyme;O;O
CYP;O;O
2D6;O;O
.;O;O
DDI-MedLine.d209.s3;;
Co;O;O
-;O;O
administration;O;O
of;O;O
tamoxifen;B-drug;B-DDI-MedLine.d209.s3.e0
with;O;O
isoenzyme;O;O
CYP;O;O
2D6;O;O
inhibitors;O;O
reduces;O;O
this;O;O
metabolism;O;O
.;O;O
DDI-MedLine.d209.s4;;
Selective;B-group;B-DDI-MedLine.d209.s4.e0
serotonin;I-group;I-DDI-MedLine.d209.s4.e0
reuptake;I-group;I-DDI-MedLine.d209.s4.e0
inhibitor;I-group;I-DDI-MedLine.d209.s4.e0
(;I-group;I-DDI-MedLine.d209.s4.e0
SSRI;I-group;I-DDI-MedLine.d209.s4.e0
);I-group;I-DDI-MedLine.d209.s4.e0
antidepressants;I-group;I-DDI-MedLine.d209.s4.e0
inhibit;O;O
isoenzyme;O;O
CYP;O;O
2D6;O;O
.;O;O
DDI-MedLine.d209.s5;;
Paroxetine;B-drug;B-DDI-MedLine.d209.s5.e0
and;O;O
fluoxetine;B-drug;B-DDI-MedLine.d209.s5.e1
reduce;O;O
the;O;O
plasma;O;O
concentration;O;O
of;O;O
endoxifen;B-drug_n;B-DDI-MedLine.d209.s5.e2
by;O;O
about;O;O
50;O;O
%;O;O
.;O;O
DDI-MedLine.d209.s6;;
Two;O;O
epidemiological;O;O
studies;O;O
involving;O;O
about;O;O
3700;O;O
women;O;O
have;O;O
shown;O;O
a;O;O
link;O;O
between;O;O
the;O;O
use;O;O
of;O;O
SSRI;B-group;B-DDI-MedLine.d209.s6.e0
antidepressants;I-group;I-DDI-MedLine.d209.s6.e0
and;O;O
an;O;O
increased;O;O
frequency;O;O
of;O;O
breast;O;O
cancer;O;O
recurrence;O;O
.;O;O
DDI-MedLine.d209.s7;;
Other;O;O
studies;O;O
,;O;O
with;O;O
a;O;O
lower;O;O
level;O;O
of;O;O
evidence;O;O
,;O;O
were;O;O
less;O;O
convincing;O;O
.;O;O
DDI-MedLine.d209.s8;;
Studies;O;O
of;O;O
other;O;O
isoenzyme;O;O
CYP;O;O
2D6;O;O
inhibitors;O;O
showed;O;O
no;O;O
increase;O;O
in;O;O
the;O;O
risk;O;O
of;O;O
breast;O;O
cancer;O;O
recurrence;O;O
,;O;O
but;O;O
they;O;O
lacked;O;O
statistical;O;O
power;O;O
.;O;O
DDI-MedLine.d209.s9;;
It;O;O
is;O;O
better;O;O
to;O;O
avoid;O;O
prescribing;O;O
isoenzyme;O;O
CYP;O;O
2D6;O;O
inhibitors;O;O
to;O;O
women;O;O
treated;O;O
with;O;O
tamoxifen;B-drug;B-DDI-MedLine.d209.s9.e0
for;O;O
breast;O;O
cancer;O;O
,;O;O
especially;O;O
SSRI;B-group;B-DDI-MedLine.d209.s9.e1
antidepressants;I-group;I-DDI-MedLine.d209.s9.e1
such;O;O
as;O;O
paroxetine;B-drug;B-DDI-MedLine.d209.s9.e2
and;O;O
fluoxetine;B-drug;B-DDI-MedLine.d209.s9.e3
.;O;O
DDI-MedLine.d209.s10;;
Depression;O;O
does;O;O
not;O;O
always;O;O
require;O;O
antidepressant;B-group;B-DDI-MedLine.d209.s10.e0
drug;I-group;I-DDI-MedLine.d209.s10.e0
therapy;O;O
,;O;O
and;O;O
antidepressants;B-group;B-DDI-MedLine.d209.s10.e1
have;O;O
no;O;O
proven;O;O
preventive;O;O
impact;O;O
on;O;O
hot;O;O
flushes;O;O
linked;O;O
to;O;O
the;O;O
menopause;O;O
.;O;O
DDI-MedLine.d209.s11;;
If;O;O
in;O;O
certain;O;O
cases;O;O
,;O;O
an;O;O
antidepressant;B-group;B-DDI-MedLine.d209.s11.e0
is;O;O
considered;O;O
necessary;O;O
,;O;O
it;O;O
may;O;O
be;O;O
advisable;O;O
to;O;O
replace;O;O
tamoxifen;B-drug;B-DDI-MedLine.d209.s11.e1
with;O;O
anastrozole;B-drug;B-DDI-MedLine.d209.s11.e2
.;O;O
DDI-MedLine.d184.s0;;
Amphetamine;B-drug;B-DDI-MedLine.d184.s0.e0
locomotor;O;O
sensitization;O;O
and;O;O
conditioned;O;O
place;O;O
preference;O;O
in;O;O
adolescent;O;O
male;O;O
and;O;O
female;O;O
rats;O;O
neonatally;O;O
treated;O;O
with;O;O
quinpirole;B-drug_n;B-DDI-MedLine.d184.s0.e1
.;O;O
DDI-MedLine.d184.s1;;
Neonatal;O;O
quinpirole;B-drug_n;B-DDI-MedLine.d184.s1.e0
treatment;O;O
has;O;O
been;O;O
shown;O;O
to;O;O
produce;O;O
an;O;O
increase;O;O
in;O;O
dopamine;O;O
D2;O;O
-;O;O
like;O;O
receptor;O;O
sensitivity;O;O
that;O;O
persists;O;O
throughout;O;O
the;O;O
subject;O;O
's;O;O
lifetime;O;O
.;O;O
DDI-MedLine.d184.s2;;
The;O;O
objective;O;O
was;O;O
to;O;O
analyze;O;O
the;O;O
effects;O;O
of;O;O
neonatal;O;O
quinpirole;B-drug_n;B-DDI-MedLine.d184.s2.e0
treatment;O;O
on;O;O
effects;O;O
of;O;O
amphetamine;B-drug;B-DDI-MedLine.d184.s2.e1
in;O;O
adolescent;O;O
rats;O;O
using;O;O
locomotor;O;O
sensitization;O;O
and;O;O
conditioned;O;O
place;O;O
preference;O;O
procedures;O;O
.;O;O
DDI-MedLine.d184.s3;;
Sprague;O;O
-;O;O
Dawley;O;O
rats;O;O
were;O;O
treated;O;O
with;O;O
quinpirole;B-drug_n;B-DDI-MedLine.d184.s3.e0
(;O;O
1;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
or;O;O
saline;O;O
from;O;O
postnatal;O;O
days;O;O
(;O;O
P)1;O;O
to;O;O
P11;O;O
and;O;O
raised;O;O
to;O;O
adolescence;O;O
.;O;O
DDI-MedLine.d184.s4;;
For;O;O
locomotor;O;O
sensitization;O;O
,;O;O
subjects;O;O
were;O;O
given;O;O
amphetamine;B-drug;B-DDI-MedLine.d184.s4.e0
(;O;O
1;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
or;O;O
saline;O;O
every;O;O
second;O;O
day;O;O
from;O;O
P35;O;O
to;O;O
P47;O;O
and;O;O
were;O;O
placed;O;O
into;O;O
a;O;O
locomotor;O;O
arena;O;O
.;O;O
DDI-MedLine.d184.s5;;
In;O;O
female;O;O
rats;O;O
,;O;O
neonatal;O;O
quinpirole;B-drug_n;B-DDI-MedLine.d184.s5.e0
treatment;O;O
enhanced;O;O
amphetamine;B-drug;B-DDI-MedLine.d184.s5.e1
locomotor;O;O
sensitization;O;O
compared;O;O
with;O;O
quinpirole;B-drug_n;B-DDI-MedLine.d184.s5.e2
-;O;O
free;O;O
controls;O;O
sensitized;O;O
to;O;O
amphetamine;B-drug;B-DDI-MedLine.d184.s5.e3
.;O;O
DDI-MedLine.d184.s6;;
Male;O;O
rats;O;O
demonstrated;O;O
sensitization;O;O
to;O;O
amphetamine;B-drug;B-DDI-MedLine.d184.s6.e0
,;O;O
although;O;O
this;O;O
was;O;O
muted;O;O
compared;O;O
with;O;O
female;O;O
rats;O;O
,;O;O
and;O;O
were;O;O
unaffected;O;O
by;O;O
neonatal;O;O
quinpirole;B-drug_n;B-DDI-MedLine.d184.s6.e1
.;O;O
DDI-MedLine.d184.s7;;
For;O;O
conditioned;O;O
place;O;O
preference;O;O
,;O;O
subjects;O;O
were;O;O
conditioned;O;O
for;O;O
8;O;O
consecutive;O;O
days;O;O
(;O;O
P32;O;O
-;O;O
39;O;O
);O;O
with;O;O
amphetamine;B-drug;B-DDI-MedLine.d184.s7.e0
(;O;O
1;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
or;O;O
saline;O;O
and;O;O
a;O;O
drug;O;O
-;O;O
free;O;O
preference;O;O
test;O;O
was;O;O
conducted;O;O
at;O;O
P40;O;O
.;O;O
DDI-MedLine.d184.s8;;
Rats;O;O
treated;O;O
with;O;O
neonatal;O;O
quinpirole;B-drug_n;B-DDI-MedLine.d184.s8.e0
enhanced;O;O
time;O;O
spent;O;O
in;O;O
the;O;O
amphetamine;B-drug;B-DDI-MedLine.d184.s8.e1
-;O;O
paired;O;O
context;O;O
compared;O;O
with;O;O
quinpirole;B-drug_n;B-DDI-MedLine.d184.s8.e2
-;O;O
free;O;O
controls;O;O
conditioned;O;O
with;O;O
amphetamine;B-drug;B-DDI-MedLine.d184.s8.e3
,;O;O
but;O;O
only;O;O
female;O;O
controls;O;O
conditioned;O;O
with;O;O
amphetamine;B-drug;B-DDI-MedLine.d184.s8.e4
spent;O;O
more;O;O
time;O;O
in;O;O
the;O;O
drug;O;O
-;O;O
paired;O;O
context;O;O
compared;O;O
with;O;O
saline;O;O
-;O;O
treated;O;O
controls;O;O
.;O;O
DDI-MedLine.d184.s9;;
Increased;O;O
D;O;O
-like;O;O
receptor;O;O
sensitivity;O;O
appears;O;O
to;O;O
have;O;O
enhanced;O;O
the;O;O
behavioral;O;O
effects;O;O
of;O;O
amphetamine;B-drug;B-DDI-MedLine.d184.s9.e0
,;O;O
but;O;O
these;O;O
effects;O;O
were;O;O
more;O;O
prevalent;O;O
in;O;O
adolescent;O;O
female;O;O
rats;O;O
compared;O;O
with;O;O
male;O;O
rats;O;O
.;O;O
DDI-MedLine.d213.s0;;
In;O;O
vivo;O;O
CYP3A;O;O
activity;O;O
is;O;O
significantly;O;O
lower;O;O
in;O;O
cyclosporine;B-drug;B-DDI-MedLine.d213.s0.e0
-;O;O
treated;O;O
as;O;O
compared;O;O
with;O;O
tacrolimus;B-drug;B-DDI-MedLine.d213.s0.e1
-;O;O
treated;O;O
renal;O;O
allograft;O;O
recipients;O;O
.;O;O
DDI-MedLine.d213.s1;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
identified;O;O
cyclosporine;B-drug;B-DDI-MedLine.d213.s1.e0
and;O;O
tacrolimus;B-drug;B-DDI-MedLine.d213.s1.e1
as;O;O
CYP3A;O;O
inhibitors;O;O
.;O;O
DDI-MedLine.d213.s2;;
In;O;O
the;O;O
current;O;O
study;O;O
in;O;O
renal;O;O
allograft;O;O
recipients;O;O
,;O;O
we;O;O
used;O;O
intravenously;O;O
and;O;O
orally;O;O
administered;O;O
midazolam;B-drug;B-DDI-MedLine.d213.s2.e0
as;O;O
a;O;O
drug;O;O
probe;O;O
to;O;O
assess;O;O
whether;O;O
the;O;O
study;O;O
drugs;O;O
at;O;O
doses;O;O
that;O;O
are;O;O
generally;O;O
used;O;O
in;O;O
clinical;O;O
practice;O;O
have;O;O
differential;O;O
effects;O;O
on;O;O
in;O;O
vivo;O;O
hepatic;O;O
and;O;O
first;O;O
-;O;O
pass;O;O
CYP3A;O;O
activities;O;O
.;O;O
DDI-MedLine.d213.s3;;
Systemic;O;O
and;O;O
apparent;O;O
oral;O;O
midazolam;B-drug;B-DDI-MedLine.d213.s3.e0
clearance;O;O
were;O;O
24;O;O
%;O;O
(;O;O
269;O;O
73;O;O
vs.;O;O
354;O;O
102;O;O
ml;O;O
/;O;O
min;O;O
,;O;O
P;O;O
=;O;O
0.022;O;O
);O;O
and;O;O
31;O;O
%;O;O
(;O;O
479;O;O
190;O;O
vs.;O;O
688;O;O
265;O;O
ml;O;O
/;O;O
min;O;O
,;O;O
P;O;O
=;O;O
0.013;O;O
);O;O
,;O;O
respectively;O;O
,;O;O
lower;O;O
in;O;O
cyclosporine;B-drug;B-DDI-MedLine.d213.s3.e1
-;O;O
treated;O;O
patients;O;O
(;O;O
n;O;O
=;O;O
20;O;O
);O;O
than;O;O
in;O;O
matched;O;O
tacrolimus;B-drug;B-DDI-MedLine.d213.s3.e2
-;O;O
treated;O;O
patients;O;O
(;O;O
n;O;O
=;O;O
20;O;O
);O;O
.;O;O
DDI-MedLine.d213.s4;;
The;O;O
latter;O;O
displayed;O;O
midazolam;B-drug;B-DDI-MedLine.d213.s4.e0
clearances;O;O
similar;O;O
to;O;O
those;O;O
in;O;O
two;O;O
larger;O;O
cohorts;O;O
of;O;O
nonmatched;O;O
tacrolimus;B-drug;B-DDI-MedLine.d213.s4.e1
-;O;O
treated;O;O
patients;O;O
(;O;O
n;O;O
=;O;O
58;O;O
and;O;O
n;O;O
=;O;O
80;O;O
);O;O
and;O;O
to;O;O
those;O;O
receiving;O;O
a;O;O
calcineurin;B-group;B-DDI-MedLine.d213.s4.e2
inhibitor;I-group;I-DDI-MedLine.d213.s4.e2
-;O;O
free;O;O
regimen;O;O
(;O;O
n;O;O
=;O;O
6;O;O
);O;O
.;O;O
DDI-MedLine.d213.s5;;
This;O;O
implies;O;O
that;O;O
in;O;O
vivo;O;O
hepatic;O;O
and;O;O
first;O;O
-;O;O
pass;O;O
CYP3A;O;O
activities;O;O
are;O;O
significantly;O;O
lower;O;O
in;O;O
patients;O;O
receiving;O;O
cyclosporine;B-drug;B-DDI-MedLine.d213.s5.e0
than;O;O
in;O;O
those;O;O
receiving;O;O
tacrolimus;B-drug;B-DDI-MedLine.d213.s5.e1
,;O;O
indicating;O;O
that;O;O
,;O;O
at;O;O
the;O;O
doses;O;O
generally;O;O
used;O;O
in;O;O
clinical;O;O
practice;O;O
,;O;O
cyclosporine;B-drug;B-DDI-MedLine.d213.s5.e2
is;O;O
the;O;O
stronger;O;O
of;O;O
the;O;O
two;O;O
with;O;O
respect;O;O
to;O;O
CYP3A;O;O
inhibition;O;O
.;O;O
DDI-MedLine.d213.s6;;
This;O;O
observation;O;O
has;O;O
important;O;O
implications;O;O
in;O;O
the;O;O
context;O;O
of;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
in;O;O
transplant;O;O
recipients;O;O
.;O;O
DDI-MedLine.d166.s0;;
Improved;O;O
parathyroid;O;O
hormone;O;O
control;O;O
by;O;O
cinacalcet;B-drug;B-DDI-MedLine.d166.s0.e0
is;O;O
associated;O;O
with;O;O
reduction;O;O
in;O;O
darbepoetin;B-drug;B-DDI-MedLine.d166.s0.e1
requirement;O;O
in;O;O
patients;O;O
with;O;O
end;O;O
-;O;O
stage;O;O
renal;O;O
disease;O;O
.;O;O
DDI-MedLine.d166.s1;;
Uncontrolled;O;O
hy;O;O
-;O;O
per;O;O
-;O;O
parathyroidism;O;O
causes;O;O
bone;O;O
marrow;O;O
fibrosis;O;O
,;O;O
leading;O;O
to;O;O
erythropoietin;B-drug;B-DDI-MedLine.d166.s1.e0
(;O;O
EPO;B-drug;B-DDI-MedLine.d166.s1.e1
);O;O
resistance;O;O
.;O;O
DDI-MedLine.d166.s2;;
Medical;O;O
treatment;O;O
with;O;O
cinacalcet;B-drug;B-DDI-MedLine.d166.s2.e0
is;O;O
effective;O;O
in;O;O
reducing;O;O
plasma;O;O
parathyroid;O;O
hormone;O;O
(;O;O
PTH;O;O
);O;O
levels;O;O
,;O;O
but;O;O
its;O;O
effect;O;O
on;O;O
darbepoetin;B-drug;B-DDI-MedLine.d166.s2.e1
dosing;O;O
is;O;O
unknown;O;O
.;O;O
DDI-MedLine.d166.s3;;
METHODS;O;O
AND;O;O
AIMS;O;O
:;O;O
We;O;O
conducted;O;O
a;O;O
retrospective;O;O
cohort;O;O
study;O;O
of;O;O
40;O;O
end;O;O
-;O;O
stage;O;O
renal;O;O
disease;O;O
(;O;O
ESRD;O;O
);O;O
patients;O;O
(;O;O
age;O;O
:;O;O
55;O;O
14;O;O
;;O;O
mean;O;O
SD;O;O
;;O;O
21;O;O
:;O;O
male;O;O
);O;O
who;O;O
had;O;O
at;O;O
least;O;O
12;O;O
months;O;O
of;O;O
cinacalcet;B-drug;B-DDI-MedLine.d166.s3.e0
therapy;O;O
.;O;O
DDI-MedLine.d166.s4;;
The;O;O
distribution;O;O
of;O;O
renal;O;O
replacement;O;O
therapies;O;O
were;O;O
:;O;O
14;O;O
peritoneal;O;O
dialysis;O;O
,;O;O
18;O;O
conventional;O;O
hemodialysis;O;O
and;O;O
8;O;O
nocturnal;O;O
hemodialysis;O;O
.;O;O
DDI-MedLine.d166.s5;;
Standard;O;O
dialysis;O;O
related;O;O
biochemical;O;O
indices;O;O
and;O;O
medications;O;O
used;O;O
were;O;O
recorded;O;O
.;O;O
DDI-MedLine.d166.s6;;
The;O;O
primary;O;O
objective;O;O
of;O;O
the;O;O
study;O;O
was;O;O
to;O;O
ascertain;O;O
the;O;O
difference;O;O
in;O;O
darbepoetin;B-drug;B-DDI-MedLine.d166.s6.e0
responsiveness;O;O
before;O;O
and;O;O
after;O;O
12;O;O
months;O;O
of;O;O
cinacalcet;B-drug;B-DDI-MedLine.d166.s6.e1
therapy;O;O
.;O;O
DDI-MedLine.d166.s7;;
Our;O;O
secondary;O;O
objective;O;O
was;O;O
to;O;O
determine;O;O
if;O;O
there;O;O
was;O;O
a;O;O
relationship;O;O
between;O;O
the;O;O
changes;O;O
in;O;O
PTH;O;O
and;O;O
darbepoetin;B-drug;B-DDI-MedLine.d166.s7.e0
requirement;O;O
.;O;O
DDI-MedLine.d166.s8;;
Overall;O;O
,;O;O
PTH;O;O
levels;O;O
decreased;O;O
from;O;O
197.5;O;O
(;O;O
151.8;O;O
;;O;O
249.2;O;O
);O;O
to;O;O
66.1;O;O
(;O;O
41.2;O;O
;;O;O
136.5;O;O
);O;O
(;O;O
median;O;O
(;O;O
25th;O;O
;;O;O
75th;O;O
percentile;O;O
);O;O
);O;O
pmol;O;O
/;O;O
l;O;O
;;O;O
DDI-MedLine.d166.s9;;
p;O;O
&;O;O
lt;O;O
;;O;O
DDI-MedLine.d166.s10;;
0.001;O;O
.;O;O
DDI-MedLine.d166.s11;;
Cinacalcet;B-drug;B-DDI-MedLine.d166.s11.e0
dose;O;O
increased;O;O
from;O;O
30.0;O;O
6;O;O
to;O;O
63;O;O
25;O;O
mg;O;O
/;O;O
day;O;O
,;O;O
p;O;O
<;O;O
DDI-MedLine.d166.s12;;
0.05;O;O
.;O;O
DDI-MedLine.d166.s13;;
Hemoglobin;O;O
remained;O;O
unchanged;O;O
(;O;O
116;O;O
13;O;O
to;O;O
116;O;O
13;O;O
g;O;O
/;O;O
l;O;O
);O;O
,;O;O
while;O;O
darbepoetin;B-drug;B-DDI-MedLine.d166.s13.e0
requirement;O;O
decreased;O;O
from;O;O
40;O;O
(;O;O
20;O;O
;;O;O
60;O;O
);O;O
to;O;O
24;O;O
(;O;O
19;O;O
;;O;O
59;O;O
);O;O
g;O;O
/;O;O
week;O;O
,;O;O
p;O;O
=;O;O
0.02;O;O
.;O;O
DDI-MedLine.d166.s14;;
The;O;O
remainder;O;O
of;O;O
the;O;O
dialysis;O;O
-;O;O
related;O;O
biochemistry;O;O
(;O;O
electrolytes;O;O
,;O;O
calcium;O;O
,;O;O
phosphate;O;O
,;O;O
iron;O;O
status;O;O
);O;O
and;O;O
vitamin;O;O
D;O;O
use;O;O
remained;O;O
unchanged;O;O
.;O;O
DDI-MedLine.d166.s15;;
A;O;O
reduction;O;O
in;O;O
PTH;O;O
level;O;O
of;O;O
greater;O;O
than;O;O
30;O;O
%;O;O
was;O;O
experienced;O;O
by;O;O
82.5;O;O
%;O;O
(;O;O
33;O;O
/;O;O
40;O;O
);O;O
of;O;O
our;O;O
cohort;O;O
.;O;O
DDI-MedLine.d166.s16;;
Among;O;O
the;O;O
responders;O;O
,;O;O
the;O;O
fall;O;O
in;O;O
PTH;O;O
and;O;O
reduction;O;O
darbepoetin;B-drug;B-DDI-MedLine.d166.s16.e0
requirement;O;O
were;O;O
related;O;O
(;O;O
R;O;O
=;O;O
-0.48;O;O
,;O;O
p;O;O
=;O;O
0.004;O;O
);O;O
.;O;O
DDI-MedLine.d166.s17;;
Reduction;O;O
of;O;O
PTH;O;O
by;O;O
cinacalcet;B-drug;B-DDI-MedLine.d166.s17.e0
is;O;O
associated;O;O
with;O;O
a;O;O
decrease;O;O
in;O;O
darbepoetin;B-drug;B-DDI-MedLine.d166.s17.e1
requirement;O;O
.;O;O
DDI-MedLine.d166.s18;;
The;O;O
interface;O;O
between;O;O
bone;O;O
and;O;O
bone;O;O
marrow;O;O
in;O;O
uremia;O;O
represents;O;O
a;O;O
critical;O;O
step;O;O
in;O;O
red;O;O
blood;O;O
cell;O;O
production;O;O
which;O;O
merits;O;O
further;O;O
investigation;O;O
.;O;O
DDI-MedLine.d217.s0;;
Interaction;O;O
of;O;O
celecoxib;B-drug;B-DDI-MedLine.d217.s0.e0
with;O;O
different;O;O
anti;B-group;B-DDI-MedLine.d217.s0.e1
-;I-group;I-DDI-MedLine.d217.s0.e1
cancer;I-group;I-DDI-MedLine.d217.s0.e1
drugs;I-group;I-DDI-MedLine.d217.s0.e1
is;O;O
antagonistic;O;O
in;O;O
breast;O;O
but;O;O
not;O;O
in;O;O
other;O;O
cancer;O;O
cells;O;O
.;O;O
DDI-MedLine.d217.s1;;
Celecoxib;B-drug;B-DDI-MedLine.d217.s1.e0
,;O;O
an;O;O
inhibitor;O;O
of;O;O
cyclooxygenase;O;O
-;O;O
2;O;O
,;O;O
is;O;O
being;O;O
investigated;O;O
for;O;O
enhancement;O;O
of;O;O
chemotherapy;O;O
efficacy;O;O
in;O;O
cancer;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-MedLine.d217.s2;;
This;O;O
study;O;O
investigates;O;O
the;O;O
ability;O;O
of;O;O
cyclooxygenase;B-group;B-DDI-MedLine.d217.s2.e0
-;I-group;I-DDI-MedLine.d217.s2.e0
2;I-group;I-DDI-MedLine.d217.s2.e0
inhibitors;I-group;I-DDI-MedLine.d217.s2.e0
to;O;O
sensitize;O;O
cells;O;O
from;O;O
different;O;O
origins;O;O
to;O;O
several;O;O
chemotherapeutic;B-group;B-DDI-MedLine.d217.s2.e1
agents;I-group;I-DDI-MedLine.d217.s2.e1
.;O;O
DDI-MedLine.d217.s3;;
The;O;O
effect;O;O
of;O;O
the;O;O
drug;O;O
's;O;O
mechanism;O;O
of;O;O
action;O;O
and;O;O
sequence;O;O
of;O;O
administration;O;O
are;O;O
also;O;O
investigated;O;O
.;O;O
DDI-MedLine.d217.s4;;
The;O;O
sensitivity;O;O
,;O;O
cell;O;O
cycle;O;O
,;O;O
apoptosis;O;O
and;O;O
DNA;O;O
damage;O;O
of;O;O
five;O;O
different;O;O
cancer;O;O
cell;O;O
lines;O;O
(;O;O
HeLa;O;O
,;O;O
HCT116;O;O
,;O;O
HepG2;O;O
,;O;O
MCF7;O;O
and;O;O
U251;O;O
);O;O
to;O;O
5;B-drug;B-DDI-MedLine.d217.s4.e0
-;I-drug;I-DDI-MedLine.d217.s4.e0
FU;I-drug;I-DDI-MedLine.d217.s4.e0
,;O;O
cisplatin;B-drug;B-DDI-MedLine.d217.s4.e1
,;O;O
doxorubicin;B-drug;B-DDI-MedLine.d217.s4.e2
and;O;O
etoposide;B-drug;B-DDI-MedLine.d217.s4.e3
celecoxib;I-drug;I-DDI-MedLine.d217.s4.e4
following;O;O
different;O;O
incubation;O;O
schedules;O;O
were;O;O
analyzed;O;O
.;O;O
DDI-MedLine.d217.s5;;
We;O;O
found;O;O
antagonism;O;O
between;O;O
celecoxib;B-drug;B-DDI-MedLine.d217.s5.e0
and;O;O
the;O;O
four;O;O
drugs;O;O
in;O;O
the;O;O
breast;O;O
cancer;O;O
cells;O;O
MCF7;O;O
following;O;O
all;O;O
incubation;O;O
schedules;O;O
and;O;O
between;O;O
celecoxib;B-drug;B-DDI-MedLine.d217.s5.e1
and;O;O
doxorubicin;B-drug;B-DDI-MedLine.d217.s5.e2
in;O;O
all;O;O
cell;O;O
lines;O;O
except;O;O
for;O;O
two;O;O
combinations;O;O
in;O;O
HCT116;O;O
cells;O;O
.;O;O
DDI-MedLine.d217.s6;;
Celecoxib;B-drug;B-DDI-MedLine.d217.s6.e0
with;O;O
the;O;O
other;O;O
three;O;O
drugs;O;O
in;O;O
the;O;O
remaining;O;O
four;O;O
cell;O;O
lines;O;O
resulted;O;O
in;O;O
variable;O;O
interactions;O;O
.;O;O
DDI-MedLine.d217.s7;;
Mechanistic;O;O
investigations;O;O
revealed;O;O
that;O;O
celecoxib;B-drug;B-DDI-MedLine.d217.s7.e0
exerts;O;O
different;O;O
molecular;O;O
effects;O;O
in;O;O
different;O;O
cells;O;O
.;O;O
DDI-MedLine.d217.s8;;
In;O;O
some;O;O
lines;O;O
,;O;O
it;O;O
abrogates;O;O
the;O;O
drug;O;O
-;O;O
induced;O;O
G2;O;O
/;O;O
M;O;O
arrest;O;O
enhancing;O;O
pre;O;O
-;O;O
mature;O;O
entry;O;O
into;O;O
mitosis;O;O
with;O;O
damaged;O;O
DNA;O;O
thus;O;O
increasing;O;O
apoptosis;O;O
and;O;O
resulting;O;O
in;O;O
synergism;O;O
.;O;O
DDI-MedLine.d217.s9;;
In;O;O
other;O;O
cells;O;O
,;O;O
it;O;O
enhances;O;O
drug;O;O
-;O;O
induced;O;O
G2;O;O
/;O;O
M;O;O
arrest;O;O
allowing;O;O
time;O;O
to;O;O
repair;O;O
drug;O;O
-;O;O
induced;O;O
DNA;O;O
damage;O;O
before;O;O
entry;O;O
into;O;O
mitosis;O;O
and;O;O
decreasing;O;O
cell;O;O
death;O;O
resulting;O;O
in;O;O
antagonism;O;O
.;O;O
DDI-MedLine.d217.s10;;
In;O;O
some;O;O
synergistic;O;O
combinations;O;O
,;O;O
celecoxib;O;O
-;O;O
induced;O;O
abrogation;O;O
of;O;O
G2;O;O
/;O;O
M;O;O
arrest;O;O
was;O;O
not;O;O
associated;O;O
with;O;O
apoptosis;O;O
but;O;O
permanent;O;O
arrest;O;O
in;O;O
G1;O;O
phase;O;O
.;O;O
DDI-MedLine.d217.s11;;
These;O;O
results;O;O
,;O;O
if;O;O
confirmed;O;O
in;O;O
-;O;O
vivo;O;O
,;O;O
indicate;O;O
that;O;O
celecoxib;B-drug;B-DDI-MedLine.d217.s11.e0
is;O;O
not;O;O
a;O;O
suitable;O;O
chemosensitizer;O;O
for;O;O
breast;O;O
cancer;O;O
or;O;O
with;O;O
doxorubicin;B-drug;B-DDI-MedLine.d217.s11.e1
for;O;O
other;O;O
cancers;O;O
.;O;O
DDI-MedLine.d217.s12;;
Moreover;O;O
,;O;O
combination;O;O
of;O;O
celecoxib;B-drug;B-DDI-MedLine.d217.s12.e0
with;O;O
other;O;O
drugs;O;O
should;O;O
be;O;O
tailored;O;O
to;O;O
the;O;O
tumor;O;O
type;O;O
,;O;O
drug;O;O
and;O;O
administration;O;O
schedule;O;O
.;O;O
DDI-MedLine.d143.s0;;
[;O;O
Interaction;O;O
between;O;O
clopidogrel;B-drug;B-DDI-MedLine.d143.s0.e0
and;O;O
proton;B-group;B-DDI-MedLine.d143.s0.e1
pump;I-group;I-DDI-MedLine.d143.s0.e1
inhibitors;I-group;I-DDI-MedLine.d143.s0.e1
];O;O
.;O;O
DDI-MedLine.d143.s1;;
The;O;O
drug;O;O
interaction;O;O
between;O;O
proton;B-group;B-DDI-MedLine.d143.s1.e0
pump;I-group;I-DDI-MedLine.d143.s1.e0
inhibitors;I-group;I-DDI-MedLine.d143.s1.e0
and;O;O
clopidogrel;B-drug;B-DDI-MedLine.d143.s1.e1
has;O;O
been;O;O
the;O;O
subject;O;O
of;O;O
much;O;O
study;O;O
in;O;O
recent;O;O
years;O;O
.;O;O
DDI-MedLine.d143.s2;;
Contradictory;O;O
results;O;O
regarding;O;O
the;O;O
effect;O;O
of;O;O
proton;B-group;B-DDI-MedLine.d143.s2.e0
pump;I-group;I-DDI-MedLine.d143.s2.e0
inhibitors;I-group;I-DDI-MedLine.d143.s2.e0
on;O;O
platelet;O;O
reactivity;O;O
and;O;O
on;O;O
clinical;O;O
outcome;O;O
in;O;O
clopidogrel;B-drug;B-DDI-MedLine.d143.s2.e1
-;O;O
treated;O;O
patients;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
literature;O;O
.;O;O
DDI-MedLine.d143.s3;;
Concomitant;O;O
use;O;O
of;O;O
omeprazole;B-drug;B-DDI-MedLine.d143.s3.e0
and;O;O
clopidogrel;B-drug;B-DDI-MedLine.d143.s3.e1
was;O;O
found;O;O
to;O;O
decrease;O;O
the;O;O
exposure;O;O
(;O;O
AUC;O;O
);O;O
to;O;O
clopidogrel;O;O
's;O;O
active;O;O
metabolite;O;O
by;O;O
50;O;O
%;O;O
and;O;O
to;O;O
sharply;O;O
increase;O;O
platelet;O;O
reactivity;O;O
,;O;O
as;O;O
a;O;O
result;O;O
of;O;O
inhibition;O;O
by;O;O
omeprazole;B-drug;B-DDI-MedLine.d143.s3.e2
of;O;O
CYP2C19;O;O
,;O;O
a;O;O
cytochrome;O;O
P450;O;O
(;O;O
CYP;O;O
);O;O
enzyme;O;O
.;O;O
DDI-MedLine.d143.s4;;
Pantoprazole;B-drug;B-DDI-MedLine.d143.s4.e0
has;O;O
a;O;O
much;O;O
weaker;O;O
effect;O;O
on;O;O
clopidogrel;B-drug;B-DDI-MedLine.d143.s4.e1
's;O;O
pharmacokinetics;O;O
and;O;O
on;O;O
platelet;O;O
reactivity;O;O
during;O;O
concomitant;O;O
use;O;O
.;O;O
DDI-MedLine.d143.s5;;
The;O;O
influence;O;O
of;O;O
the;O;O
other;O;O
proton;B-group;B-DDI-MedLine.d143.s5.e0
pump;I-group;I-DDI-MedLine.d143.s5.e0
inhibitors;I-group;I-DDI-MedLine.d143.s5.e0
when;O;O
used;O;O
simultaneously;O;O
with;O;O
clopidogrel;B-drug;B-DDI-MedLine.d143.s5.e1
has;O;O
not;O;O
yet;O;O
been;O;O
investigated;O;O
in;O;O
adequately;O;O
randomized;O;O
studies;O;O
.;O;O
DDI-MedLine.d143.s6;;
Regulatory;O;O
agencies;O;O
state;O;O
that;O;O
the;O;O
combination;O;O
of;O;O
clopidogrel;B-drug;B-DDI-MedLine.d143.s6.e0
and;O;O
the;O;O
CYP2C19;O;O
inhibitors;O;O
omeprazole;B-drug;B-DDI-MedLine.d143.s6.e1
and;O;O
esomeprazole;B-drug;B-DDI-MedLine.d143.s6.e2
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-MedLine.d143.s7;;
To;O;O
date;O;O
,;O;O
there;O;O
is;O;O
no;O;O
conclusive;O;O
evidence;O;O
of;O;O
a;O;O
clinically;O;O
-;O;O
relevant;O;O
interaction;O;O
between;O;O
any;O;O
of;O;O
the;O;O
proton;B-group;B-DDI-MedLine.d143.s7.e0
pump;I-group;I-DDI-MedLine.d143.s7.e0
inhibitors;I-group;I-DDI-MedLine.d143.s7.e0
and;O;O
clopidogrel;B-drug;B-DDI-MedLine.d143.s7.e1
.;O;O
DDI-MedLine.d163.s0;;
In;O;O
vitro;O;O
activity;O;O
of;O;O
minocycline;B-drug;B-DDI-MedLine.d163.s0.e0
combined;O;O
with;O;O
fosfomycin;B-drug;B-DDI-MedLine.d163.s0.e1
against;O;O
clinical;O;O
isolates;O;O
of;O;O
methicillin;B-drug;B-DDI-MedLine.d163.s0.e2
-;O;O
resistant;O;O
Staphylococcus;O;O
aureus;O;O
.;O;O
DDI-MedLine.d163.s1;;
This;O;O
study;O;O
aimed;O;O
to;O;O
evaluate;O;O
the;O;O
in;O;O
vitro;O;O
activity;O;O
of;O;O
minocycline;B-drug;B-DDI-MedLine.d163.s1.e0
combined;O;O
with;O;O
fosfomycin;B-drug;B-DDI-MedLine.d163.s1.e1
against;O;O
isolates;O;O
of;O;O
methicillin;B-drug;B-DDI-MedLine.d163.s1.e2
-;O;O
resistant;O;O
Staphylococcus;O;O
aureus;O;O
(;O;O
MRSA;O;O
);O;O
.;O;O
DDI-MedLine.d163.s2;;
A;O;O
total;O;O
of;O;O
87;O;O
clinical;O;O
isolates;O;O
of;O;O
MRSA;O;O
collected;O;O
from;O;O
three;O;O
Chinese;O;O
hospitals;O;O
were;O;O
included;O;O
in;O;O
the;O;O
study;O;O
.;O;O
DDI-MedLine.d163.s3;;
The;O;O
checkerboard;O;O
method;O;O
with;O;O
determination;O;O
of;O;O
the;O;O
fractional;O;O
IC;O;O
index;O;O
(;O;O
FICI;O;O
);O;O
was;O;O
used;O;O
to;O;O
determine;O;O
whether;O;O
antibiotic;B-group;B-DDI-MedLine.d163.s3.e0
combinations;O;O
act;O;O
synergistically;O;O
against;O;O
these;O;O
isolates;O;O
.;O;O
DDI-MedLine.d163.s4;;
The;O;O
susceptibility;O;O
results;O;O
for;O;O
minocycline;B-drug;B-DDI-MedLine.d163.s4.e0
and;O;O
fosfomycin;B-drug;B-DDI-MedLine.d163.s4.e1
were;O;O
interpreted;O;O
according;O;O
to;O;O
the;O;O
most;O;O
relevant;O;O
criteria;O;O
.;O;O
DDI-MedLine.d163.s5;;
The;O;O
results;O;O
demonstrated;O;O
the;O;O
following;O;O
interactions;O;O
:;O;O
76;O;O
isolates;O;O
(;O;O
87.4;O;O
%;O;O
);O;O
showed;O;O
synergistic;O;O
interactions;O;O
(;O;O
FICI;O;O
0.5;O;O
);O;O
and;O;O
11;O;O
isolates;O;O
(;O;O
12.6;O;O
%;O;O
);O;O
showed;O;O
indifferent;O;O
interactions;O;O
(;O;O
0.5&lt;O;O
;;O;O
FICI&lt;O;O
;;O;O
4;O;O
);O;O
.;O;O
DDI-MedLine.d163.s6;;
No;O;O
antagonistic;O;O
interactions;O;O
(;O;O
FICI;O;O
4;O;O
);O;O
were;O;O
observed;O;O
.;O;O
DDI-MedLine.d163.s7;;
The;O;O
combination;O;O
of;O;O
minocycline;B-drug;B-DDI-MedLine.d163.s7.e0
and;O;O
fosfomycin;B-drug;B-DDI-MedLine.d163.s7.e1
can;O;O
be;O;O
synergistic;O;O
against;O;O
MRSA;O;O
.;O;O
DDI-MedLine.d163.s8;;
Further;O;O
studies;O;O
are;O;O
required;O;O
to;O;O
determine;O;O
the;O;O
potential;O;O
clinical;O;O
role;O;O
of;O;O
this;O;O
combination;O;O
regimen;O;O
as;O;O
a;O;O
therapeutic;O;O
alternative;O;O
for;O;O
certain;O;O
types;O;O
of;O;O
MRSA;O;O
infections;O;O
.;O;O
DDI-MedLine.d181.s0;;
Drug;O;O
interaction;O;O
of;O;O
levothyroxine;B-drug;B-DDI-MedLine.d181.s0.e0
with;O;O
infant;O;O
colic;O;O
drops;O;O
.;O;O
DDI-MedLine.d181.s1;;
Infacol;B-brand;B-DDI-MedLine.d181.s1.e0
(;O;O
Forest;O;O
Laboratories;O;O
UK;O;O
,;O;O
Kent;O;O
,;O;O
UK;O;O
);O;O
is;O;O
a;O;O
widely;O;O
available;O;O
over;O;O
-;O;O
the;O;O
-;O;O
counter;O;O
preparation;O;O
used;O;O
to;O;O
relieve;O;O
colic;O;O
symptoms;O;O
in;O;O
neonates;O;O
and;O;O
infants;O;O
.;O;O
DDI-MedLine.d181.s2;;
The;O;O
active;O;O
ingredient;O;O
is;O;O
simeticone;B-drug;B-DDI-MedLine.d181.s2.e0
.;O;O
DDI-MedLine.d181.s3;;
No;O;O
drug;O;O
interactions;O;O
with;O;O
simeticone;B-drug;B-DDI-MedLine.d181.s3.e0
are;O;O
documented;O;O
in;O;O
the;O;O
current;O;O
summary;O;O
of;O;O
product;O;O
characteristics;O;O
.;O;O
DDI-MedLine.d181.s4;;
The;O;O
authors;O;O
report;O;O
the;O;O
case;O;O
of;O;O
an;O;O
infant;O;O
with;O;O
confirmed;O;O
congenital;O;O
hypothyroidism;O;O
on;O;O
levothyroxine;B-drug;B-DDI-MedLine.d181.s4.e0
who;O;O
experienced;O;O
a;O;O
possible;O;O
drug;O;O
interaction;O;O
with;O;O
simeticone;B-drug;B-DDI-MedLine.d181.s4.e1
.;O;O
DDI-MedLine.d181.s5;;
Despite;O;O
adequate;O;O
levothyroxine;B-drug;B-DDI-MedLine.d181.s5.e0
dosage;O;O
,;O;O
thyroid;O;O
stimulating;O;O
hormone;O;O
(;O;O
TSH;O;O
);O;O
was;O;O
high;O;O
,;O;O
suggesting;O;O
undertreatment;O;O
.;O;O
DDI-MedLine.d181.s6;;
Questioning;O;O
revealed;O;O
the;O;O
child;O;O
was;O;O
taking;O;O
Infacol;B-brand;B-DDI-MedLine.d181.s6.e0
drops;O;O
before;O;O
feeds;O;O
while;O;O
on;O;O
levothyroxine;B-drug;B-DDI-MedLine.d181.s6.e1
.;O;O
DDI-MedLine.d181.s7;;
The;O;O
colic;O;O
drops;O;O
were;O;O
immediately;O;O
discontinued;O;O
and;O;O
TSH;O;O
promptly;O;O
normalised;O;O
with;O;O
a;O;O
reduction;O;O
in;O;O
thyroxine;O;O
requirement;O;O
to;O;O
an;O;O
age;O;O
appropriate;O;O
dosage;O;O
.;O;O
DDI-MedLine.d181.s8;;
Drug;O;O
interaction;O;O
of;O;O
thyroxine;B-drug;B-DDI-MedLine.d181.s8.e0
with;O;O
simeticone;B-drug;B-DDI-MedLine.d181.s8.e1
has;O;O
not;O;O
been;O;O
reported;O;O
previously;O;O
and;O;O
is;O;O
not;O;O
listed;O;O
in;O;O
the;O;O
British;O;O
National;O;O
Formulary;O;O
for;O;O
Children;O;O
.;O;O
DDI-MedLine.d181.s9;;
Clinicians;O;O
and;O;O
parents;O;O
need;O;O
to;O;O
be;O;O
aware;O;O
of;O;O
this;O;O
interaction;O;O
to;O;O
avoid;O;O
unnecessary;O;O
undertreatment;O;O
and;O;O
prevent;O;O
potential;O;O
long;O;O
-;O;O
term;O;O
neurological;O;O
sequelae;O;O
.;O;O
DDI-MedLine.d169.s0;;
Calcium;B-drug;B-DDI-MedLine.d169.s0.e0
does;O;O
not;O;O
inhibit;O;O
the;O;O
absorption;O;O
of;O;O
5;O;O
milligrams;O;O
of;O;O
nonheme;B-drug;B-DDI-MedLine.d169.s0.e1
or;I-drug;I-DDI-MedLine.d169.s0.e1
heme;I-drug;I-DDI-MedLine.d169.s0.e2
iron;I-drug;I-DDI-MedLine.d169.s0.e2
at;O;O
doses;O;O
less;O;O
than;O;O
800;O;O
milligrams;O;O
in;O;O
nonpregnant;O;O
women;O;O
.;O;O
DDI-MedLine.d169.s1;;
Calcium;B-drug;B-DDI-MedLine.d169.s1.e0
is;O;O
the;O;O
only;O;O
known;O;O
component;O;O
in;O;O
the;O;O
diet;O;O
that;O;O
may;O;O
affect;O;O
absorption;O;O
of;O;O
both;O;O
nonheme;B-drug;B-DDI-MedLine.d169.s1.e1
and;I-drug;I-DDI-MedLine.d169.s1.e1
heme;I-drug;I-DDI-MedLine.d169.s1.e2
iron;I-drug;I-DDI-MedLine.d169.s1.e2
.;O;O
DDI-MedLine.d169.s2;;
However;O;O
,;O;O
the;O;O
evidence;O;O
for;O;O
a;O;O
calcium;B-drug;B-DDI-MedLine.d169.s2.e0
effect;O;O
on;O;O
iron;B-drug;B-DDI-MedLine.d169.s2.e1
absorption;O;O
mainly;O;O
comes;O;O
from;O;O
studies;O;O
that;O;O
did;O;O
not;O;O
isolate;O;O
the;O;O
effect;O;O
of;O;O
calcium;B-drug;B-DDI-MedLine.d169.s2.e2
from;O;O
that;O;O
of;O;O
other;O;O
dietary;O;O
components;O;O
,;O;O
because;O;O
it;O;O
was;O;O
detected;O;O
in;O;O
single;O;O
-;O;O
meal;O;O
studies;O;O
.;O;O
DDI-MedLine.d169.s3;;
Our;O;O
objective;O;O
was;O;O
to;O;O
establish;O;O
potential;O;O
effects;O;O
of;O;O
calcium;B-drug;B-DDI-MedLine.d169.s3.e0
on;O;O
absorption;O;O
of;O;O
nonheme;B-drug;B-DDI-MedLine.d169.s3.e1
and;I-drug;I-DDI-MedLine.d169.s3.e1
heme;I-drug;I-DDI-MedLine.d169.s3.e2
iron;I-drug;I-DDI-MedLine.d169.s3.e2
and;O;O
the;O;O
dose;O;O
response;O;O
for;O;O
this;O;O
effect;O;O
in;O;O
the;O;O
absence;O;O
of;O;O
a;O;O
meal;O;O
.;O;O
DDI-MedLine.d169.s4;;
Fifty;O;O
-;O;O
four;O;O
healthy;O;O
,;O;O
nonpregnant;O;O
women;O;O
were;O;O
selected;O;O
to;O;O
participate;O;O
in;O;O
4;O;O
iron;B-drug;B-DDI-MedLine.d169.s4.e0
absorption;O;O
studies;O;O
using;O;O
iron;O;O
radioactive;O;O
tracers;O;O
.;O;O
DDI-MedLine.d169.s5;;
We;O;O
evaluated;O;O
the;O;O
effects;O;O
of;O;O
calcium;B-drug;B-DDI-MedLine.d169.s5.e0
doses;O;O
between;O;O
200;O;O
and;O;O
1500;O;O
mg;O;O
on;O;O
absorption;O;O
of;O;O
5;O;O
mg;O;O
nonheme;B-drug;B-DDI-MedLine.d169.s5.e1
iron;I-drug;I-DDI-MedLine.d169.s5.e1
(;O;O
as;O;O
ferrous;B-drug;B-DDI-MedLine.d169.s5.e2
sulfate;I-drug;I-DDI-MedLine.d169.s5.e2
);O;O
.;O;O
DDI-MedLine.d169.s6;;
We;O;O
also;O;O
evaluated;O;O
the;O;O
effects;O;O
of;O;O
calcium;B-drug;B-DDI-MedLine.d169.s6.e0
doses;O;O
between;O;O
200;O;O
and;O;O
800;O;O
mg;O;O
on;O;O
absorption;O;O
of;O;O
5;O;O
mg;O;O
heme;B-drug;B-DDI-MedLine.d169.s6.e1
iron;I-drug;I-DDI-MedLine.d169.s6.e1
[;O;O
as;O;O
concentrated;O;O
RBC;O;O
(;O;O
CRBC;O;O
);O;O
];O;O
.;O;O
DDI-MedLine.d169.s7;;
Calcium;B-drug;B-DDI-MedLine.d169.s7.e0
was;O;O
administered;O;O
as;O;O
calcium;B-drug;B-DDI-MedLine.d169.s7.e1
chloride;I-drug;I-DDI-MedLine.d169.s7.e1
in;O;O
all;O;O
studies;O;O
and;O;O
minerals;B-group;B-DDI-MedLine.d169.s7.e2
were;O;O
ingested;O;O
on;O;O
an;O;O
empty;O;O
stomach;O;O
.;O;O
DDI-MedLine.d169.s8;;
Calcium;B-drug;B-DDI-MedLine.d169.s8.e0
doses;O;O
1000;O;O
mg;O;O
diminished;O;O
nonheme;B-drug;B-DDI-MedLine.d169.s8.e1
iron;I-drug;I-DDI-MedLine.d169.s8.e1
absorption;O;O
by;O;O
an;O;O
average;O;O
of;O;O
49.6;O;O
%;O;O
.;O;O
DDI-MedLine.d169.s9;;
A;O;O
calcium;B-drug;B-DDI-MedLine.d169.s9.e0
dose;O;O
of;O;O
800;O;O
mg;O;O
diminished;O;O
absorption;O;O
of;O;O
5;O;O
mg;O;O
heme;B-drug;B-DDI-MedLine.d169.s9.e1
iron;I-drug;I-DDI-MedLine.d169.s9.e1
by;O;O
37.7;O;O
%;O;O
.;O;O
DDI-MedLine.d169.s10;;
In;O;O
conclusion;O;O
,;O;O
we;O;O
demonstrated;O;O
an;O;O
isolated;O;O
effect;O;O
of;O;O
calcium;B-drug;B-DDI-MedLine.d169.s10.e0
(;O;O
as;O;O
chloride;O;O
);O;O
on;O;O
absorption;O;O
of;O;O
5;O;O
mg;O;O
of;O;O
iron;O;O
provided;O;O
as;O;O
nonheme;B-drug;B-DDI-MedLine.d169.s10.e1
(;I-drug;I-DDI-MedLine.d169.s10.e1
as;I-drug;I-DDI-MedLine.d169.s10.e1
sulfate;I-drug;I-DDI-MedLine.d169.s10.e1
);I-drug;I-DDI-MedLine.d169.s10.e1
and;I-drug;I-DDI-MedLine.d169.s10.e1
heme;I-drug;I-DDI-MedLine.d169.s10.e2
(;I-drug;I-DDI-MedLine.d169.s10.e2
as;I-drug;I-DDI-MedLine.d169.s10.e2
CRBC;I-drug;I-DDI-MedLine.d169.s10.e2
);I-drug;I-DDI-MedLine.d169.s10.e2
iron;I-drug;I-DDI-MedLine.d169.s10.e2
.;O;O
DDI-MedLine.d169.s11;;
This;O;O
effect;O;O
was;O;O
observed;O;O
at;O;O
doses;O;O
higher;O;O
than;O;O
previously;O;O
reported;O;O
from;O;O
single;O;O
-;O;O
meal;O;O
studies;O;O
,;O;O
starting;O;O
at;O;O
~800;O;O
mg;O;O
of;O;O
calcium;B-drug;B-DDI-MedLine.d169.s11.e0
.;O;O
DDI-MedLine.d179.s0;;
Synergistic;O;O
interaction;O;O
between;O;O
sunitinib;B-drug;B-DDI-MedLine.d179.s0.e0
and;O;O
docetaxel;B-drug;B-DDI-MedLine.d179.s0.e1
is;O;O
sequence;O;O
dependent;O;O
in;O;O
human;O;O
non;O;O
-;O;O
small;O;O
lung;O;O
cancer;O;O
with;O;O
EGFR;O;O
TKIs;O;O
-;O;O
resistant;O;O
mutation;O;O
.;O;O
DDI-MedLine.d179.s1;;
Previous;O;O
studies;O;O
have;O;O
demonstrated;O;O
that;O;O
sunitinib;B-drug;B-DDI-MedLine.d179.s1.e0
has;O;O
the;O;O
anti;O;O
-;O;O
tumor;O;O
activity;O;O
in;O;O
human;O;O
non;O;O
-;O;O
small;O;O
cell;O;O
lung;O;O
cancer;O;O
(;O;O
NSCLC;O;O
);O;O
.;O;O
DDI-MedLine.d179.s2;;
This;O;O
study;O;O
was;O;O
aimed;O;O
to;O;O
investigate;O;O
the;O;O
efficacy;O;O
of;O;O
single;O;O
use;O;O
of;O;O
sunitinib;B-drug;B-DDI-MedLine.d179.s2.e0
and;O;O
that;O;O
of;O;O
concurrent;O;O
or;O;O
sequential;O;O
administration;O;O
of;O;O
sunitinib;B-drug;B-DDI-MedLine.d179.s2.e1
and;O;O
docetaxel;B-drug;B-DDI-MedLine.d179.s2.e2
in;O;O
NSCLC;O;O
cell;O;O
lines;O;O
that;O;O
are;O;O
resistant;O;O
to;O;O
EGFR;O;O
TKIs;O;O
.;O;O
DDI-MedLine.d179.s3;;
NSCLC;O;O
cell;O;O
lines;O;O
with;O;O
EGFR;O;O
T790;O;O
M;O;O
mutation;O;O
and;O;O
K;O;O
-;O;O
ras;O;O
mutation;O;O
were;O;O
exposed;O;O
to;O;O
either;O;O
sunitinib;B-drug;B-DDI-MedLine.d179.s3.e0
or;O;O
docetaxel;B-drug;B-DDI-MedLine.d179.s3.e1
or;O;O
both;O;O
based;O;O
on;O;O
various;O;O
sequential;O;O
administrations;O;O
.;O;O
DDI-MedLine.d179.s4;;
After;O;O
exposure;O;O
,;O;O
the;O;O
cell;O;O
viability;O;O
was;O;O
measured;O;O
by;O;O
MTT;O;O
assay;O;O
,;O;O
cell;O;O
cycle;O;O
distribution;O;O
was;O;O
analyzed;O;O
by;O;O
flow;O;O
cytometry;O;O
,;O;O
and;O;O
alterations;O;O
in;O;O
signaling;O;O
pathway;O;O
were;O;O
determined;O;O
by;O;O
immunoblotting;O;O
.;O;O
DDI-MedLine.d179.s5;;
Sunitinib;B-drug;B-DDI-MedLine.d179.s5.e0
exhibited;O;O
dose;O;O
-;O;O
dependent;O;O
growth;O;O
inhibition;O;O
in;O;O
NSCLC;O;O
cell;O;O
lines;O;O
and;O;O
arrested;O;O
cell;O;O
cycle;O;O
at;O;O
G1;O;O
phase;O;O
,;O;O
whereas;O;O
docetaxel;B-drug;B-DDI-MedLine.d179.s5.e1
arrested;O;O
at;O;O
S;O;O
phase;O;O
.;O;O
DDI-MedLine.d179.s6;;
Although;O;O
single;O;O
or;O;O
concurrent;O;O
use;O;O
of;O;O
sunitinib;B-drug;B-DDI-MedLine.d179.s6.e0
and;O;O
docetaxel;B-drug;B-DDI-MedLine.d179.s6.e1
has;O;O
some;O;O
anti;O;O
-;O;O
proliferative;O;O
effects;O;O
,;O;O
the;O;O
sequential;O;O
administrations;O;O
of;O;O
both;O;O
drugs;O;O
remarkably;O;O
enhanced;O;O
anti;O;O
-;O;O
tumor;O;O
activity;O;O
.;O;O
DDI-MedLine.d179.s7;;
When;O;O
cells;O;O
were;O;O
exposed;O;O
to;O;O
docetaxel;B-drug;B-DDI-MedLine.d179.s7.e0
followed;O;O
by;O;O
sunitinib;B-drug;B-DDI-MedLine.d179.s7.e1
,;O;O
synergism;O;O
was;O;O
observed;O;O
.;O;O
DDI-MedLine.d179.s8;;
The;O;O
molecular;O;O
basis;O;O
of;O;O
this;O;O
synergism;O;O
is;O;O
that;O;O
the;O;O
signaling;O;O
pathways;O;O
that;O;O
were;O;O
initially;O;O
activated;O;O
by;O;O
docetaxel;B-drug;B-DDI-MedLine.d179.s8.e0
exposure;O;O
were;O;O
efficiently;O;O
suppressed;O;O
by;O;O
the;O;O
subsequent;O;O
exposure;O;O
to;O;O
sunitinib;B-drug;B-DDI-MedLine.d179.s8.e1
.;O;O
DDI-MedLine.d179.s9;;
In;O;O
contrast;O;O
,;O;O
the;O;O
reverse;O;O
of;O;O
this;O;O
sequential;O;O
administration;O;O
resulted;O;O
in;O;O
antagonism;O;O
,;O;O
which;O;O
may;O;O
be;O;O
due;O;O
to;O;O
differential;O;O
effects;O;O
on;O;O
cell;O;O
cycle;O;O
arrest;O;O
.;O;O
DDI-MedLine.d179.s10;;
Sunitinib;B-drug;B-DDI-MedLine.d179.s10.e0
as;O;O
a;O;O
single;O;O
agent;O;O
exhibits;O;O
anti;O;O
-;O;O
proliferative;O;O
effects;O;O
in;O;O
vitro;O;O
in;O;O
NSCLC;O;O
cell;O;O
lines;O;O
with;O;O
EGFR;O;O
T790;O;O
M;O;O
and;O;O
K;O;O
-;O;O
ras;O;O
mutations;O;O
but;O;O
the;O;O
sequential;O;O
administration;O;O
of;O;O
docetaxel;B-drug;B-DDI-MedLine.d179.s10.e1
followed;O;O
by;O;O
sunitinib;B-drug;B-DDI-MedLine.d179.s10.e2
is;O;O
superior;O;O
to;O;O
sunitinib;B-drug;B-DDI-MedLine.d179.s10.e3
followed;O;O
by;O;O
docetaxel;B-drug;B-DDI-MedLine.d179.s10.e4
and;O;O
concurrent;O;O
administration;O;O
.;O;O
DDI-MedLine.d204.s0;;
Distinct;O;O
synergistic;O;O
action;O;O
of;O;O
piperacillin;B-drug;B-DDI-MedLine.d204.s0.e0
and;O;O
methylglyoxal;B-drug_n;B-DDI-MedLine.d204.s0.e1
against;O;O
Pseudomonas;O;O
aeruginosa;O;O
.;O;O
DDI-MedLine.d204.s1;;
The;O;O
dicarbonyl;O;O
compound;O;O
methylglyoxal;B-drug_n;B-DDI-MedLine.d204.s1.e0
is;O;O
a;O;O
natural;O;O
constituent;O;O
of;O;O
Manuka;O;O
honey;O;O
produced;O;O
from;O;O
Manuka;O;O
flowers;O;O
in;O;O
New;O;O
Zealand;O;O
.;O;O
DDI-MedLine.d204.s2;;
It;O;O
is;O;O
known;O;O
to;O;O
possess;O;O
both;O;O
anticancer;O;O
and;O;O
antibacterial;O;O
activity;O;O
.;O;O
DDI-MedLine.d204.s3;;
Such;O;O
observations;O;O
prompted;O;O
to;O;O
investigate;O;O
the;O;O
ability;O;O
of;O;O
methylglyoxal;B-drug_n;B-DDI-MedLine.d204.s3.e0
as;O;O
a;O;O
potent;O;O
drug;O;O
against;O;O
multidrug;O;O
resistant;O;O
Pseudomonas;O;O
aeruginosa;O;O
.;O;O
DDI-MedLine.d204.s4;;
A;O;O
total;O;O
of;O;O
12;O;O
test;O;O
P.;O;O
DDI-MedLine.d204.s5;;
aeruginosa;O;O
strains;O;O
isolated;O;O
from;O;O
various;O;O
hospitals;O;O
were;O;O
tested;O;O
for;O;O
their;O;O
resistances;O;O
against;O;O
many;O;O
antibiotics;B-group;B-DDI-MedLine.d204.s5.e0
,;O;O
most;O;O
of;O;O
which;O;O
are;O;O
applied;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
P.;O;O
DDI-MedLine.d204.s6;;
aeruginosa;O;O
infections;O;O
.;O;O
DDI-MedLine.d204.s7;;
Results;O;O
revealed;O;O
that;O;O
the;O;O
strains;O;O
were;O;O
resistant;O;O
to;O;O
many;O;O
drugs;O;O
at;O;O
high;O;O
levels;O;O
,;O;O
only;O;O
piperacillin;B-drug;B-DDI-MedLine.d204.s7.e0
,;O;O
carbenicillin;B-drug;B-DDI-MedLine.d204.s7.e1
,;O;O
amikacin;B-drug;B-DDI-MedLine.d204.s7.e2
and;O;O
ciprofloxacin;B-drug;B-DDI-MedLine.d204.s7.e3
showed;O;O
resistances;O;O
at;O;O
comparatively;O;O
lower;O;O
levels;O;O
.;O;O
DDI-MedLine.d204.s8;;
Following;O;O
multiple;O;O
experimentations;O;O
it;O;O
was;O;O
observed;O;O
that;O;O
methylglyoxal;B-drug_n;B-DDI-MedLine.d204.s8.e0
was;O;O
also;O;O
antimicrobic;O;O
against;O;O
all;O;O
the;O;O
strains;O;O
at;O;O
comparable;O;O
levels;O;O
.;O;O
DDI-MedLine.d204.s9;;
Distinct;O;O
and;O;O
statistically;O;O
significant;O;O
synergism;O;O
was;O;O
observed;O;O
between;O;O
methylglyoxal;B-drug_n;B-DDI-MedLine.d204.s9.e0
and;O;O
piperacillin;B-drug;B-DDI-MedLine.d204.s9.e1
by;O;O
disc;O;O
diffusion;O;O
tests;O;O
when;O;O
compared;O;O
with;O;O
their;O;O
individual;O;O
effects;O;O
.;O;O
DDI-MedLine.d204.s10;;
The;O;O
fractional;O;O
inhibitory;O;O
concentration;O;O
index;O;O
of;O;O
this;O;O
combination;O;O
evaluated;O;O
by;O;O
checkerboard;O;O
analysis;O;O
,;O;O
was;O;O
0.5;O;O
,;O;O
which;O;O
confirmed;O;O
synergism;O;O
between;O;O
the;O;O
pair;O;O
.;O;O
DDI-MedLine.d204.s11;;
Synergism;O;O
was;O;O
also;O;O
noted;O;O
when;O;O
methylglyoxal;B-drug_n;B-DDI-MedLine.d204.s11.e0
was;O;O
combined;O;O
with;O;O
carbenicillin;B-drug;B-DDI-MedLine.d204.s11.e1
and;O;O
amikacin;B-drug;B-DDI-MedLine.d204.s11.e2
.;O;O
DDI-MedLine.d159.s0;;
Protective;O;O
effect;O;O
of;O;O
acetyl;B-drug;B-DDI-MedLine.d159.s0.e0
-;I-drug;I-DDI-MedLine.d159.s0.e0
l;I-drug;I-DDI-MedLine.d159.s0.e0
-;I-drug;I-DDI-MedLine.d159.s0.e0
carnitine;I-drug;I-DDI-MedLine.d159.s0.e0
and;O;O
alpha;B-drug_n;B-DDI-MedLine.d159.s0.e1
lipoic;I-drug_n;I-DDI-MedLine.d159.s0.e1
acid;I-drug_n;I-DDI-MedLine.d159.s0.e1
against;O;O
the;O;O
acute;O;O
toxicity;O;O
of;O;O
diepoxybutane;O;O
to;O;O
human;O;O
lymphocytes;O;O
.;O;O
DDI-MedLine.d159.s1;;
The;O;O
biotransformation;O;O
and;O;O
oxidative;O;O
stress;O;O
may;O;O
contribute;O;O
to;O;O
1,2:3,4;O;O
-;O;O
diepoxybutane;O;O
(;O;O
DEB);O;O
-;O;O
induced;O;O
toxicity;O;O
to;O;O
human;O;O
lymphocytes;O;O
of;O;O
Fanconi;O;O
Anemia;O;O
(;O;O
FA;O;O
);O;O
patients;O;O
.;O;O
DDI-MedLine.d159.s2;;
Thus;O;O
,;O;O
the;O;O
identification;O;O
of;O;O
putative;O;O
inhibitors;O;O
of;O;O
bioactivation;O;O
,;O;O
as;O;O
well;O;O
as;O;O
the;O;O
determination;O;O
of;O;O
the;O;O
protective;O;O
role;O;O
of;O;O
oxidant;O;O
defenses;O;O
,;O;O
on;O;O
DEB;O;O
-;O;O
induced;O;O
toxicity;O;O
,;O;O
can;O;O
help;O;O
to;O;O
understand;O;O
what;O;O
is;O;O
failing;O;O
in;O;O
FA;O;O
cells;O;O
.;O;O
DDI-MedLine.d159.s3;;
In;O;O
the;O;O
present;O;O
work;O;O
we;O;O
studied;O;O
the;O;O
contribution;O;O
of;O;O
several;O;O
biochemical;O;O
pathways;O;O
for;O;O
DEB;O;O
-;O;O
induced;O;O
acute;O;O
toxicity;O;O
in;O;O
human;O;O
lymphocyte;O;O
suspensions;O;O
,;O;O
by;O;O
using;O;O
inhibitors;O;O
of;O;O
epoxide;O;O
hydrolases;O;O
,;O;O
inhibitors;O;O
of;O;O
protective;O;O
enzymes;O;O
as;O;O
glutathione;O;O
S;O;O
-;O;O
transferase;O;O
and;O;O
catalase;O;O
,;O;O
the;O;O
depletion;O;O
of;O;O
glutathione;O;O
(;O;O
GSH;O;O
);O;O
,;O;O
and;O;O
the;O;O
inhibition;O;O
of;O;O
protein;O;O
synthesis;O;O
;;O;O
DDI-MedLine.d159.s4;;
and;O;O
a;O;O
variety;O;O
of;O;O
putative;O;O
protective;O;O
compounds;O;O
,;O;O
including;O;O
antioxidants;O;O
,;O;O
and;O;O
mitochondrial;O;O
protective;O;O
agents;O;O
.;O;O
DDI-MedLine.d159.s5;;
The;O;O
present;O;O
study;O;O
reports;O;O
two;O;O
novel;O;O
findings;O;O
:;O;O
(;O;O
i;O;O
);O;O
it;O;O
was;O;O
clearly;O;O
evidenced;O;O
,;O;O
for;O;O
the;O;O
first;O;O
time;O;O
,;O;O
that;O;O
the;O;O
acute;O;O
exposure;O;O
of;O;O
freshly;O;O
isolated;O;O
human;O;O
lymphocytes;O;O
to;O;O
DEB;O;O
results;O;O
in;O;O
severe;O;O
GSH;O;O
depletion;O;O
and;O;O
loss;O;O
of;O;O
ATP;O;O
,;O;O
followed;O;O
by;O;O
cell;O;O
death;O;O
;;O;O
DDI-MedLine.d159.s6;;
(;O;O
ii;O;O
);O;O
acetyl;B-drug;B-DDI-MedLine.d159.s6.e0
-;I-drug;I-DDI-MedLine.d159.s6.e0
l;I-drug;I-DDI-MedLine.d159.s6.e0
-;I-drug;I-DDI-MedLine.d159.s6.e0
carnitine;I-drug;I-DDI-MedLine.d159.s6.e0
elicits;O;O
a;O;O
significant;O;O
protective;O;O
effect;O;O
on;O;O
DEB;O;O
induced;O;O
toxicity;O;O
,;O;O
which;O;O
was;O;O
potentiated;O;O
by;O;O
alpha;B-drug;B-DDI-MedLine.d159.s6.e1
-;I-drug;I-DDI-MedLine.d159.s6.e1
lipoic;I-drug;I-DDI-MedLine.d159.s6.e1
acid;I-drug;I-DDI-MedLine.d159.s6.e1
.;O;O
DDI-MedLine.d159.s7;;
Collectively;O;O
,;O;O
these;O;O
findings;O;O
contribute;O;O
to;O;O
increase;O;O
our;O;O
knowledge;O;O
of;O;O
DEB;O;O
-;O;O
induce;O;O
toxicity;O;O
and;O;O
will;O;O
be;O;O
very;O;O
useful;O;O
when;O;O
applied;O;O
in;O;O
studies;O;O
with;O;O
lymphocytes;O;O
from;O;O
FA;O;O
patients;O;O
,;O;O
in;O;O
order;O;O
to;O;O
find;O;O
out;O;O
a;O;O
protective;O;O
agent;O;O
against;O;O
spontaneous;O;O
and;O;O
DEB;O;O
-;O;O
induced;O;O
chromosome;O;O
instability;O;O
.;O;O
DDI-MedLine.d214.s0;;
[;O;O
Influence;O;O
of;O;O
hemantane;B-drug_n;B-DDI-MedLine.d214.s0.e0
and;O;O
doxycycline;B-drug;B-DDI-MedLine.d214.s0.e1
on;O;O
MPTP;O;O
-;O;O
evoked;O;O
behavior;O;O
violations;O;O
in;O;O
C57BL;O;O
/;O;O
6;O;O
mice;O;O
];O;O
.;O;O
DDI-MedLine.d214.s1;;
The;O;O
effects;O;O
of;O;O
anti;B-group;B-DDI-MedLine.d214.s1.e0
-;I-group;I-DDI-MedLine.d214.s1.e0
parkinsonian;I-group;I-DDI-MedLine.d214.s1.e0
drug;I-group;I-DDI-MedLine.d214.s1.e0
hemantane;I-drug_n;I-DDI-MedLine.d214.s1.e1
[;O;O
(;B-drug_n;B-DDI-MedLine.d214.s1.e2
2;I-drug_n;I-DDI-MedLine.d214.s1.e2
-;I-drug_n;I-DDI-MedLine.d214.s1.e2
adamantyl)hexamethylenimine;I-drug_n;I-DDI-MedLine.d214.s1.e2
];O;O
(;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
p.;O;O
o.;O;O
);O;O
DDI-MedLine.d214.s2;;
and/or;O;O
antibiotic;B-group;B-DDI-MedLine.d214.s2.e0
drug;I-group;I-DDI-MedLine.d214.s2.e0
doxycycline;I-drug;I-DDI-MedLine.d214.s2.e1
(;O;O
100;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
p.;O;O
o.;O;O
);O;O
,;O;O
as;O;O
well;O;O
as;O;O
that;O;O
of;O;O
neurotoxin;O;O
1;B-drug_n;B-DDI-MedLine.d214.s2.e2
-;I-drug_n;I-DDI-MedLine.d214.s2.e2
methyl;I-drug_n;I-DDI-MedLine.d214.s2.e2
-;I-drug_n;I-DDI-MedLine.d214.s2.e2
4;I-drug_n;I-DDI-MedLine.d214.s2.e2
-;I-drug_n;I-DDI-MedLine.d214.s2.e2
phenyl;I-drug_n;I-DDI-MedLine.d214.s2.e2
-;I-drug_n;I-DDI-MedLine.d214.s2.e2
1,2,3,4;I-drug_n;I-DDI-MedLine.d214.s2.e2
-;I-drug_n;I-DDI-MedLine.d214.s2.e2
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d214.s2.e2
(;O;O
MPTP;B-drug_n;B-DDI-MedLine.d214.s2.e3
);O;O
(;O;O
4;O;O
x;O;O
20;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
i.;O;O
p.;O;O
);O;O
DDI-MedLine.d214.s3;;
were;O;O
studied;O;O
in;O;O
elevated;O;O
plus;O;O
maze;O;O
test;O;O
on;O;O
C57BL;O;O
/;O;O
6;O;O
mice;O;O
.;O;O
DDI-MedLine.d214.s4;;
On;O;O
second;O;O
day;O;O
after;O;O
injection;O;O
,;O;O
MPTP;B-drug_n;B-DDI-MedLine.d214.s4.e0
decreased;O;O
the;O;O
locomot;O;O
or;O;O
activity;O;O
in;O;O
comparison;O;O
to;O;O
saline;O;O
.;O;O
DDI-MedLine.d214.s5;;
Acute;O;O
administration;O;O
of;O;O
hemantane;B-drug_n;B-DDI-MedLine.d214.s5.e0
or;O;O
doxycycline;B-drug;B-DDI-MedLine.d214.s5.e1
failed;O;O
to;O;O
influence;O;O
locomotion;O;O
in;O;O
mice;O;O
,;O;O
while;O;O
their;O;O
combination;O;O
normalized;O;O
motor;O;O
activity;O;O
.;O;O
DDI-MedLine.d214.s6;;
The;O;O
results;O;O
obtained;O;O
confirm;O;O
the;O;O
role;O;O
of;O;O
inflammatory;O;O
processes;O;O
in;O;O
parkinsonism;O;O
and;O;O
suggest;O;O
expediency;O;O
of;O;O
combined;O;O
pharmacotherapy;O;O
of;O;O
neurodegenerative;O;O
diseases;O;O
.;O;O
DDI-MedLine.d194.s0;;
The;O;O
role;O;O
of;O;O
p27(Kip1;O;O
);O;O
in;O;O
dasatinib;B-drug;B-DDI-MedLine.d194.s0.e0
-;O;O
enhanced;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s0.e1
cytotoxicity;O;O
in;O;O
human;O;O
ovarian;O;O
cancer;O;O
cells;O;O
.;O;O
DDI-MedLine.d194.s1;;
Less;O;O
than;O;O
50;O;O
%;O;O
of;O;O
ovarian;O;O
cancers;O;O
respond;O;O
to;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s1.e0
.;O;O
DDI-MedLine.d194.s2;;
Effective;O;O
strategies;O;O
are;O;O
needed;O;O
to;O;O
enhance;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s2.e0
sensitivity;O;O
.;O;O
DDI-MedLine.d194.s3;;
A;O;O
library;O;O
of;O;O
silencing;O;O
RNAs;O;O
(;O;O
siRNAs;O;O
);O;O
was;O;O
used;O;O
to;O;O
identify;O;O
kinases;O;O
that;O;O
regulate;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s3.e0
sensitivity;O;O
in;O;O
human;O;O
ovarian;O;O
cancer;O;O
SKOv3;O;O
cells;O;O
.;O;O
DDI-MedLine.d194.s4;;
The;O;O
effect;O;O
of;O;O
dasatinib;B-drug;B-DDI-MedLine.d194.s4.e0
,;O;O
an;O;O
inhibitor;O;O
of;O;O
Src;O;O
and;O;O
Abl;O;O
kinases;O;O
,;O;O
on;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s4.e1
sensitivity;O;O
was;O;O
measured;O;O
in;O;O
ovarian;O;O
cancer;O;O
cells;O;O
and;O;O
HEY;O;O
xenografts;O;O
.;O;O
DDI-MedLine.d194.s5;;
The;O;O
roles;O;O
of;O;O
p27(Kip1;O;O
);O;O
,;O;O
Bcl;O;O
-;O;O
2;O;O
,;O;O
and;O;O
Cdk1;O;O
in;O;O
apoptosis;O;O
induced;O;O
by;O;O
dasatinib;B-drug;B-DDI-MedLine.d194.s5.e0
and;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s5.e1
were;O;O
assessed;O;O
using;O;O
a;O;O
terminal;O;O
deoxynucleotidyl;O;O
transferase;O;O
-;O;O
mediated;O;O
dUTP;O;O
nick;O;O
-;O;O
end;O;O
labeling;O;O
(;O;O
TUNEL;O;O
);O;O
assay;O;O
,;O;O
siRNA;O;O
knockdown;O;O
of;O;O
gene;O;O
expression;O;O
,;O;O
transfection;O;O
with;O;O
Bcl;O;O
-;O;O
2;O;O
and;O;O
Cdk1;O;O
expression;O;O
vectors;O;O
,;O;O
and;O;O
flow;O;O
cytometry;O;O
.;O;O
DDI-MedLine.d194.s6;;
All;O;O
statistical;O;O
tests;O;O
were;O;O
two;O;O
-;O;O
sided;O;O
.;O;O
DDI-MedLine.d194.s7;;
Src;O;O
family;O;O
and;O;O
Abl;O;O
kinases;O;O
were;O;O
identified;O;O
as;O;O
modulators;O;O
of;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s7.e0
sensitivity;O;O
in;O;O
SKOv3;O;O
cells;O;O
.;O;O
DDI-MedLine.d194.s8;;
The;O;O
siRNA;O;O
knockdown;O;O
of;O;O
Src;O;O
,;O;O
Fyn;O;O
,;O;O
or;O;O
Abl1;O;O
enhanced;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s8.e0
-;O;O
mediated;O;O
growth;O;O
inhibition;O;O
in;O;O
ovarian;O;O
cancer;O;O
cells;O;O
compared;O;O
with;O;O
a;O;O
control;O;O
siRNA;O;O
.;O;O
DDI-MedLine.d194.s9;;
HEY;O;O
cells;O;O
treated;O;O
with;O;O
dasatinib;B-drug;B-DDI-MedLine.d194.s9.e0
plus;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s9.e1
formed;O;O
fewer;O;O
colonies;O;O
than;O;O
did;O;O
cells;O;O
treated;O;O
with;O;O
either;O;O
agent;O;O
alone;O;O
.;O;O
DDI-MedLine.d194.s10;;
Treatment;O;O
of;O;O
HEY;O;O
xenograft;O;O
-;O;O
bearing;O;O
mice;O;O
with;O;O
dasatinib;B-drug;B-DDI-MedLine.d194.s10.e0
plus;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s10.e1
inhibited;O;O
tumor;O;O
growth;O;O
more;O;O
than;O;O
treatment;O;O
with;O;O
either;O;O
agent;O;O
alone;O;O
(;O;O
average;O;O
tumor;O;O
volume;O;O
per;O;O
mouse;O;O
,;O;O
dasatinib;B-drug;B-DDI-MedLine.d194.s10.e2
+;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s10.e3
vs;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s10.e4
:;O;O
0.28;O;O
vs.;O;O
0.81;O;O
cm3;O;O
,;O;O
difference;O;O
=;O;O
0.53;O;O
cm3;O;O
,;O;O
95;O;O
%;O;O
confidence;O;O
interval;O;O
[;O;O
CI;O;O
];O;O
=;O;O
0.44;O;O
to;O;O
0.62;O;O
cm3;O;O
,;O;O
P;O;O
=;O;O
.014;O;O
);O;O
;;O;O
DDI-MedLine.d194.s11;;
dasatinib;B-drug;B-DDI-MedLine.d194.s11.e0
+;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s11.e1
vs.;O;O
DDI-MedLine.d194.s12;;
dasatinib;B-drug;B-DDI-MedLine.d194.s12.e0
:;O;O
0.28;O;O
vs.;O;O
DDI-MedLine.d194.s13;;
0.55;O;O
cm3;O;O
,;O;O
difference;O;O
=;O;O
0.27;O;O
cm3;O;O
,;O;O
95;O;O
%;O;O
CI;O;O
=;O;O
0.21;O;O
to;O;O
0.33;O;O
cm3;O;O
,;O;O
P;O;O
=;O;O
.035;O;O
);O;O
.;O;O
DDI-MedLine.d194.s14;;
Combined;O;O
treatment;O;O
induced;O;O
more;O;O
TUNEL;O;O
-;O;O
positive;O;O
apoptotic;O;O
cells;O;O
than;O;O
did;O;O
either;O;O
agent;O;O
alone;O;O
.;O;O
DDI-MedLine.d194.s15;;
The;O;O
siRNA;O;O
knockdown;O;O
of;O;O
p27(Kip1;O;O
);O;O
decreased;O;O
dasatinib;B-drug;B-DDI-MedLine.d194.s15.e0
-;O;O
and;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s15.e1
-;O;O
induced;O;O
apoptosis;O;O
compared;O;O
with;O;O
a;O;O
negative;O;O
control;O;O
siRNA;O;O
(;O;O
sub;O;O
-;O;O
G1;O;O
fraction;O;O
,;O;O
control;O;O
siRNA;O;O
vs.;O;O
p27(Kip1;O;O
);O;O
siRNA;O;O
:;O;O
42.5;O;O
%;O;O
vs.;O;O
20.1;O;O
%;O;O
,;O;O
difference;O;O
=;O;O
22.4;O;O
%;O;O
,;O;O
95;O;O
%;O;O
CI;O;O
=;O;O
20.1;O;O
%;O;O
to;O;O
24.7;O;O
%;O;O
,;O;O
P;O;O
=;O;O
.017;O;O
);O;O
.;O;O
DDI-MedLine.d194.s16;;
Studies;O;O
with;O;O
forced;O;O
expression;O;O
and;O;O
siRNA;O;O
knockdown;O;O
of;O;O
Bcl;O;O
-;O;O
2;O;O
and;O;O
Cdk1;O;O
suggest;O;O
that;O;O
dasatinib;B-drug;B-DDI-MedLine.d194.s16.e0
-;O;O
mediated;O;O
induction;O;O
of;O;O
p27(Kip1;O;O
);O;O
enhanced;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s16.e1
-;O;O
induced;O;O
apoptosis;O;O
by;O;O
negatively;O;O
regulating;O;O
Bcl;O;O
-;O;O
2;O;O
and;O;O
Cdk1;O;O
expression;O;O
.;O;O
DDI-MedLine.d194.s17;;
Inhibition;O;O
of;O;O
Src;O;O
family;O;O
and;O;O
Abl;O;O
kinases;O;O
with;O;O
either;O;O
siRNAs;O;O
or;O;O
dasatinib;B-drug;B-DDI-MedLine.d194.s17.e0
enhances;O;O
paclitaxel;B-drug;B-DDI-MedLine.d194.s17.e1
sensitivity;O;O
of;O;O
ovarian;O;O
cancer;O;O
cells;O;O
through;O;O
p27(Kip1);O;O
-;O;O
mediated;O;O
suppression;O;O
of;O;O
Bcl;O;O
-;O;O
2;O;O
and;O;O
Cdk1;O;O
expression;O;O
.;O;O
DDI-MedLine.d211.s0;;
Phase;O;O
I;O;O
trial;O;O
of;O;O
lenalidomide;B-drug;B-DDI-MedLine.d211.s0.e0
and;O;O
CCI;B-drug;B-DDI-MedLine.d211.s0.e1
-;I-drug;I-DDI-MedLine.d211.s0.e1
779;I-drug;I-DDI-MedLine.d211.s0.e1
in;O;O
patients;O;O
with;O;O
relapsed;O;O
multiple;O;O
myeloma;O;O
:;O;O
evidence;O;O
for;O;O
lenalidomide;B-drug;B-DDI-MedLine.d211.s0.e2
-;O;O
CCI;B-drug;B-DDI-MedLine.d211.s0.e3
-;I-drug;I-DDI-MedLine.d211.s0.e3
779;I-drug;I-DDI-MedLine.d211.s0.e3
interaction;O;O
via;O;O
P;O;O
-;O;O
glycoprotein;O;O
.;O;O
DDI-MedLine.d211.s1;;
Multiple;O;O
myeloma;O;O
(;O;O
MM;O;O
);O;O
is;O;O
an;O;O
incurable;O;O
plasma;O;O
-;O;O
cell;O;O
neoplasm;O;O
for;O;O
which;O;O
most;O;O
treatments;O;O
involve;O;O
a;O;O
therapeutic;O;O
agent;O;O
combined;O;O
with;O;O
dexamethasone;B-drug;B-DDI-MedLine.d211.s1.e0
.;O;O
DDI-MedLine.d211.s2;;
The;O;O
preclinical;O;O
combination;O;O
of;O;O
lenalidomide;B-drug;B-DDI-MedLine.d211.s2.e0
with;O;O
the;O;O
mTOR;O;O
inhibitor;O;O
CCI;B-drug;B-DDI-MedLine.d211.s2.e1
-;I-drug;I-DDI-MedLine.d211.s2.e1
779;I-drug;I-DDI-MedLine.d211.s2.e1
has;O;O
displayed;O;O
synergy;O;O
in;O;O
vitro;O;O
and;O;O
represents;O;O
a;O;O
novel;O;O
combination;O;O
in;O;O
MM;O;O
.;O;O
DDI-MedLine.d154.s0;;
Enhancement;O;O
of;O;O
humoral;O;O
immune;O;O
responses;O;O
to;O;O
inactivated;O;O
Newcastle;O;O
disease;O;O
and;O;O
avian;B-group;B-DDI-MedLine.d154.s0.e0
influenza;I-group;I-DDI-MedLine.d154.s0.e0
vaccines;I-group;I-DDI-MedLine.d154.s0.e0
by;O;O
oral;O;O
administration;O;O
of;O;O
ginseng;B-drug_n;B-DDI-MedLine.d154.s0.e1
stem;I-drug_n;I-DDI-MedLine.d154.s0.e1
-;I-drug_n;I-DDI-MedLine.d154.s0.e1
and;I-drug_n;I-DDI-MedLine.d154.s0.e1
-;I-drug_n;I-DDI-MedLine.d154.s0.e1
leaf;I-drug_n;I-DDI-MedLine.d154.s0.e1
saponins;I-drug_n;I-DDI-MedLine.d154.s0.e1
in;O;O
chickens;O;O
.;O;O
DDI-MedLine.d154.s1;;
Newcastle;O;O
disease;O;O
(;O;O
ND;O;O
);O;O
and;O;O
avian;O;O
influenza;O;O
(;O;O
AI;O;O
);O;O
are;O;O
common;O;O
in;O;O
the;O;O
poultry;O;O
industry;O;O
.;O;O
DDI-MedLine.d154.s2;;
The;O;O
objective;O;O
of;O;O
this;O;O
study;O;O
was;O;O
to;O;O
evaluate;O;O
the;O;O
effect;O;O
of;O;O
oral;O;O
administration;O;O
of;O;O
ginseng;B-drug_n;B-DDI-MedLine.d154.s2.e0
stem;I-drug_n;I-DDI-MedLine.d154.s2.e0
-;I-drug_n;I-DDI-MedLine.d154.s2.e0
and;I-drug_n;I-DDI-MedLine.d154.s2.e0
-;I-drug_n;I-DDI-MedLine.d154.s2.e0
leaf;I-drug_n;I-DDI-MedLine.d154.s2.e0
saponins;I-drug_n;I-DDI-MedLine.d154.s2.e0
(;O;O
GSLS;B-drug_n;B-DDI-MedLine.d154.s2.e1
);O;O
on;O;O
the;O;O
humoral;O;O
immune;O;O
responses;O;O
of;O;O
chickens;O;O
to;O;O
inactivated;B-drug;B-DDI-MedLine.d154.s2.e3
ND;I-drug;I-DDI-MedLine.d154.s2.e3
and;I-drug;I-DDI-MedLine.d154.s2.e3
AI;I-drug;I-DDI-MedLine.d154.s2.e3
vaccines;O;O
.;O;O
DDI-MedLine.d154.s3;;
In;O;O
experiment;O;O
1;O;O
,;O;O
oral;O;O
administration;O;O
of;O;O
GSLS;B-drug_n;B-DDI-MedLine.d154.s3.e0
at;O;O
a;O;O
dose;O;O
of;O;O
5;O;O
mg;O;O
/;O;O
kg;O;O
of;O;O
BW;O;O
for;O;O
7;O;O
d;O;O
on;O;O
the;O;O
immune;O;O
response;O;O
in;O;O
chickens;O;O
intramuscularly;O;O
injected;O;O
with;O;O
inactivated;B-drug;B-DDI-MedLine.d154.s3.e1
ND;I-drug;I-DDI-MedLine.d154.s3.e1
vaccine;I-drug;I-DDI-MedLine.d154.s3.e1
was;O;O
evaluated;O;O
.;O;O
DDI-MedLine.d154.s4;;
Results;O;O
showed;O;O
that;O;O
GSLS;B-drug_n;B-DDI-MedLine.d154.s4.e0
significantly;O;O
increased;O;O
the;O;O
antibody;O;O
level;O;O
against;O;O
ND;O;O
in;O;O
the;O;O
serum;O;O
of;O;O
chickens;O;O
.;O;O
DDI-MedLine.d154.s5;;
In;O;O
experiment;O;O
2;O;O
,;O;O
the;O;O
same;O;O
regimen;O;O
of;O;O
GSLS;B-drug_n;B-DDI-MedLine.d154.s5.e0
was;O;O
administered;O;O
to;O;O
chickens;O;O
inoculated;O;O
with;O;O
inactivated;B-drug;B-DDI-MedLine.d154.s5.e1
AI;I-drug;I-DDI-MedLine.d154.s5.e1
vaccines;I-drug;I-DDI-MedLine.d154.s5.e1
,;O;O
and;O;O
an;O;O
enhanced;O;O
serum;O;O
antibody;O;O
response;O;O
to;O;O
AI;O;O
vaccination;O;O
was;O;O
also;O;O
observed;O;O
.;O;O
DDI-MedLine.d154.s6;;
Considering;O;O
the;O;O
safety;O;O
of;O;O
GSLS;B-drug_n;B-DDI-MedLine.d154.s6.e0
,;O;O
because;O;O
no;O;O
adverse;O;O
effect;O;O
was;O;O
found;O;O
throughout;O;O
the;O;O
experiments;O;O
,;O;O
GSLS;B-drug_n;B-DDI-MedLine.d154.s6.e1
may;O;O
be;O;O
a;O;O
promising;O;O
oral;O;O
adjuvant;O;O
to;O;O
improve;O;O
immunization;O;O
in;O;O
poultry;O;O
.;O;O
DDI-MedLine.d147.s0;;
Interaction;O;O
of;O;O
dacarbazine;B-drug;B-DDI-MedLine.d147.s0.e0
and;O;O
imexon;B-drug_n;B-DDI-MedLine.d147.s0.e1
,;O;O
in;O;O
vitro;O;O
and;O;O
in;O;O
vivo;O;O
,;O;O
in;O;O
human;O;O
A375;O;O
melanoma;O;O
cells;O;O
.;O;O
DDI-MedLine.d147.s1;;
We;O;O
evaluated;O;O
mechanisms;O;O
of;O;O
interaction;O;O
between;O;O
the;O;O
alkyating;O;O
agent;O;O
dacarbazine;B-drug;B-DDI-MedLine.d147.s1.e0
(;O;O
DTIC;B-drug;B-DDI-MedLine.d147.s1.e1
);O;O
and;O;O
the;O;O
pro;O;O
-;O;O
oxidant;O;O
,;O;O
imexon;B-drug;B-DDI-MedLine.d147.s1.e2
,;O;O
in;O;O
the;O;O
human;O;O
A375;O;O
melanoma;O;O
cell;O;O
line;O;O
.;O;O
DDI-MedLine.d147.s2;;
The;O;O
effect;O;O
of;O;O
DTIC;B-drug;B-DDI-MedLine.d147.s2.e0
and;O;O
imexon;B-drug;B-DDI-MedLine.d147.s2.e1
,;O;O
alone;O;O
and;O;O
in;O;O
combination;O;O
,;O;O
was;O;O
evaluated;O;O
for;O;O
growth;O;O
inhibition;O;O
(;O;O
MTT;O;O
);O;O
,;O;O
radiolabeled;O;O
drug;O;O
uptake;O;O
,;O;O
cellular;O;O
thiol;O;O
content;O;O
(;O;O
HPLC;O;O
);O;O
,;O;O
and;O;O
DNA;O;O
strand;O;O
breaks;O;O
(;O;O
Comet;O;O
assay;O;O
);O;O
.;O;O
DDI-MedLine.d147.s3;;
Pharmacokinetic;O;O
and;O;O
antitumor;O;O
effects;O;O
were;O;O
evaluated;O;O
in;O;O
mice;O;O
.;O;O
DDI-MedLine.d147.s4;;
Growth;O;O
inhibition;O;O
in;O;O
vitro;O;O
was;O;O
additive;O;O
with;O;O
the;O;O
two;O;O
drugs;O;O
.;O;O
DDI-MedLine.d147.s5;;
There;O;O
was;O;O
no;O;O
effect;O;O
on;O;O
drug;O;O
uptake;O;O
or;O;O
on;O;O
the;O;O
number;O;O
of;O;O
DNA;O;O
strand;O;O
breaks;O;O
.;O;O
DDI-MedLine.d147.s6;;
There;O;O
was;O;O
a;O;O
>;O;O
75;O;O
%;O;O
reduction;O;O
in;O;O
cellular;O;O
glutathione;O;O
and;O;O
cysteine;O;O
with;O;O
imexon;B-drug;B-DDI-MedLine.d147.s6.e0
but;O;O
not;O;O
DTIC;B-drug;B-DDI-MedLine.d147.s6.e1
.;O;O
DDI-MedLine.d147.s7;;
Co;O;O
-;O;O
administration;O;O
of;O;O
the;O;O
two;O;O
drugs;O;O
in;O;O
mice;O;O
caused;O;O
an;O;O
increase;O;O
in;O;O
the;O;O
area;O;O
under;O;O
the;O;O
curve;O;O
of;O;O
both;O;O
drugs;O;O
,;O;O
but;O;O
the;O;O
combination;O;O
was;O;O
not;O;O
effective;O;O
in;O;O
reducing;O;O
human;O;O
A375;O;O
melanoma;O;O
tumors;O;O
in;O;O
vivo;O;O
.;O;O
DDI-MedLine.d147.s8;;
Imexon;B-drug;B-DDI-MedLine.d147.s8.e0
and;O;O
dacarbazine;B-drug;B-DDI-MedLine.d147.s8.e1
show;O;O
additive;O;O
effects;O;O
in;O;O
vitro;O;O
but;O;O
not;O;O
in;O;O
vivo;O;O
in;O;O
human;O;O
A375;O;O
melanoma;O;O
cells;O;O
.;O;O
DDI-MedLine.d164.s0;;
Lapatinib;B-drug;B-DDI-MedLine.d164.s0.e0
enhances;O;O
herceptin;B-brand;B-DDI-MedLine.d164.s0.e1
-;O;O
mediated;O;O
antibody;O;O
-;O;O
dependent;O;O
cellular;O;O
cytotoxicity;O;O
by;O;O
up;O;O
-;O;O
regulation;O;O
of;O;O
cell;O;O
surface;O;O
HER2;O;O
expression;O;O
.;O;O
DDI-MedLine.d164.s1;;
Although;O;O
it;O;O
was;O;O
previously;O;O
reported;O;O
that;O;O
lapatinib;B-drug;B-DDI-MedLine.d164.s1.e0
combined;O;O
with;O;O
Herceptin;B-brand;B-DDI-MedLine.d164.s1.e1
improved;O;O
the;O;O
progression;O;O
-;O;O
free;O;O
survival;O;O
rate;O;O
compared;O;O
with;O;O
lapatinib;B-drug;B-DDI-MedLine.d164.s1.e2
alone;O;O
for;O;O
patients;O;O
with;O;O
Herceptin;B-brand;B-DDI-MedLine.d164.s1.e3
-;O;O
refractory;O;O
HER2;O;O
-;O;O
positive;O;O
metastatic;O;O
breast;O;O
cancer;O;O
,;O;O
the;O;O
mechanism;O;O
is;O;O
purported;O;O
to;O;O
be;O;O
an;O;O
antiproliferative;O;O
effect;O;O
relating;O;O
to;O;O
the;O;O
synergism;O;O
of;O;O
these;O;O
two;O;O
agents;O;O
.;O;O
DDI-MedLine.d164.s2;;
We;O;O
evaluated;O;O
how;O;O
lapatinib;B-drug;B-DDI-MedLine.d164.s2.e0
interacts;O;O
with;O;O
Herceptin;B-brand;B-DDI-MedLine.d164.s2.e1
in;O;O
HER2;O;O
-;O;O
positive;O;O
breast;O;O
cancer;O;O
,;O;O
with;O;O
a;O;O
particular;O;O
focus;O;O
on;O;O
Herceptin;B-brand;B-DDI-MedLine.d164.s2.e2
-;O;O
mediated;O;O
antibody;O;O
-;O;O
dependent;O;O
cellular;O;O
cytotoxicity;O;O
(;O;O
ADCC;O;O
);O;O
.;O;O
DDI-MedLine.d164.s3;;
In;O;O
an;O;O
in;O;O
vitro;O;O
assay;O;O
,;O;O
lapatinib;B-drug;B-DDI-MedLine.d164.s3.e0
induced;O;O
HER2;O;O
expression;O;O
at;O;O
the;O;O
cell;O;O
surface;O;O
of;O;O
HER2;O;O
-;O;O
positive;O;O
breast;O;O
cancer;O;O
cell;O;O
lines;O;O
,;O;O
leading;O;O
to;O;O
the;O;O
enhancement;O;O
of;O;O
Herceptin;B-brand;B-DDI-MedLine.d164.s3.e1
-;O;O
mediated;O;O
ADCC;O;O
.;O;O
DDI-MedLine.d164.s4;;
Furthermore;O;O
,;O;O
we;O;O
present;O;O
a;O;O
case;O;O
report;O;O
in;O;O
which;O;O
a;O;O
second;O;O
Herceptin;B-brand;B-DDI-MedLine.d164.s4.e0
treatment;O;O
following;O;O
lapatinib;B-drug;B-DDI-MedLine.d164.s4.e1
resulted;O;O
in;O;O
the;O;O
marked;O;O
shrinkage;O;O
of;O;O
multiple;O;O
metastatic;O;O
tumors;O;O
in;O;O
HER2;O;O
-;O;O
positive;O;O
breast;O;O
cancer;O;O
.;O;O
DDI-MedLine.d164.s5;;
Lapatinib;B-drug;B-DDI-MedLine.d164.s5.e0
may;O;O
have;O;O
the;O;O
potential;O;O
to;O;O
convert;O;O
Herceptin;B-brand;B-DDI-MedLine.d164.s5.e1
-;O;O
refractory;O;O
to;O;O
Herceptin;B-brand;B-DDI-MedLine.d164.s5.e2
-;O;O
sensitive;O;O
tumors;O;O
in;O;O
HER2;O;O
-;O;O
positive;O;O
breast;O;O
cancer;O;O
by;O;O
up;O;O
-;O;O
regulation;O;O
of;O;O
the;O;O
cell;O;O
surface;O;O
expression;O;O
of;O;O
HER2;O;O
.;O;O
DDI-MedLine.d201.s0;;
Antitumor;O;O
effects;O;O
of;O;O
CRM197;B-drug_n;B-DDI-MedLine.d201.s0.e0
,;O;O
a;O;O
specific;O;O
inhibitor;O;O
of;O;O
HB;O;O
-;O;O
EGF;O;O
,;O;O
in;O;O
T;O;O
-;O;O
cell;O;O
acute;O;O
lymphoblastic;O;O
leukemia;O;O
.;O;O
DDI-MedLine.d201.s1;;
The;O;O
therapeutic;O;O
outcome;O;O
for;O;O
T;O;O
-;O;O
cell;O;O
acute;O;O
lymphoblastic;O;O
leukemia;O;O
(;O;O
T;O;O
-;O;O
ALL;O;O
);O;O
remains;O;O
poor;O;O
;;O;O
DDI-MedLine.d201.s2;;
thus;O;O
,;O;O
novel;O;O
,;O;O
targeted;O;O
therapies;O;O
are;O;O
urgently;O;O
needed;O;O
.;O;O
DDI-MedLine.d201.s3;;
Recently;O;O
,;O;O
we;O;O
showed;O;O
that;O;O
heparin;O;O
-;O;O
binding;O;O
epidermal;O;O
growth;O;O
factor;O;O
-;O;O
like;O;O
growth;O;O
factor;O;O
(;O;O
HB;O;O
-;O;O
EGF;O;O
);O;O
,;O;O
a;O;O
member;O;O
of;O;O
the;O;O
EGF;O;O
family;O;O
,;O;O
is;O;O
a;O;O
promising;O;O
target;O;O
for;O;O
the;O;O
treatment;O;O
of;O;O
various;O;O
types;O;O
of;O;O
cancer;O;O
.;O;O
DDI-MedLine.d201.s4;;
The;O;O
aim;O;O
of;O;O
the;O;O
present;O;O
study;O;O
was;O;O
to;O;O
investigate;O;O
whether;O;O
HB;O;O
-;O;O
EGF;O;O
is;O;O
a;O;O
therapeutic;O;O
target;O;O
for;O;O
T;O;O
-;O;O
ALL;O;O
,;O;O
and;O;O
to;O;O
further;O;O
elucidate;O;O
the;O;O
antitumor;O;O
effects;O;O
of;O;O
a;O;O
specific;O;O
inhibitor;O;O
of;O;O
HB;O;O
-;O;O
EGF;O;O
,;O;O
cross;B-drug_n;B-DDI-MedLine.d201.s4.e0
-;I-drug_n;I-DDI-MedLine.d201.s4.e0
reacting;I-drug_n;I-DDI-MedLine.d201.s4.e0
material;I-drug_n;I-DDI-MedLine.d201.s4.e0
197;I-drug_n;I-DDI-MedLine.d201.s4.e0
(;O;O
CRM197;B-drug_n;B-DDI-MedLine.d201.s4.e1
);O;O
.;O;O
DDI-MedLine.d201.s5;;
We;O;O
elucidated;O;O
the;O;O
expression;O;O
of;O;O
HB;O;O
-;O;O
EGF;O;O
in;O;O
T;O;O
-;O;O
ALL;O;O
cell;O;O
lines;O;O
,;O;O
and;O;O
evaluated;O;O
the;O;O
effect;O;O
of;O;O
CRM197;B-drug_n;B-DDI-MedLine.d201.s5.e0
on;O;O
these;O;O
cells;O;O
alone;O;O
or;O;O
in;O;O
combination;O;O
with;O;O
anticancer;B-group;B-DDI-MedLine.d201.s5.e1
agent;I-group;I-DDI-MedLine.d201.s5.e1
.;O;O
DDI-MedLine.d201.s6;;
The;O;O
expression;O;O
of;O;O
EGFR;O;O
and;O;O
EGFR;O;O
ligands;O;O
was;O;O
determined;O;O
by;O;O
flow;O;O
cytometry;O;O
,;O;O
RT;O;O
-;O;O
PCR;O;O
and;O;O
real;O;O
-;O;O
time;O;O
quantitative;O;O
PCR;O;O
.;O;O
DDI-MedLine.d201.s7;;
Induction;O;O
of;O;O
apoptosis;O;O
was;O;O
assessed;O;O
by;O;O
TUNEL;O;O
assay;O;O
.;O;O
DDI-MedLine.d201.s8;;
HB;O;O
-;O;O
EGF;O;O
was;O;O
strongly;O;O
expressed;O;O
by;O;O
T;O;O
-;O;O
ALL;O;O
cell;O;O
lines;O;O
,;O;O
and;O;O
the;O;O
expression;O;O
of;O;O
both;O;O
HB;O;O
-;O;O
EGF;O;O
and;O;O
EGFR;O;O
was;O;O
enhanced;O;O
by;O;O
doxorubicin;B-drug;B-DDI-MedLine.d201.s8.e0
.;O;O
DDI-MedLine.d201.s9;;
CRM197;B-drug_n;B-DDI-MedLine.d201.s9.e0
induced;O;O
apoptosis;O;O
,;O;O
and;O;O
furthermore;O;O
,;O;O
the;O;O
combination;O;O
of;O;O
CRM197;B-drug_n;B-DDI-MedLine.d201.s9.e1
plus;O;O
doxorubicin;B-drug;B-DDI-MedLine.d201.s9.e2
enhanced;O;O
cytotoxicity;O;O
in;O;O
a;O;O
T;O;O
-;O;O
ALL;O;O
cell;O;O
line;O;O
.;O;O
DDI-MedLine.d201.s10;;
These;O;O
results;O;O
suggest;O;O
that;O;O
HB;O;O
-;O;O
EGF;O;O
is;O;O
a;O;O
promising;O;O
therapeutic;O;O
target;O;O
for;O;O
T;O;O
-;O;O
ALL;O;O
.;O;O
DDI-MedLine.d227.s0;;
Ephedrine;B-drug;B-DDI-MedLine.d227.s0.e0
enhances;O;O
the;O;O
antinociceptive;O;O
effect;O;O
of;O;O
dexmedetomidine;B-drug;B-DDI-MedLine.d227.s0.e1
in;O;O
mice;O;O
.;O;O
DDI-MedLine.d227.s1;;
Dexmedetomidine;B-drug;B-DDI-MedLine.d227.s1.e0
,;O;O
a;O;O
highly;O;O
selective;O;O
alpha;O;O
-;O;O
2;O;O
-;O;O
adrenoceptor;O;O
agonist;O;O
,;O;O
was;O;O
recently;O;O
introduced;O;O
into;O;O
clinical;O;O
practice;O;O
for;O;O
its;O;O
sedative;O;O
and;O;O
analgesic;O;O
properties;O;O
.;O;O
DDI-MedLine.d227.s2;;
The;O;O
purpose;O;O
of;O;O
this;O;O
study;O;O
was;O;O
to;O;O
evaluate;O;O
whether;O;O
the;O;O
psychostimulant;O;O
drug;O;O
ephedrine;B-drug;B-DDI-MedLine.d227.s2.e0
has;O;O
any;O;O
effect;O;O
on;O;O
dexmedetomidine;B-drug;B-DDI-MedLine.d227.s2.e1
-;O;O
induced;O;O
antinociception;O;O
and;O;O
locomotor;O;O
inhibitor;O;O
activity;O;O
in;O;O
mice;O;O
in;O;O
acute;O;O
application;O;O
.;O;O
DDI-MedLine.d227.s3;;
In;O;O
both;O;O
sexes;O;O
of;O;O
swiss;O;O
albino;O;O
mice;O;O
;;O;O
DDI-MedLine.d227.s4;;
antinociception;O;O
was;O;O
assessed;O;O
with;O;O
hot;O;O
-;O;O
plate;O;O
test;O;O
and;O;O
the;O;O
locomotor;O;O
,;O;O
exploratory;O;O
activities;O;O
were;O;O
assessed;O;O
with;O;O
holed;O;O
open;O;O
field;O;O
test;O;O
.;O;O
DDI-MedLine.d227.s5;;
The;O;O
animals;O;O
were;O;O
received;O;O
;;O;O
DDI-MedLine.d227.s6;;
saline;O;O
+;O;O
saline;O;O
,;O;O
ephedrine;B-drug;B-DDI-MedLine.d227.s6.e0
(;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
+;O;O
saline;O;O
,;O;O
saline;O;O
+;O;O
dexmedetomidine;B-drug;B-DDI-MedLine.d227.s6.e1
(;O;O
15;O;O
g;O;O
/;O;O
kg;O;O
);O;O
and;O;O
ephedrine;B-drug;B-DDI-MedLine.d227.s6.e2
(;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
+;O;O
dexmedetomidine;B-drug;B-DDI-MedLine.d227.s6.e3
(;O;O
15;O;O
g;O;O
/;O;O
kg;O;O
);O;O
,;O;O
intraperitoneally;O;O
,;O;O
30;O;O
min;O;O
before;O;O
hot;O;O
plate;O;O
or;O;O
holed;O;O
open;O;O
field;O;O
tests;O;O
.;O;O
DDI-MedLine.d227.s7;;
In;O;O
the;O;O
hot;O;O
plate;O;O
test;O;O
in;O;O
mice;O;O
,;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
15;O;O
g;O;O
/;O;O
kg;O;O
dexmedetomidine;B-drug;B-DDI-MedLine.d227.s7.e0
with;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
ephedrine;B-drug;B-DDI-MedLine.d227.s7.e1
intraperitoneally;O;O
not;O;O
only;O;O
enhanced;O;O
,;O;O
but;O;O
also;O;O
prolonged;O;O
the;O;O
duration;O;O
of;O;O
antinociception;O;O
induced;O;O
by;O;O
dexmedetomidine;B-drug;B-DDI-MedLine.d227.s7.e2
.;O;O
DDI-MedLine.d227.s8;;
At;O;O
the;O;O
same;O;O
time;O;O
,;O;O
the;O;O
locomotor;O;O
inhibitory;O;O
effect;O;O
of;O;O
dexmedetomidine;B-drug;B-DDI-MedLine.d227.s8.e0
was;O;O
counteracted;O;O
by;O;O
ephedrine;B-drug;B-DDI-MedLine.d227.s8.e1
.;O;O
DDI-MedLine.d227.s9;;
We;O;O
concluded;O;O
that;O;O
the;O;O
combined;O;O
administration;O;O
of;O;O
dexmedetomidine;B-drug;B-DDI-MedLine.d227.s9.e0
with;O;O
ephedrine;B-drug;B-DDI-MedLine.d227.s9.e1
may;O;O
have;O;O
beneficial;O;O
effects;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
pain;O;O
without;O;O
causing;O;O
sedation;O;O
,;O;O
which;O;O
limits;O;O
the;O;O
use;O;O
of;O;O
dexmedetomidine;B-drug;B-DDI-MedLine.d227.s9.e2
as;O;O
an;O;O
analgesic;B-group;B-DDI-MedLine.d227.s9.e3
in;O;O
humans;O;O
.;O;O
DDI-MedLine.d200.s0;;
[;O;O
Efficacy;O;O
of;O;O
fixed;O;O
combination;O;O
amlodipine;B-drug;B-DDI-MedLine.d200.s0.e0
/;O;O
valsartan;B-drug;B-DDI-MedLine.d200.s0.e1
in;O;O
hospitalized;O;O
patients;O;O
with;O;O
hypertensive;O;O
disease;O;O
];O;O
DDI-MedLine.d200.s1;;
Efficacy;O;O
and;O;O
tolerability;O;O
of;O;O
fixed;O;O
amlodipine;B-drug;B-DDI-MedLine.d200.s1.e0
/;O;O
valsartan;B-drug;B-DDI-MedLine.d200.s1.e1
combination;O;O
was;O;O
studied;O;O
in;O;O
86;O;O
patients;O;O
with;O;O
hypertensive;O;O
disease;O;O
hospitalized;O;O
in;O;O
departments;O;O
of;O;O
general;O;O
internal;O;O
medicine;O;O
or;O;O
cardiology;O;O
.;O;O
DDI-MedLine.d200.s2;;
All;O;O
patients;O;O
had;O;O
indications;O;O
for;O;O
antihypertensive;O;O
therapy;O;O
and;O;O
were;O;O
randomized;O;O
either;O;O
to;O;O
fixed;O;O
combination;O;O
amlodipine;B-drug;B-DDI-MedLine.d200.s2.e0
/;O;O
valsartan;B-drug;B-DDI-MedLine.d200.s2.e1
(;O;O
n=43;O;O
);O;O
or;O;O
to;O;O
therapy;O;O
which;O;O
corresponded;O;O
to;O;O
the;O;O
hospital;O;O
formulary;O;O
(;O;O
n=43;O;O
);O;O
.;O;O
DDI-MedLine.d200.s3;;
Correction;O;O
of;O;O
antihypertensive;B-group;B-DDI-MedLine.d200.s3.e0
therapy;O;O
was;O;O
performed;O;O
by;O;O
treating;O;O
physician;O;O
at;O;O
daily;O;O
rounds;O;O
.;O;O
DDI-MedLine.d200.s4;;
Self;O;O
-;O;O
control;O;O
of;O;O
blood;O;O
pressure;O;O
(;O;O
BP;O;O
);O;O
was;O;O
performed;O;O
by;O;O
patients;O;O
with;O;O
the;O;O
use;O;O
of;O;O
UA767PC;O;O
apparatus;O;O
.;O;O
DDI-MedLine.d200.s5;;
Results;O;O
of;O;O
BP;O;O
self;O;O
-;O;O
control;O;O
were;O;O
compared;O;O
with;O;O
clinical;O;O
measurements;O;O
in;O;O
order;O;O
to;O;O
detect;O;O
concealed;O;O
inefficacy;O;O
of;O;O
treatment;O;O
.;O;O
DDI-MedLine.d200.s6;;
Results;O;O
.;O;O
DDI-MedLine.d200.s7;;
Rate;O;O
of;O;O
achievement;O;O
of;O;O
target;O;O
BP;O;O
with;O;O
fixed;O;O
combination;O;O
amlodipine;B-drug;B-DDI-MedLine.d200.s7.e0
/;O;O
valsartan;B-drug;B-DDI-MedLine.d200.s7.e1
(;O;O
93;O;O
%;O;O
);O;O
was;O;O
comparable;O;O
with;O;O
that;O;O
on;O;O
traditional;O;O
therapy;O;O
(;O;O
90;O;O
%;O;O
);O;O
.;O;O
DDI-MedLine.d200.s8;;
But;O;O
the;O;O
use;O;O
of;O;O
fixed;O;O
combination;O;O
amlodipine;B-drug;B-DDI-MedLine.d200.s8.e0
/;O;O
valsartan;B-drug;B-DDI-MedLine.d200.s8.e1
compared;O;O
with;O;O
traditional;O;O
therapy;O;O
was;O;O
associated;O;O
with;O;O
lower;O;O
clinical;O;O
and;O;O
self;O;O
measured;O;O
BP;O;O
,;O;O
quicker;O;O
achievement;O;O
of;O;O
target;O;O
BP;O;O
(;O;O
5.8+;O;O
/;O;O
-;O;O
2.3;O;O
and;O;O
9.2+;O;O
/;O;O
-;O;O
1.8;O;O
days;O;O
,;O;O
respectively;O;O
,;O;O
0.05;O;O
);O;O
,;O;O
lesser;O;O
number;O;O
of;O;O
antihypertensive;B-group;B-DDI-MedLine.d200.s8.e2
drugs;I-group;I-DDI-MedLine.d200.s8.e2
(;O;O
2.5+;O;O
/;O;O
-;O;O
0.6;O;O
and;O;O
3.0+;O;O
/;O;O
-;O;O
0.9;O;O
days;O;O
,;O;O
respectively;O;O
);O;O
,;O;O
lower;O;O
rate;O;O
of;O;O
concealed;O;O
inefficacy;O;O
of;O;O
treatment;O;O
(;O;O
12;O;O
and;O;O
31;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
0.05;O;O
);O;O
.;O;O
DDI-MedLine.d200.s9;;
Conclusions;O;O
.;O;O
DDI-MedLine.d200.s10;;
We;O;O
have;O;O
demonstrated;O;O
appropriateness;O;O
of;O;O
inhospital;O;O
administration;O;O
of;O;O
fixed;O;O
amlodipine;B-drug;B-DDI-MedLine.d200.s10.e0
/;O;O
valsartan;B-drug;B-DDI-MedLine.d200.s10.e1
combination;O;O
as;O;O
an;O;O
approach;O;O
allowing;O;O
to;O;O
achieve;O;O
target;O;O
BP;O;O
in;O;O
shorter;O;O
time;O;O
,;O;O
with;O;O
the;O;O
use;O;O
of;O;O
fewer;O;O
antihypertensive;B-group;B-DDI-MedLine.d200.s10.e2
drugs;I-group;I-DDI-MedLine.d200.s10.e2
,;O;O
and;O;O
diminishing;O;O
concealed;O;O
inefficacy;O;O
of;O;O
treatment;O;O
.;O;O
DDI-MedLine.d193.s0;;
Ticagrelor;B-drug;B-DDI-MedLine.d193.s0.e0
(;O;O
Brilinta);B-brand;B-DDI-MedLine.d193.s0.e1
-;O;O
-;O;O
better;O;O
than;O;O
clopidogrel;B-drug;B-DDI-MedLine.d193.s0.e2
(;O;O
Plavix;B-brand;B-DDI-MedLine.d193.s0.e3
);O;O
DDI-MedLine.d193.s1;;
The;O;O
FDA;O;O
has;O;O
approved;O;O
ticagrelor;B-drug;B-DDI-MedLine.d193.s1.e0
(;O;O
Brilinta;B-brand;B-DDI-MedLine.d193.s1.e1
-;O;O
AstraZeneca;O;O
);O;O
,;O;O
an;O;O
oral;O;O
antiplatelet;B-group;B-DDI-MedLine.d193.s1.e2
drug;I-group;I-DDI-MedLine.d193.s1.e2
,;O;O
for;O;O
use;O;O
with;O;O
low;O;O
-;O;O
dose;O;O
aspirin;B-brand;B-DDI-MedLine.d193.s1.e3
to;O;O
reduce;O;O
the;O;O
rate;O;O
of;O;O
thrombotic;O;O
cardiovascular;O;O
events;O;O
in;O;O
patients;O;O
with;O;O
acute;O;O
coronary;O;O
syndrome;O;O
(;O;O
ACS;O;O
);O;O
.;O;O
DDI-MedLine.d193.s2;;
It;O;O
will;O;O
compete;O;O
with;O;O
clopidogrel;B-drug;B-DDI-MedLine.d193.s2.e0
(;O;O
Plavix;B-brand;B-DDI-MedLine.d193.s2.e1
);O;O
and;O;O
prasugrel;B-drug;B-DDI-MedLine.d193.s2.e2
(;O;O
Effient;B-brand;B-DDI-MedLine.d193.s2.e3
);O;O
for;O;O
such;O;O
use;O;O
.;O;O
DDI-MedLine.d193.s3;;
Clopidogrel;B-drug;B-DDI-MedLine.d193.s3.e0
is;O;O
expected;O;O
to;O;O
become;O;O
available;O;O
generically;O;O
in;O;O
the;O;O
US;O;O
within;O;O
the;O;O
next;O;O
few;O;O
months;O;O
.;O;O
DDI-MedLine.d195.s0;;
Influence;O;O
of;O;O
piperine;B-drug_n;B-DDI-MedLine.d195.s0.e0
on;O;O
ibuprofen;B-drug;B-DDI-MedLine.d195.s0.e1
induced;O;O
antinociception;O;O
and;O;O
its;O;O
pharmacokinetics;O;O
.;O;O
DDI-MedLine.d195.s1;;
Piperine;B-drug_n;B-DDI-MedLine.d195.s1.e0
(;O;O
CAS;O;O
94;O;O
-;O;O
62;O;O
-;O;O
2;O;O
);O;O
,;O;O
an;O;O
alkaloid;O;O
obtained;O;O
from;O;O
Piper;O;O
nigrum;O;O
and;O;O
P.;O;O
DDI-MedLine.d195.s2;;
longum;O;O
,;O;O
is;O;O
a;O;O
known;O;O
inhibitor;O;O
of;O;O
various;O;O
enzymes;O;O
(;O;O
CYP;O;O
isozymes;O;O
);O;O
responsible;O;O
for;O;O
biotransformation;O;O
of;O;O
drugs;O;O
.;O;O
DDI-MedLine.d195.s3;;
By;O;O
inhibiting;O;O
the;O;O
metabolism;O;O
of;O;O
drugs;O;O
,;O;O
piperine;B-drug_n;B-DDI-MedLine.d195.s3.e0
improves;O;O
the;O;O
bioavailability;O;O
of;O;O
drugs;O;O
.;O;O
DDI-MedLine.d195.s4;;
In;O;O
the;O;O
present;O;O
study;O;O
piperine;B-drug_n;B-DDI-MedLine.d195.s4.e0
(;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
significantly;O;O
increased;O;O
the;O;O
dose;O;O
-;O;O
dependent;O;O
antinociceptive;O;O
activity;O;O
of;O;O
ibuprofen;B-drug;B-DDI-MedLine.d195.s4.e1
evaluated;O;O
by;O;O
both;O;O
acetic;B-drug;B-DDI-MedLine.d195.s4.e2
acid;I-drug;I-DDI-MedLine.d195.s4.e2
writhing;O;O
and;O;O
formalin;O;O
test;O;O
,;O;O
when;O;O
it;O;O
was;O;O
administered;O;O
with;O;O
ibuprofen;B-drug;B-DDI-MedLine.d195.s4.e3
.;O;O
DDI-MedLine.d195.s5;;
Ibuprofen;B-drug;B-DDI-MedLine.d195.s5.e0
plasma;O;O
concentration;O;O
was;O;O
also;O;O
increased;O;O
when;O;O
it;O;O
was;O;O
administered;O;O
with;O;O
piperine;B-drug_n;B-DDI-MedLine.d195.s5.e1
.;O;O
DDI-MedLine.d195.s6;;
The;O;O
synergistic;O;O
antinociception;O;O
activity;O;O
of;O;O
ibuprofen;B-drug;B-DDI-MedLine.d195.s6.e0
when;O;O
administered;O;O
with;O;O
piperine;B-drug_n;B-DDI-MedLine.d195.s6.e1
can;O;O
be;O;O
attributed;O;O
to;O;O
increased;O;O
plasma;O;O
concentration;O;O
of;O;O
ibuprofen;B-drug;B-DDI-MedLine.d195.s6.e2
.;O;O
DDI-MedLine.d195.s7;;
From;O;O
this;O;O
study;O;O
it;O;O
can;O;O
be;O;O
concluded;O;O
that;O;O
piperine;B-drug_n;B-DDI-MedLine.d195.s7.e0
can;O;O
be;O;O
used;O;O
as;O;O
a;O;O
bioenhancer;O;O
along;O;O
with;O;O
ibuprofen;B-drug;B-DDI-MedLine.d195.s7.e1
.;O;O
DDI-DrugBank.d610.s0;;
Pharmacokinetic;O;O
properties;O;O
of;O;O
abacavir;B-drug;B-DDI-DrugBank.d610.s0.e0
were;O;O
not;O;O
altered;O;O
by;O;O
the;O;O
addition;O;O
of;O;O
either;O;O
lamivudine;B-drug;B-DDI-DrugBank.d610.s0.e1
or;O;O
zidovudine;B-drug;B-DDI-DrugBank.d610.s0.e2
or;O;O
the;O;O
combination;O;O
of;O;O
lamivudine;B-drug;B-DDI-DrugBank.d610.s0.e3
and;O;O
zidovudine;B-drug;B-DDI-DrugBank.d610.s0.e4
.;O;O
DDI-DrugBank.d610.s1;;
No;O;O
clinically;O;O
significant;O;O
changes;O;O
to;O;O
lamivudine;B-drug;B-DDI-DrugBank.d610.s1.e0
or;O;O
zidovudine;B-drug;B-DDI-DrugBank.d610.s1.e1
pharmacokinetics;O;O
were;O;O
observed;O;O
following;O;O
concomitant;O;O
administration;O;O
of;O;O
abacavir;B-drug;B-DDI-DrugBank.d610.s1.e2
.;O;O
DDI-DrugBank.d610.s2;;
Abacavir;B-drug;B-DDI-DrugBank.d610.s2.e0
has;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetic;O;O
properties;O;O
of;O;O
ethanol;B-drug;B-DDI-DrugBank.d610.s2.e1
.;O;O
DDI-DrugBank.d610.s3;;
Ethanol;B-drug;B-DDI-DrugBank.d610.s3.e0
decreases;O;O
the;O;O
elimination;O;O
of;O;O
abacavir;B-drug;B-DDI-DrugBank.d610.s3.e1
causing;O;O
an;O;O
increase;O;O
in;O;O
overall;O;O
exposure;O;O
.;O;O
The;O;O
addition;O;O
of;O;O
methadone;B-drug;B-DDI-DrugBank.d610.s3.e2
has;O;O
no;O;O
clinically;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetic;O;O
properties;O;O
of;O;O
abacavir;B-drug;B-DDI-DrugBank.d610.s3.e3
.;O;O
DDI-DrugBank.d610.s4;;
In;O;O
a;O;O
study;O;O
of;O;O
11;O;O
HIV;O;O
-;O;O
infected;O;O
patients;O;O
receiving;O;O
methadone;B-drug;B-DDI-DrugBank.d610.s4.e0
-;O;O
maintenance;O;O
therapy;O;O
(;O;O
40;O;O
mg;O;O
and;O;O
90;O;O
mg;O;O
daily;O;O
);O;O
with;O;O
600;O;O
mg;O;O
of;O;O
ZIAGEN;B-brand;B-DDI-DrugBank.d610.s4.e1
twice;O;O
daily;O;O
(;O;O
twice;O;O
the;O;O
currently;O;O
recommended;O;O
dose;O;O
);O;O
,;O;O
oral;O;O
methadone;B-drug;B-DDI-DrugBank.d610.s4.e2
clearance;O;O
increased;O;O
22;O;O
%;O;O
(;O;O
90;O;O
%;O;O
CI;O;O
6;O;O
%;O;O
to;O;O
42;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d610.s5;;
This;O;O
alteration;O;O
will;O;O
not;O;O
result;O;O
in;O;O
a;O;O
methadone;B-drug;B-DDI-DrugBank.d610.s5.e0
dose;O;O
modification;O;O
in;O;O
the;O;O
majority;O;O
of;O;O
patients;O;O
;;O;O
DDI-DrugBank.d610.s6;;
however;O;O
,;O;O
an;O;O
increased;O;O
methadone;B-drug;B-DDI-DrugBank.d610.s6.e0
dose;O;O
may;O;O
be;O;O
required;O;O
in;O;O
a;O;O
small;O;O
number;O;O
of;O;O
patients;O;O
.;O;O
DDI-DrugBank.d572.s0;;
Cholestyramine;B-drug;B-DDI-DrugBank.d572.s0.e0
:;O;O
Concomitant;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d572.s0.e1
administration;O;O
decreased;O;O
the;O;O
mean;O;O
AUC;O;O
of;O;O
total;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s0.e2
approximately;O;O
55;O;O
%;O;O
.;O;O
DDI-DrugBank.d572.s1;;
The;O;O
incremental;O;O
LDL;O;O
-;O;O
C;O;O
reduction;O;O
due;O;O
to;O;O
adding;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s1.e0
to;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d572.s1.e1
may;O;O
be;O;O
reduced;O;O
by;O;O
this;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d572.s2;;
Fibrates;B-group;B-DDI-DrugBank.d572.s2.e0
:;O;O
The;O;O
safety;O;O
and;O;O
effectiveness;O;O
of;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s2.e1
administered;O;O
with;O;O
fibrates;B-group;B-DDI-DrugBank.d572.s2.e2
have;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d572.s3;;
Fibrates;B-group;B-DDI-DrugBank.d572.s3.e0
may;O;O
increase;O;O
cholesterol;O;O
excretion;O;O
into;O;O
the;O;O
bile;O;O
,;O;O
leading;O;O
to;O;O
cholelithiasis;O;O
.;O;O
DDI-DrugBank.d572.s4;;
In;O;O
a;O;O
preclinical;O;O
study;O;O
in;O;O
dogs;O;O
,;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s4.e0
increased;O;O
cholesterol;O;O
in;O;O
the;O;O
gallbladder;O;O
bile;O;O
.;O;O
DDI-DrugBank.d572.s5;;
Co;O;O
-;O;O
administration;O;O
of;O;O
ZETIA;B-brand;B-DDI-DrugBank.d572.s5.e0
with;O;O
fibrates;B-group;B-DDI-DrugBank.d572.s5.e1
is;O;O
not;O;O
recommended;O;O
until;O;O
use;O;O
in;O;O
patients;O;O
is;O;O
studied;O;O
.;O;O
DDI-DrugBank.d572.s6;;
Fenofibrate;B-drug;B-DDI-DrugBank.d572.s6.e0
:;O;O
In;O;O
a;O;O
pharmacokinetic;O;O
study;O;O
,;O;O
concomitant;O;O
fenofibrate;B-drug;B-DDI-DrugBank.d572.s6.e1
administration;O;O
increased;O;O
total;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s6.e2
concentrations;O;O
approximately;O;O
1.5;O;O
-;O;O
fold;O;O
.;O;O
DDI-DrugBank.d572.s7;;
Gemfibrozil;B-drug;B-DDI-DrugBank.d572.s7.e0
:;O;O
In;O;O
a;O;O
pharmacokinetic;O;O
study;O;O
,;O;O
concomitant;O;O
gemfibrozil;B-drug;B-DDI-DrugBank.d572.s7.e1
administration;O;O
increased;O;O
total;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s7.e2
concentrations;O;O
approximately;O;O
1.7;O;O
-;O;O
fold;O;O
.;O;O
DDI-DrugBank.d572.s8;;
HMG;B-group;B-DDI-DrugBank.d572.s8.e0
-;I-group;I-DDI-DrugBank.d572.s8.e0
CoA;I-group;I-DDI-DrugBank.d572.s8.e0
reductase;I-group;I-DDI-DrugBank.d572.s8.e0
inhibitors;I-group;I-DDI-DrugBank.d572.s8.e0
:;O;O
No;O;O
clinically;O;O
significant;O;O
pharmacokinetic;O;O
interactions;O;O
were;O;O
seen;O;O
when;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s8.e1
was;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d572.s8.e2
,;O;O
simvastatin;B-drug;B-DDI-DrugBank.d572.s8.e3
,;O;O
pravastatin;B-drug;B-DDI-DrugBank.d572.s8.e4
,;O;O
lovastatin;B-drug;B-DDI-DrugBank.d572.s8.e5
,;O;O
or;O;O
fluvastatin;B-drug;B-DDI-DrugBank.d572.s8.e6
.;O;O
DDI-DrugBank.d572.s9;;
Cyclosporine;B-drug;B-DDI-DrugBank.d572.s9.e0
:;O;O
The;O;O
total;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s9.e1
level;O;O
increased;O;O
12;O;O
-;O;O
fold;O;O
in;O;O
one;O;O
renal;O;O
transplant;O;O
patient;O;O
receiving;O;O
multiple;O;O
medications;O;O
,;O;O
including;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d572.s9.e2
.;O;O
DDI-DrugBank.d572.s10;;
Patients;O;O
who;O;O
take;O;O
both;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s10.e0
and;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d572.s10.e1
should;O;O
be;O;O
carefully;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d572.s11;;
Carcinogenesis;O;O
,;O;O
Mutagenesis;O;O
,;O;O
Impairment;O;O
of;O;O
Fertility;O;O
A;O;O
104;O;O
-;O;O
week;O;O
dietary;O;O
carcinogenicity;O;O
study;O;O
with;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s11.e0
was;O;O
conducted;O;O
in;O;O
rats;O;O
at;O;O
doses;O;O
up;O;O
to;O;O
1500;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
(;O;O
males;O;O
);O;O
and;O;O
500;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
(;O;O
females;O;O
);O;O
(;O;O
~20;O;O
times;O;O
the;O;O
human;O;O
exposure;O;O
at;O;O
10;O;O
mg;O;O
daily;O;O
based;O;O
on;O;O
AUC0;O;O
-;O;O
24hr;O;O
for;O;O
total;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s11.e1
);O;O
.;O;O
DDI-DrugBank.d572.s12;;
A;O;O
104;O;O
-;O;O
week;O;O
dietary;O;O
carcinogenicity;O;O
study;O;O
with;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s12.e0
was;O;O
also;O;O
conducted;O;O
in;O;O
mice;O;O
at;O;O
doses;O;O
up;O;O
to;O;O
500;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
(;O;O
>;O;O
150;O;O
times;O;O
the;O;O
human;O;O
exposure;O;O
at;O;O
10;O;O
mg;O;O
daily;O;O
based;O;O
on;O;O
AUC0;O;O
-;O;O
24hr;O;O
for;O;O
total;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s12.e1
);O;O
.;O;O
DDI-DrugBank.d572.s13;;
There;O;O
were;O;O
no;O;O
statistically;O;O
significant;O;O
increases;O;O
in;O;O
tumor;O;O
incidences;O;O
in;O;O
drug;O;O
-;O;O
treated;O;O
rats;O;O
or;O;O
mice;O;O
.;O;O
DDI-DrugBank.d572.s14;;
No;O;O
evidence;O;O
of;O;O
mutagenicity;O;O
was;O;O
observed;O;O
in;O;O
vitro;O;O
in;O;O
a;O;O
microbial;O;O
mutagenicity;O;O
(;O;O
Ames;O;O
);O;O
test;O;O
with;O;O
Salmonella;O;O
typhimurium;O;O
and;O;O
Escherichia;O;O
coli;O;O
with;O;O
or;O;O
without;O;O
metabolic;O;O
activation;O;O
.;O;O
DDI-DrugBank.d572.s15;;
No;O;O
evidence;O;O
of;O;O
clastogenicity;O;O
was;O;O
observed;O;O
in;O;O
vitro;O;O
in;O;O
a;O;O
chromosomal;O;O
aberration;O;O
assay;O;O
in;O;O
human;O;O
peripheral;O;O
blood;O;O
lymphocytes;O;O
with;O;O
or;O;O
without;O;O
metabolic;O;O
activation;O;O
.;O;O
DDI-DrugBank.d572.s16;;
In;O;O
addition;O;O
,;O;O
there;O;O
was;O;O
no;O;O
evidence;O;O
of;O;O
genotoxicity;O;O
in;O;O
the;O;O
in;O;O
vivo;O;O
mouse;O;O
micronucleus;O;O
test;O;O
.;O;O
DDI-DrugBank.d572.s17;;
In;O;O
oral;O;O
(;O;O
gavage;O;O
);O;O
fertility;O;O
studies;O;O
of;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s17.e0
conducted;O;O
in;O;O
rats;O;O
,;O;O
there;O;O
was;O;O
no;O;O
evidence;O;O
of;O;O
reproductive;O;O
toxicity;O;O
at;O;O
doses;O;O
up;O;O
to;O;O
1000;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
in;O;O
male;O;O
or;O;O
female;O;O
rats;O;O
(;O;O
~7;O;O
times;O;O
the;O;O
human;O;O
exposure;O;O
at;O;O
10;O;O
mg;O;O
daily;O;O
based;O;O
on;O;O
AUC0;O;O
-;O;O
24hr;O;O
for;O;O
total;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s17.e1
);O;O
.;O;O
DDI-DrugBank.d572.s18;;
Pregnancy;O;O
Pregnancy;O;O
Category;O;O
:;O;O
C;O;O
There;O;O
are;O;O
no;O;O
adequate;O;O
and;O;O
well;O;O
-;O;O
controlled;O;O
studies;O;O
of;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s18.e0
in;O;O
pregnant;O;O
women;O;O
.;O;O
DDI-DrugBank.d572.s19;;
Ezetimibe;B-drug;B-DDI-DrugBank.d572.s19.e0
should;O;O
be;O;O
used;O;O
during;O;O
pregnancy;O;O
only;O;O
if;O;O
the;O;O
potential;O;O
benefit;O;O
justifies;O;O
the;O;O
risk;O;O
to;O;O
the;O;O
fetus;O;O
.;O;O
DDI-DrugBank.d572.s20;;
In;O;O
oral;O;O
(;O;O
gavage;O;O
);O;O
embryo;O;O
-;O;O
fetal;O;O
development;O;O
studies;O;O
of;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s20.e0
conducted;O;O
in;O;O
rats;O;O
and;O;O
rabbits;O;O
during;O;O
organogenesis;O;O
,;O;O
there;O;O
was;O;O
no;O;O
evidence;O;O
of;O;O
embryolethal;O;O
effects;O;O
at;O;O
the;O;O
doses;O;O
tested;O;O
(;O;O
250;O;O
,;O;O
500;O;O
,;O;O
1000;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
);O;O
.;O;O
DDI-DrugBank.d572.s21;;
In;O;O
rats;O;O
,;O;O
increased;O;O
incidences;O;O
of;O;O
common;O;O
fetal;O;O
skeletal;O;O
findings;O;O
(;O;O
extra;O;O
pair;O;O
of;O;O
thoracic;O;O
ribs;O;O
,;O;O
unossified;O;O
cervical;O;O
vertebral;O;O
centra;O;O
,;O;O
shortened;O;O
ribs;O;O
);O;O
were;O;O
observed;O;O
at;O;O
1000;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
(;O;O
~10;O;O
times;O;O
the;O;O
human;O;O
exposure;O;O
at;O;O
10;O;O
mg;O;O
daily;O;O
based;O;O
on;O;O
AUC0;O;O
-;O;O
24hr;O;O
for;O;O
total;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s21.e0
);O;O
.;O;O
DDI-DrugBank.d572.s22;;
In;O;O
rabbits;O;O
treated;O;O
with;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s22.e0
,;O;O
an;O;O
increased;O;O
incidence;O;O
of;O;O
extra;O;O
thoracic;O;O
ribs;O;O
was;O;O
observed;O;O
at;O;O
1000;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
(;O;O
150;O;O
times;O;O
the;O;O
human;O;O
exposure;O;O
at;O;O
10;O;O
mg;O;O
daily;O;O
based;O;O
on;O;O
AUC0;O;O
-;O;O
24hr;O;O
for;O;O
total;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s22.e1
);O;O
.;O;O
DDI-DrugBank.d572.s23;;
Ezetimibe;B-drug;B-DDI-DrugBank.d572.s23.e0
crossed;O;O
the;O;O
placenta;O;O
when;O;O
pregnant;O;O
rats;O;O
and;O;O
rabbits;O;O
were;O;O
given;O;O
multiple;O;O
oral;O;O
doses;O;O
.;O;O
DDI-DrugBank.d572.s24;;
Multiple;O;O
dose;O;O
studies;O;O
of;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s24.e0
given;O;O
in;O;O
combination;O;O
with;O;O
HMG;B-group;B-DDI-DrugBank.d572.s24.e1
-;I-group;I-DDI-DrugBank.d572.s24.e1
CoA;I-group;I-DDI-DrugBank.d572.s24.e1
reductase;I-group;I-DDI-DrugBank.d572.s24.e1
inhibitors;I-group;I-DDI-DrugBank.d572.s24.e1
(;O;O
statins;B-group;B-DDI-DrugBank.d572.s24.e2
);O;O
in;O;O
rats;O;O
and;O;O
rabbits;O;O
during;O;O
organogenesis;O;O
result;O;O
in;O;O
higher;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s24.e3
and;O;O
statin;O;O
exposures;O;O
.;O;O
DDI-DrugBank.d572.s25;;
Reproductive;O;O
findings;O;O
occur;O;O
at;O;O
lower;O;O
doses;O;O
in;O;O
combination;O;O
therapy;O;O
compared;O;O
to;O;O
monotherapy;O;O
.;O;O
DDI-DrugBank.d572.s26;;
All;O;O
HMG;B-group;B-DDI-DrugBank.d572.s26.e0
-;I-group;I-DDI-DrugBank.d572.s26.e0
CoA;I-group;I-DDI-DrugBank.d572.s26.e0
reductase;I-group;I-DDI-DrugBank.d572.s26.e0
inhibitors;I-group;I-DDI-DrugBank.d572.s26.e0
are;O;O
contraindicated;O;O
in;O;O
pregnant;O;O
and;O;O
nursing;O;O
women;O;O
.;O;O
DDI-DrugBank.d572.s27;;
When;O;O
ZETIA;B-brand;B-DDI-DrugBank.d572.s27.e0
is;O;O
administered;O;O
with;O;O
an;O;O
HMG;B-group;B-DDI-DrugBank.d572.s27.e1
-;I-group;I-DDI-DrugBank.d572.s27.e1
CoA;I-group;I-DDI-DrugBank.d572.s27.e1
reductase;I-group;I-DDI-DrugBank.d572.s27.e1
inhibitor;I-group;I-DDI-DrugBank.d572.s27.e1
in;O;O
a;O;O
woman;O;O
of;O;O
childbearing;O;O
potential;O;O
,;O;O
refer;O;O
to;O;O
the;O;O
pregnancy;O;O
category;O;O
and;O;O
package;O;O
labeling;O;O
for;O;O
the;O;O
HMG;B-drug;B-DDI-DrugBank.d572.s27.e2
-;I-drug;I-DDI-DrugBank.d572.s27.e2
CoA;I-drug;I-DDI-DrugBank.d572.s27.e2
reductase;I-drug;I-DDI-DrugBank.d572.s27.e2
inhibitor;I-drug;I-DDI-DrugBank.d572.s27.e2
.;O;O
DDI-DrugBank.d572.s28;;
Labor;O;O
and;O;O
Delivery;O;O
The;O;O
effects;O;O
of;O;O
ZETIA;B-brand;B-DDI-DrugBank.d572.s28.e0
on;O;O
labor;O;O
and;O;O
delivery;O;O
in;O;O
pregnant;O;O
women;O;O
are;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d572.s29;;
Nursing;O;O
Mothers;O;O
In;O;O
rat;O;O
studies;O;O
,;O;O
exposure;O;O
to;O;O
total;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s29.e0
in;O;O
nursing;O;O
pups;O;O
was;O;O
up;O;O
to;O;O
half;O;O
of;O;O
that;O;O
observed;O;O
in;O;O
maternal;O;O
plasma;O;O
.;O;O
DDI-DrugBank.d572.s30;;
It;O;O
is;O;O
not;O;O
known;O;O
whether;O;O
ezetimibe;B-drug;B-DDI-DrugBank.d572.s30.e0
is;O;O
excreted;O;O
into;O;O
human;O;O
breast;O;O
milk;O;O
;;O;O
DDI-DrugBank.d572.s31;;
therefore;O;O
,;O;O
ZETIA;B-brand;B-DDI-DrugBank.d572.s31.e0
should;O;O
not;O;O
be;O;O
used;O;O
in;O;O
nursing;O;O
mothers;O;O
unless;O;O
the;O;O
potential;O;O
benefit;O;O
justifies;O;O
the;O;O
potential;O;O
risk;O;O
to;O;O
the;O;O
infant;O;O
.;O;O
DDI-DrugBank.d572.s32;;
Pediatric;O;O
Use;O;O
The;O;O
pharmacokinetics;O;O
of;O;O
ZETIA;B-brand;B-DDI-DrugBank.d572.s32.e0
in;O;O
adolescents;O;O
(;O;O
10;O;O
to;O;O
18;O;O
years;O;O
);O;O
have;O;O
been;O;O
shown;O;O
to;O;O
be;O;O
similar;O;O
to;O;O
that;O;O
in;O;O
adults;O;O
.;O;O
DDI-DrugBank.d572.s33;;
Treatment;O;O
experience;O;O
with;O;O
ZETIA;B-brand;B-DDI-DrugBank.d572.s33.e0
in;O;O
the;O;O
pediatric;O;O
population;O;O
is;O;O
limited;O;O
to;O;O
4;O;O
patients;O;O
(;O;O
9;O;O
to;O;O
17;O;O
years;O;O
);O;O
in;O;O
the;O;O
sitosterolemia;O;O
study;O;O
and;O;O
5;O;O
patients;O;O
(;O;O
11;O;O
to;O;O
17;O;O
years;O;O
);O;O
in;O;O
the;O;O
HoFH;O;O
study;O;O
.;O;O
DDI-DrugBank.d572.s34;;
Treatment;O;O
with;O;O
ZETIA;B-brand;B-DDI-DrugBank.d572.s34.e0
in;O;O
children;O;O
(;O;O
<;O;O
10;O;O
years;O;O
);O;O
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d572.s35;;
Geriatric;O;O
Use;O;O
Of;O;O
the;O;O
patients;O;O
who;O;O
received;O;O
ZETIA;B-brand;B-DDI-DrugBank.d572.s35.e0
in;O;O
clinical;O;O
studies;O;O
,;O;O
948;O;O
were;O;O
65;O;O
and;O;O
older;O;O
(;O;O
this;O;O
included;O;O
206;O;O
who;O;O
were;O;O
75;O;O
and;O;O
older;O;O
);O;O
.;O;O
DDI-DrugBank.d572.s36;;
The;O;O
effectiveness;O;O
and;O;O
safety;O;O
of;O;O
ZETIA;B-brand;B-DDI-DrugBank.d572.s36.e0
were;O;O
similar;O;O
between;O;O
these;O;O
patients;O;O
and;O;O
younger;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d572.s37;;
Greater;O;O
sensitivity;O;O
of;O;O
some;O;O
older;O;O
individuals;O;O
can;O;O
not;O;O
be;O;O
ruled;O;O
out;O;O
.;O;O
DDI-DrugBank.d776.s0;;
Clinically;O;O
or;O;O
potentially;O;O
significant;O;O
drug;O;O
interactions;O;O
between;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s0.e0
and;O;O
the;O;O
following;O;O
agents;O;O
/;O;O
classes;O;O
have;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d776.s1;;
These;O;O
are;O;O
described;O;O
in;O;O
greater;O;O
detail;O;O
below;O;O
:;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s1.e0
and;O;O
the;O;O
following;O;O
agents;O;O
/;O;O
classes;O;O
have;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d776.s2;;
These;O;O
are;O;O
described;O;O
in;O;O
greater;O;O
detail;O;O
below;O;O
:;O;O
Oral;O;O
hypoglycemics;B-group;B-DDI-DrugBank.d776.s2.e0
,;O;O
Coumarin;B-group;B-DDI-DrugBank.d776.s2.e1
-;I-group;I-DDI-DrugBank.d776.s2.e1
type;I-group;I-DDI-DrugBank.d776.s2.e1
anticoagulants;I-group;I-DDI-DrugBank.d776.s2.e1
,;O;O
Phenytoin;B-drug;B-DDI-DrugBank.d776.s2.e2
,;O;O
Cyclosporine;B-drug;B-DDI-DrugBank.d776.s2.e3
,;O;O
Rifampin;B-drug;B-DDI-DrugBank.d776.s2.e4
,;O;O
Theophylline;B-drug;B-DDI-DrugBank.d776.s2.e5
,;O;O
Terfenadine;B-drug;B-DDI-DrugBank.d776.s2.e6
,;O;O
Cisapride;B-drug;B-DDI-DrugBank.d776.s2.e7
,;O;O
Astemizole;B-drug;B-DDI-DrugBank.d776.s2.e8
,;O;O
Rifabutin;B-drug;B-DDI-DrugBank.d776.s2.e9
,;O;O
Tacrolimus;B-drug;B-DDI-DrugBank.d776.s2.e10
,;O;O
Short;B-group;B-DDI-DrugBank.d776.s2.e11
-;I-group;I-DDI-DrugBank.d776.s2.e11
acting;I-group;I-DDI-DrugBank.d776.s2.e11
benzodiazepines;I-group;I-DDI-DrugBank.d776.s2.e11
,;O;O
Oral;O;O
hypoglycemics;B-group;B-DDI-DrugBank.d776.s2.e12
:;O;O
Clinically;O;O
significant;O;O
hypoglycemia;O;O
may;O;O
be;O;O
precipitated;O;O
by;O;O
the;O;O
use;O;O
of;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s2.e13
with;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d776.s2.e14
agents;I-group;I-DDI-DrugBank.d776.s2.e14
;;O;O
DDI-DrugBank.d776.s3;;
one;O;O
fatality;O;O
has;O;O
been;O;O
reported;O;O
from;O;O
hypoglycemia;O;O
in;O;O
association;O;O
with;O;O
combined;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s3.e0
and;O;O
glyburide;B-drug;B-DDI-DrugBank.d776.s3.e1
use;O;O
.;O;O
DDI-DrugBank.d776.s4;;
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s4.e0
reduces;O;O
the;O;O
metabolism;O;O
of;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d776.s4.e1
,;O;O
glyburide;B-drug;B-DDI-DrugBank.d776.s4.e2
,;O;O
and;O;O
glipizide;B-drug;B-DDI-DrugBank.d776.s4.e3
and;O;O
increases;O;O
the;O;O
plasma;O;O
concentration;O;O
of;O;O
these;O;O
agents;O;O
.;O;O
DDI-DrugBank.d776.s5;;
When;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s5.e0
is;O;O
used;O;O
concomitantly;O;O
with;O;O
these;O;O
or;O;O
other;O;O
sulfonylurea;B-group;B-DDI-DrugBank.d776.s5.e1
oral;I-group;I-DDI-DrugBank.d776.s5.e1
hypoglycemic;I-group;I-DDI-DrugBank.d776.s5.e1
agents;I-group;I-DDI-DrugBank.d776.s5.e1
,;O;O
blood;O;O
glucose;O;O
concentrations;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
and;O;O
the;O;O
dose;O;O
of;O;O
the;O;O
sulfonylurea;B-group;B-DDI-DrugBank.d776.s5.e2
should;O;O
be;O;O
adjusted;O;O
as;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d776.s6;;
Coumarin;B-group;B-DDI-DrugBank.d776.s6.e0
-;I-group;I-DDI-DrugBank.d776.s6.e0
type;I-group;I-DDI-DrugBank.d776.s6.e0
anticoagulants;I-group;I-DDI-DrugBank.d776.s6.e0
:;O;O
Prothrombin;O;O
time;O;O
may;O;O
be;O;O
increased;O;O
in;O;O
patients;O;O
receiving;O;O
concomitant;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s6.e1
and;O;O
coumarin;B-group;B-DDI-DrugBank.d776.s6.e2
-;I-group;I-DDI-DrugBank.d776.s6.e2
type;I-group;I-DDI-DrugBank.d776.s6.e2
anticoagulants;I-group;I-DDI-DrugBank.d776.s6.e2
.;O;O
DDI-DrugBank.d776.s7;;
In;O;O
post;O;O
-;O;O
marketing;O;O
experience;O;O
,;O;O
as;O;O
with;O;O
other;O;O
azole;B-group;B-DDI-DrugBank.d776.s7.e0
antifungals;I-group;I-DDI-DrugBank.d776.s7.e0
,;O;O
bleeding;O;O
events;O;O
(;O;O
bruising;O;O
,;O;O
epistaxis;O;O
,;O;O
gastrointestinal;O;O
bleeding;O;O
,;O;O
hematuria;O;O
,;O;O
and;O;O
melena;O;O
);O;O
have;O;O
been;O;O
reported;O;O
in;O;O
association;O;O
with;O;O
increases;O;O
in;O;O
prothrombin;O;O
time;O;O
in;O;O
patients;O;O
receiving;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s7.e1
concurrently;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d776.s7.e2
.;O;O
DDI-DrugBank.d776.s8;;
Careful;O;O
monitoring;O;O
of;O;O
prothrombin;O;O
time;O;O
in;O;O
patients;O;O
receiving;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s8.e0
and;O;O
coumarin;B-group;B-DDI-DrugBank.d776.s8.e1
-;I-group;I-DDI-DrugBank.d776.s8.e1
type;I-group;I-DDI-DrugBank.d776.s8.e1
anticoagulants;I-group;I-DDI-DrugBank.d776.s8.e1
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d776.s9;;
(;O;O
See;O;O
<;O;O
a;O;O
href=;O;O
";O;O
flucon_cp.htm#CP">CLINICAL;O;O
PHARMACOLOGY;O;O
:;O;O
Drug;O;O
Interaction;O;O
Studies;O;O
.;O;O
);O;O
DDI-DrugBank.d776.s10;;
Phenytoin;B-drug;B-DDI-DrugBank.d776.s10.e0
:;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s10.e1
increases;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d776.s10.e2
.;O;O
DDI-DrugBank.d776.s11;;
Careful;O;O
monitoring;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d776.s11.e0
concentrations;O;O
in;O;O
patients;O;O
receiving;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s11.e1
and;O;O
phenytoin;B-drug;B-DDI-DrugBank.d776.s11.e2
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d776.s12;;
(;O;O
See;O;O
<;O;O
a;O;O
href=;O;O
";O;O
flucon_cp.htm#CP">CLINICAL;O;O
PHARMACOLOGY;O;O
:;O;O
Drug;O;O
Interaction;O;O
Studies;O;O
.;O;O
);O;O
DDI-DrugBank.d776.s13;;
Cyclosporine;B-drug;B-DDI-DrugBank.d776.s13.e0
:;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s13.e1
may;O;O
significantly;O;O
increase;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d776.s13.e2
levels;O;O
in;O;O
renal;O;O
transplant;O;O
patients;O;O
with;O;O
or;O;O
without;O;O
renal;O;O
impairment;O;O
.;O;O
DDI-DrugBank.d776.s14;;
Careful;O;O
monitoring;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d776.s14.e0
concentrations;O;O
and;O;O
serum;O;O
creatinine;O;O
is;O;O
recommended;O;O
in;O;O
patients;O;O
receiving;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s14.e1
and;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d776.s14.e2
.;O;O
DDI-DrugBank.d776.s15;;
(;O;O
See;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
:;O;O
Drug;O;O
Interaction;O;O
Studies;O;O
.;O;O
);O;O
DDI-DrugBank.d776.s16;;
Rifampin;B-drug;B-DDI-DrugBank.d776.s16.e0
:;O;O
Rifampin;B-drug;B-DDI-DrugBank.d776.s16.e1
enhances;O;O
the;O;O
metabolism;O;O
of;O;O
concurrently;O;O
administered;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s16.e2
.;O;O
DDI-DrugBank.d776.s17;;
Depending;O;O
on;O;O
clinical;O;O
circumstances;O;O
,;O;O
consideration;O;O
should;O;O
be;O;O
given;O;O
to;O;O
increasing;O;O
the;O;O
dose;O;O
of;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s17.e0
when;O;O
it;O;O
is;O;O
administered;O;O
with;O;O
rifampin;B-drug;B-DDI-DrugBank.d776.s17.e1
.;O;O
DDI-DrugBank.d776.s18;;
Theophylline;B-drug;B-DDI-DrugBank.d776.s18.e0
:;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s18.e1
increases;O;O
the;O;O
serum;O;O
concentrations;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d776.s18.e2
.;O;O
DDI-DrugBank.d776.s19;;
Careful;O;O
monitoring;O;O
of;O;O
serum;O;O
theophylline;B-drug;B-DDI-DrugBank.d776.s19.e0
concentrations;O;O
in;O;O
patients;O;O
receiving;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s19.e1
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d776.s19.e2
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d776.s20;;
Terfenadine;B-drug;B-DDI-DrugBank.d776.s20.e0
:;O;O
Because;O;O
of;O;O
the;O;O
occurrence;O;O
of;O;O
serious;O;O
cardiac;O;O
dysrhythmias;O;O
secondary;O;O
to;O;O
prolongation;O;O
of;O;O
the;O;O
QTc;O;O
interval;O;O
in;O;O
patients;O;O
receiving;O;O
azole;B-group;B-DDI-DrugBank.d776.s20.e1
antifungals;I-group;I-DDI-DrugBank.d776.s20.e1
in;O;O
conjunction;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d776.s20.e2
,;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d776.s21;;
One;O;O
study;O;O
at;O;O
a;O;O
200;O;O
-;O;O
mg;O;O
daily;O;O
dose;O;O
of;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s21.e0
failed;O;O
to;O;O
demonstrate;O;O
a;O;O
prolongation;O;O
in;O;O
QTc;O;O
interval;O;O
.;O;O
DDI-DrugBank.d776.s22;;
Another;O;O
study;O;O
at;O;O
a;O;O
400;O;O
-;O;O
mg;O;O
and;O;O
800;O;O
-;O;O
mg;O;O
daily;O;O
dose;O;O
of;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s22.e0
demonstrated;O;O
that;O;O
DIFLUCAN;B-brand;B-DDI-DrugBank.d776.s22.e1
taken;O;O
in;O;O
doses;O;O
of;O;O
400;O;O
mg;O;O
per;O;O
day;O;O
or;O;O
greater;O;O
significantly;O;O
increases;O;O
plasma;O;O
levels;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d776.s22.e2
when;O;O
taken;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d776.s23;;
The;O;O
combined;O;O
use;O;O
of;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s23.e0
at;O;O
doses;O;O
of;O;O
400;O;O
mg;O;O
or;O;O
greater;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d776.s23.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d776.s24;;
The;O;O
coadministration;O;O
of;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s24.e0
at;O;O
doses;O;O
lower;O;O
than;O;O
400;O;O
mg;O;O
/;O;O
day;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d776.s24.e1
should;O;O
be;O;O
carefully;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d776.s25;;
Cisapride;B-drug;B-DDI-DrugBank.d776.s25.e0
:;O;O
There;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
cardiac;O;O
events;O;O
,;O;O
including;O;O
torsade;O;O
de;O;O
pointes;O;O
in;O;O
patients;O;O
to;O;O
whom;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s25.e1
and;O;O
cisapride;B-drug;B-DDI-DrugBank.d776.s25.e2
were;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d776.s26;;
A;O;O
controlled;O;O
study;O;O
found;O;O
that;O;O
concomitant;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s26.e0
200;O;O
mg;O;O
once;O;O
daily;O;O
and;O;O
cisapride;B-drug;B-DDI-DrugBank.d776.s26.e1
20;O;O
mg;O;O
four;O;O
times;O;O
a;O;O
day;O;O
yielded;O;O
a;O;O
significant;O;O
increase;O;O
in;O;O
cisapride;B-drug;B-DDI-DrugBank.d776.s26.e2
plasma;O;O
levels;O;O
and;O;O
prolongation;O;O
of;O;O
QTc;O;O
interval;O;O
.;O;O
DDI-DrugBank.d776.s27;;
The;O;O
combined;O;O
use;O;O
of;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s27.e0
with;O;O
cisapride;B-drug;B-DDI-DrugBank.d776.s27.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d776.s28;;
Astemizole;B-drug;B-DDI-DrugBank.d776.s28.e0
:;O;O
The;O;O
use;O;O
of;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s28.e1
in;O;O
patients;O;O
concurrently;O;O
taking;O;O
astemizole;B-drug;B-DDI-DrugBank.d776.s28.e2
or;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
may;O;O
be;O;O
associated;O;O
with;O;O
elevations;O;O
in;O;O
serum;O;O
levels;O;O
of;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d776.s29;;
In;O;O
the;O;O
absence;O;O
of;O;O
definitive;O;O
information;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
coadministering;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s29.e0
.;O;O
DDI-DrugBank.d776.s30;;
Patients;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d776.s31;;
Rifabutin;B-drug;B-DDI-DrugBank.d776.s31.e0
:;O;O
There;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
uveitis;O;O
in;O;O
patients;O;O
to;O;O
whom;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s31.e1
and;O;O
rifabutin;B-drug;B-DDI-DrugBank.d776.s31.e2
were;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d776.s32;;
Patients;O;O
receiving;O;O
rifabutin;B-drug;B-DDI-DrugBank.d776.s32.e0
and;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s32.e1
concomitantly;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d776.s33;;
Tacrolimus;B-drug;B-DDI-DrugBank.d776.s33.e0
:;O;O
There;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
nephrotoxicity;O;O
in;O;O
patients;O;O
to;O;O
whom;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s33.e1
and;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d776.s33.e2
were;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d776.s34;;
Patients;O;O
receiving;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d776.s34.e0
and;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s34.e1
concomitantly;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d776.s35;;
Short;B-group;B-DDI-DrugBank.d776.s35.e0
-;I-group;I-DDI-DrugBank.d776.s35.e0
acting;I-group;I-DDI-DrugBank.d776.s35.e0
Benzodiazepines;I-group;I-DDI-DrugBank.d776.s35.e0
:;O;O
Following;O;O
oral;O;O
administration;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d776.s35.e1
,;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s35.e2
resulted;O;O
in;O;O
substantial;O;O
increases;O;O
in;O;O
midazolam;B-drug;B-DDI-DrugBank.d776.s35.e3
concentrations;O;O
and;O;O
psychomotor;O;O
effects;O;O
.;O;O
DDI-DrugBank.d776.s36;;
This;O;O
effect;O;O
on;O;O
midazolam;B-drug;B-DDI-DrugBank.d776.s36.e0
appears;O;O
to;O;O
be;O;O
more;O;O
pronounced;O;O
following;O;O
oral;O;O
administration;O;O
of;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s36.e1
than;O;O
with;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s36.e2
administered;O;O
intravenously;O;O
.;O;O
DDI-DrugBank.d776.s37;;
If;O;O
short;B-group;B-DDI-DrugBank.d776.s37.e0
-;I-group;I-DDI-DrugBank.d776.s37.e0
acting;I-group;I-DDI-DrugBank.d776.s37.e0
benzodiazepines;I-group;I-DDI-DrugBank.d776.s37.e0
,;O;O
which;O;O
are;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
,;O;O
are;O;O
concomitantly;O;O
administered;O;O
with;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s37.e1
,;O;O
consideration;O;O
should;O;O
be;O;O
given;O;O
to;O;O
decreasing;O;O
the;O;O
benzodiazepine;B-group;B-DDI-DrugBank.d776.s37.e2
dosage;O;O
,;O;O
and;O;O
the;O;O
patients;O;O
should;O;O
be;O;O
appropriately;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d776.s38;;
Fluconazole;B-drug;B-DDI-DrugBank.d776.s38.e0
tablets;O;O
coadministered;O;O
with;O;O
ethinyl;B-drug;B-DDI-DrugBank.d776.s38.e1
estradiol;I-drug;I-DDI-DrugBank.d776.s38.e1
-;O;O
and;O;O
levonorgestrel;B-drug;B-DDI-DrugBank.d776.s38.e2
-;O;O
containing;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d776.s38.e3
produced;O;O
an;O;O
overall;O;O
mean;O;O
increase;O;O
in;O;O
ethinyl;B-drug;B-DDI-DrugBank.d776.s38.e4
estradiol;I-drug;I-DDI-DrugBank.d776.s38.e4
and;O;O
levonorgestrel;B-drug;B-DDI-DrugBank.d776.s38.e5
levels;O;O
;;O;O
DDI-DrugBank.d776.s39;;
however;O;O
,;O;O
in;O;O
some;O;O
patients;O;O
there;O;O
were;O;O
decreases;O;O
up;O;O
to;O;O
47;O;O
%;O;O
and;O;O
33;O;O
%;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d776.s39.e0
estradiol;I-drug;I-DDI-DrugBank.d776.s39.e0
and;O;O
levonorgestrel;B-drug;B-DDI-DrugBank.d776.s39.e1
levels;O;O
.;O;O
DDI-DrugBank.d776.s40;;
The;O;O
data;O;O
presently;O;O
available;O;O
indicate;O;O
that;O;O
the;O;O
decreases;O;O
in;O;O
some;O;O
individual;O;O
ethinyl;B-drug;B-DDI-DrugBank.d776.s40.e0
estradiol;I-drug;I-DDI-DrugBank.d776.s40.e0
and;O;O
levonorgestrel;B-drug;B-DDI-DrugBank.d776.s40.e1
AUC;O;O
values;O;O
with;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s40.e2
treatment;O;O
are;O;O
likely;O;O
the;O;O
result;O;O
of;O;O
random;O;O
variation;O;O
.;O;O
DDI-DrugBank.d776.s41;;
While;O;O
there;O;O
is;O;O
evidence;O;O
that;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s41.e0
can;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d776.s41.e1
estradiol;I-drug;I-DDI-DrugBank.d776.s41.e1
and;O;O
levonorgestrel;B-drug;B-DDI-DrugBank.d776.s41.e2
,;O;O
there;O;O
is;O;O
no;O;O
evidence;O;O
that;O;O
fluconazole;B-drug;B-DDI-DrugBank.d776.s41.e3
is;O;O
a;O;O
net;O;O
inducer;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d776.s41.e4
estradiol;I-drug;I-DDI-DrugBank.d776.s41.e4
or;O;O
levonorgestrel;B-drug;B-DDI-DrugBank.d776.s41.e5
metabolism;O;O
.;O;O
DDI-DrugBank.d776.s42;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
these;O;O
effects;O;O
is;O;O
presently;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d776.s43;;
Physicians;O;O
should;O;O
be;O;O
aware;O;O
that;O;O
interaction;O;O
studies;O;O
with;O;O
medications;O;O
other;O;O
than;O;O
those;O;O
listed;O;O
in;O;O
the;O;O
<;O;O
a;O;O
href=;O;O
";O;O
flucon_cp.htm#CP">CLINICAL;O;O
PHARMACOLOGY;O;O
section;O;O
have;O;O
not;O;O
been;O;O
conducted;O;O
,;O;O
but;O;O
such;O;O
interactions;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d716.s0;;
You;O;O
can;O;O
not;O;O
take;O;O
mazindol;B-drug;B-DDI-DrugBank.d716.s0.e0
if;O;O
you;O;O
have;O;O
taken;O;O
a;O;O
monoamine;B-group;B-DDI-DrugBank.d716.s0.e1
oxidase;I-group;I-DDI-DrugBank.d716.s0.e1
inhibitor;I-group;I-DDI-DrugBank.d716.s0.e1
(;O;O
MAOI;B-group;B-DDI-DrugBank.d716.s0.e2
);O;O
such;O;O
as;O;O
isocarboxazid;B-drug;B-DDI-DrugBank.d716.s0.e3
(;O;O
Marplan;B-brand;B-DDI-DrugBank.d716.s0.e4
);O;O
,;O;O
tranylcypromine;B-drug;B-DDI-DrugBank.d716.s0.e5
(;O;O
Parnate;B-brand;B-DDI-DrugBank.d716.s0.e6
);O;O
,;O;O
or;O;O
phenelzine;B-drug;B-DDI-DrugBank.d716.s0.e7
(;O;O
Nardil;B-brand;B-DDI-DrugBank.d716.s0.e8
);O;O
in;O;O
the;O;O
last;O;O
14;O;O
days;O;O
.;O;O
DDI-DrugBank.d716.s1;;
Changes;O;O
in;O;O
insulin;B-drug;B-DDI-DrugBank.d716.s1.e0
and;O;O
other;O;O
diabetes;O;O
drug;O;O
therapies;O;O
may;O;O
be;O;O
necessary;O;O
during;O;O
treatment;O;O
with;O;O
mazindol;B-drug;B-DDI-DrugBank.d716.s1.e1
.;O;O
DDI-DrugBank.d716.s2;;
Mazindol;B-drug;B-DDI-DrugBank.d716.s2.e0
may;O;O
reduce;O;O
the;O;O
effects;O;O
of;O;O
guanethidine;B-drug;B-DDI-DrugBank.d716.s2.e1
(;O;O
Ismelin;B-brand;B-DDI-DrugBank.d716.s2.e2
);O;O
.;O;O
DDI-DrugBank.d716.s3;;
This;O;O
could;O;O
lead;O;O
to;O;O
an;O;O
increase;O;O
in;O;O
blood;O;O
pressure;O;O
.;O;O
DDI-DrugBank.d716.s4;;
Tell;O;O
your;O;O
doctor;O;O
if;O;O
you;O;O
are;O;O
taking;O;O
guanethidine;B-drug;B-DDI-DrugBank.d716.s4.e0
.;O;O
DDI-DrugBank.d716.s5;;
Before;O;O
taking;O;O
this;O;O
medication;O;O
,;O;O
tell;O;O
your;O;O
doctor;O;O
if;O;O
you;O;O
are;O;O
taking;O;O
a;O;O
tricyclic;B-group;B-DDI-DrugBank.d716.s5.e0
antidepressant;I-group;I-DDI-DrugBank.d716.s5.e0
such;O;O
as;O;O
amitriptyline;B-drug;B-DDI-DrugBank.d716.s5.e1
(;O;O
Elavil;B-brand;B-DDI-DrugBank.d716.s5.e2
);O;O
,;O;O
amoxapine;B-drug;B-DDI-DrugBank.d716.s5.e3
(;O;O
Asendin;B-brand;B-DDI-DrugBank.d716.s5.e4
);O;O
,;O;O
doxepin;B-drug;B-DDI-DrugBank.d716.s5.e5
(;O;O
Sinequan;B-brand;B-DDI-DrugBank.d716.s5.e6
);O;O
,;O;O
nortriptyline;B-drug;B-DDI-DrugBank.d716.s5.e7
(;O;O
Pamelor;B-brand;B-DDI-DrugBank.d716.s5.e8
);O;O
,;O;O
imipramine;B-drug;B-DDI-DrugBank.d716.s5.e9
(;O;O
Tofranil;B-brand;B-DDI-DrugBank.d716.s5.e10
);O;O
,;O;O
clomipramine;B-drug;B-DDI-DrugBank.d716.s5.e11
(;O;O
Anafranil;B-brand;B-DDI-DrugBank.d716.s5.e12
);O;O
,;O;O
protriptyline;B-drug;B-DDI-DrugBank.d716.s5.e13
(;O;O
Vivactil;B-brand;B-DDI-DrugBank.d716.s5.e14
);O;O
,;O;O
or;O;O
desipramine;B-drug;B-DDI-DrugBank.d716.s5.e15
(;O;O
Norpramin;B-brand;B-DDI-DrugBank.d716.s5.e16
);O;O
.;O;O
DDI-DrugBank.d716.s6;;
These;O;O
drugs;O;O
may;O;O
decrease;O;O
the;O;O
effects;O;O
of;O;O
mazindol;B-drug;B-DDI-DrugBank.d716.s6.e0
.;O;O
DDI-DrugBank.d679.s0;;
Preliminary;O;O
evidence;O;O
suggests;O;O
that;O;O
cimetidine;B-drug;B-DDI-DrugBank.d679.s0.e0
inhibits;O;O
mebendazole;B-drug;B-DDI-DrugBank.d679.s0.e1
metabolism;O;O
and;O;O
may;O;O
result;O;O
in;O;O
an;O;O
increase;O;O
in;O;O
plasma;O;O
concentrations;O;O
of;O;O
mebendazole;B-drug;B-DDI-DrugBank.d679.s0.e2
.;O;O
DDI-DrugBank.d579.s0;;
Patients;O;O
receiving;O;O
antibiotics;B-group;B-DDI-DrugBank.d579.s0.e0
and;O;O
sulfonamides;B-group;B-DDI-DrugBank.d579.s0.e1
generally;O;O
should;O;O
not;O;O
be;O;O
treated;O;O
with;O;O
ganglion;B-group;B-DDI-DrugBank.d579.s0.e2
blockers;I-group;I-DDI-DrugBank.d579.s0.e2
.;O;O
DDI-DrugBank.d579.s1;;
The;O;O
action;O;O
of;O;O
Mecamylamine;B-drug;B-DDI-DrugBank.d579.s1.e0
may;O;O
be;O;O
potentiated;O;O
by;O;O
anesthesia;O;O
,;O;O
other;O;O
antihypertensive;B-group;B-DDI-DrugBank.d579.s1.e1
drugs;I-group;I-DDI-DrugBank.d579.s1.e1
and;O;O
alcohol;B-drug;B-DDI-DrugBank.d579.s1.e2
.;O;O
DDI-DrugBank.d623.s0;;
No;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
with;O;O
depo;B-brand;B-DDI-DrugBank.d623.s0.e0
-;I-brand;I-DDI-DrugBank.d623.s0.e0
subQ;I-brand;I-DDI-DrugBank.d623.s0.e0
provera;I-brand;I-DDI-DrugBank.d623.s0.e0
104;I-brand;I-DDI-DrugBank.d623.s0.e0
.;O;O
DDI-DrugBank.d623.s1;;
Aminoglutethimide;B-drug;B-DDI-DrugBank.d623.s1.e0
administered;O;O
concomitantly;O;O
with;O;O
depo;B-brand;B-DDI-DrugBank.d623.s1.e1
-;I-brand;I-DDI-DrugBank.d623.s1.e1
subQ;I-brand;I-DDI-DrugBank.d623.s1.e1
provera;I-brand;I-DDI-DrugBank.d623.s1.e1
104;I-brand;I-DDI-DrugBank.d623.s1.e1
may;O;O
significantly;O;O
decrease;O;O
the;O;O
serum;O;O
concentrations;O;O
of;O;O
MPA;B-drug;B-DDI-DrugBank.d623.s1.e2
.;O;O
DDI-DrugBank.d623.s2;;
Laboratory;O;O
Tests;O;O
The;O;O
pathologist;O;O
should;O;O
be;O;O
advised;O;O
of;O;O
progestin;O;O
therapy;O;O
when;O;O
relevant;O;O
specimens;O;O
are;O;O
submitted;O;O
.;O;O
DDI-DrugBank.d623.s3;;
The;O;O
physician;O;O
should;O;O
be;O;O
informed;O;O
that;O;O
certain;O;O
endocrine;O;O
and;O;O
liver;O;O
function;O;O
tests;O;O
,;O;O
and;O;O
blood;O;O
components;O;O
may;O;O
be;O;O
affected;O;O
by;O;O
progestin;O;O
therapy;O;O
:;O;O
(;O;O
a;O;O
);O;O
Plasma;O;O
and;O;O
urinary;O;O
steroid;O;O
levels;O;O
are;O;O
decreased;O;O
(;O;O
e.g.;O;O
,;O;O
progesterone;O;O
,;O;O
estradiol;O;O
,;O;O
pregnanediol;O;O
,;O;O
testosterone;O;O
,;O;O
cortisol;O;O
);O;O
.;O;O
DDI-DrugBank.d623.s4;;
(;O;O
b;O;O
);O;O
Plasma;O;O
and;O;O
urinary;O;O
gonadotropin;O;O
levels;O;O
are;O;O
decreased;O;O
(;O;O
e.g.;O;O
,;O;O
LH;O;O
,;O;O
FSH;O;O
);O;O
.;O;O
DDI-DrugBank.d623.s5;;
(;O;O
c;O;O
);O;O
SHBG;O;O
concentrations;O;O
are;O;O
decreased;O;O
.;O;O
DDI-DrugBank.d623.s6;;
(;O;O
d;O;O
);O;O
T3;O;O
-;O;O
uptake;O;O
values;O;O
may;O;O
decrease;O;O
.;O;O
DDI-DrugBank.d623.s7;;
(;O;O
e;O;O
);O;O
There;O;O
may;O;O
be;O;O
small;O;O
changes;O;O
in;O;O
coagulation;O;O
factors;O;O
.;O;O
DDI-DrugBank.d623.s8;;
(;O;O
f;O;O
);O;O
Sulfobromophthalein;O;O
and;O;O
other;O;O
liver;O;O
function;O;O
test;O;O
values;O;O
may;O;O
be;O;O
increased;O;O
slightly;O;O
.;O;O
DDI-DrugBank.d623.s9;;
(;O;O
g;O;O
);O;O
There;O;O
may;O;O
be;O;O
small;O;O
changes;O;O
in;O;O
lipid;O;O
profiles;O;O
.;O;O
DDI-DrugBank.d688.s0;;
Pharmacokinetic;O;O
studies;O;O
show;O;O
that;O;O
there;O;O
are;O;O
no;O;O
significant;O;O
alterations;O;O
in;O;O
pharmacokinetic;O;O
parameters;O;O
of;O;O
zidovudine;B-drug;B-DDI-DrugBank.d688.s0.e0
or;O;O
rifabutin;B-drug;B-DDI-DrugBank.d688.s0.e1
to;O;O
warrant;O;O
dosage;O;O
adjustment;O;O
when;O;O
megestrol;B-drug;B-DDI-DrugBank.d688.s0.e2
acetate;I-drug;I-DDI-DrugBank.d688.s0.e2
is;O;O
administered;O;O
with;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d688.s1;;
A;O;O
pharmacokinetic;O;O
study;O;O
demonstrated;O;O
that;O;O
coadministration;O;O
of;O;O
megestrol;B-drug;B-DDI-DrugBank.d688.s1.e0
acetate;I-drug;I-DDI-DrugBank.d688.s1.e0
and;O;O
indinavir;B-drug;B-DDI-DrugBank.d688.s1.e1
results;O;O
in;O;O
a;O;O
significant;O;O
decrease;O;O
in;O;O
the;O;O
pharmacokinetic;O;O
parameters;O;O
(;O;O
~36;O;O
%;O;O
for;O;O
Cmax;O;O
and;O;O
~28;O;O
%;O;O
for;O;O
AUC;O;O
);O;O
of;O;O
indinavir;B-drug;B-DDI-DrugBank.d688.s1.e2
.;O;O
DDI-DrugBank.d688.s2;;
Administration;O;O
of;O;O
a;O;O
higher;O;O
dose;O;O
of;O;O
indinavir;B-drug;B-DDI-DrugBank.d688.s2.e0
should;O;O
be;O;O
considered;O;O
when;O;O
coadministering;O;O
with;O;O
megestrol;B-drug;B-DDI-DrugBank.d688.s2.e1
acetate;I-drug;I-DDI-DrugBank.d688.s2.e1
.;O;O
DDI-DrugBank.d688.s3;;
The;O;O
effects;O;O
of;O;O
indinavir;B-drug;B-DDI-DrugBank.d688.s3.e0
,;O;O
zidovudine;B-drug;B-DDI-DrugBank.d688.s3.e1
or;O;O
rifabutin;B-drug;B-DDI-DrugBank.d688.s3.e2
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
megestrol;B-drug;B-DDI-DrugBank.d688.s3.e3
acetate;I-drug;I-DDI-DrugBank.d688.s3.e3
were;O;O
not;O;O
studied;O;O
.;O;O
DDI-DrugBank.d643.s0;;
Melatonin;B-drug;B-DDI-DrugBank.d643.s0.e0
may;O;O
interact;O;O
with;O;O
the;O;O
following;O;O
drugs;O;O
:;O;O
aspirin;B-brand;B-DDI-DrugBank.d643.s0.e1
and;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d643.s0.e2
(;O;O
may;O;O
lower;O;O
melatonin;B-drug;B-DDI-DrugBank.d643.s0.e3
levels;O;O
);O;O
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d643.s0.e4
(;O;O
bioavailability;O;O
of;O;O
oral;O;O
melatonin;B-drug;B-DDI-DrugBank.d643.s0.e5
is;O;O
increased;O;O
with;O;O
coadministration;O;O
);O;O
,;O;O
beta;B-group;B-DDI-DrugBank.d643.s0.e6
blockers;I-group;I-DDI-DrugBank.d643.s0.e6
(;O;O
may;O;O
decrease;O;O
melatonin;B-drug;B-DDI-DrugBank.d643.s0.e7
levels;O;O
);O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d643.s0.e8
(;O;O
reports;O;O
of;O;O
psychotic;O;O
episodes;O;O
when;O;O
coadministered;O;O
);O;O
,;O;O
progestin;B-group;B-DDI-DrugBank.d643.s0.e9
(;O;O
coadministration;O;O
of;O;O
melatonin;B-drug;B-DDI-DrugBank.d643.s0.e10
with;O;O
progestin;B-group;B-DDI-DrugBank.d643.s0.e11
can;O;O
inhibit;O;O
ovarian;O;O
function;O;O
in;O;O
women;O;O
);O;O
,;O;O
benzodiazepenes;B-group;B-DDI-DrugBank.d643.s0.e12
and;O;O
other;O;O
sedating;O;O
drugs;O;O
(;O;O
may;O;O
result;O;O
in;O;O
additive;O;O
sedation;O;O
and;O;O
an;O;O
increased;O;O
incidence;O;O
of;O;O
adverse;O;O
effects;O;O
);O;O
,;O;O
and;O;O
corticosteroids;B-group;B-DDI-DrugBank.d643.s0.e13
(;O;O
coadministration;O;O
of;O;O
melatonin;B-drug;B-DDI-DrugBank.d643.s0.e14
and;O;O
corticosteroids;B-group;B-DDI-DrugBank.d643.s0.e15
may;O;O
interfere;O;O
with;O;O
the;O;O
efficacy;O;O
of;O;O
the;O;O
corticosteroids;B-group;B-DDI-DrugBank.d643.s0.e16
);O;O
.;O;O
DDI-DrugBank.d597.s0;;
ACE;B-group;B-DDI-DrugBank.d597.s0.e0
inhibitors;I-group;I-DDI-DrugBank.d597.s0.e0
Reports;O;O
suggest;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d597.s0.e1
may;O;O
diminish;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
angiotensin;B-group;B-DDI-DrugBank.d597.s0.e2
-;I-group;I-DDI-DrugBank.d597.s0.e2
converting;I-group;I-DDI-DrugBank.d597.s0.e2
enzyme;I-group;I-DDI-DrugBank.d597.s0.e2
(;I-group;I-DDI-DrugBank.d597.s0.e2
ACE;I-group;I-DDI-DrugBank.d597.s0.e2
);I-group;I-DDI-DrugBank.d597.s0.e2
inhibitors;I-group;I-DDI-DrugBank.d597.s0.e2
.;O;O
DDI-DrugBank.d597.s1;;
This;O;O
interaction;O;O
should;O;O
be;O;O
given;O;O
consideration;O;O
in;O;O
patients;O;O
taking;O;O
NSAIDs;B-group;B-DDI-DrugBank.d597.s1.e0
concomitantly;O;O
with;O;O
ACE;B-group;B-DDI-DrugBank.d597.s1.e1
inhibitors;I-group;I-DDI-DrugBank.d597.s1.e1
.;O;O
DDI-DrugBank.d597.s2;;
Aspirin;B-brand;B-DDI-DrugBank.d597.s2.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d597.s2.e1
(;O;O
1000;O;O
mg;O;O
TID;O;O
);O;O
to;O;O
healthy;O;O
volunteers;O;O
tended;O;O
to;O;O
increase;O;O
the;O;O
AUC;O;O
(;O;O
10;O;O
%;O;O
);O;O
and;O;O
Cmax;O;O
(;O;O
24;O;O
%;O;O
);O;O
of;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s2.e2
.;O;O
DDI-DrugBank.d597.s3;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
interaction;O;O
is;O;O
not;O;O
known;O;O
;;O;O
DDI-DrugBank.d597.s4;;
however;O;O
,;O;O
as;O;O
with;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d597.s4.e0
,;O;O
concomitant;O;O
administration;O;O
of;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s4.e1
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d597.s4.e2
is;O;O
not;O;O
generally;O;O
recommended;O;O
because;O;O
of;O;O
the;O;O
potential;O;O
for;O;O
increased;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d597.s5;;
Concomitant;O;O
administration;O;O
of;O;O
low;O;O
-;O;O
dose;O;O
aspirin;B-brand;B-DDI-DrugBank.d597.s5.e0
with;O;O
MOBIC;B-brand;B-DDI-DrugBank.d597.s5.e1
may;O;O
result;O;O
in;O;O
an;O;O
increased;O;O
rate;O;O
of;O;O
GI;O;O
ulceration;O;O
or;O;O
other;O;O
complications;O;O
,;O;O
compared;O;O
to;O;O
use;O;O
of;O;O
MOBIC;B-brand;B-DDI-DrugBank.d597.s5.e2
alone;O;O
.;O;O
DDI-DrugBank.d597.s6;;
MOBIC;B-brand;B-DDI-DrugBank.d597.s6.e0
is;O;O
not;O;O
a;O;O
substitute;O;O
for;O;O
aspirin;B-brand;B-DDI-DrugBank.d597.s6.e1
for;O;O
cardiovascular;O;O
prophylaxis;O;O
.;O;O
DDI-DrugBank.d597.s7;;
Cholestyramine;B-drug;B-DDI-DrugBank.d597.s7.e0
:;O;O
Pretreatment;O;O
for;O;O
four;O;O
days;O;O
with;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d597.s7.e1
significantly;O;O
increased;O;O
the;O;O
clearance;O;O
of;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s7.e2
by;O;O
50;O;O
%;O;O
.;O;O
DDI-DrugBank.d597.s8;;
This;O;O
resulted;O;O
in;O;O
a;O;O
decrease;O;O
in;O;O
t1;O;O
/;O;O
2;O;O
,;O;O
from;O;O
19.2;O;O
hours;O;O
to;O;O
12.5;O;O
hours;O;O
,;O;O
and;O;O
a;O;O
35;O;O
%;O;O
reduction;O;O
in;O;O
AUC;O;O
.;O;O
DDI-DrugBank.d597.s9;;
This;O;O
suggests;O;O
the;O;O
existence;O;O
of;O;O
a;O;O
recirculation;O;O
pathway;O;O
for;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s9.e0
in;O;O
the;O;O
gastrointestinal;O;O
tract;O;O
.;O;O
DDI-DrugBank.d597.s10;;
The;O;O
clinical;O;O
relevance;O;O
of;O;O
this;O;O
interaction;O;O
has;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d597.s11;;
Cimetidine;B-drug;B-DDI-DrugBank.d597.s11.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
200;O;O
mg;O;O
cimetidine;B-drug;B-DDI-DrugBank.d597.s11.e1
QID;O;O
did;O;O
not;O;O
alter;O;O
the;O;O
single;O;O
-;O;O
dose;O;O
pharmacokinetics;O;O
of;O;O
30;O;O
mg;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s11.e2
.;O;O
DDI-DrugBank.d597.s12;;
Digoxin;B-drug;B-DDI-DrugBank.d597.s12.e0
:;O;O
Meloxicam;B-drug;B-DDI-DrugBank.d597.s12.e1
15;O;O
mg;O;O
once;O;O
daily;O;O
for;O;O
7;O;O
days;O;O
did;O;O
not;O;O
alter;O;O
the;O;O
plasma;O;O
concentration;O;O
profile;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d597.s12.e2
after;O;O
b;O;O
-;O;O
acetyldigoxin;O;O
administration;O;O
for;O;O
7;O;O
days;O;O
at;O;O
clinical;O;O
doses;O;O
.;O;O
DDI-DrugBank.d597.s13;;
In;O;O
vitro;O;O
testing;O;O
found;O;O
no;O;O
protein;O;O
binding;O;O
drug;O;O
interaction;O;O
between;O;O
digoxin;B-drug;B-DDI-DrugBank.d597.s13.e0
and;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s13.e1
.;O;O
DDI-DrugBank.d597.s14;;
Furosemide;B-drug;B-DDI-DrugBank.d597.s14.e0
:;O;O
Clinical;O;O
studies;O;O
,;O;O
as;O;O
well;O;O
as;O;O
post;O;O
-;O;O
marketing;O;O
observations;O;O
,;O;O
have;O;O
shown;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d597.s14.e1
can;O;O
reduce;O;O
the;O;O
natriuretic;O;O
effect;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d597.s14.e2
and;O;O
thiazide;B-group;B-DDI-DrugBank.d597.s14.e3
diuretics;I-group;I-DDI-DrugBank.d597.s14.e3
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d597.s15;;
This;O;O
effect;O;O
has;O;O
been;O;O
attributed;O;O
to;O;O
inhibition;O;O
of;O;O
renal;O;O
prostaglandin;O;O
synthesis;O;O
.;O;O
DDI-DrugBank.d597.s16;;
Studies;O;O
with;O;O
furosemide;B-drug;B-DDI-DrugBank.d597.s16.e0
agents;O;O
and;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s16.e1
have;O;O
not;O;O
demonstrated;O;O
a;O;O
reduction;O;O
in;O;O
natriuretic;O;O
effect;O;O
.;O;O
DDI-DrugBank.d597.s17;;
Furosemide;B-drug;B-DDI-DrugBank.d597.s17.e0
:;O;O
single;O;O
and;O;O
multiple;O;O
dose;O;O
pharmacodynamics;O;O
and;O;O
pharmacokinetics;O;O
are;O;O
not;O;O
affected;O;O
by;O;O
multiple;O;O
doses;O;O
of;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s17.e1
.;O;O
DDI-DrugBank.d597.s18;;
Nevertheless;O;O
,;O;O
during;O;O
concomitant;O;O
therapy;O;O
with;O;O
furosemide;B-drug;B-DDI-DrugBank.d597.s18.e0
and;O;O
MOBIC;B-brand;B-DDI-DrugBank.d597.s18.e1
,;O;O
patients;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
signs;O;O
of;O;O
declining;O;O
renal;O;O
function;O;O
,;O;O
as;O;O
well;O;O
as;O;O
to;O;O
assure;O;O
diuretic;O;O
efficacy;O;O
.;O;O
DDI-DrugBank.d597.s19;;
Lithium;B-drug;B-DDI-DrugBank.d597.s19.e0
:;O;O
In;O;O
clinical;O;O
trials;O;O
,;O;O
NSAIDs;B-group;B-DDI-DrugBank.d597.s19.e1
have;O;O
produced;O;O
an;O;O
elevation;O;O
of;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d597.s19.e2
levels;O;O
and;O;O
a;O;O
reduction;O;O
in;O;O
renal;O;O
lithium;B-drug;B-DDI-DrugBank.d597.s19.e3
clearance;O;O
.;O;O
DDI-DrugBank.d597.s20;;
In;O;O
a;O;O
study;O;O
conducted;O;O
in;O;O
healthy;O;O
subjects;O;O
,;O;O
mean;O;O
pre;O;O
-;O;O
dose;O;O
lithium;B-drug;B-DDI-DrugBank.d597.s20.e0
concentration;O;O
and;O;O
AUC;O;O
were;O;O
increased;O;O
by;O;O
21;O;O
%;O;O
in;O;O
subjects;O;O
receiving;O;O
lithium;B-drug;B-DDI-DrugBank.d597.s20.e1
doses;O;O
ranging;O;O
from;O;O
804;O;O
to;O;O
1072;O;O
mg;O;O
BID;O;O
with;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s20.e2
15;O;O
mg;O;O
QD;O;O
as;O;O
compared;O;O
to;O;O
subjects;O;O
receiving;O;O
lithium;B-drug;B-DDI-DrugBank.d597.s20.e3
alone;O;O
.;O;O
DDI-DrugBank.d597.s21;;
These;O;O
effects;O;O
have;O;O
been;O;O
attributed;O;O
to;O;O
inhibition;O;O
of;O;O
renal;O;O
prostaglandin;O;O
synthesis;O;O
by;O;O
MOBIC;B-brand;B-DDI-DrugBank.d597.s21.e0
.;O;O
DDI-DrugBank.d597.s22;;
Patients;O;O
on;O;O
lithium;B-drug;B-DDI-DrugBank.d597.s22.e0
treatment;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
when;O;O
MOBIC;B-brand;B-DDI-DrugBank.d597.s22.e1
is;O;O
introduced;O;O
or;O;O
withdrawn;O;O
.;O;O
DDI-DrugBank.d597.s23;;
Methotrexate;B-drug;B-DDI-DrugBank.d597.s23.e0
:;O;O
A;O;O
study;O;O
in;O;O
13;O;O
rheumatoid;O;O
arthritis;O;O
(;O;O
RA;O;O
);O;O
patients;O;O
evaluated;O;O
the;O;O
effects;O;O
of;O;O
multiple;O;O
doses;O;O
of;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s23.e1
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d597.s23.e2
taken;O;O
once;O;O
weekly;O;O
.;O;O
DDI-DrugBank.d597.s24;;
Meloxicam;B-drug;B-DDI-DrugBank.d597.s24.e0
did;O;O
not;O;O
have;O;O
a;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
single;O;O
doses;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d597.s24.e1
.;O;O
DDI-DrugBank.d597.s25;;
In;O;O
vitro;O;O
,;O;O
methotrexate;B-drug;B-DDI-DrugBank.d597.s25.e0
did;O;O
not;O;O
displace;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s25.e1
from;O;O
its;O;O
human;O;O
serum;O;O
binding;O;O
sites;O;O
.;O;O
DDI-DrugBank.d597.s26;;
Warfarin;B-drug;B-DDI-DrugBank.d597.s26.e0
:;O;O
Anticoagulant;O;O
activity;O;O
should;O;O
be;O;O
monitored;O;O
,;O;O
particularly;O;O
in;O;O
the;O;O
first;O;O
few;O;O
days;O;O
after;O;O
initiating;O;O
or;O;O
changing;O;O
MOBIC;B-brand;B-DDI-DrugBank.d597.s26.e1
therapy;O;O
in;O;O
patients;O;O
receiving;O;O
warfarin;B-drug;B-DDI-DrugBank.d597.s26.e2
or;O;O
similar;O;O
agents;O;O
,;O;O
since;O;O
these;O;O
patients;O;O
are;O;O
at;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d597.s27;;
The;O;O
effect;O;O
of;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s27.e0
on;O;O
the;O;O
anticoagulant;O;O
effect;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d597.s27.e1
was;O;O
studied;O;O
in;O;O
a;O;O
group;O;O
of;O;O
healthy;O;O
subjects;O;O
receiving;O;O
daily;O;O
doses;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d597.s27.e2
that;O;O
produced;O;O
an;O;O
INR;O;O
(;O;O
International;O;O
Normalized;O;O
Ratio;O;O
);O;O
between;O;O
1.2;O;O
and;O;O
1.8;O;O
.;O;O
DDI-DrugBank.d597.s28;;
In;O;O
these;O;O
subjects;O;O
,;O;O
meloxicam;B-drug;B-DDI-DrugBank.d597.s28.e0
did;O;O
not;O;O
alter;O;O
warfarin;B-drug;B-DDI-DrugBank.d597.s28.e1
pharmacokinetics;O;O
and;O;O
the;O;O
average;O;O
anticoagulant;O;O
effect;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d597.s28.e2
as;O;O
determined;O;O
by;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d597.s29;;
However;O;O
,;O;O
one;O;O
subject;O;O
showed;O;O
an;O;O
increase;O;O
in;O;O
INR;O;O
from;O;O
1.5;O;O
to;O;O
2.1;O;O
.;O;O
DDI-DrugBank.d597.s30;;
Caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
administering;O;O
MOBIC;B-brand;B-DDI-DrugBank.d597.s30.e0
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d597.s30.e1
since;O;O
patients;O;O
on;O;O
warfarin;B-drug;B-DDI-DrugBank.d597.s30.e2
may;O;O
experience;O;O
changes;O;O
in;O;O
INR;O;O
and;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
bleeding;O;O
complications;O;O
when;O;O
a;O;O
new;O;O
medication;O;O
is;O;O
introduced;O;O
.;O;O
DDI-DrugBank.d625.s0;;
DRUG;O;O
INTERACTIONS;O;O
There;O;O
are;O;O
no;O;O
known;O;O
drug;O;O
/;O;O
drug;O;O
interactions;O;O
with;O;O
oral;O;O
ALKERAN;B-brand;B-DDI-DrugBank.d625.s0.e0
Vaccinations;O;O
with;O;O
live;B-group;B-DDI-DrugBank.d625.s0.e1
organism;I-group;I-DDI-DrugBank.d625.s0.e1
vaccines;I-group;I-DDI-DrugBank.d625.s0.e1
are;O;O
not;O;O
recommended;O;O
in;O;O
immunocompromised;O;O
individuals;O;O
Nalidixic;B-drug;B-DDI-DrugBank.d625.s0.e2
acid;I-drug;I-DDI-DrugBank.d625.s0.e2
together;O;O
with;O;O
high;O;O
-;O;O
dose;O;O
intravenous;O;O
melphalan;B-drug;B-DDI-DrugBank.d625.s0.e3
has;O;O
caused;O;O
deaths;O;O
in;O;O
children;O;O
due;O;O
to;O;O
haemorrhagic;O;O
enterocolitis;O;O
.;O;O
DDI-DrugBank.d625.s1;;
Impaired;O;O
renal;O;O
function;O;O
has;O;O
been;O;O
described;O;O
in;O;O
bone;O;O
marrow;O;O
transplant;O;O
patients;O;O
who;O;O
were;O;O
conditioned;O;O
with;O;O
high;O;O
-;O;O
dose;O;O
intravenous;O;O
melphalan;B-drug;B-DDI-DrugBank.d625.s1.e0
and;O;O
who;O;O
subsequently;O;O
received;O;O
cyclosporin;B-drug;B-DDI-DrugBank.d625.s1.e1
to;O;O
prevent;O;O
graft;O;O
-;O;O
versus;O;O
-;O;O
host;O;O
disease;O;O
DDI-DrugBank.d585.s0;;
The;O;O
following;O;O
agents;O;O
may;O;O
increase;O;O
certain;O;O
actions;O;O
or;O;O
side;O;O
effects;O;O
of;O;O
anticholinergic;B-group;B-DDI-DrugBank.d585.s0.e0
drugs;I-group;I-DDI-DrugBank.d585.s0.e0
:;O;O
amantadine;B-drug;B-DDI-DrugBank.d585.s0.e1
,;O;O
antiarrhythmic;B-group;B-DDI-DrugBank.d585.s0.e2
agents;I-group;I-DDI-DrugBank.d585.s0.e2
of;I-group;I-DDI-DrugBank.d585.s0.e2
class;I-group;I-DDI-DrugBank.d585.s0.e2
I;I-group;I-DDI-DrugBank.d585.s0.e2
(;O;O
e.g.;O;O
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d585.s0.e3
);O;O
,;O;O
antihistamines;B-group;B-DDI-DrugBank.d585.s0.e4
,;O;O
antipsychotic;B-group;B-DDI-DrugBank.d585.s0.e5
agents;I-group;I-DDI-DrugBank.d585.s0.e5
(;O;O
e.g.;O;O
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d585.s0.e6
);O;O
,;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d585.s0.e7
,;O;O
MAO;B-group;B-DDI-DrugBank.d585.s0.e8
inhibitors;I-group;I-DDI-DrugBank.d585.s0.e8
,;O;O
narcotic;B-group;B-DDI-DrugBank.d585.s0.e9
analgesics;I-group;I-DDI-DrugBank.d585.s0.e9
(;O;O
e.g.;O;O
,;O;O
meperidine;B-drug;B-DDI-DrugBank.d585.s0.e10
);O;O
,;O;O
nitrates;B-group;B-DDI-DrugBank.d585.s0.e11
and;O;O
nitrites;B-group;B-DDI-DrugBank.d585.s0.e12
,;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d585.s0.e13
agents;I-group;I-DDI-DrugBank.d585.s0.e13
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d585.s0.e14
antidepressants;I-group;I-DDI-DrugBank.d585.s0.e14
,;O;O
and;O;O
other;O;O
drugs;O;O
having;O;O
anticholinergic;O;O
activity;O;O
.;O;O
DDI-DrugBank.d585.s1;;
Anticholinergics;B-group;B-DDI-DrugBank.d585.s1.e0
antagonize;O;O
the;O;O
effects;O;O
of;O;O
antiglaucoma;B-group;B-DDI-DrugBank.d585.s1.e1
agents;I-group;I-DDI-DrugBank.d585.s1.e1
.;O;O
DDI-DrugBank.d585.s2;;
Anticholinergic;B-group;B-DDI-DrugBank.d585.s2.e0
drugs;I-group;I-DDI-DrugBank.d585.s2.e0
in;O;O
the;O;O
presence;O;O
of;O;O
increased;O;O
intraocular;O;O
pressure;O;O
may;O;O
be;O;O
hazardous;O;O
when;O;O
taken;O;O
concurrently;O;O
with;O;O
agents;O;O
such;O;O
as;O;O
corticosteroids;B-group;B-DDI-DrugBank.d585.s2.e1
.;O;O
DDI-DrugBank.d585.s3;;
Anticholinergic;B-group;B-DDI-DrugBank.d585.s3.e0
agents;I-group;I-DDI-DrugBank.d585.s3.e0
may;O;O
affect;O;O
gastrointestinal;O;O
absorption;O;O
of;O;O
various;O;O
drugs;O;O
,;O;O
such;O;O
as;O;O
slowly;O;O
dissolving;O;O
dosage;O;O
forms;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d585.s3.e1
;;O;O
DDI-DrugBank.d585.s4;;
increased;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d585.s4.e0
concentrations;O;O
may;O;O
result;O;O
.;O;O
DDI-DrugBank.d585.s5;;
Anticholinergic;B-group;B-DDI-DrugBank.d585.s5.e0
drugs;I-group;I-DDI-DrugBank.d585.s5.e0
may;O;O
antagonize;O;O
the;O;O
effects;O;O
of;O;O
drugs;O;O
that;O;O
alter;O;O
gastrointestinal;O;O
motility;O;O
,;O;O
such;O;O
as;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d585.s5.e1
.;O;O
DDI-DrugBank.d585.s6;;
Because;O;O
antacids;B-group;B-DDI-DrugBank.d585.s6.e0
may;O;O
interfere;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
anticholinergic;B-group;B-DDI-DrugBank.d585.s6.e1
agents;I-group;I-DDI-DrugBank.d585.s6.e1
,;O;O
simultaneous;O;O
use;O;O
of;O;O
these;O;O
drugs;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d585.s7;;
The;O;O
inhibiting;O;O
effects;O;O
of;O;O
anticholinergic;B-group;B-DDI-DrugBank.d585.s7.e0
drugs;I-group;I-DDI-DrugBank.d585.s7.e0
on;O;O
gastric;O;O
hydrochloric;O;O
acid;O;O
secretion;O;O
are;O;O
antagonized;O;O
by;O;O
agents;O;O
used;O;O
to;O;O
treat;O;O
achlorhydria;O;O
and;O;O
those;O;O
used;O;O
to;O;O
test;O;O
gastric;O;O
secretion;O;O
.;O;O
DDI-DrugBank.d703.s0;;
Interaction;O;O
with;O;O
Other;O;O
Central;B-group;B-DDI-DrugBank.d703.s0.e0
Nervous;I-group;I-DDI-DrugBank.d703.s0.e0
System;I-group;I-DDI-DrugBank.d703.s0.e0
Depressants;I-group;I-DDI-DrugBank.d703.s0.e0
:;O;O
MEPERIDINE;B-drug;B-DDI-DrugBank.d703.s0.e1
SHOULD;O;O
BE;O;O
USED;O;O
WITH;O;O
GREAT;O;O
CAUTION;O;O
AND;O;O
IN;O;O
REDUCED;O;O
DOSAGE;O;O
IN;O;O
PATIENTS;O;O
WHO;O;O
ARE;O;O
CONCURRENTLY;O;O
RECEIVING;O;O
OTHER;O;O
NARCOTIC;B-group;B-DDI-DrugBank.d703.s0.e2
ANALGESICS;I-group;I-DDI-DrugBank.d703.s0.e2
,;O;O
GENERAL;O;O
ANESTHETICS;B-group;B-DDI-DrugBank.d703.s0.e3
,;O;O
PHENOTHIAZINES;B-group;B-DDI-DrugBank.d703.s0.e4
,;O;O
OTHER;O;O
TRANQUILIZERS;B-group;B-DDI-DrugBank.d703.s0.e5
,;O;O
SEDATIVE;B-group;B-DDI-DrugBank.d703.s0.e6
-;I-group;I-DDI-DrugBank.d703.s0.e6
HYPNOTICS;I-group;I-DDI-DrugBank.d703.s0.e6
(;O;O
INCLUDING;O;O
BARBITURATES;B-group;B-DDI-DrugBank.d703.s0.e7
);O;O
,;O;O
TRICYCLIC;B-group;B-DDI-DrugBank.d703.s0.e8
ANTIDEPRESSANTS;I-group;I-DDI-DrugBank.d703.s0.e8
AND;O;O
OTHER;O;O
CNS;B-group;B-DDI-DrugBank.d703.s0.e9
DEPRESSANTS;I-group;I-DDI-DrugBank.d703.s0.e9
(;O;O
INCLUDING;O;O
ALCOHOL;B-drug;B-DDI-DrugBank.d703.s0.e10
);O;O
.;O;O
DDI-DrugBank.d703.s1;;
RESPIRATORY;O;O
DEPRESSION;O;O
,;O;O
HYPOTENSION;O;O
,;O;O
AND;O;O
PROFOUND;O;O
SEDATION;O;O
OR;O;O
COMA;O;O
MAY;O;O
RESULT;O;O
.;O;O
DDI-DrugBank.d636.s0;;
Some;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d636.s0.e0
may;O;O
interact;O;O
with;O;O
Mephenytoin;B-drug;B-DDI-DrugBank.d636.s0.e1
.;O;O
DDI-DrugBank.d636.s1;;
They;O;O
can;O;O
either;O;O
increase;O;O
or;O;O
decrease;O;O
the;O;O
effect;O;O
of;O;O
Mephenytoin;B-drug;B-DDI-DrugBank.d636.s1.e0
.;O;O
DDI-DrugBank.d636.s2;;
Those;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d636.s2.e0
include;O;O
divalproex;B-drug;B-DDI-DrugBank.d636.s2.e1
sodium;I-drug;I-DDI-DrugBank.d636.s2.e1
,;O;O
valproic;B-drug;B-DDI-DrugBank.d636.s2.e2
acid;I-drug;I-DDI-DrugBank.d636.s2.e2
,;O;O
and;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d636.s2.e3
.;O;O
DDI-DrugBank.d636.s3;;
Mephenytoin;B-drug;B-DDI-DrugBank.d636.s3.e0
may;O;O
also;O;O
affect;O;O
the;O;O
effects;O;O
of;O;O
other;O;O
drugs;O;O
,;O;O
which;O;O
include;O;O
some;O;O
steroid;B-group;B-DDI-DrugBank.d636.s3.e1
medications;I-group;I-DDI-DrugBank.d636.s3.e1
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d636.s3.e2
,;O;O
certain;O;O
heart;O;O
medicines;O;O
,;O;O
birth;O;O
control;O;O
pills;O;O
,;O;O
anti;B-group;B-DDI-DrugBank.d636.s3.e3
-;I-group;I-DDI-DrugBank.d636.s3.e3
infective;I-group;I-DDI-DrugBank.d636.s3.e3
medicines;I-group;I-DDI-DrugBank.d636.s3.e3
,;O;O
furosemide;B-drug;B-DDI-DrugBank.d636.s3.e4
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d636.s3.e5
Please;O;O
note;O;O
that;O;O
Mephenytoin;B-drug;B-DDI-DrugBank.d636.s3.e6
may;O;O
interact;O;O
with;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
not;O;O
listed;O;O
here;O;O
.;O;O
DDI-DrugBank.d699.s0;;
Mequitazine;B-drug;B-DDI-DrugBank.d699.s0.e0
can;O;O
interact;O;O
with;O;O
CNS;B-group;B-DDI-DrugBank.d699.s0.e1
depressant;I-group;I-DDI-DrugBank.d699.s0.e1
,;O;O
antichlolinergic;B-group;B-DDI-DrugBank.d699.s0.e2
,;O;O
TCA;B-group;B-DDI-DrugBank.d699.s0.e3
,;O;O
MAOIs;B-group;B-DDI-DrugBank.d699.s0.e4
,;O;O
and;O;O
alcohol;B-drug;B-DDI-DrugBank.d699.s0.e5
.;O;O
DDI-DrugBank.d762.s0;;
Probenecid;B-drug;B-DDI-DrugBank.d762.s0.e0
competes;O;O
with;O;O
meropenem;B-drug;B-DDI-DrugBank.d762.s0.e1
for;O;O
active;O;O
tubular;O;O
secretion;O;O
and;O;O
thus;O;O
inhibits;O;O
the;O;O
renal;O;O
excretion;O;O
of;O;O
meropenem;B-drug;B-DDI-DrugBank.d762.s0.e2
.;O;O
DDI-DrugBank.d762.s1;;
This;O;O
led;O;O
to;O;O
statistically;O;O
significant;O;O
increases;O;O
in;O;O
the;O;O
elimination;O;O
half;O;O
-;O;O
life;O;O
(;O;O
38;O;O
%;O;O
);O;O
and;O;O
in;O;O
the;O;O
extent;O;O
of;O;O
systemic;O;O
exposure;O;O
(;O;O
56;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d762.s2;;
Therefore;O;O
,;O;O
the;O;O
coadministration;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d762.s2.e0
with;O;O
meropenem;B-drug;B-DDI-DrugBank.d762.s2.e1
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d762.s3;;
There;O;O
is;O;O
evidence;O;O
that;O;O
meropenem;B-drug;B-DDI-DrugBank.d762.s3.e0
may;O;O
reduce;O;O
serum;O;O
levels;O;O
of;O;O
valproic;B-drug;B-DDI-DrugBank.d762.s3.e1
acid;I-drug;I-DDI-DrugBank.d762.s3.e1
to;O;O
subtherapeutic;O;O
levels;O;O
(;O;O
therapeutic;O;O
range;O;O
considered;O;O
to;O;O
be;O;O
50;O;O
to;O;O
100;O;O
g;O;O
/;O;O
mL;O;O
total;O;O
valproate;B-drug;B-DDI-DrugBank.d762.s3.e2
);O;O
.;O;O
DDI-DrugBank.d746.s0;;
ARAMINE;B-brand;B-DDI-DrugBank.d746.s0.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
digitalized;O;O
patients;O;O
,;O;O
since;O;O
the;O;O
combination;O;O
of;O;O
digitalis;B-group;B-DDI-DrugBank.d746.s0.e1
and;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d746.s0.e2
amines;I-group;I-DDI-DrugBank.d746.s0.e2
may;O;O
cause;O;O
ectopic;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d746.s1;;
Monoamine;B-group;B-DDI-DrugBank.d746.s1.e0
oxidase;I-group;I-DDI-DrugBank.d746.s1.e0
inhibitors;I-group;I-DDI-DrugBank.d746.s1.e0
or;O;O
tricyclic;B-group;B-DDI-DrugBank.d746.s1.e1
antidepressants;I-group;I-DDI-DrugBank.d746.s1.e1
may;O;O
potentiate;O;O
the;O;O
action;O;O
of;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d746.s1.e2
amines;I-group;I-DDI-DrugBank.d746.s1.e2
.;O;O
DDI-DrugBank.d746.s2;;
Therefore;O;O
,;O;O
when;O;O
initiating;O;O
pressor;O;O
therapy;O;O
in;O;O
patients;O;O
receiving;O;O
these;O;O
drugs;O;O
,;O;O
the;O;O
initial;O;O
dose;O;O
should;O;O
be;O;O
small;O;O
and;O;O
given;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d605.s0;;
SKELAXIN;B-brand;B-DDI-DrugBank.d605.s0.e0
may;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d605.s0.e1
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d605.s0.e2
and;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d605.s0.e3
depressants;I-group;I-DDI-DrugBank.d605.s0.e3
.;O;O
DDI-DrugBank.d630.s0;;
Methazolamide;B-drug;B-DDI-DrugBank.d630.s0.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
on;O;O
steroid;O;O
therapy;O;O
because;O;O
of;O;O
the;O;O
potential;O;O
for;O;O
developing;O;O
hypokalemia;O;O
.;O;O
DDI-DrugBank.d630.s1;;
Caution;O;O
is;O;O
advised;O;O
for;O;O
patients;O;O
receiving;O;O
high;O;O
-;O;O
dose;O;O
aspirin;B-brand;B-DDI-DrugBank.d630.s1.e0
and;O;O
methazolamide;B-drug;B-DDI-DrugBank.d630.s1.e1
concomitantly;O;O
,;O;O
as;O;O
anorexia;O;O
,;O;O
tachypnea;O;O
,;O;O
lethargy;O;O
,;O;O
coma;O;O
and;O;O
death;O;O
have;O;O
been;O;O
reported;O;O
with;O;O
concomitant;O;O
use;O;O
of;O;O
high;O;O
-;O;O
dose;O;O
aspirin;B-brand;B-DDI-DrugBank.d630.s1.e2
and;O;O
carbonic;B-group;B-DDI-DrugBank.d630.s1.e3
anhydrase;I-group;I-DDI-DrugBank.d630.s1.e3
inhibitors;I-group;I-DDI-DrugBank.d630.s1.e3
.;O;O
DDI-DrugBank.d634.s0;;
Anticoagulants;B-group;B-DDI-DrugBank.d634.s0.e0
(;O;O
oral;O;O
);O;O
:;O;O
The;O;O
activity;O;O
of;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d634.s0.e1
may;O;O
be;O;O
potentiated;O;O
by;O;O
anti;O;O
-;O;O
vitamin;O;O
-;O;O
K;O;O
activity;O;O
attributed;O;O
to;O;O
methimazole;B-drug;B-DDI-DrugBank.d634.s0.e2
.;O;O
DDI-DrugBank.d634.s1;;
-adrenergic;O;O
blocking;O;O
agents;O;O
:;O;O
Hyperthyroidism;O;O
may;O;O
cause;O;O
an;O;O
increased;O;O
clearance;O;O
of;O;O
beta;O;O
ratio;O;O
.;O;O
DDI-DrugBank.d634.s2;;
A;O;O
dose;O;O
reduction;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d634.s2.e0
-;I-group;I-DDI-DrugBank.d634.s2.e0
adrenergic;I-group;I-DDI-DrugBank.d634.s2.e0
blockers;I-group;I-DDI-DrugBank.d634.s2.e0
may;O;O
be;O;O
needed;O;O
when;O;O
a;O;O
hyperthyroid;O;O
patient;O;O
becomes;O;O
euthyroid;O;O
.;O;O
DDI-DrugBank.d634.s3;;
Digitalis;B-group;B-DDI-DrugBank.d634.s3.e0
glycosides;I-group;I-DDI-DrugBank.d634.s3.e0
:;O;O
Serum;O;O
digitalis;O;O
levels;O;O
may;O;O
be;O;O
increased;O;O
when;O;O
hyperthyroid;O;O
patients;O;O
on;O;O
a;O;O
stable;O;O
digitalis;B-group;B-DDI-DrugBank.d634.s3.e1
glycoside;I-group;I-DDI-DrugBank.d634.s3.e1
regimen;O;O
become;O;O
euthyroid;O;O
;;O;O
DDI-DrugBank.d634.s4;;
reduced;O;O
dosage;O;O
of;O;O
digitalis;B-group;B-DDI-DrugBank.d634.s4.e0
glycosides;I-group;I-DDI-DrugBank.d634.s4.e0
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d634.s5;;
Theophylline;B-drug;B-DDI-DrugBank.d634.s5.e0
:;O;O
Theophylline;B-drug;B-DDI-DrugBank.d634.s5.e1
clearance;O;O
may;O;O
decrease;O;O
when;O;O
hyperthyroid;O;O
patients;O;O
on;O;O
a;O;O
stable;O;O
theophylline;B-drug;B-DDI-DrugBank.d634.s5.e2
regimen;O;O
become;O;O
euthyroid;O;O
;;O;O
DDI-DrugBank.d634.s6;;
a;O;O
reduced;O;O
dose;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d634.s6.e0
may;O;O
be;O;O
needed;O;O
.;O;O
DDI-DrugBank.d756.s0;;
Dosages;O;O
of;O;O
concomitantly;O;O
administered;O;O
opioids;B-group;B-DDI-DrugBank.d756.s0.e0
should;O;O
be;O;O
reduced;O;O
by;O;O
approximately;O;O
half;O;O
,;O;O
because;O;O
levomepromazine;B-drug;B-DDI-DrugBank.d756.s0.e1
amplifies;O;O
the;O;O
therapeutic;O;O
actions;O;O
and;O;O
side;O;O
-;O;O
effects;O;O
of;O;O
opioids;B-group;B-DDI-DrugBank.d756.s0.e2
.;O;O
DDI-DrugBank.d756.s1;;
Combination;O;O
with;O;O
tramadol;B-drug;B-DDI-DrugBank.d756.s1.e0
(;O;O
Ultram;B-brand;B-DDI-DrugBank.d756.s1.e1
);O;O
is;O;O
associated;O;O
with;O;O
increased;O;O
risk;O;O
of;O;O
seizures;O;O
.;O;O
DDI-DrugBank.d756.s2;;
Additive;O;O
sedative;O;O
effects;O;O
and;O;O
confusional;O;O
states;O;O
may;O;O
emerge;O;O
if;O;O
levomepromazine;B-drug;B-DDI-DrugBank.d756.s2.e0
is;O;O
given;O;O
with;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d756.s2.e1
or;O;O
barbiturates;B-group;B-DDI-DrugBank.d756.s2.e2
.;O;O
DDI-DrugBank.d756.s3;;
This;O;O
may;O;O
be;O;O
avoided;O;O
by;O;O
using;O;O
the;O;O
lowest;O;O
dose;O;O
possible;O;O
with;O;O
the;O;O
substances;O;O
in;O;O
question;O;O
.;O;O
DDI-DrugBank.d756.s4;;
Exert;O;O
particular;O;O
caution;O;O
in;O;O
combining;O;O
levomepromazine;B-drug;B-DDI-DrugBank.d756.s4.e0
with;O;O
other;O;O
anticholinergic;B-group;B-DDI-DrugBank.d756.s4.e1
drugs;I-group;I-DDI-DrugBank.d756.s4.e1
(;O;O
tricyclic;B-group;B-DDI-DrugBank.d756.s4.e2
antidepressants;I-group;I-DDI-DrugBank.d756.s4.e2
and;O;O
antiparkinsonian;B-group;B-DDI-DrugBank.d756.s4.e3
-;I-group;I-DDI-DrugBank.d756.s4.e3
agents;I-group;I-DDI-DrugBank.d756.s4.e3
);O;O
:;O;O
Particularly;O;O
the;O;O
elderly;O;O
may;O;O
develop;O;O
delirium;O;O
,;O;O
high;O;O
fever;O;O
,;O;O
severe;O;O
obstipation;O;O
,;O;O
even;O;O
ileus;O;O
and;O;O
glaucoma;O;O
.;O;O
DDI-DrugBank.d756.s5;;
Reduce;O;O
both;O;O
the;O;O
dose;O;O
of;O;O
levomepromazine;B-drug;B-DDI-DrugBank.d756.s5.e0
and;O;O
the;O;O
dose;O;O
of;O;O
the;O;O
other;O;O
drug;O;O
.;O;O
DDI-DrugBank.d756.s6;;
If;O;O
possible;O;O
,;O;O
avoid;O;O
such;O;O
combinations;O;O
.;O;O
DDI-DrugBank.d756.s7;;
Caffeine;B-drug;B-DDI-DrugBank.d756.s7.e0
and/or;O;O
stimulantes;O;O
of;O;O
the;O;O
ephedrine;B-drug;B-DDI-DrugBank.d756.s7.e1
/;O;O
amphetamine;B-drug;B-DDI-DrugBank.d756.s7.e2
type;O;O
may;O;O
counteract;O;O
the;O;O
specific;O;O
actions;O;O
of;O;O
levomepromazine;B-drug;B-DDI-DrugBank.d756.s7.e3
.;O;O
DDI-DrugBank.d756.s8;;
Concomitant;O;O
use;O;O
of;O;O
these;O;O
substances;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d756.s9;;
Coffee;O;O
and;O;O
black;O;O
tea;O;O
should;O;O
be;O;O
avoided;O;O
because;O;O
they;O;O
decrease;O;O
the;O;O
absorption;O;O
of;O;O
levomepromazine;B-drug;B-DDI-DrugBank.d756.s9.e0
considerably;O;O
.;O;O
DDI-DrugBank.d756.s10;;
The;O;O
same;O;O
is;O;O
true;O;O
for;O;O
antacids;B-group;B-DDI-DrugBank.d756.s10.e0
;;O;O
DDI-DrugBank.d756.s11;;
these;O;O
should;O;O
be;O;O
given;O;O
1;O;O
to;O;O
2;O;O
hours;O;O
before;O;O
or;O;O
after;O;O
oral;O;O
administration;O;O
of;O;O
leveomepromazine;B-drug;B-DDI-DrugBank.d756.s11.e0
.;O;O
DDI-DrugBank.d587.s0;;
Since;O;O
Celontin;B-brand;B-DDI-DrugBank.d587.s0.e0
(;O;O
methsuximide;B-drug;B-DDI-DrugBank.d587.s0.e1
);O;O
may;O;O
interact;O;O
with;O;O
concurrently;O;O
administered;O;O
antiepileptic;B-group;B-DDI-DrugBank.d587.s0.e2
drugs;I-group;I-DDI-DrugBank.d587.s0.e2
,;O;O
periodic;O;O
serum;O;O
level;O;O
determinations;O;O
of;O;O
these;O;O
drugs;O;O
may;O;O
be;O;O
necessary;O;O
(;O;O
eg;O;O
methsuximide;B-drug;B-DDI-DrugBank.d587.s0.e3
may;O;O
increase;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d587.s0.e4
and;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d587.s0.e5
);O;O
.;O;O
DDI-DrugBank.d736.s0;;
Hypokalemia;O;O
can;O;O
sensitize;O;O
or;O;O
exaggerate;O;O
the;O;O
response;O;O
of;O;O
the;O;O
heart;O;O
to;O;O
the;O;O
toxic;O;O
effects;O;O
of;O;O
digitalis;B-group;B-DDI-DrugBank.d736.s0.e0
(;O;O
e.g.;O;O
,;O;O
increased;O;O
ventricular;O;O
irritability;O;O
);O;O
.;O;O
DDI-DrugBank.d736.s1;;
Hypokalemia;O;O
may;O;O
develop;O;O
during;O;O
concomitant;O;O
use;O;O
of;O;O
steroids;B-group;B-DDI-DrugBank.d736.s1.e0
or;O;O
ACTH;B-drug;B-DDI-DrugBank.d736.s1.e1
.;O;O
DDI-DrugBank.d736.s2;;
Insulin;B-drug;B-DDI-DrugBank.d736.s2.e0
requirements;O;O
in;O;O
diabetic;O;O
patients;O;O
may;O;O
be;O;O
increased;O;O
,;O;O
decreased;O;O
,;O;O
or;O;O
unchanged;O;O
.;O;O
DDI-DrugBank.d736.s3;;
Thiazides;B-group;B-DDI-DrugBank.d736.s3.e0
may;O;O
decrease;O;O
arterial;O;O
responsiveness;O;O
to;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d736.s3.e1
.;O;O
DDI-DrugBank.d736.s4;;
This;O;O
diminution;O;O
is;O;O
not;O;O
sufficient;O;O
to;O;O
preclude;O;O
effectiveness;O;O
of;O;O
the;O;O
pressor;O;O
agent;O;O
for;O;O
therapeutic;O;O
use;O;O
.;O;O
DDI-DrugBank.d736.s5;;
Thiazide;B-group;B-DDI-DrugBank.d736.s5.e0
drugs;I-group;I-DDI-DrugBank.d736.s5.e0
may;O;O
increase;O;O
the;O;O
responsiveness;O;O
of;O;O
tubocurarine;B-drug;B-DDI-DrugBank.d736.s5.e1
.;O;O
DDI-DrugBank.d736.s6;;
Lithium;B-drug;B-DDI-DrugBank.d736.s6.e0
renal;O;O
clearance;O;O
is;O;O
reduced;O;O
by;O;O
thiazides;B-group;B-DDI-DrugBank.d736.s6.e1
,;O;O
increasing;O;O
the;O;O
risk;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d736.s6.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d736.s7;;
Thiazides;B-group;B-DDI-DrugBank.d736.s7.e0
may;O;O
add;O;O
to;O;O
or;O;O
potentiate;O;O
the;O;O
action;O;O
of;O;O
other;O;O
antihypertensive;B-group;B-DDI-DrugBank.d736.s7.e1
drugs;I-group;I-DDI-DrugBank.d736.s7.e1
.;O;O
DDI-DrugBank.d736.s8;;
Potentiation;O;O
occurs;O;O
with;O;O
ganglionic;B-group;B-DDI-DrugBank.d736.s8.e0
or;I-group;I-DDI-DrugBank.d736.s8.e0
peripheral;I-group;I-DDI-DrugBank.d736.s8.e1
adrenergic;I-group;I-DDI-DrugBank.d736.s8.e1
blocking;I-group;I-DDI-DrugBank.d736.s8.e1
drugs;I-group;I-DDI-DrugBank.d736.s8.e1
.;O;O
DDI-DrugBank.d779.s0;;
When;O;O
methyldopa;B-drug;B-DDI-DrugBank.d779.s0.e0
is;O;O
used;O;O
with;O;O
other;O;O
antihypertensive;B-group;B-DDI-DrugBank.d779.s0.e1
drugs;I-group;I-DDI-DrugBank.d779.s0.e1
,;O;O
potentiation;O;O
of;O;O
antihypertensive;O;O
effect;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d779.s1;;
Patients;O;O
should;O;O
be;O;O
followed;O;O
carefully;O;O
to;O;O
detect;O;O
side;O;O
reactions;O;O
or;O;O
unusual;O;O
manifestations;O;O
of;O;O
drug;O;O
idiosyncrasy;O;O
.;O;O
DDI-DrugBank.d779.s2;;
Patients;O;O
may;O;O
require;O;O
reduced;O;O
doses;O;O
of;O;O
anesthetics;B-group;B-DDI-DrugBank.d779.s2.e0
when;O;O
on;O;O
methyldopa;B-drug;B-DDI-DrugBank.d779.s2.e1
.;O;O
DDI-DrugBank.d779.s3;;
If;O;O
hypotension;O;O
does;O;O
occur;O;O
during;O;O
anesthesia;O;O
,;O;O
it;O;O
usually;O;O
can;O;O
be;O;O
controlled;O;O
by;O;O
vasopressors;B-group;B-DDI-DrugBank.d779.s3.e0
.;O;O
DDI-DrugBank.d779.s4;;
The;O;O
adrenergic;O;O
receptors;O;O
remain;O;O
sensitive;O;O
during;O;O
treatment;O;O
with;O;O
methyldopa;B-drug;B-DDI-DrugBank.d779.s4.e0
.;O;O
DDI-DrugBank.d779.s5;;
When;O;O
methyldopa;B-drug;B-DDI-DrugBank.d779.s5.e0
and;O;O
lithium;B-drug;B-DDI-DrugBank.d779.s5.e1
are;O;O
given;O;O
concomitantly;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
for;O;O
symptoms;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d779.s5.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d779.s6;;
Read;O;O
the;O;O
circular;O;O
for;O;O
lithium;B-drug;B-DDI-DrugBank.d779.s6.e0
preparations;O;O
.;O;O
DDI-DrugBank.d779.s7;;
Several;O;O
studies;O;O
demonstrate;O;O
a;O;O
decrease;O;O
in;O;O
the;O;O
bioavailability;O;O
of;O;O
methyldopa;B-drug;B-DDI-DrugBank.d779.s7.e0
when;O;O
it;O;O
is;O;O
ingested;O;O
with;O;O
ferrous;B-drug;B-DDI-DrugBank.d779.s7.e1
sulfate;I-drug;I-DDI-DrugBank.d779.s7.e1
or;O;O
ferrous;B-drug;B-DDI-DrugBank.d779.s7.e2
gluconate;I-drug;I-DDI-DrugBank.d779.s7.e2
.;O;O
DDI-DrugBank.d779.s8;;
This;O;O
may;O;O
adversely;O;O
affect;O;O
blood;O;O
pressure;O;O
control;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
methyldopa;B-drug;B-DDI-DrugBank.d779.s8.e0
.;O;O
DDI-DrugBank.d779.s9;;
Coadministration;O;O
of;O;O
methyldopa;B-drug;B-DDI-DrugBank.d779.s9.e0
with;O;O
ferrous;B-drug;B-DDI-DrugBank.d779.s9.e1
sulfate;I-drug;I-DDI-DrugBank.d779.s9.e1
or;O;O
ferrous;B-drug;B-DDI-DrugBank.d779.s9.e2
gluconate;I-drug;I-DDI-DrugBank.d779.s9.e2
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d779.s10;;
Monoamine;B-group;B-DDI-DrugBank.d779.s10.e0
oxidase;I-group;I-DDI-DrugBank.d779.s10.e0
(;I-group;I-DDI-DrugBank.d779.s10.e0
MAO;I-group;I-DDI-DrugBank.d779.s10.e0
);I-group;I-DDI-DrugBank.d779.s10.e0
inhibitors;I-group;I-DDI-DrugBank.d779.s10.e0
:;O;O
See;O;O
CONTRAINDICATIONS;O;O
.;O;O
DDI-DrugBank.d779.s11;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Methyldopa;B-drug;B-DDI-DrugBank.d779.s11.e0
may;O;O
interfere;O;O
with;O;O
measurement;O;O
of;O;O
:;O;O
urinary;O;O
uric;O;O
acid;O;O
by;O;O
the;O;O
phosphotungstate;O;O
method;O;O
,;O;O
serum;O;O
creatinine;O;O
by;O;O
the;O;O
alkaline;O;O
picrate;O;O
method;O;O
,;O;O
and;O;O
SGOT;O;O
by;O;O
colorimetric;O;O
methods;O;O
.;O;O
DDI-DrugBank.d779.s12;;
Interference;O;O
with;O;O
spectrophotometric;O;O
methods;O;O
for;O;O
SGOT;O;O
analysis;O;O
has;O;O
not;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d779.s13;;
Since;O;O
methyldopa;B-drug;B-DDI-DrugBank.d779.s13.e0
causes;O;O
fluorescence;O;O
in;O;O
urine;O;O
samples;O;O
at;O;O
the;O;O
same;O;O
wave;O;O
lengths;O;O
as;O;O
catecholamines;O;O
,;O;O
falsely;O;O
high;O;O
levels;O;O
of;O;O
urinary;O;O
catecholamines;O;O
may;O;O
be;O;O
reported;O;O
.;O;O
DDI-DrugBank.d779.s14;;
This;O;O
will;O;O
interfere;O;O
with;O;O
the;O;O
diagnosis;O;O
of;O;O
pheochromocytoma;O;O
.;O;O
DDI-DrugBank.d779.s15;;
It;O;O
is;O;O
important;O;O
to;O;O
recognize;O;O
this;O;O
phenomenon;O;O
before;O;O
a;O;O
patient;O;O
with;O;O
a;O;O
possible;O;O
pheochromocytoma;O;O
is;O;O
subjected;O;O
to;O;O
surgery;O;O
.;O;O
DDI-DrugBank.d779.s16;;
Methyldopa;B-drug;B-DDI-DrugBank.d779.s16.e0
does;O;O
not;O;O
interfere;O;O
with;O;O
measurement;O;O
of;O;O
VMA;B-drug_n;B-DDI-DrugBank.d779.s16.e1
(;O;O
vanillylmandelic;B-drug_n;B-DDI-DrugBank.d779.s16.e2
acid;I-drug_n;I-DDI-DrugBank.d779.s16.e2
);O;O
,;O;O
a;O;O
test;O;O
for;O;O
pheochromocytoma;O;O
,;O;O
by;O;O
those;O;O
methods;O;O
which;O;O
convert;O;O
VMA;B-drug_n;B-DDI-DrugBank.d779.s16.e3
to;O;O
vanillin;B-drug_n;B-DDI-DrugBank.d779.s16.e4
.;O;O
DDI-DrugBank.d779.s17;;
Methyldopa;B-drug;B-DDI-DrugBank.d779.s17.e0
is;O;O
not;O;O
recommended;O;O
for;O;O
the;O;O
treatment;O;O
of;O;O
patients;O;O
with;O;O
pheochromocytoma;O;O
.;O;O
DDI-DrugBank.d779.s18;;
Rarely;O;O
,;O;O
when;O;O
urine;O;O
is;O;O
exposed;O;O
to;O;O
air;O;O
after;O;O
voiding;O;O
,;O;O
it;O;O
may;O;O
darken;O;O
because;O;O
of;O;O
breakdown;O;O
of;O;O
methyldopa;B-drug;B-DDI-DrugBank.d779.s18.e0
or;O;O
its;O;O
metabolites;O;O
.;O;O
DDI-DrugBank.d675.s0;;
CYP;O;O
3A4;O;O
Inhibitors;O;O
(;O;O
e.g.;O;O
Macrolide;B-group;B-DDI-DrugBank.d675.s0.e0
Antibiotics;I-group;I-DDI-DrugBank.d675.s0.e0
and;O;O
Protease;B-group;B-DDI-DrugBank.d675.s0.e1
Inhibitors;I-group;I-DDI-DrugBank.d675.s0.e1
);O;O
There;O;O
have;O;O
been;O;O
rare;O;O
reports;O;O
of;O;O
serious;O;O
adverse;O;O
events;O;O
in;O;O
connection;O;O
with;O;O
the;O;O
coadministration;O;O
of;O;O
certain;O;O
ergot;B-group;B-DDI-DrugBank.d675.s0.e2
alkaloid;I-group;I-DDI-DrugBank.d675.s0.e2
drugs;I-group;I-DDI-DrugBank.d675.s0.e2
(;O;O
e.g.;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d675.s0.e3
and;O;O
ergotamine;B-drug;B-DDI-DrugBank.d675.s0.e4
);O;O
and;O;O
potent;O;O
CYP;O;O
3A4;O;O
inhibitors;O;O
,;O;O
resulting;O;O
in;O;O
vasospasm;O;O
leading;O;O
to;O;O
cerebral;O;O
ischemia;O;O
and/or;O;O
ischemia;O;O
of;O;O
the;O;O
extremities;O;O
.;O;O
DDI-DrugBank.d675.s1;;
Although;O;O
there;O;O
have;O;O
been;O;O
no;O;O
reports;O;O
of;O;O
such;O;O
interactions;O;O
with;O;O
methylergonovine;B-drug;B-DDI-DrugBank.d675.s1.e0
alone;O;O
,;O;O
potent;O;O
CYP;O;O
3A4;O;O
inhibitors;O;O
should;O;O
not;O;O
be;O;O
coadministered;O;O
with;O;O
methylergonovine;O;O
.;O;O
DDI-DrugBank.d675.s2;;
Examples;O;O
of;O;O
some;O;O
of;O;O
the;O;O
more;O;O
potent;O;O
CYP;O;O
3A4;O;O
inhibitors;O;O
include;O;O
macrolide;B-group;B-DDI-DrugBank.d675.s2.e0
antibiotics;I-group;I-DDI-DrugBank.d675.s2.e0
(;O;O
e.g.;O;O
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d675.s2.e1
,;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d675.s2.e2
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d675.s2.e3
);O;O
,;O;O
HIV;B-group;B-DDI-DrugBank.d675.s2.e4
protease;I-group;I-DDI-DrugBank.d675.s2.e4
or;I-group;I-DDI-DrugBank.d675.s2.e4
reverse;I-group;I-DDI-DrugBank.d675.s2.e5
transcriptase;I-group;I-DDI-DrugBank.d675.s2.e5
inhibitors;I-group;I-DDI-DrugBank.d675.s2.e5
(;O;O
e.g.;O;O
,;O;O
ritonavir;B-drug;B-DDI-DrugBank.d675.s2.e6
,;O;O
indinavir;B-drug;B-DDI-DrugBank.d675.s2.e7
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d675.s2.e8
,;O;O
delavirdine;B-drug;B-DDI-DrugBank.d675.s2.e9
);O;O
or;O;O
azole;B-group;B-DDI-DrugBank.d675.s2.e10
antifungals;I-group;I-DDI-DrugBank.d675.s2.e10
(;O;O
e.g.;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d675.s2.e11
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d675.s2.e12
,;O;O
voriconazole;B-drug;B-DDI-DrugBank.d675.s2.e13
);O;O
.;O;O
DDI-DrugBank.d675.s3;;
Less;O;O
potent;O;O
CYP;O;O
3A4;O;O
inhibitors;O;O
should;O;O
be;O;O
administered;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d675.s4;;
Less;O;O
potent;O;O
inhibitors;O;O
include;O;O
saquinavir;B-drug;B-DDI-DrugBank.d675.s4.e0
,;O;O
nefazodone;B-drug;B-DDI-DrugBank.d675.s4.e1
,;O;O
fluconazole;B-drug;B-DDI-DrugBank.d675.s4.e2
,;O;O
grapefruit;O;O
juice;O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d675.s4.e3
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d675.s4.e4
,;O;O
zileuton;B-drug;B-DDI-DrugBank.d675.s4.e5
,;O;O
and;O;O
clotrimazole;B-drug;B-DDI-DrugBank.d675.s4.e6
.;O;O
DDI-DrugBank.d675.s5;;
These;O;O
lists;O;O
are;O;O
not;O;O
exhaustive;O;O
,;O;O
and;O;O
the;O;O
prescriber;O;O
should;O;O
consider;O;O
the;O;O
effects;O;O
on;O;O
CYP;O;O
3A4;O;O
of;O;O
other;O;O
agents;O;O
being;O;O
considered;O;O
for;O;O
concomitant;O;O
use;O;O
with;O;O
methylergonovine;B-drug;B-DDI-DrugBank.d675.s5.e0
.;O;O
DDI-DrugBank.d675.s6;;
No;O;O
pharmacokinetic;O;O
interactions;O;O
involving;O;O
other;O;O
cytochrome;O;O
P450;O;O
isoenzymes;O;O
are;O;O
known;O;O
.;O;O
DDI-DrugBank.d675.s7;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
Methergine;B-brand;B-DDI-DrugBank.d675.s7.e0
(;O;O
methylergonovine;B-drug;B-DDI-DrugBank.d675.s7.e1
maleate;I-drug;I-DDI-DrugBank.d675.s7.e1
);O;O
is;O;O
used;O;O
concurrently;O;O
with;O;O
other;O;O
vasoconstrictors;B-group;B-DDI-DrugBank.d675.s7.e2
or;O;O
ergot;B-group;B-DDI-DrugBank.d675.s7.e3
alkaloids;I-group;I-DDI-DrugBank.d675.s7.e3
.;O;O
DDI-DrugBank.d638.s0;;
Ritalin;B-brand;B-DDI-DrugBank.d638.s0.e0
may;O;O
decrease;O;O
the;O;O
hypotensive;O;O
effect;O;O
of;O;O
guanethidine;B-drug;B-DDI-DrugBank.d638.s0.e1
.;O;O
DDI-DrugBank.d638.s1;;
Use;O;O
cautiously;O;O
with;O;O
pressor;O;O
agents;O;O
.;O;O
DDI-DrugBank.d638.s2;;
Human;O;O
pharmacologic;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
Ritalin;B-brand;B-DDI-DrugBank.d638.s2.e0
may;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
coumarin;B-group;B-DDI-DrugBank.d638.s2.e1
anticoagulants;I-group;I-DDI-DrugBank.d638.s2.e1
,;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d638.s2.e2
(;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d638.s2.e3
,;O;O
diphenylhydantoin;B-drug;B-DDI-DrugBank.d638.s2.e4
,;O;O
primidone;B-drug;B-DDI-DrugBank.d638.s2.e5
);O;O
,;O;O
phenylbutazone;B-drug;B-DDI-DrugBank.d638.s2.e6
,;O;O
and;O;O
tricyclic;B-group;B-DDI-DrugBank.d638.s2.e7
drugs;I-group;I-DDI-DrugBank.d638.s2.e7
(;O;O
imipramine;B-drug;B-DDI-DrugBank.d638.s2.e8
,;O;O
clomipramine;B-drug;B-DDI-DrugBank.d638.s2.e9
,;O;O
desipramine;B-drug;B-DDI-DrugBank.d638.s2.e10
);O;O
.;O;O
DDI-DrugBank.d638.s3;;
Downward;O;O
dosage;O;O
adjustments;O;O
of;O;O
these;O;O
drugs;O;O
may;O;O
be;O;O
required;O;O
when;O;O
given;O;O
concomitantly;O;O
with;O;O
Ritalin;B-brand;B-DDI-DrugBank.d638.s3.e0
.;O;O
DDI-DrugBank.d638.s4;;
Serious;O;O
adverse;O;O
events;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
concomitant;O;O
use;O;O
with;O;O
clonidine;B-drug;B-DDI-DrugBank.d638.s4.e0
,;O;O
although;O;O
no;O;O
causality;O;O
for;O;O
the;O;O
combination;O;O
has;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d638.s5;;
The;O;O
safety;O;O
of;O;O
using;O;O
methylphenidate;B-drug;B-DDI-DrugBank.d638.s5.e0
in;O;O
combination;O;O
with;O;O
clonidine;B-drug;B-DDI-DrugBank.d638.s5.e1
or;O;O
other;O;O
centrally;O;O
acting;O;O
alpha;B-group;B-DDI-DrugBank.d638.s5.e2
-;I-group;I-DDI-DrugBank.d638.s5.e2
2;I-group;I-DDI-DrugBank.d638.s5.e2
agonists;I-group;I-DDI-DrugBank.d638.s5.e2
has;O;O
not;O;O
been;O;O
systemically;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d578.s0;;
The;O;O
pharmacokinetic;O;O
interactions;O;O
listed;O;O
below;O;O
are;O;O
potentially;O;O
clinically;O;O
important;O;O
.;O;O
DDI-DrugBank.d578.s1;;
Mutual;O;O
inhibition;O;O
of;O;O
metabolism;O;O
occurs;O;O
with;O;O
concurrent;O;O
use;O;O
of;O;O
cyclosporin;B-drug;B-DDI-DrugBank.d578.s1.e0
and;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d578.s1.e1
;;O;O
DDI-DrugBank.d578.s2;;
therefore;O;O
,;O;O
it;O;O
is;O;O
possible;O;O
that;O;O
adverse;O;O
events;O;O
associated;O;O
with;O;O
the;O;O
individual;O;O
use;O;O
of;O;O
either;O;O
drug;O;O
may;O;O
be;O;O
more;O;O
apt;O;O
to;O;O
occur;O;O
.;O;O
DDI-DrugBank.d578.s3;;
convulsions;O;O
have;O;O
been;O;O
reported;O;O
with;O;O
concurrent;O;O
use;O;O
of;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d578.s3.e0
and;O;O
cyclosporin;B-drug;B-DDI-DrugBank.d578.s3.e1
.;O;O
DDI-DrugBank.d578.s4;;
Drugs;O;O
that;O;O
induce;O;O
hepatic;O;O
enzymes;O;O
such;O;O
as;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d578.s4.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d578.s4.e1
,;O;O
and;O;O
rifampin;B-drug;B-DDI-DrugBank.d578.s4.e2
may;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d578.s4.e3
and;O;O
may;O;O
require;O;O
increased;O;O
in;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d578.s4.e4
dose;O;O
to;O;O
achieve;O;O
the;O;O
desired;O;O
response;O;O
.;O;O
DDI-DrugBank.d578.s5;;
Drugs;O;O
such;O;O
as;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d578.s5.e0
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d578.s5.e1
may;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d578.s5.e2
and;O;O
thus;O;O
decrease;O;O
its;O;O
clearance;O;O
.;O;O
DDI-DrugBank.d578.s6;;
Therefore;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d578.s6.e0
should;O;O
be;O;O
titrated;O;O
to;O;O
avoid;O;O
steroid;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d578.s7;;
Methylprednisolone;B-drug;B-DDI-DrugBank.d578.s7.e0
may;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
chronic;O;O
high;O;O
dose;O;O
aspirin;B-brand;B-DDI-DrugBank.d578.s7.e1
.;O;O
DDI-DrugBank.d578.s8;;
This;O;O
could;O;O
lead;O;O
to;O;O
decreased;O;O
salicylate;B-group;B-DDI-DrugBank.d578.s8.e0
serum;O;O
levels;O;O
or;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
salicylate;B-group;B-DDI-DrugBank.d578.s8.e1
toxicity;O;O
when;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d578.s8.e2
is;O;O
withdrawn;O;O
.;O;O
DDI-DrugBank.d578.s9;;
Aspirin;B-brand;B-DDI-DrugBank.d578.s9.e0
should;O;O
be;O;O
used;O;O
cautiously;O;O
in;O;O
conjunction;O;O
with;O;O
corticosteroids;B-group;B-DDI-DrugBank.d578.s9.e1
in;O;O
patients;O;O
suffering;O;O
from;O;O
hypoprothrombinemia;O;O
.;O;O
DDI-DrugBank.d578.s10;;
The;O;O
effect;O;O
of;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d578.s10.e0
on;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d578.s10.e1
is;O;O
variable;O;O
.;O;O
DDI-DrugBank.d578.s11;;
There;O;O
are;O;O
reports;O;O
of;O;O
enhanced;O;O
as;O;O
well;O;O
as;O;O
diminished;O;O
effects;O;O
of;O;O
anticoagulant;B-group;B-DDI-DrugBank.d578.s11.e0
when;O;O
given;O;O
concurrently;O;O
with;O;O
corticosteroids;B-group;B-DDI-DrugBank.d578.s11.e1
.;O;O
DDI-DrugBank.d578.s12;;
Therefore;O;O
,;O;O
coagulation;O;O
indices;O;O
should;O;O
be;O;O
monitored;O;O
to;O;O
maintain;O;O
the;O;O
desired;O;O
anticoagulant;O;O
effect;O;O
.;O;O
DDI-DrugBank.d655.s0;;
Methscopolamine;B-drug;B-DDI-DrugBank.d655.s0.e0
may;O;O
interact;O;O
with;O;O
antidepressants;B-group;B-DDI-DrugBank.d655.s0.e1
(;O;O
tricyclic;B-group;B-DDI-DrugBank.d655.s0.e2
type;O;O
);O;O
,;O;O
MAO;B-group;B-DDI-DrugBank.d655.s0.e3
inhibitors;I-group;I-DDI-DrugBank.d655.s0.e3
(;O;O
e.g.;O;O
,;O;O
phenelzine;B-drug;B-DDI-DrugBank.d655.s0.e4
,;O;O
linezolid;B-drug;B-DDI-DrugBank.d655.s0.e5
,;O;O
tranylcypromine;B-drug;B-DDI-DrugBank.d655.s0.e6
,;O;O
isocarboxazid;B-drug;B-DDI-DrugBank.d655.s0.e7
,;O;O
selegiline;B-drug;B-DDI-DrugBank.d655.s0.e8
,;O;O
furazolidone;B-drug;B-DDI-DrugBank.d655.s0.e9
);O;O
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d655.s0.e10
,;O;O
amantadine;B-drug;B-DDI-DrugBank.d655.s0.e11
,;O;O
antihistamines;B-group;B-DDI-DrugBank.d655.s0.e12
(;O;O
e.g.;O;O
,;O;O
diphenhydramine;B-drug;B-DDI-DrugBank.d655.s0.e13
);O;O
,;O;O
other;O;O
anticholinergics;B-group;B-DDI-DrugBank.d655.s0.e14
,;O;O
potassium;B-drug;B-DDI-DrugBank.d655.s0.e15
chloride;I-drug;I-DDI-DrugBank.d655.s0.e15
supplements;O;O
,;O;O
antacids;B-group;B-DDI-DrugBank.d655.s0.e16
,;O;O
absorbent;B-group;B-DDI-DrugBank.d655.s0.e17
-;I-group;I-DDI-DrugBank.d655.s0.e17
type;I-group;I-DDI-DrugBank.d655.s0.e17
anti;I-group;I-DDI-DrugBank.d655.s0.e17
-;I-group;I-DDI-DrugBank.d655.s0.e17
diarrhea;I-group;I-DDI-DrugBank.d655.s0.e17
medicines;I-group;I-DDI-DrugBank.d655.s0.e17
(;O;O
e.g.;O;O
,;O;O
kaolin;B-drug;B-DDI-DrugBank.d655.s0.e18
-;O;O
pectin;B-drug;B-DDI-DrugBank.d655.s0.e19
);O;O
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d655.s0.e20
(;O;O
e.g.;O;O
,;O;O
chlorpromazine;B-drug;B-DDI-DrugBank.d655.s0.e21
,;O;O
promethazine;B-drug;B-DDI-DrugBank.d655.s0.e22
);O;O
.;O;O
DDI-DrugBank.d600.s0;;
Methyprylon;B-drug;B-DDI-DrugBank.d600.s0.e0
may;O;O
interact;O;O
with;O;O
other;O;O
addictive;O;O
medications;O;O
,;O;O
in;O;O
that;O;O
it;O;O
may;O;O
increase;O;O
the;O;O
likelyhood;O;O
of;O;O
addiction;O;O
and;O;O
abuse;O;O
.;O;O
DDI-DrugBank.d600.s1;;
Concurrent;O;O
use;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d600.s1.e0
and;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d600.s1.e1
depression;I-group;I-DDI-DrugBank.d600.s1.e1
-;I-group;I-DDI-DrugBank.d600.s1.e1
producing;I-group;I-DDI-DrugBank.d600.s1.e1
drugs;I-group;I-DDI-DrugBank.d600.s1.e1
may;O;O
increase;O;O
the;O;O
CNS;O;O
depressant;O;O
effects;O;O
of;O;O
methyprylon;B-drug;B-DDI-DrugBank.d600.s1.e2
or;O;O
these;O;O
other;O;O
medications;O;O
.;O;O
DDI-DrugBank.d696.s0;;
Methysergide;B-drug;B-DDI-DrugBank.d696.s0.e0
may;O;O
reverse;O;O
the;O;O
analgesic;O;O
activity;O;O
of;O;O
narcotic;B-group;B-DDI-DrugBank.d696.s0.e1
analgesics;I-group;I-DDI-DrugBank.d696.s0.e1
.;O;O
DDI-DrugBank.d696.s1;;
Concurrent;O;O
use;O;O
with;O;O
vasoconstrictor;B-group;B-DDI-DrugBank.d696.s1.e0
agents;I-group;I-DDI-DrugBank.d696.s1.e0
including;O;O
ergot;B-group;B-DDI-DrugBank.d696.s1.e1
alkaloids;I-group;I-DDI-DrugBank.d696.s1.e1
,;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d696.s1.e2
,;O;O
and;O;O
nicotine;B-drug;B-DDI-DrugBank.d696.s1.e3
(;O;O
e.g.;O;O
smoking;O;O
);O;O
may;O;O
result;O;O
in;O;O
enhanced;O;O
vasoconstriction;O;O
.;O;O
DDI-DrugBank.d652.s0;;
The;O;O
effects;O;O
of;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d652.s0.e0
on;O;O
gastrointestinal;O;O
motility;O;O
are;O;O
antagonized;O;O
by;O;O
anticholinergic;B-group;B-DDI-DrugBank.d652.s0.e1
drugs;I-group;I-DDI-DrugBank.d652.s0.e1
and;O;O
narcotic;B-group;B-DDI-DrugBank.d652.s0.e2
analgesics;I-group;I-DDI-DrugBank.d652.s0.e2
.;O;O
DDI-DrugBank.d652.s1;;
Additive;O;O
sedative;O;O
effects;O;O
can;O;O
occur;O;O
when;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d652.s1.e0
is;O;O
given;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d652.s1.e1
,;O;O
sedatives;B-group;B-DDI-DrugBank.d652.s1.e2
,;O;O
hypnotics;B-group;B-DDI-DrugBank.d652.s1.e3
,;O;O
narcotics;B-group;B-DDI-DrugBank.d652.s1.e4
,;O;O
or;O;O
tranquilizers;B-group;B-DDI-DrugBank.d652.s1.e5
.;O;O
DDI-DrugBank.d652.s2;;
The;O;O
finding;O;O
that;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d652.s2.e0
releases;O;O
catecholamines;O;O
in;O;O
patients;O;O
with;O;O
essential;O;O
hypertension;O;O
suggests;O;O
that;O;O
it;O;O
should;O;O
be;O;O
used;O;O
cautiously;O;O
,;O;O
if;O;O
at;O;O
all;O;O
,;O;O
in;O;O
patients;O;O
receiving;O;O
monoamine;B-group;B-DDI-DrugBank.d652.s2.e1
oxi;I-group;I-DDI-DrugBank.d652.s2.e1
-;I-group;I-DDI-DrugBank.d652.s2.e1
dase;I-group;I-DDI-DrugBank.d652.s2.e1
inhibitors;I-group;I-DDI-DrugBank.d652.s2.e1
.;O;O
DDI-DrugBank.d652.s3;;
Absorption;O;O
of;O;O
drugs;O;O
from;O;O
the;O;O
stomach;O;O
may;O;O
be;O;O
diminished;O;O
(;O;O
e.g.;O;O
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d652.s3.e0
);O;O
by;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d652.s3.e1
,;O;O
whereas;O;O
the;O;O
rate;O;O
and/or;O;O
extent;O;O
of;O;O
absorption;O;O
of;O;O
drugs;O;O
from;O;O
the;O;O
small;O;O
bowel;O;O
may;O;O
be;O;O
increased;O;O
(;O;O
e.g.;O;O
,;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d652.s3.e2
,;O;O
tetracycline;B-drug;B-DDI-DrugBank.d652.s3.e3
,;O;O
levodopa;B-drug;B-DDI-DrugBank.d652.s3.e4
,;O;O
ethanol;B-drug;B-DDI-DrugBank.d652.s3.e5
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d652.s3.e6
);O;O
.;O;O
DDI-DrugBank.d652.s4;;
Gastroparesis;O;O
(;O;O
gastric;O;O
stasis;O;O
);O;O
may;O;O
be;O;O
responsible;O;O
for;O;O
poor;O;O
diabetic;O;O
control;O;O
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d652.s5;;
Exogenously;O;O
administered;O;O
insulin;B-drug;B-DDI-DrugBank.d652.s5.e0
may;O;O
begin;O;O
to;O;O
act;O;O
before;O;O
food;O;O
has;O;O
left;O;O
the;O;O
stomach;O;O
and;O;O
lead;O;O
to;O;O
hypoglycemia;O;O
.;O;O
DDI-DrugBank.d652.s6;;
Because;O;O
the;O;O
action;O;O
of;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d652.s6.e0
will;O;O
influence;O;O
the;O;O
delivery;O;O
of;O;O
food;O;O
to;O;O
the;O;O
intestines;O;O
and;O;O
thus;O;O
the;O;O
rate;O;O
of;O;O
absorption;O;O
,;O;O
insulin;B-drug;B-DDI-DrugBank.d652.s6.e1
dosage;O;O
or;O;O
timing;O;O
of;O;O
dosage;O;O
may;O;O
require;O;O
adjustment;O;O
.;O;O
DDI-DrugBank.d588.s0;;
Diuretics;B-group;B-DDI-DrugBank.d588.s0.e0
:;O;O
Furosemide;B-drug;B-DDI-DrugBank.d588.s0.e1
and;O;O
probably;O;O
other;O;O
loop;B-group;B-DDI-DrugBank.d588.s0.e2
diuretics;I-group;I-DDI-DrugBank.d588.s0.e2
given;O;O
concomitantly;O;O
with;O;O
metolazone;B-drug;B-DDI-DrugBank.d588.s0.e3
can;O;O
cause;O;O
unusually;O;O
large;O;O
or;O;O
prolonged;O;O
losses;O;O
of;O;O
fluid;O;O
and;O;O
electrolytes;O;O
.;O;O
DDI-DrugBank.d588.s1;;
Other;O;O
Antihypertensives;B-group;B-DDI-DrugBank.d588.s1.e0
:;O;O
When;O;O
MYKROX;B-brand;B-DDI-DrugBank.d588.s1.e1
Tablets;O;O
are;O;O
used;O;O
with;O;O
other;O;O
antihypertensive;B-group;B-DDI-DrugBank.d588.s1.e2
drugs;I-group;I-DDI-DrugBank.d588.s1.e2
,;O;O
care;O;O
must;O;O
be;O;O
taken;O;O
,;O;O
especially;O;O
during;O;O
initial;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d588.s2;;
Dosage;O;O
adjustments;O;O
of;O;O
other;O;O
antihypertensives;B-group;B-DDI-DrugBank.d588.s2.e0
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d588.s3;;
Alcohol;B-drug;B-DDI-DrugBank.d588.s3.e0
,;O;O
Barbiturates;B-group;B-DDI-DrugBank.d588.s3.e1
,;O;O
and;O;O
Narcotics;B-group;B-DDI-DrugBank.d588.s3.e2
:;O;O
The;O;O
hypotensive;O;O
effects;O;O
of;O;O
these;O;O
drugs;O;O
may;O;O
be;O;O
potentiated;O;O
by;O;O
the;O;O
volume;O;O
contraction;O;O
that;O;O
may;O;O
be;O;O
associated;O;O
with;O;O
metolazone;B-drug;B-DDI-DrugBank.d588.s3.e3
therapy;O;O
.;O;O
DDI-DrugBank.d588.s4;;
Digitalis;B-group;B-DDI-DrugBank.d588.s4.e0
Glycosides;I-group;I-DDI-DrugBank.d588.s4.e0
:;O;O
Diuretic;B-group;B-DDI-DrugBank.d588.s4.e1
-;O;O
induced;O;O
hypokalemia;O;O
can;O;O
increase;O;O
the;O;O
sensitivity;O;O
of;O;O
the;O;O
myocardium;O;O
to;O;O
digitalis;B-group;B-DDI-DrugBank.d588.s4.e2
.;O;O
DDI-DrugBank.d588.s5;;
Serious;O;O
arrhythmias;O;O
can;O;O
result;O;O
.;O;O
DDI-DrugBank.d588.s6;;
Corticosteroids;B-group;B-DDI-DrugBank.d588.s6.e0
or;O;O
ACTH;B-drug;B-DDI-DrugBank.d588.s6.e1
:;O;O
May;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
hypokalemia;O;O
and;O;O
increase;O;O
salt;O;O
and;O;O
water;O;O
retention;O;O
.;O;O
DDI-DrugBank.d588.s7;;
Lithium;B-drug;B-DDI-DrugBank.d588.s7.e0
:;O;O
Serum;O;O
lithium;B-drug;B-DDI-DrugBank.d588.s7.e1
levels;O;O
may;O;O
increase;O;O
.;O;O
DDI-DrugBank.d588.s8;;
Curariform;B-group;B-DDI-DrugBank.d588.s8.e0
Drugs;I-group;I-DDI-DrugBank.d588.s8.e0
:;O;O
Diuretic;B-group;B-DDI-DrugBank.d588.s8.e1
-;O;O
induced;O;O
hypokalemia;O;O
may;O;O
enhance;O;O
neuromuscular;O;O
blocking;O;O
effects;O;O
of;O;O
curariform;B-group;B-DDI-DrugBank.d588.s8.e2
drugs;I-group;I-DDI-DrugBank.d588.s8.e2
(;O;O
such;O;O
as;O;O
tubocurarine;B-drug;B-DDI-DrugBank.d588.s8.e3
);O;O
the;O;O
most;O;O
serious;O;O
effect;O;O
would;O;O
be;O;O
respiratory;O;O
depression;O;O
which;O;O
could;O;O
proceed;O;O
to;O;O
apnea;O;O
.;O;O
DDI-DrugBank.d588.s9;;
Accordingly;O;O
,;O;O
it;O;O
may;O;O
be;O;O
advisable;O;O
to;O;O
discontinue;O;O
MYKROX;B-brand;B-DDI-DrugBank.d588.s9.e0
Tablets;O;O
three;O;O
days;O;O
before;O;O
elective;O;O
surgery;O;O
.;O;O
DDI-DrugBank.d588.s10;;
Salicylates;B-group;B-DDI-DrugBank.d588.s10.e0
and;O;O
Other;O;O
Non;B-group;B-DDI-DrugBank.d588.s10.e1
-;I-group;I-DDI-DrugBank.d588.s10.e1
Steroidal;I-group;I-DDI-DrugBank.d588.s10.e1
Anti;I-group;I-DDI-DrugBank.d588.s10.e1
-;I-group;I-DDI-DrugBank.d588.s10.e1
Inflammatory;I-group;I-DDI-DrugBank.d588.s10.e1
Drugs;I-group;I-DDI-DrugBank.d588.s10.e1
:;O;O
May;O;O
decrease;O;O
the;O;O
antihypertensive;O;O
effects;O;O
of;O;O
MYKROX;B-brand;B-DDI-DrugBank.d588.s10.e2
Tablets;O;O
.;O;O
DDI-DrugBank.d588.s11;;
Sympathomimetics;B-group;B-DDI-DrugBank.d588.s11.e0
:;O;O
Metolazone;B-drug;B-DDI-DrugBank.d588.s11.e1
may;O;O
decrease;O;O
arterial;O;O
responsiveness;O;O
to;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d588.s11.e2
,;O;O
but;O;O
this;O;O
diminution;O;O
is;O;O
not;O;O
sufficient;O;O
to;O;O
preclude;O;O
effectiveness;O;O
of;O;O
the;O;O
pressor;O;O
agent;O;O
for;O;O
therapeutic;O;O
use;O;O
.;O;O
DDI-DrugBank.d588.s12;;
Methenamine;B-drug;B-DDI-DrugBank.d588.s12.e0
:;O;O
Efficacy;O;O
may;O;O
be;O;O
decreased;O;O
due;O;O
to;O;O
urinary;O;O
alkalizing;O;O
effect;O;O
of;O;O
metolazone;B-drug;B-DDI-DrugBank.d588.s12.e1
.;O;O
DDI-DrugBank.d588.s13;;
Anticoagulants;B-group;B-DDI-DrugBank.d588.s13.e0
:;O;O
Metolazone;B-drug;B-DDI-DrugBank.d588.s13.e1
,;O;O
as;O;O
well;O;O
as;O;O
other;O;O
thiazide;B-group;B-DDI-DrugBank.d588.s13.e2
-;I-group;I-DDI-DrugBank.d588.s13.e2
like;I-group;I-DDI-DrugBank.d588.s13.e2
diuretics;I-group;I-DDI-DrugBank.d588.s13.e2
,;O;O
may;O;O
affect;O;O
the;O;O
hypoprothrombinemic;O;O
response;O;O
to;O;O
anticoagulants;B-group;B-DDI-DrugBank.d588.s13.e3
;;O;O
DDI-DrugBank.d588.s14;;
dosage;O;O
adjustments;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d706.s0;;
Catecholamine;O;O
-;O;O
depleting;O;O
drugs;O;O
(;O;O
e.g.;O;O
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d706.s0.e0
);O;O
may;O;O
have;O;O
an;O;O
additive;O;O
effect;O;O
when;O;O
given;O;O
with;O;O
beta;B-group;B-DDI-DrugBank.d706.s0.e1
-;I-group;I-DDI-DrugBank.d706.s0.e1
blocking;I-group;I-DDI-DrugBank.d706.s0.e1
agents;I-group;I-DDI-DrugBank.d706.s0.e1
.;O;O
DDI-DrugBank.d706.s1;;
Patients;O;O
treated;O;O
with;O;O
extended;O;O
release;O;O
metoprolol;B-drug;B-DDI-DrugBank.d706.s1.e0
succinate;I-drug;I-DDI-DrugBank.d706.s1.e0
plus;O;O
a;O;O
catecholamine;O;O
depletor;O;O
should;O;O
therefore;O;O
be;O;O
closely;O;O
observed;O;O
for;O;O
evidence;O;O
of;O;O
hypotension;O;O
or;O;O
marked;O;O
bradycardia;O;O
,;O;O
which;O;O
may;O;O
produce;O;O
vertigo;O;O
,;O;O
syncope;O;O
,;O;O
or;O;O
postural;O;O
hypotension;O;O
.;O;O
DDI-DrugBank.d629.s0;;
Oral;O;O
metronidazole;B-drug;B-DDI-DrugBank.d629.s0.e0
has;O;O
been;O;O
reported;O;O
to;O;O
potentiate;O;O
the;O;O
anticoagulant;O;O
effect;O;O
of;O;O
coumarin;B-group;B-DDI-DrugBank.d629.s0.e1
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d629.s0.e2
,;O;O
resulting;O;O
in;O;O
a;O;O
prolongation;O;O
of;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d629.s1;;
Drug;O;O
interactions;O;O
should;O;O
be;O;O
kept;O;O
in;O;O
mind;O;O
when;O;O
METROGEL;B-brand;B-DDI-DrugBank.d629.s1.e0
(;O;O
metronidazole;B-drug;B-DDI-DrugBank.d629.s1.e1
gel;O;O
);O;O
,;O;O
1;O;O
%;O;O
is;O;O
prescribed;O;O
for;O;O
patients;O;O
who;O;O
are;O;O
receiving;O;O
anticoagulant;O;O
treatment;O;O
,;O;O
although;O;O
they;O;O
are;O;O
less;O;O
likely;O;O
to;O;O
occur;O;O
with;O;O
topical;O;O
metronidazole;B-drug;B-DDI-DrugBank.d629.s1.e2
administration;O;O
because;O;O
of;O;O
low;O;O
absorption;O;O
.;O;O
DDI-DrugBank.d678.s0;;
Drugs;O;O
affecting;O;O
pituitary;O;O
or;O;O
adrenocortical;O;O
function;O;O
,;O;O
including;O;O
all;O;O
corticosteroid;O;O
therapy;O;O
,;O;O
must;O;O
be;O;O
discontinued;O;O
prior;O;O
to;O;O
and;O;O
during;O;O
testing;O;O
with;O;O
Metopirone;B-brand;B-DDI-DrugBank.d678.s0.e0
.;O;O
DDI-DrugBank.d678.s1;;
The;O;O
metabolism;O;O
of;O;O
Metopirone;B-brand;B-DDI-DrugBank.d678.s1.e0
is;O;O
accelerated;O;O
by;O;O
phenytoin;B-drug;B-DDI-DrugBank.d678.s1.e1
;;O;O
DDI-DrugBank.d678.s2;;
therefore;O;O
,;O;O
results;O;O
of;O;O
the;O;O
test;O;O
may;O;O
be;O;O
inaccurate;O;O
in;O;O
patients;O;O
taking;O;O
phenytoin;B-drug;B-DDI-DrugBank.d678.s2.e0
within;O;O
two;O;O
weeks;O;O
before;O;O
.;O;O
DDI-DrugBank.d678.s3;;
Asubnormal;O;O
response;O;O
may;O;O
occur;O;O
in;O;O
patients;O;O
on;O;O
estrogen;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d678.s4;;
Metopirone;B-brand;B-DDI-DrugBank.d678.s4.e0
inhibits;O;O
the;O;O
glucuronidation;O;O
of;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d678.s4.e1
and;O;O
could;O;O
possibly;O;O
potentiate;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d678.s4.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d715.s0;;
Caution;O;O
should;O;O
be;O;O
observed;O;O
in;O;O
administering;O;O
DEMSER;B-brand;B-DDI-DrugBank.d715.s0.e0
to;O;O
patients;O;O
receiving;O;O
phenothiazines;B-group;B-DDI-DrugBank.d715.s0.e1
or;O;O
haloperidol;B-drug;B-DDI-DrugBank.d715.s0.e2
because;O;O
the;O;O
extrapyramidal;O;O
effects;O;O
of;O;O
these;O;O
drugs;O;O
can;O;O
be;O;O
expected;O;O
to;O;O
be;O;O
potentiated;O;O
by;O;O
inhibition;O;O
of;O;O
catecholamine;O;O
synthesis;O;O
.;O;O
DDI-DrugBank.d715.s1;;
Concurrent;O;O
use;O;O
of;O;O
DEMSER;B-brand;B-DDI-DrugBank.d715.s1.e0
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d715.s1.e1
or;O;O
other;O;O
CNS;B-drug;B-DDI-DrugBank.d715.s1.e2
depressants;I-drug;I-DDI-DrugBank.d715.s1.e2
can;O;O
increase;O;O
their;O;O
sedative;O;O
effects;O;O
.;O;O
DDI-DrugBank.d633.s0;;
Since;O;O
MEXITIL;B-brand;B-DDI-DrugBank.d633.s0.e0
is;O;O
a;O;O
substrate;O;O
for;O;O
the;O;O
metabolic;O;O
pathways;O;O
involving;O;O
CYP2D6;O;O
and;O;O
CYP1A2;O;O
enzymes;O;O
,;O;O
inhibition;O;O
or;O;O
induction;O;O
of;O;O
either;O;O
of;O;O
these;O;O
enzymes;O;O
would;O;O
be;O;O
expected;O;O
to;O;O
alter;O;O
mexiletine;B-drug;B-DDI-DrugBank.d633.s0.e1
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d633.s1;;
In;O;O
a;O;O
formal;O;O
,;O;O
single;O;O
-;O;O
dose;O;O
interaction;O;O
study;O;O
(;O;O
n;O;O
=;O;O
6;O;O
males;O;O
);O;O
the;O;O
clearance;O;O
of;O;O
mexiletine;B-drug;B-DDI-DrugBank.d633.s1.e0
was;O;O
decreased;O;O
by;O;O
38;O;O
%;O;O
following;O;O
the;O;O
coadministration;O;O
of;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d633.s1.e1
,;O;O
an;O;O
inhibitor;O;O
of;O;O
CYP1A2;O;O
.;O;O
DDI-DrugBank.d633.s2;;
In;O;O
another;O;O
formal;O;O
study;O;O
(;O;O
n;O;O
=;O;O
8;O;O
extensive;O;O
and;O;O
n;O;O
=;O;O
7;O;O
poor;O;O
metabolizers;O;O
of;O;O
CYP2D6;O;O
);O;O
,;O;O
coadministration;O;O
of;O;O
propafenone;B-drug;B-DDI-DrugBank.d633.s2.e0
did;O;O
not;O;O
alter;O;O
the;O;O
kinetics;O;O
of;O;O
mexiletine;B-drug;B-DDI-DrugBank.d633.s2.e1
in;O;O
the;O;O
poor;O;O
CYP2D6;O;O
metabolizer;O;O
group;O;O
.;O;O
DDI-DrugBank.d633.s3;;
However;O;O
,;O;O
the;O;O
metabolic;O;O
clearance;O;O
of;O;O
mexiletine;B-drug;B-DDI-DrugBank.d633.s3.e0
in;O;O
the;O;O
extensive;O;O
metabolizer;O;O
phenotype;O;O
decreased;O;O
by;O;O
about;O;O
70;O;O
%;O;O
making;O;O
the;O;O
poor;O;O
and;O;O
extensive;O;O
metabolizer;O;O
groups;O;O
indistinguishable;O;O
.;O;O
DDI-DrugBank.d633.s4;;
In;O;O
this;O;O
crossover;O;O
steady;O;O
state;O;O
study;O;O
,;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
propafenone;B-drug;B-DDI-DrugBank.d633.s4.e0
were;O;O
unaffected;O;O
in;O;O
either;O;O
phenotype;O;O
by;O;O
the;O;O
coadministration;O;O
of;O;O
mexiletine;B-drug;B-DDI-DrugBank.d633.s4.e1
.;O;O
DDI-DrugBank.d633.s5;;
Addition;O;O
of;O;O
mexiletine;B-drug;B-DDI-DrugBank.d633.s5.e0
to;O;O
propafenone;B-drug;B-DDI-DrugBank.d633.s5.e1
did;O;O
not;O;O
lead;O;O
to;O;O
further;O;O
electrocardiographic;O;O
parameters;O;O
changes;O;O
of;O;O
QRS;O;O
,;O;O
QTc;O;O
,;O;O
RR;O;O
,;O;O
and;O;O
PR;O;O
intervals;O;O
than;O;O
propafenone;B-drug;B-DDI-DrugBank.d633.s5.e2
alone;O;O
.;O;O
DDI-DrugBank.d633.s6;;
When;O;O
concomitant;O;O
administration;O;O
of;O;O
either;O;O
of;O;O
these;O;O
two;O;O
drugs;O;O
with;O;O
mexiletine;B-drug;B-DDI-DrugBank.d633.s6.e0
is;O;O
initiated;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
mexiletine;B-drug;B-DDI-DrugBank.d633.s6.e1
should;O;O
be;O;O
slowly;O;O
titrated;O;O
to;O;O
desired;O;O
effect;O;O
.;O;O
DDI-DrugBank.d633.s7;;
In;O;O
a;O;O
large;O;O
compassionate;O;O
use;O;O
program;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s7.e0
has;O;O
been;O;O
used;O;O
concurrently;O;O
with;O;O
commonly;O;O
employed;O;O
antianginal;O;O
,;O;O
antihypertensive;B-group;B-DDI-DrugBank.d633.s7.e1
,;O;O
and;O;O
anticoagulant;B-group;B-DDI-DrugBank.d633.s7.e2
drugs;I-group;I-DDI-DrugBank.d633.s7.e2
without;O;O
observed;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d633.s8;;
A;O;O
variety;O;O
of;O;O
antiarrhythmics;B-group;B-DDI-DrugBank.d633.s8.e0
such;O;O
as;O;O
quinidine;B-drug;B-DDI-DrugBank.d633.s8.e1
or;O;O
propranolol;B-drug;B-DDI-DrugBank.d633.s8.e2
were;O;O
also;O;O
added;O;O
,;O;O
sometimes;O;O
with;O;O
improved;O;O
control;O;O
of;O;O
ventricular;O;O
ectopy;O;O
.;O;O
DDI-DrugBank.d633.s9;;
When;O;O
phenytoin;B-drug;B-DDI-DrugBank.d633.s9.e0
or;O;O
other;O;O
hepatic;O;O
enzyme;O;O
inducers;O;O
such;O;O
as;O;O
rifampin;B-drug;B-DDI-DrugBank.d633.s9.e1
and;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d633.s9.e2
have;O;O
been;O;O
taken;O;O
concurrently;O;O
with;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s9.e3
,;O;O
lowered;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s9.e4
plasma;O;O
levels;O;O
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d633.s10;;
Monitoring;O;O
of;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s10.e0
plasma;O;O
levels;O;O
is;O;O
recommended;O;O
during;O;O
such;O;O
concurrent;O;O
use;O;O
to;O;O
avoid;O;O
ineffective;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d633.s11;;
In;O;O
a;O;O
formal;O;O
study;O;O
,;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d633.s11.e0
were;O;O
shown;O;O
not;O;O
to;O;O
affect;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s11.e1
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d633.s12;;
ECG;O;O
intervals;O;O
(;O;O
PR;O;O
,;O;O
QRS;O;O
,;O;O
and;O;O
QT;O;O
);O;O
were;O;O
not;O;O
affected;O;O
by;O;O
concurrent;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s12.e0
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d633.s12.e1
,;O;O
diuretics;B-group;B-DDI-DrugBank.d633.s12.e2
,;O;O
or;O;O
propranolol;B-drug;B-DDI-DrugBank.d633.s12.e3
.;O;O
DDI-DrugBank.d633.s13;;
Concurrent;O;O
administration;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d633.s13.e0
and;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s13.e1
has;O;O
been;O;O
reported;O;O
to;O;O
increase;O;O
,;O;O
decrease;O;O
,;O;O
or;O;O
leave;O;O
unchanged;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s13.e2
plasma;O;O
levels;O;O
;;O;O
DDI-DrugBank.d633.s14;;
therefore;O;O
patients;O;O
should;O;O
be;O;O
followed;O;O
carefully;O;O
during;O;O
concurrent;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d633.s15;;
Mexitil;B-brand;B-DDI-DrugBank.d633.s15.e0
does;O;O
not;O;O
alter;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d633.s15.e1
levels;O;O
but;O;O
magnesium;B-drug;B-DDI-DrugBank.d633.s15.e2
-;I-drug;I-DDI-DrugBank.d633.s15.e2
aluminum;I-drug;I-DDI-DrugBank.d633.s15.e2
hydroxide;I-drug;I-DDI-DrugBank.d633.s15.e2
,;O;O
when;O;O
used;O;O
to;O;O
treat;O;O
gastrointestinal;O;O
symptoms;O;O
due;O;O
to;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s15.e3
,;O;O
has;O;O
been;O;O
reported;O;O
to;O;O
lower;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d633.s15.e4
levels;O;O
.;O;O
DDI-DrugBank.d633.s16;;
Concurrent;O;O
use;O;O
of;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s16.e0
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d633.s16.e1
may;O;O
lead;O;O
to;O;O
increased;O;O
plasma;O;O
theophylline;B-drug;B-DDI-DrugBank.d633.s16.e2
levels;O;O
.;O;O
DDI-DrugBank.d633.s17;;
One;O;O
controlled;O;O
study;O;O
in;O;O
eight;O;O
normal;O;O
subjects;O;O
showed;O;O
a;O;O
72;O;O
%;O;O
mean;O;O
increase;O;O
(;O;O
range;O;O
35;O;O
-;O;O
136;O;O
%;O;O
);O;O
in;O;O
plasma;O;O
theophylline;B-drug;B-DDI-DrugBank.d633.s17.e0
levels;O;O
.;O;O
DDI-DrugBank.d633.s18;;
This;O;O
increase;O;O
was;O;O
observed;O;O
at;O;O
the;O;O
first;O;O
test;O;O
point;O;O
which;O;O
was;O;O
the;O;O
second;O;O
day;O;O
after;O;O
starting;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s18.e0
.;O;O
Theophylline;B-drug;B-DDI-DrugBank.d633.s18.e1
plasma;O;O
levels;O;O
returned;O;O
to;O;O
pre;O;O
-;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s18.e2
values;O;O
within;O;O
48;O;O
hours;O;O
after;O;O
discontinuing;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s18.e3
.;O;O
If;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s18.e4
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d633.s18.e5
are;O;O
to;O;O
be;O;O
used;O;O
concurrently;O;O
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d633.s18.e6
blood;O;O
levels;O;O
should;O;O
be;O;O
monitored;O;O
,;O;O
particularly;O;O
when;O;O
the;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s18.e7
dose;O;O
is;O;O
changed;O;O
.;O;O
DDI-DrugBank.d633.s19;;
An;O;O
appropriate;O;O
adjustment;O;O
in;O;O
theophylline;B-drug;B-DDI-DrugBank.d633.s19.e0
dose;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d633.s20;;
Additionally;O;O
,;O;O
in;O;O
one;O;O
controlled;O;O
study;O;O
in;O;O
five;O;O
normal;O;O
subjects;O;O
and;O;O
seven;O;O
patients;O;O
,;O;O
the;O;O
clearance;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d633.s20.e0
was;O;O
decreased;O;O
50;O;O
%;O;O
following;O;O
the;O;O
administration;O;O
of;O;O
Mexitil;B-brand;B-DDI-DrugBank.d633.s20.e1
.;O;O
DDI-DrugBank.d783.s0;;
Posicor;B-brand;B-DDI-DrugBank.d783.s0.e0
inhibits;O;O
some;O;O
of;O;O
the;O;O
liver;O;O
's;O;O
ability;O;O
to;O;O
metabolize;O;O
some;O;O
other;O;O
drugs;O;O
-;O;O
terfenadine;B-drug;B-DDI-DrugBank.d783.s0.e1
,;O;O
astemizole;B-drug;B-DDI-DrugBank.d783.s0.e2
,;O;O
cisapride;B-drug;B-DDI-DrugBank.d783.s0.e3
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d783.s0.e4
,;O;O
and;O;O
tricyclic;B-group;B-DDI-DrugBank.d783.s0.e5
antidepressants;I-group;I-DDI-DrugBank.d783.s0.e5
.;O;O
DDI-DrugBank.d783.s1;;
Thus;O;O
the;O;O
concentrations;O;O
of;O;O
these;O;O
drugs;O;O
would;O;O
increase;O;O
meaning;O;O
side;O;O
effects;O;O
may;O;O
be;O;O
seen;O;O
.;O;O
DDI-DrugBank.d783.s2;;
A;O;O
dose;O;O
adjustment;O;O
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d735.s0;;
A;O;O
total;O;O
of;O;O
11;O;O
clinical;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
were;O;O
conducted;O;O
in;O;O
healthy;O;O
volunteers;O;O
to;O;O
evaluate;O;O
the;O;O
potential;O;O
for;O;O
interaction;O;O
between;O;O
MYCAMINE;B-brand;B-DDI-DrugBank.d735.s0.e0
and;O;O
mycophenolate;B-drug;B-DDI-DrugBank.d735.s0.e1
mofetil;I-drug;I-DDI-DrugBank.d735.s0.e1
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d735.s0.e2
,;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d735.s0.e3
,;O;O
prednisolone;B-drug;B-DDI-DrugBank.d735.s0.e4
,;O;O
sirolimus;B-drug;B-DDI-DrugBank.d735.s0.e5
,;O;O
nifedipine;B-drug;B-DDI-DrugBank.d735.s0.e6
,;O;O
fluconazole;B-drug;B-DDI-DrugBank.d735.s0.e7
,;O;O
ritonavir;B-drug;B-DDI-DrugBank.d735.s0.e8
,;O;O
and;O;O
rifampin;B-drug;B-DDI-DrugBank.d735.s0.e9
.;O;O
DDI-DrugBank.d735.s1;;
In;O;O
these;O;O
studies;O;O
,;O;O
no;O;O
interaction;O;O
that;O;O
altered;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
micafungin;B-drug;B-DDI-DrugBank.d735.s1.e0
was;O;O
observed;O;O
.;O;O
DDI-DrugBank.d735.s2;;
There;O;O
was;O;O
no;O;O
effect;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
or;O;O
multiple;O;O
doses;O;O
of;O;O
MYCAMINE;B-brand;B-DDI-DrugBank.d735.s2.e0
on;O;O
mycophenolate;B-drug;B-DDI-DrugBank.d735.s2.e1
mofetil;I-drug;I-DDI-DrugBank.d735.s2.e1
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d735.s2.e2
,;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d735.s2.e3
,;O;O
prednisolone;B-drug;B-DDI-DrugBank.d735.s2.e4
,;O;O
and;O;O
fluconazole;B-drug;B-DDI-DrugBank.d735.s2.e5
pharmacokinetics;O;O
.;O;O
DDI-DrugBank.d735.s3;;
Sirolimus;B-drug;B-DDI-DrugBank.d735.s3.e0
AUC;O;O
was;O;O
increased;O;O
by;O;O
21;O;O
%;O;O
with;O;O
no;O;O
effect;O;O
on;O;O
Cmax;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
steady;O;O
-;O;O
state;O;O
MYCAMINE;B-brand;B-DDI-DrugBank.d735.s3.e1
compared;O;O
with;O;O
sirolimus;B-drug;B-DDI-DrugBank.d735.s3.e2
alone;O;O
.;O;O
DDI-DrugBank.d735.s4;;
Nifedipine;B-drug;B-DDI-DrugBank.d735.s4.e0
AUC;O;O
and;O;O
Cmax;O;O
were;O;O
increased;O;O
by;O;O
18;O;O
%;O;O
and;O;O
42;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
steady;O;O
-;O;O
state;O;O
MYCAMINE;B-brand;B-DDI-DrugBank.d735.s4.e1
compared;O;O
with;O;O
nifedipine;B-drug;B-DDI-DrugBank.d735.s4.e2
alone;O;O
.;O;O
DDI-DrugBank.d735.s5;;
Patients;O;O
receiving;O;O
sirolimus;B-drug;B-DDI-DrugBank.d735.s5.e0
or;O;O
nifedipine;B-drug;B-DDI-DrugBank.d735.s5.e1
in;O;O
combination;O;O
with;O;O
MYCAMINE;B-brand;B-DDI-DrugBank.d735.s5.e2
should;O;O
be;O;O
monitored;O;O
for;O;O
sirolimus;B-drug;B-DDI-DrugBank.d735.s5.e3
or;O;O
nifedipine;B-drug;B-DDI-DrugBank.d735.s5.e4
toxicity;O;O
and;O;O
sirolimus;B-drug;B-DDI-DrugBank.d735.s5.e5
or;O;O
nifedipine;B-drug;B-DDI-DrugBank.d735.s5.e6
dosage;O;O
should;O;O
be;O;O
reduced;O;O
if;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d735.s6;;
Micafungin;B-drug;B-DDI-DrugBank.d735.s6.e0
is;O;O
not;O;O
an;O;O
inhibitor;O;O
of;O;O
P;O;O
-;O;O
glycoprotein;O;O
and;O;O
,;O;O
therefore;O;O
,;O;O
would;O;O
not;O;O
be;O;O
expected;O;O
to;O;O
alter;O;O
P;O;O
-;O;O
glycoprotein;O;O
-;O;O
mediated;O;O
drug;O;O
transport;O;O
activity;O;O
.;O;O
DDI-DrugBank.d752.s0;;
Drug;O;O
Interactions;O;O
:;O;O
Inhibitors;O;O
of;O;O
CYP3A4;O;O
Isozymes;O;O
:;O;O
Caution;O;O
is;O;O
advised;O;O
when;O;O
midazolam;B-drug;B-DDI-DrugBank.d752.s0.e0
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
drugs;O;O
that;O;O
are;O;O
known;O;O
to;O;O
inhibit;O;O
the;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
enzyme;O;O
system;O;O
(;O;O
ie;O;O
,;O;O
some;O;O
drugs;O;O
in;O;O
the;O;O
drug;O;O
classes;O;O
of;O;O
azole;B-group;B-DDI-DrugBank.d752.s0.e1
antimycotics;I-group;I-DDI-DrugBank.d752.s0.e1
,;O;O
protease;B-group;B-DDI-DrugBank.d752.s0.e2
inhibitors;I-group;I-DDI-DrugBank.d752.s0.e2
,;O;O
calcium;B-group;B-DDI-DrugBank.d752.s0.e3
channel;I-group;I-DDI-DrugBank.d752.s0.e3
antagonists;I-group;I-DDI-DrugBank.d752.s0.e3
,;O;O
and;O;O
macrolide;B-group;B-DDI-DrugBank.d752.s0.e4
antibiotics;I-group;I-DDI-DrugBank.d752.s0.e4
);O;O
.;O;O
DDI-DrugBank.d752.s1;;
Drugs;O;O
such;O;O
as;O;O
erythromycin;B-drug;B-DDI-DrugBank.d752.s1.e0
,;O;O
diltiazem;B-drug;B-DDI-DrugBank.d752.s1.e1
,;O;O
verapamil;B-drug;B-DDI-DrugBank.d752.s1.e2
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d752.s1.e3
,;O;O
fluconazole;B-drug;B-DDI-DrugBank.d752.s1.e4
and;O;O
itraconazole;B-drug;B-DDI-DrugBank.d752.s1.e5
were;O;O
shown;O;O
to;O;O
significantly;O;O
increase;O;O
the;O;O
C;O;O
max;O;O
and;O;O
AUC;O;O
of;O;O
orally;O;O
administered;O;O
midazolam;B-drug;B-DDI-DrugBank.d752.s1.e6
.;O;O
DDI-DrugBank.d752.s2;;
These;O;O
drug;O;O
interactions;O;O
may;O;O
result;O;O
in;O;O
increased;O;O
and;O;O
prolonged;O;O
sedation;O;O
due;O;O
to;O;O
a;O;O
decrease;O;O
in;O;O
plasma;O;O
clearance;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d752.s2.e0
.;O;O
DDI-DrugBank.d752.s3;;
Although;O;O
not;O;O
studied;O;O
,;O;O
the;O;O
potent;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
inhibitors;O;O
ritonavir;B-drug;B-DDI-DrugBank.d752.s3.e0
and;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d752.s3.e1
may;O;O
cause;O;O
intense;O;O
and;O;O
prolonged;O;O
sedation;O;O
and;O;O
respiratory;O;O
depression;O;O
due;O;O
to;O;O
a;O;O
decrease;O;O
in;O;O
plasma;O;O
clearance;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d752.s3.e2
.;O;O
DDI-DrugBank.d752.s4;;
Caution;O;O
is;O;O
advised;O;O
when;O;O
VERSED;B-brand;B-DDI-DrugBank.d752.s4.e0
Syrup;I-brand;I-DDI-DrugBank.d752.s4.e0
is;O;O
used;O;O
concomitantly;O;O
with;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d752.s5;;
Dose;O;O
adjustments;O;O
should;O;O
be;O;O
considered;O;O
and;O;O
possible;O;O
prolongation;O;O
and;O;O
intensity;O;O
of;O;O
effect;O;O
should;O;O
be;O;O
anticipated;O;O
.;O;O
DDI-DrugBank.d752.s6;;
Inducers;O;O
of;O;O
CYP3A4;O;O
Isozymes;O;O
:;O;O
Cytochrome;O;O
P450;O;O
inducers;O;O
,;O;O
such;O;O
as;O;O
rifampin;B-drug;B-DDI-DrugBank.d752.s6.e0
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d752.s6.e1
,;O;O
and;O;O
phenytoin;B-drug;B-DDI-DrugBank.d752.s6.e2
,;O;O
induce;O;O
metabolism;O;O
and;O;O
caused;O;O
a;O;O
markedly;O;O
decreased;O;O
C;O;O
max;O;O
and;O;O
AUC;O;O
of;O;O
oral;O;O
midazolam;B-drug;B-DDI-DrugBank.d752.s6.e3
in;O;O
adult;O;O
studies;O;O
.;O;O
DDI-DrugBank.d752.s7;;
Although;O;O
clinical;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
performed;O;O
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d752.s7.e0
is;O;O
expected;O;O
to;O;O
have;O;O
the;O;O
same;O;O
effect;O;O
.;O;O
DDI-DrugBank.d752.s8;;
Caution;O;O
is;O;O
advised;O;O
when;O;O
administering;O;O
VERSED;B-brand;B-DDI-DrugBank.d752.s8.e0
Syrup;I-brand;I-DDI-DrugBank.d752.s8.e0
to;O;O
patients;O;O
receiving;O;O
these;O;O
medications;O;O
and;O;O
if;O;O
necessary;O;O
dose;O;O
adjustments;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d752.s9;;
The;O;O
difficulty;O;O
in;O;O
achieving;O;O
adequate;O;O
sedation;O;O
may;O;O
have;O;O
been;O;O
the;O;O
result;O;O
of;O;O
decreased;O;O
absorption;O;O
of;O;O
the;O;O
sedatives;B-group;B-DDI-DrugBank.d752.s9.e0
due;O;O
to;O;O
both;O;O
the;O;O
gastrointestinal;O;O
effects;O;O
and;O;O
stimulant;O;O
effects;O;O
of;O;O
methylphenidate;B-drug;B-DDI-DrugBank.d752.s9.e1
.;O;O
DDI-DrugBank.d752.s10;;
The;O;O
sedative;O;O
effect;O;O
of;O;O
VERSED;B-brand;B-DDI-DrugBank.d752.s10.e0
Syrup;I-brand;I-DDI-DrugBank.d752.s10.e0
is;O;O
accentuated;O;O
by;O;O
any;O;O
concomitantly;O;O
administered;O;O
medication;O;O
which;O;O
depresses;O;O
the;O;O
central;O;O
nervous;O;O
system;O;O
,;O;O
particularly;O;O
narcotics;B-group;B-DDI-DrugBank.d752.s10.e1
(;O;O
eg;O;O
,;O;O
morphine;B-drug;B-DDI-DrugBank.d752.s10.e2
,;O;O
meperidine;B-drug;B-DDI-DrugBank.d752.s10.e3
and;O;O
fentanyl;B-drug;B-DDI-DrugBank.d752.s10.e4
);O;O
,;O;O
propofol;B-drug;B-DDI-DrugBank.d752.s10.e5
,;O;O
ketamine;B-drug;B-DDI-DrugBank.d752.s10.e6
,;O;O
nitrous;B-drug;B-DDI-DrugBank.d752.s10.e7
oxide;I-drug;I-DDI-DrugBank.d752.s10.e7
,;O;O
secobarbital;B-drug;B-DDI-DrugBank.d752.s10.e8
and;O;O
droperidol;B-drug;B-DDI-DrugBank.d752.s10.e9
.;O;O
DDI-DrugBank.d752.s11;;
Consequently;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
VERSED;B-brand;B-DDI-DrugBank.d752.s11.e0
Syrup;I-brand;I-DDI-DrugBank.d752.s11.e0
should;O;O
be;O;O
adjusted;O;O
according;O;O
to;O;O
the;O;O
type;O;O
and;O;O
amount;O;O
of;O;O
concomitant;O;O
medications;O;O
administered;O;O
and;O;O
the;O;O
desired;O;O
clinical;O;O
response;O;O
.;O;O
DDI-DrugBank.d752.s12;;
No;O;O
significant;O;O
adverse;O;O
interactions;O;O
with;O;O
common;O;O
premedications;O;O
(;O;O
such;O;O
as;O;O
atropine;B-drug;B-DDI-DrugBank.d752.s12.e0
,;O;O
scopolamine;B-drug;B-DDI-DrugBank.d752.s12.e1
,;O;O
glycopyrrolate;B-drug;B-DDI-DrugBank.d752.s12.e2
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d752.s12.e3
,;O;O
hydroxyzine;B-drug;B-DDI-DrugBank.d752.s12.e4
,;O;O
and;O;O
other;O;O
muscle;B-group;B-DDI-DrugBank.d752.s12.e5
relaxants;I-group;I-DDI-DrugBank.d752.s12.e5
);O;O
or;O;O
local;O;O
anesthetics;B-group;B-DDI-DrugBank.d752.s12.e6
have;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d603.s0;;
When;O;O
administered;O;O
concomitantly;O;O
with;O;O
ProAmatine;B-brand;B-DDI-DrugBank.d603.s0.e0
,;O;O
cardiac;B-group;B-DDI-DrugBank.d603.s0.e1
glycosides;I-group;I-DDI-DrugBank.d603.s0.e1
may;O;O
enhance;O;O
or;O;O
precipitate;O;O
bradycardia;O;O
,;O;O
A.V.;O;O
DDI-DrugBank.d603.s1;;
block;O;O
or;O;O
arrhythmia;O;O
.;O;O
DDI-DrugBank.d603.s2;;
The;O;O
use;O;O
of;O;O
drugs;O;O
that;O;O
stimulate;O;O
alpha;O;O
-;O;O
adrenergic;O;O
receptors;O;O
(;O;O
e.g.;O;O
,;O;O
phenylephrine;B-drug;B-DDI-DrugBank.d603.s2.e0
,;O;O
pseudoephedrine;B-drug;B-DDI-DrugBank.d603.s2.e1
,;O;O
ephedrine;B-drug;B-DDI-DrugBank.d603.s2.e2
,;O;O
phenylpropanolamine;B-drug;B-DDI-DrugBank.d603.s2.e3
or;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d603.s2.e4
);O;O
may;O;O
enhance;O;O
or;O;O
potentiate;O;O
the;O;O
pressor;O;O
effects;O;O
of;O;O
ProAmatine;B-brand;B-DDI-DrugBank.d603.s2.e5
.;O;O
Therefore;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
ProAmatine;B-brand;B-DDI-DrugBank.d603.s2.e6
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
agents;O;O
that;O;O
cause;O;O
vasoconstriction;O;O
.;O;O
DDI-DrugBank.d603.s3;;
ProAmatine;B-brand;B-DDI-DrugBank.d603.s3.e0
has;O;O
been;O;O
used;O;O
in;O;O
patients;O;O
concomitantly;O;O
treated;O;O
with;O;O
salt;O;O
-;O;O
retaining;O;O
steroid;O;O
therapy;O;O
(;O;O
i.e.;O;O
,;O;O
fludrocortisone;B-drug;B-DDI-DrugBank.d603.s3.e1
acetate;I-drug;I-DDI-DrugBank.d603.s3.e1
);O;O
,;O;O
with;O;O
or;O;O
without;O;O
salt;O;O
supplementation;O;O
.;O;O
DDI-DrugBank.d603.s4;;
The;O;O
potential;O;O
for;O;O
supine;O;O
hypertension;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
in;O;O
these;O;O
patients;O;O
and;O;O
may;O;O
be;O;O
minimized;O;O
by;O;O
either;O;O
reducing;O;O
the;O;O
dose;O;O
of;O;O
fludrocortisone;B-drug;B-DDI-DrugBank.d603.s4.e0
acetate;I-drug;I-DDI-DrugBank.d603.s4.e0
or;O;O
decreasing;O;O
the;O;O
salt;O;O
intake;O;O
prior;O;O
to;O;O
initiation;O;O
of;O;O
treatment;O;O
with;O;O
.;O;O
DDI-DrugBank.d603.s5;;
ProAmatine;B-brand;B-DDI-DrugBank.d603.s5.e0
.;O;O
Alpha;B-group;B-DDI-DrugBank.d603.s5.e1
-;I-group;I-DDI-DrugBank.d603.s5.e1
adrenergic;I-group;I-DDI-DrugBank.d603.s5.e1
blocking;I-group;I-DDI-DrugBank.d603.s5.e1
agents;I-group;I-DDI-DrugBank.d603.s5.e1
,;O;O
such;O;O
as;O;O
prazosin;B-drug;B-DDI-DrugBank.d603.s5.e2
,;O;O
terazosin;B-drug;B-DDI-DrugBank.d603.s5.e3
,;O;O
and;O;O
doxazosin;B-drug;B-DDI-DrugBank.d603.s5.e4
,;O;O
can;O;O
antagonize;O;O
the;O;O
effects;O;O
of;O;O
ProAmatine;B-brand;B-DDI-DrugBank.d603.s5.e5
.;O;O
Potential;O;O
for;O;O
Drug;O;O
Interactions;O;O
:;O;O
It;O;O
appears;O;O
possible;O;O
,;O;O
although;O;O
there;O;O
is;O;O
no;O;O
supporting;O;O
experimental;O;O
evidence;O;O
,;O;O
that;O;O
the;O;O
high;O;O
renal;O;O
clearance;O;O
of;O;O
desglymidodrine;B-drug_n;B-DDI-DrugBank.d603.s5.e6
(;O;O
a;O;O
base;O;O
);O;O
is;O;O
due;O;O
to;O;O
active;O;O
tubular;O;O
secretion;O;O
by;O;O
the;O;O
base;O;O
-;O;O
secreting;O;O
system;O;O
also;O;O
responsible;O;O
for;O;O
the;O;O
secretion;O;O
of;O;O
such;O;O
drugs;O;O
as;O;O
metformin;B-drug;B-DDI-DrugBank.d603.s5.e7
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d603.s5.e8
,;O;O
ranitidine;B-drug;B-DDI-DrugBank.d603.s5.e9
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d603.s5.e10
,;O;O
triamterene;B-drug;B-DDI-DrugBank.d603.s5.e11
,;O;O
flecainide;B-drug;B-DDI-DrugBank.d603.s5.e12
,;O;O
and;O;O
quinidine;B-drug;B-DDI-DrugBank.d603.s5.e13
.;O;O
DDI-DrugBank.d603.s6;;
Thus;O;O
there;O;O
may;O;O
be;O;O
a;O;O
potential;O;O
for;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
with;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d668.s0;;
Although;O;O
specific;O;O
drug;O;O
or;O;O
food;O;O
interactions;O;O
with;O;O
mifepristone;B-drug;B-DDI-DrugBank.d668.s0.e0
have;O;O
not;O;O
been;O;O
studied;O;O
,;O;O
on;O;O
the;O;O
basis;O;O
of;O;O
this;O;O
drug;O;O
s;O;O
metabolism;O;O
by;O;O
CYP;O;O
3A4;O;O
,;O;O
it;O;O
is;O;O
possible;O;O
that;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d668.s0.e1
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d668.s0.e2
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d668.s0.e3
,;O;O
and;O;O
grapefruit;O;O
juice;O;O
may;O;O
inhibit;O;O
its;O;O
metabolism;O;O
(;O;O
increasing;O;O
serum;O;O
levels;O;O
of;O;O
mifepristone;B-drug;B-DDI-DrugBank.d668.s0.e4
);O;O
.;O;O
DDI-DrugBank.d668.s1;;
Furthermore;O;O
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d668.s1.e0
,;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d668.s1.e1
,;O;O
St.;O;O
DDI-DrugBank.d668.s2;;
John;O;O
s;O;O
Wort;O;O
,;O;O
and;O;O
certain;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d668.s2.e0
(;O;O
phenytoin;B-drug;B-DDI-DrugBank.d668.s2.e1
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d668.s2.e2
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d668.s2.e3
);O;O
may;O;O
induce;O;O
mifepristone;B-drug;B-DDI-DrugBank.d668.s2.e4
metabolism;O;O
(;O;O
lowering;O;O
serum;O;O
levels;O;O
of;O;O
mifepristone;B-drug;B-DDI-DrugBank.d668.s2.e5
);O;O
.;O;O
DDI-DrugBank.d668.s3;;
Based;O;O
on;O;O
in;O;O
vitro;O;O
inhibition;O;O
information;O;O
,;O;O
coadministration;O;O
of;O;O
mifepristone;B-drug;B-DDI-DrugBank.d668.s3.e0
may;O;O
lead;O;O
to;O;O
an;O;O
increase;O;O
in;O;O
serum;O;O
levels;O;O
of;O;O
drugs;O;O
that;O;O
are;O;O
CYP;O;O
3A4;O;O
substrates;O;O
.;O;O
DDI-DrugBank.d668.s4;;
Due;O;O
to;O;O
the;O;O
slow;O;O
elimination;O;O
of;O;O
mifepristone;B-drug;B-DDI-DrugBank.d668.s4.e0
from;O;O
the;O;O
body;O;O
,;O;O
such;O;O
interaction;O;O
may;O;O
be;O;O
observed;O;O
for;O;O
a;O;O
prolonged;O;O
period;O;O
after;O;O
its;O;O
administration;O;O
.;O;O
DDI-DrugBank.d668.s5;;
Therefore;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
mifepristone;B-drug;B-DDI-DrugBank.d668.s5.e0
is;O;O
administered;O;O
with;O;O
drugs;O;O
that;O;O
are;O;O
CYP;O;O
3A4;O;O
substrates;O;O
and;O;O
have;O;O
narrow;O;O
therapeutic;O;O
range;O;O
,;O;O
including;O;O
some;O;O
agents;O;O
used;O;O
during;O;O
general;O;O
anesthesia;O;O
.;O;O
DDI-DrugBank.d695.s0;;
While;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
ZAVESCA;B-brand;B-DDI-DrugBank.d695.s0.e0
appeared;O;O
to;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
Cerezyme;B-brand;B-DDI-DrugBank.d695.s0.e1
by;O;O
70;O;O
%;O;O
,;O;O
these;O;O
results;O;O
are;O;O
not;O;O
conclusive;O;O
because;O;O
of;O;O
the;O;O
small;O;O
number;O;O
of;O;O
subjects;O;O
studied;O;O
and;O;O
because;O;O
patients;O;O
took;O;O
variable;O;O
doses;O;O
of;O;O
Cerezyme;B-brand;B-DDI-DrugBank.d695.s0.e2
.;O;O
DDI-DrugBank.d695.s1;;
Combination;O;O
therapy;O;O
with;O;O
Cerezyme;B-brand;B-DDI-DrugBank.d695.s1.e0
(;O;O
imiglucerase;B-drug;B-DDI-DrugBank.d695.s1.e1
);O;O
and;O;O
ZAVESCA;B-brand;B-DDI-DrugBank.d695.s1.e2
is;O;O
not;O;O
indicated;O;O
.;O;O
DDI-DrugBank.d711.s0;;
Because;O;O
tetracyclines;B-group;B-DDI-DrugBank.d711.s0.e0
have;O;O
been;O;O
shown;O;O
to;O;O
depress;O;O
plasma;O;O
prothrombin;O;O
activity;O;O
,;O;O
patients;O;O
who;O;O
are;O;O
on;O;O
anticoagulant;B-group;B-DDI-DrugBank.d711.s0.e1
therapy;O;O
may;O;O
require;O;O
downward;O;O
adjustment;O;O
of;O;O
their;O;O
anticoagulant;B-group;B-DDI-DrugBank.d711.s0.e2
dosage;O;O
.;O;O
DDI-DrugBank.d711.s1;;
Since;O;O
bacteriostatic;O;O
drugs;O;O
may;O;O
interfere;O;O
with;O;O
the;O;O
bactericidal;O;O
action;O;O
of;O;O
penicillin;B-drug;B-DDI-DrugBank.d711.s1.e0
,;O;O
it;O;O
is;O;O
advisable;O;O
to;O;O
avoid;O;O
giving;O;O
tetracycline;B-group;B-DDI-DrugBank.d711.s1.e1
class;I-group;I-DDI-DrugBank.d711.s1.e1
drugs;I-group;I-DDI-DrugBank.d711.s1.e1
in;O;O
conjunction;O;O
with;O;O
penicillin;B-drug;B-DDI-DrugBank.d711.s1.e2
.;O;O
DDI-DrugBank.d711.s2;;
Absorption;O;O
of;O;O
tetracyclines;B-group;B-DDI-DrugBank.d711.s2.e0
is;O;O
impaired;O;O
by;O;O
antacids;B-group;B-DDI-DrugBank.d711.s2.e1
containing;O;O
aluminum;B-drug;B-DDI-DrugBank.d711.s2.e2
,;O;O
calcium;B-drug;B-DDI-DrugBank.d711.s2.e3
or;O;O
magnesium;B-drug;B-DDI-DrugBank.d711.s2.e4
,;O;O
and;O;O
iron;B-drug;B-DDI-DrugBank.d711.s2.e5
-;O;O
containing;O;O
preparations;O;O
.;O;O
DDI-DrugBank.d711.s3;;
The;O;O
concurrent;O;O
use;O;O
of;O;O
tetracycline;B-group;B-DDI-DrugBank.d711.s3.e0
and;O;O
methoxyflurane;B-drug;B-DDI-DrugBank.d711.s3.e1
has;O;O
been;O;O
reported;O;O
to;O;O
result;O;O
in;O;O
fatal;O;O
renal;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d711.s4;;
Concurrent;O;O
use;O;O
of;O;O
tetracyclines;B-group;B-DDI-DrugBank.d711.s4.e0
with;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d711.s4.e1
may;O;O
render;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d711.s4.e2
less;O;O
effective;O;O
.;O;O
DDI-DrugBank.d573.s0;;
Interaction;O;O
with;O;O
Guanethidine;B-drug;B-DDI-DrugBank.d573.s0.e0
:;O;O
Although;O;O
minoxidil;B-drug;B-DDI-DrugBank.d573.s0.e1
does;O;O
not;O;O
itself;O;O
cause;O;O
orthostatic;O;O
hypotension;O;O
,;O;O
its;O;O
administration;O;O
to;O;O
patients;O;O
already;O;O
receiving;O;O
guanethidine;B-drug;B-DDI-DrugBank.d573.s0.e2
can;O;O
result;O;O
in;O;O
profound;O;O
orthostatic;O;O
effects;O;O
.;O;O
DDI-DrugBank.d573.s1;;
If;O;O
at;O;O
all;O;O
possible;O;O
guanethidine;B-drug;B-DDI-DrugBank.d573.s1.e0
should;O;O
be;O;O
discontinued;O;O
well;O;O
before;O;O
minoxidil;B-drug;B-DDI-DrugBank.d573.s1.e1
is;O;O
begun;O;O
.;O;O
DDI-DrugBank.d573.s2;;
Where;O;O
this;O;O
is;O;O
not;O;O
possible;O;O
,;O;O
minoxidil;B-drug;B-DDI-DrugBank.d573.s2.e0
therapy;O;O
should;O;O
be;O;O
started;O;O
in;O;O
the;O;O
hospital;O;O
and;O;O
the;O;O
patient;O;O
should;O;O
remain;O;O
institutionalized;O;O
until;O;O
severe;O;O
orthostatic;O;O
effects;O;O
are;O;O
no;O;O
longer;O;O
present;O;O
or;O;O
the;O;O
patient;O;O
has;O;O
learned;O;O
to;O;O
avoid;O;O
activities;O;O
that;O;O
provoke;O;O
them;O;O
.;O;O
DDI-DrugBank.d742.s0;;
As;O;O
with;O;O
other;O;O
drugs;O;O
,;O;O
the;O;O
potential;O;O
for;O;O
interaction;O;O
by;O;O
a;O;O
variety;O;O
of;O;O
mechanisms;O;O
(;O;O
e.g.;O;O
,;O;O
pharmacodynamic;O;O
,;O;O
pharmacokinetic;O;O
inhibition;O;O
or;O;O
enhancement;O;O
,;O;O
etc;O;O
.;O;O
);O;O
DDI-DrugBank.d742.s1;;
is;O;O
a;O;O
possibility;O;O
.;O;O
DDI-DrugBank.d742.s2;;
Drugs;O;O
Affecting;O;O
Hepatic;O;O
Metabolism;O;O
The;O;O
metabolism;O;O
and;O;O
pharmacokinetics;O;O
of;O;O
REMERON;B-brand;B-DDI-DrugBank.d742.s2.e0
SolTab;I-brand;I-DDI-DrugBank.d742.s2.e0
(;O;O
mirtazapine;B-drug;B-DDI-DrugBank.d742.s2.e1
);O;O
Orally;O;O
Disintegrating;O;O
Tablets;O;O
may;O;O
be;O;O
affected;O;O
by;O;O
the;O;O
induction;O;O
or;O;O
inhibition;O;O
of;O;O
drug;O;O
-;O;O
metab;O;O
-;O;O
olizing;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d742.s3;;
Drugs;O;O
that;O;O
are;O;O
Metabolized;O;O
by;O;O
and/or;O;O
Inhibit;O;O
Cytochrome;O;O
P450;O;O
Enzymes;O;O
Many;O;O
drugs;O;O
are;O;O
metabolized;O;O
by;O;O
and/or;O;O
inhibit;O;O
various;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
,;O;O
e.g.;O;O
,;O;O
2D6;O;O
,;O;O
1A2;O;O
,;O;O
3A4;O;O
,;O;O
etc;O;O
.;O;O
DDI-DrugBank.d742.s4;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
mirtazapine;B-drug;B-DDI-DrugBank.d742.s4.e0
is;O;O
a;O;O
substrate;O;O
for;O;O
several;O;O
of;O;O
these;O;O
enzymes;O;O
,;O;O
including;O;O
2D6;O;O
,;O;O
1A2;O;O
,;O;O
and;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d742.s5;;
While;O;O
in;O;O
vitro;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
mirtazapine;B-drug;B-DDI-DrugBank.d742.s5.e0
is;O;O
not;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
any;O;O
of;O;O
these;O;O
enzymes;O;O
,;O;O
an;O;O
indication;O;O
that;O;O
mirtazapine;B-drug;B-DDI-DrugBank.d742.s5.e1
is;O;O
not;O;O
likely;O;O
to;O;O
have;O;O
a;O;O
clinically;O;O
significant;O;O
inhibitory;O;O
effect;O;O
on;O;O
the;O;O
metabolism;O;O
of;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
substrates;O;O
for;O;O
these;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
,;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
REMERON;B-brand;B-DDI-DrugBank.d742.s5.e2
SolTab;I-brand;I-DDI-DrugBank.d742.s5.e2
with;O;O
most;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
these;O;O
enzymes;O;O
has;O;O
not;O;O
been;O;O
formally;O;O
studied;O;O
.;O;O
DDI-DrugBank.d742.s6;;
Consequently;O;O
,;O;O
it;O;O
is;O;O
not;O;O
possible;O;O
to;O;O
make;O;O
any;O;O
definitive;O;O
statements;O;O
about;O;O
the;O;O
risks;O;O
of;O;O
coadministration;O;O
of;O;O
REMERON;B-brand;B-DDI-DrugBank.d742.s6.e0
SolTab;I-brand;I-DDI-DrugBank.d742.s6.e0
with;O;O
such;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d742.s7;;
Alcohol;B-drug;B-DDI-DrugBank.d742.s7.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d742.s7.e1
(;O;O
equivalent;O;O
to;O;O
60;O;O
g;O;O
);O;O
had;O;O
a;O;O
minimal;O;O
effect;O;O
on;O;O
plasma;O;O
levels;O;O
of;O;O
mirtazapine;B-drug;B-DDI-DrugBank.d742.s7.e2
(;O;O
15;O;O
mg;O;O
);O;O
in;O;O
6;O;O
healthy;O;O
male;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d742.s8;;
However;O;O
,;O;O
the;O;O
impairment;O;O
of;O;O
cognitive;O;O
and;O;O
motor;O;O
skills;O;O
produced;O;O
by;O;O
REMERON;B-brand;B-DDI-DrugBank.d742.s8.e0
were;O;O
shown;O;O
to;O;O
be;O;O
additive;O;O
with;O;O
those;O;O
produced;O;O
by;O;O
alcohol;B-drug;B-DDI-DrugBank.d742.s8.e1
.;O;O
DDI-DrugBank.d742.s9;;
Accordingly;O;O
,;O;O
patients;O;O
should;O;O
be;O;O
advised;O;O
to;O;O
avoid;O;O
alcohol;B-drug;B-DDI-DrugBank.d742.s9.e0
while;O;O
taking;O;O
REMERON;B-brand;B-DDI-DrugBank.d742.s9.e1
SolTab;I-brand;I-DDI-DrugBank.d742.s9.e1
.;O;O
Diazepam;B-drug;B-DDI-DrugBank.d742.s9.e2
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
diazepam;B-drug;B-DDI-DrugBank.d742.s9.e3
(;O;O
15;O;O
mg;O;O
);O;O
had;O;O
a;O;O
minimal;O;O
effect;O;O
on;O;O
plasma;O;O
levels;O;O
of;O;O
mirtazapine;B-drug;B-DDI-DrugBank.d742.s9.e4
(;O;O
15;O;O
mg;O;O
);O;O
in;O;O
12;O;O
healthy;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d742.s10;;
However;O;O
,;O;O
the;O;O
impairment;O;O
of;O;O
motor;O;O
skills;O;O
produced;O;O
by;O;O
REMERON;B-brand;B-DDI-DrugBank.d742.s10.e0
has;O;O
been;O;O
shown;O;O
to;O;O
be;O;O
additive;O;O
with;O;O
those;O;O
caused;O;O
by;O;O
diazepam;B-drug;B-DDI-DrugBank.d742.s10.e1
.;O;O
DDI-DrugBank.d742.s11;;
Accordingly;O;O
,;O;O
patients;O;O
should;O;O
be;O;O
advised;O;O
to;O;O
avoid;O;O
diazepam;B-drug;B-DDI-DrugBank.d742.s11.e0
and;O;O
other;O;O
similar;O;O
drugs;O;O
while;O;O
taking;O;O
REMERON;B-brand;B-DDI-DrugBank.d742.s11.e1
SolTab;I-brand;I-DDI-DrugBank.d742.s11.e1
.;O;O
DDI-DrugBank.d717.s0;;
Mitotane;B-drug;B-DDI-DrugBank.d717.s0.e0
has;O;O
been;O;O
reported;O;O
to;O;O
accelerate;O;O
the;O;O
metabolism;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d717.s0.e1
by;O;O
the;O;O
mechanism;O;O
of;O;O
hepatic;O;O
microsomal;O;O
enzyme;O;O
induction;O;O
,;O;O
leading;O;O
to;O;O
an;O;O
increase;O;O
in;O;O
dosage;O;O
requirements;O;O
for;O;O
warfarin;B-drug;B-DDI-DrugBank.d717.s0.e2
.;O;O
DDI-DrugBank.d717.s1;;
Therefore;O;O
,;O;O
physicians;O;O
should;O;O
closely;O;O
monitor;O;O
patients;O;O
for;O;O
a;O;O
change;O;O
in;O;O
anticoagulant;B-group;B-DDI-DrugBank.d717.s1.e0
dosage;O;O
requirements;O;O
when;O;O
administering;O;O
Mitotane;B-drug;B-DDI-DrugBank.d717.s1.e1
to;O;O
patients;O;O
on;O;O
coumarin;B-group;B-DDI-DrugBank.d717.s1.e2
-;I-group;I-DDI-DrugBank.d717.s1.e2
type;I-group;I-DDI-DrugBank.d717.s1.e2
anticoagulants;I-group;I-DDI-DrugBank.d717.s1.e2
.;O;O
DDI-DrugBank.d717.s2;;
In;O;O
addition;O;O
,;O;O
Mitotane;B-drug;B-DDI-DrugBank.d717.s2.e0
should;O;O
be;O;O
given;O;O
with;O;O
caution;O;O
to;O;O
patients;O;O
receiving;O;O
other;O;O
drugs;O;O
susceptible;O;O
to;O;O
the;O;O
influence;O;O
of;O;O
hepatic;O;O
enzyme;O;O
induction;O;O
.;O;O
DDI-DrugBank.d775.s0;;
Although;O;O
MIVACRON;B-brand;B-DDI-DrugBank.d775.s0.e0
(;O;O
a;O;O
mixture;O;O
of;O;O
three;O;O
stereoisomers;O;O
);O;O
has;O;O
been;O;O
administered;O;O
safely;O;O
following;O;O
succinylcholine;O;O
-;O;O
facilitated;O;O
tracheal;O;O
intubation;O;O
,;O;O
the;O;O
interaction;O;O
between;O;O
MIVACRON;B-brand;B-DDI-DrugBank.d775.s0.e1
and;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d775.s0.e2
has;O;O
not;O;O
been;O;O
systematically;O;O
studied;O;O
.;O;O
DDI-DrugBank.d775.s1;;
Prior;O;O
administration;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d775.s1.e0
can;O;O
potentiate;O;O
the;O;O
neuromuscular;O;O
blocking;O;O
effects;O;O
of;O;O
nondepolarizing;B-group;B-DDI-DrugBank.d775.s1.e1
agents;I-group;I-DDI-DrugBank.d775.s1.e1
.;O;O
DDI-DrugBank.d775.s2;;
Evidence;O;O
of;O;O
spontaneous;O;O
recovery;O;O
from;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d775.s2.e0
should;O;O
be;O;O
observed;O;O
before;O;O
the;O;O
administration;O;O
of;O;O
MIVACRON;B-brand;B-DDI-DrugBank.d775.s2.e1
.;O;O
DDI-DrugBank.d775.s3;;
The;O;O
use;O;O
of;O;O
MIVACRON;B-brand;B-DDI-DrugBank.d775.s3.e0
before;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d775.s3.e1
to;O;O
attenuate;O;O
some;O;O
of;O;O
the;O;O
side;O;O
effects;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d775.s3.e2
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d775.s4;;
There;O;O
are;O;O
no;O;O
clinical;O;O
data;O;O
on;O;O
the;O;O
use;O;O
of;O;O
MIVACRON;B-brand;B-DDI-DrugBank.d775.s4.e0
with;O;O
other;O;O
nondepolarizing;B-group;B-DDI-DrugBank.d775.s4.e1
neuromuscular;I-group;I-DDI-DrugBank.d775.s4.e1
blocking;I-group;I-DDI-DrugBank.d775.s4.e1
agents;I-group;I-DDI-DrugBank.d775.s4.e1
.;O;O
DDI-DrugBank.d775.s5;;
Isoflurane;B-drug;B-DDI-DrugBank.d775.s5.e0
and;O;O
enflurane;B-drug;B-DDI-DrugBank.d775.s5.e1
(;O;O
administered;O;O
with;O;O
nitrous;B-drug;B-DDI-DrugBank.d775.s5.e2
oxide;I-drug;I-DDI-DrugBank.d775.s5.e2
/;O;O
oxygen;B-drug;B-DDI-DrugBank.d775.s5.e3
to;O;O
achieve;O;O
1.25;O;O
M.C.;O;O
DDI-DrugBank.d775.s6;;
decrease;O;O
the;O;O
ED50;O;O
of;O;O
MIVACRON;B-brand;B-DDI-DrugBank.d775.s6.e0
by;O;O
as;O;O
much;O;O
as;O;O
25;O;O
%;O;O
(;O;O
see;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
:;O;O
Pharmacodynamics;O;O
and;O;O
Individualization;O;O
of;O;O
Dosages;O;O
);O;O
.;O;O
DDI-DrugBank.d775.s7;;
These;O;O
agents;O;O
may;O;O
also;O;O
prolong;O;O
the;O;O
clinically;O;O
effective;O;O
duration;O;O
of;O;O
action;O;O
and;O;O
decrease;O;O
the;O;O
average;O;O
infusion;O;O
requirement;O;O
of;O;O
MIVACRON;B-brand;B-DDI-DrugBank.d775.s7.e0
by;O;O
as;O;O
much;O;O
as;O;O
35;O;O
%;O;O
to;O;O
40;O;O
%;O;O
.;O;O
DDI-DrugBank.d775.s8;;
A;O;O
greater;O;O
potentiation;O;O
of;O;O
the;O;O
neuromuscular;O;O
blocking;O;O
effects;O;O
of;O;O
MIVACRON;B-brand;B-DDI-DrugBank.d775.s8.e0
may;O;O
be;O;O
expected;O;O
with;O;O
higher;O;O
concentrations;O;O
of;O;O
enflurane;B-drug;B-DDI-DrugBank.d775.s8.e1
or;O;O
isoflurane;B-drug;B-DDI-DrugBank.d775.s8.e2
.;O;O
DDI-DrugBank.d775.s9;;
Halothane;B-drug;B-DDI-DrugBank.d775.s9.e0
has;O;O
little;O;O
or;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
ED50;O;O
,;O;O
but;O;O
may;O;O
prolong;O;O
the;O;O
duration;O;O
of;O;O
action;O;O
and;O;O
decrease;O;O
the;O;O
average;O;O
infusion;O;O
requirement;O;O
by;O;O
as;O;O
much;O;O
as;O;O
20;O;O
%;O;O
.;O;O
DDI-DrugBank.d775.s10;;
Other;O;O
drugs;O;O
which;O;O
may;O;O
enhance;O;O
the;O;O
neuromuscular;O;O
blocking;O;O
action;O;O
of;O;O
nondepolarizing;B-drug;B-DDI-DrugBank.d775.s10.e0
agents;I-drug;I-DDI-DrugBank.d775.s10.e0
such;O;O
as;O;O
MIVACRON;B-brand;B-DDI-DrugBank.d775.s10.e1
include;O;O
certain;O;O
antibiotics;B-group;B-DDI-DrugBank.d775.s10.e2
(;O;O
e.g.;O;O
,;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d775.s10.e3
,;O;O
tetracyclines;B-group;B-DDI-DrugBank.d775.s10.e4
,;O;O
bacitracin;B-drug;B-DDI-DrugBank.d775.s10.e5
,;O;O
polymyxins;B-group;B-DDI-DrugBank.d775.s10.e6
,;O;O
lincomycin;B-drug;B-DDI-DrugBank.d775.s10.e7
,;O;O
clindamycin;B-drug;B-DDI-DrugBank.d775.s10.e8
,;O;O
colistin;B-drug;B-DDI-DrugBank.d775.s10.e9
,;O;O
and;O;O
sodium;B-drug;B-DDI-DrugBank.d775.s10.e10
colistimethate;I-drug;I-DDI-DrugBank.d775.s10.e10
);O;O
,;O;O
magnesium;B-group;B-DDI-DrugBank.d775.s10.e11
salts;O;O
,;O;O
lithium;B-drug;B-DDI-DrugBank.d775.s10.e12
,;O;O
local;O;O
anesthetics;B-group;B-DDI-DrugBank.d775.s10.e13
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d775.s10.e14
,;O;O
and;O;O
quinidine;B-drug;B-DDI-DrugBank.d775.s10.e15
.;O;O
DDI-DrugBank.d775.s11;;
The;O;O
neuromuscular;O;O
blocking;O;O
effect;O;O
of;O;O
MIVACRON;B-brand;B-DDI-DrugBank.d775.s11.e0
may;O;O
be;O;O
enhanced;O;O
by;O;O
drugs;O;O
that;O;O
reduce;O;O
plasma;O;O
cholinesterase;O;O
activity;O;O
(;O;O
e.g.;O;O
,;O;O
chronically;O;O
administered;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d775.s11.e1
,;O;O
glucocorticoids;B-group;B-DDI-DrugBank.d775.s11.e2
,;O;O
or;O;O
certain;O;O
monoamine;B-group;B-DDI-DrugBank.d775.s11.e3
oxidase;I-group;I-DDI-DrugBank.d775.s11.e3
inhibitors;I-group;I-DDI-DrugBank.d775.s11.e3
);O;O
or;O;O
by;O;O
drugs;O;O
that;O;O
irreversibly;O;O
inhibit;O;O
plasma;O;O
cholinesterase;O;O
.;O;O
Resistance;O;O
to;O;O
the;O;O
neuromuscular;O;O
blocking;O;O
action;O;O
of;O;O
nondepolarizing;O;O
neuromuscular;B-group;B-DDI-DrugBank.d775.s11.e4
blocking;I-group;I-DDI-DrugBank.d775.s11.e4
agents;I-group;I-DDI-DrugBank.d775.s11.e4
has;O;O
been;O;O
demonstrated;O;O
in;O;O
patients;O;O
chronically;O;O
administered;O;O
phenytoin;B-drug;B-DDI-DrugBank.d775.s11.e5
or;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d775.s11.e6
.;O;O
DDI-DrugBank.d775.s12;;
While;O;O
the;O;O
effects;O;O
of;O;O
chronic;O;O
phenytoin;B-drug;B-DDI-DrugBank.d775.s12.e0
or;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d775.s12.e1
therapy;O;O
on;O;O
the;O;O
action;O;O
of;O;O
MIVACRON;B-brand;B-DDI-DrugBank.d775.s12.e2
are;O;O
unknown;O;O
,;O;O
slightly;O;O
shorter;O;O
durations;O;O
of;O;O
neuromuscular;O;O
block;O;O
may;O;O
be;O;O
anticipated;O;O
and;O;O
infusion;O;O
rate;O;O
requirements;O;O
may;O;O
be;O;O
higher;O;O
.;O;O
DDI-DrugBank.d775.s13;;
Some;O;O
drug;O;O
interactions;O;O
are;O;O
:;O;O
-;O;O
birth;O;O
control;O;O
pills;O;O
-;O;O
corticosteroids;B-group;B-DDI-DrugBank.d775.s13.e0
-;O;O
medicines;O;O
for;O;O
angina;O;O
or;O;O
high;O;O
blood;O;O
pressure;O;O
-;O;O
medicines;O;O
for;O;O
pain;O;O
-;O;O
medicines;O;O
to;O;O
control;O;O
seizures;O;O
such;O;O
as;O;O
phenytoin;B-drug;B-DDI-DrugBank.d775.s13.e1
or;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d775.s13.e2
-;O;O
certain;O;O
antibiotics;B-group;B-DDI-DrugBank.d775.s13.e3
given;O;O
by;O;O
injection;O;O
-;O;O
cisplatin;B-drug;B-DDI-DrugBank.d775.s13.e4
-;O;O
edrophonium;B-drug;B-DDI-DrugBank.d775.s13.e5
-;O;O
neostigmine;B-drug;B-DDI-DrugBank.d775.s13.e6
-;O;O
polymyxin;B-drug;B-DDI-DrugBank.d775.s13.e7
B;I-drug;I-DDI-DrugBank.d775.s13.e7
or;O;O
bacitracin;B-drug;B-DDI-DrugBank.d775.s13.e8
-;O;O
local;O;O
anesthetics;B-group;B-DDI-DrugBank.d775.s13.e9
such;O;O
as;O;O
procaine;B-drug;B-DDI-DrugBank.d775.s13.e10
-;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d775.s13.e11
-;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d775.s13.e12
or;O;O
other;O;O
muscle;B-group;B-DDI-DrugBank.d775.s13.e13
relaxants;I-group;I-DDI-DrugBank.d775.s13.e13
DDI-DrugBank.d640.s0;;
Diuretics;I-group;I-DDI-DrugBank.d640.s0.e0
:;O;O
Excessive;O;O
reductions;O;O
in;O;O
blood;O;O
pressure;O;O
may;O;O
occur;O;O
in;O;O
patients;O;O
on;O;O
diuretic;O;O
therapy;O;O
when;O;O
ACE;B-group;B-DDI-DrugBank.d640.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d640.s0.e1
are;O;O
started;O;O
.;O;O
DDI-DrugBank.d640.s1;;
The;O;O
possibility;O;O
of;O;O
hypotensive;O;O
effects;O;O
with;O;O
UNIVASC;B-brand;B-DDI-DrugBank.d640.s1.e0
can;O;O
be;O;O
minimized;O;O
by;O;O
discontinuing;O;O
diuretic;O;O
therapy;O;O
for;O;O
several;O;O
days;O;O
or;O;O
cautiously;O;O
increasing;O;O
salt;O;O
intake;O;O
before;O;O
initiation;O;O
of;O;O
treatment;O;O
with;O;O
UNIVASC;B-brand;B-DDI-DrugBank.d640.s1.e1
.;O;O
If;O;O
this;O;O
is;O;O
not;O;O
possible;O;O
,;O;O
the;O;O
starting;O;O
dose;O;O
of;O;O
moexpril;B-drug;B-DDI-DrugBank.d640.s1.e2
should;O;O
be;O;O
reduced;O;O
..;O;O
DDI-DrugBank.d640.s2;;
Potassium;B-drug;B-DDI-DrugBank.d640.s2.e0
Supplements;O;O
and;O;O
Potassium;B-group;B-DDI-DrugBank.d640.s2.e1
-;I-group;I-DDI-DrugBank.d640.s2.e1
Sparing;I-group;I-DDI-DrugBank.d640.s2.e1
Diuretics;I-group;I-DDI-DrugBank.d640.s2.e1
:;O;O
UNIVASC;B-brand;B-DDI-DrugBank.d640.s2.e2
can;O;O
increase;O;O
serum;O;O
potassium;O;O
because;O;O
it;O;O
decreases;O;O
aldosterone;O;O
secretion;O;O
.;O;O
DDI-DrugBank.d640.s3;;
Use;O;O
of;O;O
potassium;B-group;B-DDI-DrugBank.d640.s3.e0
-;I-group;I-DDI-DrugBank.d640.s3.e0
sparing;I-group;I-DDI-DrugBank.d640.s3.e0
diuretics;I-group;I-DDI-DrugBank.d640.s3.e0
(;O;O
spironolactone;B-drug;B-DDI-DrugBank.d640.s3.e1
,;O;O
triamterene;B-drug;B-DDI-DrugBank.d640.s3.e2
,;O;O
amiloride;B-drug;B-DDI-DrugBank.d640.s3.e3
);O;O
or;O;O
potassium;B-drug;B-DDI-DrugBank.d640.s3.e4
supplements;O;O
concomitantly;O;O
with;O;O
ACE;B-group;B-DDI-DrugBank.d640.s3.e5
inhibitors;I-group;I-DDI-DrugBank.d640.s3.e5
can;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
hyperkalemia;O;O
.;O;O
DDI-DrugBank.d640.s4;;
Therefore;O;O
,;O;O
if;O;O
concomitant;O;O
use;O;O
of;O;O
such;O;O
agents;O;O
is;O;O
indicated;O;O
,;O;O
they;O;O
should;O;O
be;O;O
given;O;O
with;O;O
caution;O;O
and;O;O
the;O;O
patient;O;O
's;O;O
serum;O;O
potassium;O;O
should;O;O
be;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d640.s5;;
Oral;O;O
Anticoagulants;B-group;B-DDI-DrugBank.d640.s5.e0
:;O;O
Interaction;O;O
studies;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d640.s5.e1
failed;O;O
to;O;O
identify;O;O
any;O;O
clinically;O;O
important;O;O
effect;O;O
on;O;O
the;O;O
serum;O;O
concentrations;O;O
of;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d640.s5.e2
or;O;O
on;O;O
its;O;O
anticoagulant;O;O
effect;O;O
.;O;O
DDI-DrugBank.d640.s6;;
Lithium;B-drug;B-DDI-DrugBank.d640.s6.e0
:;O;O
Increased;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d640.s6.e1
levels;O;O
and;O;O
symptoms;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d640.s6.e2
toxicity;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
ACE;B-group;B-DDI-DrugBank.d640.s6.e3
inhibitors;I-group;I-DDI-DrugBank.d640.s6.e3
during;O;O
therapy;O;O
with;O;O
lithium;B-drug;B-DDI-DrugBank.d640.s6.e4
.;O;O
DDI-DrugBank.d640.s7;;
These;O;O
drugs;O;O
should;O;O
be;O;O
coadministered;O;O
with;O;O
caution;O;O
,;O;O
and;O;O
frequent;O;O
monitoring;O;O
of;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d640.s7.e0
levels;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d640.s8;;
If;O;O
a;O;O
diuretic;B-group;B-DDI-DrugBank.d640.s8.e0
is;O;O
also;O;O
used;O;O
,;O;O
the;O;O
risk;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d640.s8.e1
toxicity;O;O
may;O;O
be;O;O
increased;O;O
.;O;O
DDI-DrugBank.d640.s9;;
Other;O;O
Agents;O;O
:;O;O
No;O;O
clinically;O;O
important;O;O
pharmacokinetic;O;O
interactions;O;O
occurred;O;O
when;O;O
UNIVASC;B-brand;B-DDI-DrugBank.d640.s9.e0
was;O;O
administered;O;O
concomitantly;O;O
with;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d640.s9.e1
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d640.s9.e2
,;O;O
or;O;O
cimetidine;B-drug;B-DDI-DrugBank.d640.s9.e3
.;O;O
DDI-DrugBank.d640.s10;;
UNIVASC;B-brand;B-DDI-DrugBank.d640.s10.e0
has;O;O
been;O;O
used;O;O
in;O;O
clinical;O;O
trials;O;O
concomitantly;O;O
with;O;O
calcium;B-group;B-DDI-DrugBank.d640.s10.e1
-;I-group;I-DDI-DrugBank.d640.s10.e1
channel;I-group;I-DDI-DrugBank.d640.s10.e1
-;I-group;I-DDI-DrugBank.d640.s10.e1
blocking;I-group;I-DDI-DrugBank.d640.s10.e1
agents;I-group;I-DDI-DrugBank.d640.s10.e1
,;O;O
diuretics;B-group;B-DDI-DrugBank.d640.s10.e2
,;O;O
H2;B-group;B-DDI-DrugBank.d640.s10.e3
blockers;I-group;I-DDI-DrugBank.d640.s10.e3
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d640.s10.e4
,;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d640.s10.e5
agents;I-group;I-DDI-DrugBank.d640.s10.e5
,;O;O
and;O;O
cholesterol;O;O
-;O;O
lowering;O;O
agents;O;O
.;O;O
DDI-DrugBank.d640.s11;;
There;O;O
was;O;O
no;O;O
evidence;O;O
of;O;O
clinically;O;O
important;O;O
adverse;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d580.s0;;
In;O;O
clinical;O;O
studies;O;O
,;O;O
the;O;O
concurrent;O;O
administration;O;O
of;O;O
the;O;O
ASMANEX;B-brand;B-DDI-DrugBank.d580.s0.e0
TWISTHALER;I-brand;I-DDI-DrugBank.d580.s0.e0
inhaler;O;O
and;O;O
other;O;O
drugs;O;O
commonly;O;O
used;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
asthma;O;O
was;O;O
not;O;O
associated;O;O
with;O;O
any;O;O
unusual;O;O
adverse;O;O
events;O;O
.;O;O
DDI-DrugBank.d580.s1;;
However;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d580.s1.e0
,;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
,;O;O
may;O;O
increase;O;O
plasma;O;O
levels;O;O
of;O;O
mometasone;B-drug;B-DDI-DrugBank.d580.s1.e1
furoate;I-drug;I-DDI-DrugBank.d580.s1.e1
during;O;O
concomitant;O;O
dosing;O;O
.;O;O
DDI-DrugBank.d739.s0;;
Montelukast;B-drug;B-DDI-DrugBank.d739.s0.e0
at;O;O
a;O;O
Dose;O;O
of;O;O
10;O;O
mg;O;O
Once;O;O
Daily;O;O
Dosed;O;O
to;O;O
Pharmacokinetic;O;O
Steady;O;O
State;O;O
-;O;O
did;O;O
not;O;O
cause;O;O
clinically;O;O
significant;O;O
changes;O;O
in;O;O
the;O;O
kinetics;O;O
of;O;O
a;O;O
single;O;O
intravenous;O;O
dose;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d739.s0.e1
(;O;O
predominantly;O;O
a;O;O
cytochrome;O;O
P450;O;O
1A2;O;O
substrate;O;O
);O;O
.;O;O
DDI-DrugBank.d739.s1;;
-;O;O
did;O;O
not;O;O
change;O;O
the;O;O
pharmacokinetic;O;O
profile;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d739.s1.e0
(;O;O
a;O;O
substrate;O;O
of;O;O
cytochromes;O;O
P450;O;O
2A6;O;O
and;O;O
2C9;O;O
);O;O
or;O;O
influence;O;O
the;O;O
effect;O;O
of;O;O
a;O;O
single;O;O
30;O;O
-;O;O
mg;O;O
oral;O;O
dose;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d739.s1.e1
on;O;O
prothrombin;O;O
time;O;O
or;O;O
the;O;O
INR;O;O
(;O;O
International;O;O
Normalized;O;O
Ratio;O;O
);O;O
.;O;O
DDI-DrugBank.d739.s2;;
-;O;O
did;O;O
not;O;O
change;O;O
the;O;O
pharmacokinetic;O;O
profile;O;O
or;O;O
urinary;O;O
excretion;O;O
of;O;O
immunoreactive;O;O
digoxin;B-drug;B-DDI-DrugBank.d739.s2.e0
.;O;O
DDI-DrugBank.d739.s3;;
-;O;O
did;O;O
not;O;O
change;O;O
the;O;O
plasma;O;O
concentration;O;O
profile;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d739.s3.e0
(;O;O
a;O;O
substrate;O;O
of;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
);O;O
or;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d739.s3.e1
,;O;O
its;O;O
carboxylated;O;O
metabolite;O;O
,;O;O
and;O;O
did;O;O
not;O;O
prolong;O;O
the;O;O
QTc;O;O
interval;O;O
following;O;O
co;O;O
-;O;O
administration;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d739.s3.e2
60;O;O
mg;O;O
twice;O;O
daily;O;O
.;O;O
DDI-DrugBank.d739.s4;;
Montelukast;B-drug;B-DDI-DrugBank.d739.s4.e0
at;O;O
Doses;O;O
of;O;O
100;O;O
mg;O;O
Daily;O;O
Dosed;O;O
to;O;O
Pharmacokinetic;O;O
Steady;O;O
State;O;O
:;O;O
-;O;O
did;O;O
not;O;O
significantly;O;O
alter;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
either;O;O
component;O;O
of;O;O
an;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d739.s4.e1
containing;O;O
norethindrone;B-drug;B-DDI-DrugBank.d739.s4.e2
1;O;O
mg;O;O
/;O;O
ethinyl;O;O
estradiol;B-drug;B-DDI-DrugBank.d739.s4.e3
35;O;O
mcg;O;O
.;O;O
DDI-DrugBank.d739.s5;;
-;O;O
did;O;O
not;O;O
cause;O;O
any;O;O
clinically;O;O
significant;O;O
change;O;O
in;O;O
plasma;O;O
profiles;O;O
of;O;O
prednisone;B-drug;B-DDI-DrugBank.d739.s5.e0
or;O;O
prednisolone;B-drug;B-DDI-DrugBank.d739.s5.e1
following;O;O
administration;O;O
of;O;O
either;O;O
oral;O;O
prednisone;B-drug;B-DDI-DrugBank.d739.s5.e2
or;O;O
intravenous;O;O
prednisolone;B-drug;B-DDI-DrugBank.d739.s5.e3
.;O;O
DDI-DrugBank.d739.s6;;
Phenobarbital;B-drug;B-DDI-DrugBank.d739.s6.e0
,;O;O
which;O;O
induces;O;O
hepatic;O;O
metabolism;O;O
,;O;O
decreased;O;O
the;O;O
AUC;O;O
of;O;O
montelukast;B-drug;B-DDI-DrugBank.d739.s6.e1
approximately;O;O
40;O;O
%;O;O
following;O;O
a;O;O
single;O;O
10;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
montelukast;B-drug;B-DDI-DrugBank.d739.s6.e2
.;O;O
DDI-DrugBank.d739.s7;;
No;O;O
dosage;O;O
adjustment;O;O
for;O;O
montelukast;B-drug;B-DDI-DrugBank.d739.s7.e0
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d739.s8;;
It;O;O
is;O;O
reasonable;O;O
to;O;O
employ;O;O
appropriate;O;O
clinical;O;O
monitoring;O;O
when;O;O
potent;O;O
cytochrome;O;O
P450;O;O
enzyme;O;O
inducers;O;O
,;O;O
such;O;O
as;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d739.s8.e0
or;O;O
rifampin;B-drug;B-DDI-DrugBank.d739.s8.e1
,;O;O
are;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
montelukast;B-drug;B-DDI-DrugBank.d739.s8.e2
.;O;O
DDI-DrugBank.d739.s9;;
Montelukast;B-drug;B-DDI-DrugBank.d739.s9.e0
has;O;O
been;O;O
administered;O;O
with;O;O
other;O;O
therapies;O;O
routinely;O;O
used;O;O
in;O;O
the;O;O
prophylaxis;O;O
and;O;O
chronic;O;O
treatment;O;O
of;O;O
asthma;O;O
with;O;O
no;O;O
apparent;O;O
increase;O;O
in;O;O
adverse;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d739.s10;;
In;O;O
drug;O;O
-;O;O
interaction;O;O
studies;O;O
,;O;O
the;O;O
recommended;O;O
clinical;O;O
dose;O;O
of;O;O
montelukast;B-drug;B-DDI-DrugBank.d739.s10.e0
did;O;O
not;O;O
have;O;O
clinically;O;O
important;O;O
effects;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
the;O;O
following;O;O
drugs;O;O
:;O;O
theophylline;B-drug;B-DDI-DrugBank.d739.s10.e1
,;O;O
prednisone;B-drug;B-DDI-DrugBank.d739.s10.e2
,;O;O
prednisolone;B-drug;B-DDI-DrugBank.d739.s10.e3
,;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d739.s10.e4
(;O;O
norethindrone;B-drug;B-DDI-DrugBank.d739.s10.e5
1;O;O
mg;O;O
/;O;O
ethinyl;B-drug;B-DDI-DrugBank.d739.s10.e6
estradiol;I-drug;I-DDI-DrugBank.d739.s10.e6
35;O;O
mcg;O;O
);O;O
,;O;O
terfenadine;B-drug;B-DDI-DrugBank.d739.s10.e7
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d739.s10.e8
,;O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d739.s10.e9
.;O;O
DDI-DrugBank.d739.s11;;
Although;O;O
additional;O;O
specific;O;O
interaction;O;O
studies;O;O
were;O;O
not;O;O
performed;O;O
,;O;O
montelukast;B-drug;B-DDI-DrugBank.d739.s11.e0
was;O;O
used;O;O
concomitantly;O;O
with;O;O
a;O;O
wide;O;O
range;O;O
of;O;O
commonly;O;O
prescribed;O;O
drugs;O;O
in;O;O
clinical;O;O
studies;O;O
without;O;O
evidence;O;O
of;O;O
clinical;O;O
adverse;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d739.s12;;
These;O;O
medications;O;O
included;O;O
thyroid;B-group;B-DDI-DrugBank.d739.s12.e0
hormones;I-group;I-DDI-DrugBank.d739.s12.e0
,;O;O
sedative;B-group;B-DDI-DrugBank.d739.s12.e1
hypnotics;I-group;I-DDI-DrugBank.d739.s12.e1
,;O;O
non;B-group;B-DDI-DrugBank.d739.s12.e2
-;I-group;I-DDI-DrugBank.d739.s12.e2
steroidal;I-group;I-DDI-DrugBank.d739.s12.e2
anti;I-group;I-DDI-DrugBank.d739.s12.e2
-;I-group;I-DDI-DrugBank.d739.s12.e2
inflammatory;I-group;I-DDI-DrugBank.d739.s12.e2
agents;I-group;I-DDI-DrugBank.d739.s12.e2
,;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d739.s12.e3
,;O;O
and;O;O
decongestants;B-group;B-DDI-DrugBank.d739.s12.e4
.;O;O
DDI-DrugBank.d739.s13;;
Phenobarbital;B-drug;B-DDI-DrugBank.d739.s13.e0
,;O;O
which;O;O
induces;O;O
hepatic;O;O
metabolism;O;O
,;O;O
decreased;O;O
the;O;O
AUC;O;O
of;O;O
montelukast;B-drug;B-DDI-DrugBank.d739.s13.e1
approximately;O;O
40;O;O
%;O;O
following;O;O
a;O;O
single;O;O
10;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
montelukast;B-drug;B-DDI-DrugBank.d739.s13.e2
.;O;O
DDI-DrugBank.d739.s14;;
No;O;O
dosage;O;O
adjustment;O;O
for;O;O
montelukast;B-drug;B-DDI-DrugBank.d739.s14.e0
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d739.s15;;
It;O;O
is;O;O
reasonable;O;O
to;O;O
employ;O;O
appropriate;O;O
clinical;O;O
monitoring;O;O
when;O;O
potent;O;O
cytochrome;O;O
P450;O;O
enzyme;O;O
inducers;O;O
,;O;O
such;O;O
as;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d739.s15.e0
or;O;O
rifampin;B-drug;B-DDI-DrugBank.d739.s15.e1
,;O;O
are;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
montelukast;B-drug;B-DDI-DrugBank.d739.s15.e2
.;O;O
DDI-DrugBank.d637.s0;;
Use;O;O
with;O;O
Other;O;O
Central;B-group;B-DDI-DrugBank.d637.s0.e0
Nervous;I-group;I-DDI-DrugBank.d637.s0.e0
System;I-group;I-DDI-DrugBank.d637.s0.e0
Depressants;I-group;I-DDI-DrugBank.d637.s0.e0
:;O;O
The;O;O
depressant;O;O
effects;O;O
of;O;O
morphine;B-drug;B-DDI-DrugBank.d637.s0.e1
are;O;O
potentiated;O;O
by;O;O
the;O;O
presence;O;O
of;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d637.s0.e2
depressants;I-group;I-DDI-DrugBank.d637.s0.e2
such;O;O
as;O;O
alcohol;B-drug;B-DDI-DrugBank.d637.s0.e3
,;O;O
sedatives;B-group;B-DDI-DrugBank.d637.s0.e4
,;O;O
antihistaminics;B-group;B-DDI-DrugBank.d637.s0.e5
,;O;O
or;O;O
psychotropic;B-group;B-DDI-DrugBank.d637.s0.e6
drugs;I-group;I-DDI-DrugBank.d637.s0.e6
.;O;O
DDI-DrugBank.d637.s1;;
Use;O;O
of;O;O
neuroleptics;B-group;B-DDI-DrugBank.d637.s1.e0
in;O;O
conjunction;O;O
with;O;O
oral;O;O
morphine;B-drug;B-DDI-DrugBank.d637.s1.e1
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
respiratory;O;O
depression;O;O
,;O;O
hypotension;O;O
and;O;O
profound;O;O
sedation;O;O
or;O;O
coma;O;O
.;O;O
DDI-DrugBank.d637.s2;;
Interaction;O;O
with;O;O
Mixed;B-group;B-DDI-DrugBank.d637.s2.e0
Agonist;I-group;I-DDI-DrugBank.d637.s2.e0
/;I-group;I-DDI-DrugBank.d637.s2.e0
Antagonist;I-group;I-DDI-DrugBank.d637.s2.e0
Opioid;I-group;I-DDI-DrugBank.d637.s2.e0
Analgesics;I-group;I-DDI-DrugBank.d637.s2.e0
:;O;O
Agonist;B-group;B-DDI-DrugBank.d637.s2.e1
/;I-group;I-DDI-DrugBank.d637.s2.e1
antagonist;I-group;I-DDI-DrugBank.d637.s2.e1
analgesics;I-group;I-DDI-DrugBank.d637.s2.e1
(;O;O
i.e.;O;O
,;O;O
pentazocine;B-drug;B-DDI-DrugBank.d637.s2.e2
,;O;O
nalbuphine;B-drug;B-DDI-DrugBank.d637.s2.e3
,;O;O
butorphanol;B-drug;B-DDI-DrugBank.d637.s2.e4
,;O;O
or;O;O
buprenorphine;B-drug;B-DDI-DrugBank.d637.s2.e5
);O;O
should;O;O
NOT;O;O
be;O;O
administered;O;O
to;O;O
patients;O;O
who;O;O
have;O;O
received;O;O
or;O;O
are;O;O
receiving;O;O
a;O;O
course;O;O
of;O;O
therapy;O;O
with;O;O
a;O;O
proof;O;O
opioid;B-group;B-DDI-DrugBank.d637.s2.e6
agonist;I-group;I-DDI-DrugBank.d637.s2.e6
analgesic;I-group;I-DDI-DrugBank.d637.s2.e6
.;O;O
DDI-DrugBank.d637.s3;;
In;O;O
these;O;O
patients;O;O
,;O;O
the;O;O
mixed;O;O
agonist;O;O
/;O;O
antagonist;O;O
may;O;O
alter;O;O
the;O;O
analgesic;O;O
effect;O;O
or;O;O
may;O;O
precipitate;O;O
withdrawal;O;O
symptoms;O;O
.;O;O
DDI-DrugBank.d700.s0;;
Antacids;B-group;B-DDI-DrugBank.d700.s0.e0
:;O;O
Absorption;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
Myfortic;B-brand;B-DDI-DrugBank.d700.s0.e1
was;O;O
decreased;O;O
when;O;O
administered;O;O
to;O;O
12;O;O
stable;O;O
renal;O;O
transplant;O;O
patients;O;O
also;O;O
taking;O;O
magnesium;B-drug;B-DDI-DrugBank.d700.s0.e2
-;O;O
aluminum;B-drug;B-DDI-DrugBank.d700.s0.e3
containing;O;O
antacids;B-group;B-DDI-DrugBank.d700.s0.e4
(;O;O
30;O;O
mL;O;O
);O;O
:;O;O
the;O;O
mean;O;O
Cmax;O;O
and;O;O
AUC(0;O;O
-;O;O
t;O;O
);O;O
values;O;O
for;O;O
MPA;O;O
were;O;O
25;O;O
%;O;O
and;O;O
37;O;O
%;O;O
lower;O;O
,;O;O
respectively;O;O
,;O;O
than;O;O
when;O;O
Myfortic;B-brand;B-DDI-DrugBank.d700.s0.e5
was;O;O
administered;O;O
alone;O;O
under;O;O
fasting;O;O
conditions;O;O
.;O;O
DDI-DrugBank.d700.s1;;
It;O;O
is;O;O
recommended;O;O
that;O;O
Myfortic;B-drug;B-DDI-DrugBank.d700.s1.e0
and;O;O
antacids;B-group;B-DDI-DrugBank.d700.s1.e1
not;O;O
be;O;O
administered;O;O
simultaneously;O;O
.;O;O
DDI-DrugBank.d700.s2;;
Cyclosporine;B-drug;B-DDI-DrugBank.d700.s2.e0
:;O;O
When;O;O
studied;O;O
in;O;O
stable;O;O
renal;O;O
transplant;O;O
patients;O;O
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d700.s2.e1
,;O;O
USP;O;O
(;O;O
MODIFIED;O;O
);O;O
pharmacokinetics;O;O
were;O;O
unaffected;O;O
by;O;O
steady;O;O
state;O;O
dosing;O;O
of;O;O
Myfortic;B-brand;B-DDI-DrugBank.d700.s2.e2
.;O;O
DDI-DrugBank.d700.s3;;
Acyclovir;B-drug;B-DDI-DrugBank.d700.s3.e0
/;O;O
Ganciclovir;B-drug;B-DDI-DrugBank.d700.s3.e1
:;O;O
may;O;O
be;O;O
taken;O;O
with;O;O
Myfortic;B-brand;B-DDI-DrugBank.d700.s3.e2
;;O;O
DDI-DrugBank.d700.s4;;
however;O;O
,;O;O
during;O;O
the;O;O
period;O;O
of;O;O
treatment;O;O
,;O;O
physicians;O;O
should;O;O
monitor;O;O
blood;O;O
cell;O;O
counts;O;O
.;O;O
DDI-DrugBank.d700.s5;;
Both;O;O
acyclovir;B-drug;B-DDI-DrugBank.d700.s5.e0
/;O;O
ganciclovir;B-drug;B-DDI-DrugBank.d700.s5.e1
and;O;O
MPAG;B-drug_n;B-DDI-DrugBank.d700.s5.e2
concentrations;O;O
are;O;O
increased;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
renal;O;O
impairment;O;O
,;O;O
their;O;O
coexistence;O;O
may;O;O
compete;O;O
for;O;O
tubular;O;O
secretion;O;O
and;O;O
further;O;O
increase;O;O
in;O;O
the;O;O
concentrations;O;O
of;O;O
the;O;O
two;O;O
.;O;O
DDI-DrugBank.d700.s6;;
Azathioprine;B-drug;B-DDI-DrugBank.d700.s6.e0
/;O;O
Mycophenolate;B-drug;B-DDI-DrugBank.d700.s6.e1
Mofetil;I-drug;I-DDI-DrugBank.d700.s6.e1
:;O;O
Given;O;O
that;O;O
azathioprine;B-drug;B-DDI-DrugBank.d700.s6.e2
and;O;O
mycophenolate;B-drug;B-DDI-DrugBank.d700.s6.e3
mofetil;I-drug;I-DDI-DrugBank.d700.s6.e3
inhibit;O;O
purine;O;O
metabolism;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
Myfortic;B-brand;B-DDI-DrugBank.d700.s6.e4
not;O;O
be;O;O
administered;O;O
concomitantly;O;O
with;O;O
azathioprine;B-drug;B-DDI-DrugBank.d700.s6.e5
or;O;O
mycophenolate;B-drug;B-DDI-DrugBank.d700.s6.e6
mofetil;I-drug;I-DDI-DrugBank.d700.s6.e6
.;O;O
DDI-DrugBank.d700.s7;;
Cholestyramine;B-drug;B-DDI-DrugBank.d700.s7.e0
and;O;O
Drugs;O;O
that;O;O
Bind;O;O
Bile;O;O
Acids;O;O
:;O;O
These;O;O
drugs;O;O
interrupt;O;O
enterohepatic;O;O
recirculation;O;O
and;O;O
reduce;O;O
MPA;B-drug_n;B-DDI-DrugBank.d700.s7.e1
exposure;O;O
when;O;O
coadministered;O;O
with;O;O
mycophenolate;B-drug;B-DDI-DrugBank.d700.s7.e2
mofetil;I-drug;I-DDI-DrugBank.d700.s7.e2
.;O;O
DDI-DrugBank.d700.s8;;
Therefore;O;O
,;O;O
do;O;O
not;O;O
administer;O;O
Myfortic;B-drug;B-DDI-DrugBank.d700.s8.e0
with;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d700.s8.e1
or;O;O
other;O;O
agents;O;O
that;O;O
may;O;O
interfere;O;O
with;O;O
enterohepatic;O;O
recirculation;O;O
or;O;O
drugs;O;O
that;O;O
may;O;O
bind;O;O
bile;O;O
acids;O;O
,;O;O
for;O;O
example;O;O
bile;O;O
acid;O;O
sequestrates;O;O
or;O;O
oral;O;O
activated;B-drug;B-DDI-DrugBank.d700.s8.e2
charcoal;I-drug;I-DDI-DrugBank.d700.s8.e2
,;O;O
because;O;O
of;O;O
the;O;O
potential;O;O
to;O;O
reduce;O;O
the;O;O
efficacy;O;O
of;O;O
Myfortic;B-brand;B-DDI-DrugBank.d700.s8.e3
.;O;O
DDI-DrugBank.d700.s9;;
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d700.s9.e0
:;O;O
Given;O;O
the;O;O
different;O;O
metabolism;O;O
of;O;O
Myfortic;B-brand;B-DDI-DrugBank.d700.s9.e1
and;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d700.s9.e2
,;O;O
no;O;O
drug;O;O
interaction;O;O
between;O;O
these;O;O
two;O;O
classes;O;O
of;O;O
drug;O;O
is;O;O
expected;O;O
.;O;O
DDI-DrugBank.d700.s10;;
However;O;O
,;O;O
in;O;O
a;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
study;O;O
,;O;O
mean;O;O
levonorgesterol;B-drug;B-DDI-DrugBank.d700.s10.e0
AUC;O;O
was;O;O
decreased;O;O
by;O;O
15;O;O
%;O;O
when;O;O
coadministered;O;O
with;O;O
mycophenolate;B-drug;B-DDI-DrugBank.d700.s10.e1
mofetil;I-drug;I-DDI-DrugBank.d700.s10.e1
.;O;O
DDI-DrugBank.d700.s11;;
Therefore;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d700.s11.e0
are;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
Myfortic;B-brand;B-DDI-DrugBank.d700.s11.e1
with;O;O
caution;O;O
and;O;O
additional;O;O
birth;O;O
control;O;O
methods;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d700.s12;;
Live;B-group;B-DDI-DrugBank.d700.s12.e0
Vaccines;I-group;I-DDI-DrugBank.d700.s12.e0
:;O;O
During;O;O
treatment;O;O
with;O;O
Myfortic;B-drug;B-DDI-DrugBank.d700.s12.e1
,;O;O
the;O;O
use;O;O
of;O;O
live;B-group;B-DDI-DrugBank.d700.s12.e2
attenuated;I-group;I-DDI-DrugBank.d700.s12.e2
vaccines;I-group;I-DDI-DrugBank.d700.s12.e2
should;O;O
be;O;O
avoided;O;O
and;O;O
patients;O;O
should;O;O
be;O;O
advised;O;O
that;O;O
vaccinations;O;O
may;O;O
be;O;O
less;O;O
effective;O;O
.;O;O
DDI-DrugBank.d700.s13;;
Influenza;O;O
vaccination;O;O
may;O;O
be;O;O
of;O;O
value;O;O
.;O;O
DDI-DrugBank.d700.s14;;
Prescribers;O;O
should;O;O
refer;O;O
to;O;O
national;O;O
guidelines;O;O
for;O;O
influenza;O;O
vaccination;O;O
.;O;O
DDI-DrugBank.d700.s15;;
Drugs;O;O
that;O;O
alter;O;O
the;O;O
gastrointestinal;O;O
flora;O;O
may;O;O
interact;O;O
with;O;O
Myfortic;B-brand;B-DDI-DrugBank.d700.s15.e0
by;O;O
disrupting;O;O
enterohepatic;O;O
recirculation;O;O
.;O;O
DDI-DrugBank.d700.s16;;
Interference;O;O
of;O;O
MPAG;B-drug_n;B-DDI-DrugBank.d700.s16.e0
hydrolysis;O;O
may;O;O
lead;O;O
to;O;O
less;O;O
MPA;B-drug_n;B-DDI-DrugBank.d700.s16.e1
available;O;O
for;O;O
absorption;O;O
.;O;O
DDI-DrugBank.d763.s0;;
Ondansetron;B-drug;B-DDI-DrugBank.d763.s0.e0
does;O;O
not;O;O
itself;O;O
appear;O;O
to;O;O
induce;O;O
or;O;O
inhibit;O;O
the;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
drug;O;O
-;O;O
metabolizing;O;O
enzyme;O;O
system;O;O
of;O;O
the;O;O
liver;O;O
.;O;O
DDI-DrugBank.d763.s1;;
Because;O;O
ondansetron;B-drug;B-DDI-DrugBank.d763.s1.e0
is;O;O
metabolized;O;O
by;O;O
hepatic;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
drug;O;O
-;O;O
metabolizing;O;O
enzymes;O;O
(;O;O
CYP3A4;O;O
,;O;O
CYP2D6;O;O
,;O;O
CYP1A2;O;O
);O;O
,;O;O
inducers;O;O
or;O;O
inhibitors;O;O
of;O;O
these;O;O
enzymes;O;O
may;O;O
change;O;O
the;O;O
clearance;O;O
and;O;O
,;O;O
hence;O;O
,;O;O
the;O;O
half;O;O
-;O;O
life;O;O
of;O;O
ondansetron;B-drug;B-DDI-DrugBank.d763.s1.e1
.;O;O
DDI-DrugBank.d763.s2;;
On;O;O
the;O;O
basis;O;O
of;O;O
limited;O;O
available;O;O
data;O;O
,;O;O
no;O;O
dosage;O;O
adjustment;O;O
is;O;O
recommended;O;O
for;O;O
patients;O;O
on;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d763.s3;;
Phenytoin;B-drug;B-DDI-DrugBank.d763.s3.e0
,;O;O
Carbamazepine;B-drug;B-DDI-DrugBank.d763.s3.e1
,;O;O
and;O;O
Rifampicin;B-drug;B-DDI-DrugBank.d763.s3.e2
:;O;O
In;O;O
patients;O;O
treated;O;O
with;O;O
potent;O;O
inducers;O;O
of;O;O
CYP3A4;O;O
(;O;O
i.e.;O;O
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d763.s3.e3
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d763.s3.e4
,;O;O
and;O;O
rifampicin;B-drug;B-DDI-DrugBank.d763.s3.e5
);O;O
,;O;O
the;O;O
clearance;O;O
of;O;O
ondansetron;B-drug;B-DDI-DrugBank.d763.s3.e6
was;O;O
significantly;O;O
increased;O;O
and;O;O
ondansetron;B-drug;B-DDI-DrugBank.d763.s3.e7
blood;O;O
concentrations;O;O
were;O;O
decreased;O;O
.;O;O
DDI-DrugBank.d763.s4;;
However;O;O
,;O;O
on;O;O
the;O;O
basis;O;O
of;O;O
available;O;O
data;O;O
,;O;O
no;O;O
dosage;O;O
adjustment;O;O
for;O;O
ondansetron;B-drug;B-DDI-DrugBank.d763.s4.e0
is;O;O
recommended;O;O
for;O;O
patients;O;O
on;O;O
these;O;O
drugs.1,3;O;O
Tramadol;B-drug;B-DDI-DrugBank.d763.s4.e1
:;O;O
Although;O;O
no;O;O
pharmacokinetic;O;O
drug;O;O
interaction;O;O
between;O;O
ondansetron;B-drug;B-DDI-DrugBank.d763.s4.e2
and;O;O
tramadol;B-drug;B-DDI-DrugBank.d763.s4.e3
has;O;O
been;O;O
observed;O;O
,;O;O
data;O;O
from;O;O
2;O;O
small;O;O
studies;O;O
indicate;O;O
that;O;O
ondansetron;B-drug;B-DDI-DrugBank.d763.s4.e4
may;O;O
be;O;O
associated;O;O
with;O;O
an;O;O
increase;O;O
in;O;O
patient;O;O
controlled;O;O
administration;O;O
of;O;O
tramadol.4,5;B-drug;B-DDI-DrugBank.d763.s4.e5
Chemotherapy;O;O
:;O;O
Tumor;O;O
response;O;O
to;O;O
chemotherapy;O;O
in;O;O
the;O;O
P;O;O
388;O;O
mouse;O;O
leukemia;O;O
model;O;O
is;O;O
not;O;O
affected;O;O
by;O;O
ondansetron;B-drug;B-DDI-DrugBank.d763.s4.e6
.;O;O
DDI-DrugBank.d763.s5;;
In;O;O
humans;O;O
,;O;O
carmustine;B-drug;B-DDI-DrugBank.d763.s5.e0
,;O;O
etoposide;B-drug;B-DDI-DrugBank.d763.s5.e1
,;O;O
and;O;O
cisplatin;B-drug;B-DDI-DrugBank.d763.s5.e2
do;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
ondansetron;B-drug;B-DDI-DrugBank.d763.s5.e3
.;O;O
DDI-DrugBank.d763.s6;;
In;O;O
a;O;O
crossover;O;O
study;O;O
in;O;O
76;O;O
pediatric;O;O
patients;O;O
,;O;O
I.V.;O;O
DDI-DrugBank.d763.s7;;
ondansetron;B-drug;B-DDI-DrugBank.d763.s7.e0
did;O;O
not;O;O
increase;O;O
blood;O;O
levels;O;O
of;O;O
high;O;O
-;O;O
dose;O;O
methotrexate;B-drug;B-DDI-DrugBank.d763.s7.e1
.;O;O
DDI-DrugBank.d611.s0;;
Other;O;O
beta;B-group;B-DDI-DrugBank.d611.s0.e0
adrenergic;I-group;I-DDI-DrugBank.d611.s0.e0
aerosol;I-group;I-DDI-DrugBank.d611.s0.e0
bronchodilators;I-group;I-DDI-DrugBank.d611.s0.e0
should;O;O
not;O;O
be;O;O
used;O;O
concomitantly;O;O
with;O;O
Alupent;B-brand;B-DDI-DrugBank.d611.s0.e1
(;O;O
metaproterenol;B-drug;B-DDI-DrugBank.d611.s0.e2
sulfate;I-drug;I-DDI-DrugBank.d611.s0.e2
USP;O;O
);O;O
because;O;O
they;O;O
may;O;O
have;O;O
additive;O;O
effects;O;O
.;O;O
DDI-DrugBank.d611.s1;;
Beta;B-group;B-DDI-DrugBank.d611.s1.e0
adrenergic;I-group;I-DDI-DrugBank.d611.s1.e0
agonists;I-group;I-DDI-DrugBank.d611.s1.e0
should;O;O
be;O;O
administered;O;O
with;O;O
caution;O;O
to;O;O
patients;O;O
being;O;O
treated;O;O
with;O;O
monoamine;B-group;B-DDI-DrugBank.d611.s1.e1
oxidase;I-group;I-DDI-DrugBank.d611.s1.e1
inhibitors;I-group;I-DDI-DrugBank.d611.s1.e1
or;O;O
tricyclic;B-group;B-DDI-DrugBank.d611.s1.e2
antidepressants;I-group;I-DDI-DrugBank.d611.s1.e2
,;O;O
since;O;O
the;O;O
action;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d611.s1.e3
adrenergic;I-group;I-DDI-DrugBank.d611.s1.e3
agonists;I-group;I-DDI-DrugBank.d611.s1.e3
on;O;O
the;O;O
vascular;O;O
system;O;O
may;O;O
be;O;O
potentiated;O;O
.;O;O
DDI-DrugBank.d761.s0;;
Alcohol;B-drug;B-DDI-DrugBank.d761.s0.e0
:;O;O
In;O;O
a;O;O
multiple;O;O
-;O;O
dose;O;O
study;O;O
in;O;O
30;O;O
normal;O;O
weight;O;O
subjects;O;O
,;O;O
coadministration;O;O
of;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s0.e1
and;O;O
40;O;O
grams;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d761.s0.e2
(;O;O
e.g.;O;O
,;O;O
approximately;O;O
3;O;O
glasses;O;O
of;O;O
wine;O;O
);O;O
did;O;O
not;O;O
result;O;O
in;O;O
alteration;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d761.s0.e3
pharmacokinetics;O;O
,;O;O
orlistat;B-drug;B-DDI-DrugBank.d761.s0.e4
pharmacodynamics;O;O
(;O;O
fecal;O;O
fat;O;O
excretion;O;O
);O;O
,;O;O
or;O;O
systemic;O;O
exposure;O;O
to;O;O
orlistat;B-drug;B-DDI-DrugBank.d761.s0.e5
.;O;O
DDI-DrugBank.d761.s1;;
Cyclosporine;B-drug;B-DDI-DrugBank.d761.s1.e0
:;O;O
Preliminary;O;O
data;O;O
from;O;O
a;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s1.e1
and;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d761.s1.e2
drug;O;O
interaction;O;O
study;O;O
indicate;O;O
a;O;O
reduction;O;O
in;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d761.s1.e3
plasma;O;O
levels;O;O
when;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s1.e4
was;O;O
coadministered;O;O
with;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d761.s1.e5
.;O;O
DDI-DrugBank.d761.s2;;
Digoxin;B-drug;B-DDI-DrugBank.d761.s2.e0
:;O;O
In;O;O
12;O;O
normal;O;O
-;O;O
weight;O;O
subjects;O;O
receiving;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s2.e1
120;O;O
mg;O;O
three;O;O
times;O;O
a;O;O
day;O;O
for;O;O
6;O;O
days;O;O
,;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s2.e2
did;O;O
not;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d761.s2.e3
.;O;O
DDI-DrugBank.d761.s3;;
Fat;B-group;B-DDI-DrugBank.d761.s3.e0
-;I-group;I-DDI-DrugBank.d761.s3.e0
soluble;I-group;I-DDI-DrugBank.d761.s3.e0
Vitamin;I-group;I-DDI-DrugBank.d761.s3.e0
Supplements;I-group;I-DDI-DrugBank.d761.s3.e0
and;O;O
Analogues;O;O
:;O;O
A;O;O
pharmacokinetic;O;O
interaction;O;O
study;O;O
showed;O;O
a;O;O
30;O;O
%;O;O
reduction;O;O
in;O;O
beta;B-drug;B-DDI-DrugBank.d761.s3.e1
-;I-drug;I-DDI-DrugBank.d761.s3.e1
carotene;I-drug;I-DDI-DrugBank.d761.s3.e1
supplement;O;O
absorption;O;O
when;O;O
concomitantly;O;O
administered;O;O
with;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s3.e2
.;O;O
DDI-DrugBank.d761.s4;;
XENICAL;B-brand;B-DDI-DrugBank.d761.s4.e0
inhibited;O;O
absorption;O;O
of;O;O
a;O;O
vitamin;B-drug;B-DDI-DrugBank.d761.s4.e1
E;I-drug;I-DDI-DrugBank.d761.s4.e1
acetate;I-drug;I-DDI-DrugBank.d761.s4.e1
supplement;O;O
by;O;O
approximately;O;O
60;O;O
%;O;O
.;O;O
DDI-DrugBank.d761.s5;;
The;O;O
effect;O;O
of;O;O
orlistat;B-drug;B-DDI-DrugBank.d761.s5.e0
on;O;O
the;O;O
absorption;O;O
of;O;O
supplemental;O;O
vitamin;B-group;B-DDI-DrugBank.d761.s5.e1
D;I-group;I-DDI-DrugBank.d761.s5.e1
,;O;O
vitamin;B-group;B-DDI-DrugBank.d761.s5.e2
A;I-group;I-DDI-DrugBank.d761.s5.e2
,;O;O
and;O;O
nutritionally;O;O
-;O;O
derived;O;O
vitamin;B-group;B-DDI-DrugBank.d761.s5.e3
K;I-group;I-DDI-DrugBank.d761.s5.e3
is;O;O
not;O;O
known;O;O
at;O;O
this;O;O
time;O;O
.;O;O
DDI-DrugBank.d761.s6;;
Glyburide;B-drug;B-DDI-DrugBank.d761.s6.e0
:;O;O
In;O;O
12;O;O
normal;O;O
-;O;O
weight;O;O
subjects;O;O
receiving;O;O
orlistat;B-drug;B-DDI-DrugBank.d761.s6.e1
80;O;O
mg;O;O
three;O;O
times;O;O
a;O;O
day;O;O
for;O;O
5;O;O
days;O;O
,;O;O
orlistat;B-drug;B-DDI-DrugBank.d761.s6.e2
did;O;O
not;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
or;O;O
pharmacodynamics;O;O
(;O;O
blood;O;O
glucose;O;O
-;O;O
lowering;O;O
);O;O
of;O;O
glyburide;B-drug;B-DDI-DrugBank.d761.s6.e3
.;O;O
DDI-DrugBank.d761.s7;;
Nifedipine;B-drug;B-DDI-DrugBank.d761.s7.e0
(;O;O
extended;O;O
-;O;O
release;O;O
tablets;O;O
);O;O
:;O;O
In;O;O
17;O;O
normal;O;O
-;O;O
weight;O;O
subjects;O;O
receiving;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s7.e1
120;O;O
mg;O;O
three;O;O
times;O;O
a;O;O
day;O;O
for;O;O
6;O;O
days;O;O
,;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s7.e2
did;O;O
not;O;O
alter;O;O
the;O;O
bioavailability;O;O
of;O;O
nifedipine;B-drug;B-DDI-DrugBank.d761.s7.e3
(;O;O
extended;O;O
-;O;O
release;O;O
tablets;O;O
);O;O
.;O;O
DDI-DrugBank.d761.s8;;
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d761.s8.e0
:;O;O
In;O;O
20;O;O
normal;O;O
-;O;O
weight;O;O
female;O;O
subjects;O;O
,;O;O
the;O;O
treatment;O;O
of;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s8.e1
120;O;O
mg;O;O
three;O;O
times;O;O
a;O;O
day;O;O
for;O;O
23;O;O
days;O;O
resulted;O;O
in;O;O
no;O;O
changes;O;O
in;O;O
the;O;O
ovulation;O;O
-;O;O
suppressing;O;O
action;O;O
of;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d761.s8.e2
.;O;O
DDI-DrugBank.d761.s9;;
Phenytoin;B-drug;B-DDI-DrugBank.d761.s9.e0
:;O;O
In;O;O
12;O;O
normal;O;O
-;O;O
weight;O;O
subjects;O;O
receiving;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s9.e1
120;O;O
mg;O;O
three;O;O
times;O;O
a;O;O
day;O;O
for;O;O
7;O;O
days;O;O
,;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s9.e2
did;O;O
not;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
a;O;O
single;O;O
300;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d761.s9.e3
.;O;O
DDI-DrugBank.d761.s10;;
Pravastatin;B-drug;B-DDI-DrugBank.d761.s10.e0
:;O;O
In;O;O
a;O;O
2;O;O
-;O;O
way;O;O
crossover;O;O
study;O;O
of;O;O
24;O;O
normal;O;O
-;O;O
weight;O;O
,;O;O
mildly;O;O
hypercholesterolemic;O;O
patients;O;O
receiving;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s10.e1
120;O;O
mg;O;O
three;O;O
times;O;O
a;O;O
day;O;O
for;O;O
6;O;O
days;O;O
,;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s10.e2
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
pravastatin;B-drug;B-DDI-DrugBank.d761.s10.e3
.;O;O
DDI-DrugBank.d761.s11;;
Warfarin;B-drug;B-DDI-DrugBank.d761.s11.e0
:;O;O
In;O;O
12;O;O
normal;O;O
-;O;O
weight;O;O
subjects;O;O
,;O;O
administration;O;O
of;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s11.e1
120;O;O
mg;O;O
three;O;O
times;O;O
a;O;O
day;O;O
for;O;O
16;O;O
days;O;O
did;O;O
not;O;O
result;O;O
in;O;O
any;O;O
change;O;O
in;O;O
either;O;O
warfarin;B-drug;B-DDI-DrugBank.d761.s11.e2
pharmacokinetics;O;O
(;O;O
both;O;O
R;O;O
-;O;O
and;O;O
S;O;O
-;O;O
enantiomers;O;O
);O;O
or;O;O
pharmacodynamics;O;O
(;O;O
prothrombin;O;O
time;O;O
and;O;O
serum;O;O
Factor;O;O
VII;O;O
);O;O
.;O;O
DDI-DrugBank.d761.s12;;
Although;O;O
undercarboxylated;O;O
osteocalcin;O;O
,;O;O
a;O;O
marker;O;O
of;O;O
vitamin;O;O
K;O;O
nutritional;O;O
status;O;O
,;O;O
was;O;O
unaltered;O;O
with;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s12.e0
administration;O;O
,;O;O
vitamin;O;O
K;O;O
levels;O;O
tended;O;O
to;O;O
decline;O;O
in;O;O
subjects;O;O
taking;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s12.e1
.;O;O
DDI-DrugBank.d761.s13;;
Therefore;O;O
,;O;O
as;O;O
vitamin;B-group;B-DDI-DrugBank.d761.s13.e0
K;I-group;I-DDI-DrugBank.d761.s13.e0
absorption;O;O
may;O;O
be;O;O
decreased;O;O
with;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s13.e1
,;O;O
patients;O;O
on;O;O
chronic;O;O
stable;O;O
doses;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d761.s13.e2
who;O;O
are;O;O
prescribed;O;O
XENICAL;B-brand;B-DDI-DrugBank.d761.s13.e3
should;O;O
be;O;O
monitored;O;O
closely;O;O
for;O;O
changes;O;O
in;O;O
coagulation;O;O
parameters;O;O
.;O;O
DDI-DrugBank.d747.s0;;
Tetracycline;B-group;B-DDI-DrugBank.d747.s0.e0
,;O;O
a;O;O
bacteriostatic;O;O
antibiotic;B-group;B-DDI-DrugBank.d747.s0.e1
,;O;O
may;O;O
antagonize;O;O
the;O;O
bactericidal;O;O
effect;O;O
of;O;O
penicillin;B-drug;B-DDI-DrugBank.d747.s0.e2
and;O;O
concurrent;O;O
use;O;O
of;O;O
these;O;O
drugs;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d728.s0;;
No;O;O
specific;O;O
cytochrome;O;O
P450;O;O
-;O;O
based;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d728.s1;;
No;O;O
pharmacokinetic;O;O
interaction;O;O
between;O;O
85;O;O
mg;O;O
/;O;O
m2;O;O
ELOXATIN;B-brand;B-DDI-DrugBank.d728.s1.e0
and;O;O
infusional;O;O
5;B-drug;B-DDI-DrugBank.d728.s1.e1
-;I-drug;I-DDI-DrugBank.d728.s1.e1
FU;I-drug;I-DDI-DrugBank.d728.s1.e1
has;O;O
been;O;O
observed;O;O
in;O;O
patients;O;O
treated;O;O
every;O;O
2;O;O
weeks;O;O
.;O;O
DDI-DrugBank.d728.s2;;
Increases;O;O
of;O;O
5;B-drug;B-DDI-DrugBank.d728.s2.e0
-;I-drug;I-DDI-DrugBank.d728.s2.e0
FU;I-drug;I-DDI-DrugBank.d728.s2.e0
plasma;O;O
concentrations;O;O
by;O;O
approximately;O;O
20;O;O
%;O;O
have;O;O
been;O;O
observed;O;O
with;O;O
doses;O;O
of;O;O
130;O;O
mg;O;O
/;O;O
m2;O;O
ELOXATIN;B-brand;B-DDI-DrugBank.d728.s2.e1
dosed;O;O
every;O;O
3;O;O
weeks;O;O
.;O;O
DDI-DrugBank.d728.s3;;
Since;O;O
platinum;O;O
containing;O;O
species;O;O
are;O;O
eliminated;O;O
primarily;O;O
through;O;O
the;O;O
kidney;O;O
,;O;O
clearance;O;O
of;O;O
these;O;O
products;O;O
may;O;O
be;O;O
decreased;O;O
by;O;O
coadministration;O;O
of;O;O
potentially;O;O
nephrotoxic;O;O
compounds;O;O
;;O;O
DDI-DrugBank.d728.s4;;
although;O;O
,;O;O
this;O;O
has;O;O
not;O;O
been;O;O
specifically;O;O
studied;O;O
.;O;O
DDI-DrugBank.d584.s0;;
Anticoagulants;B-group;B-DDI-DrugBank.d584.s0.e0
Anabolic;I-group;I-DDI-DrugBank.d584.s0.e1
steroids;I-group;I-DDI-DrugBank.d584.s0.e1
may;O;O
increase;O;O
sensitivity;O;O
to;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d584.s0.e2
.;O;O
DDI-DrugBank.d584.s1;;
Dosage;O;O
of;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d584.s1.e0
may;O;O
have;O;O
to;O;O
be;O;O
decreased;O;O
in;O;O
order;O;O
to;O;O
maintain;O;O
desired;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d584.s2;;
Patients;O;O
receiving;O;O
oral;O;O
anticoagulant;O;O
therapy;O;O
require;O;O
close;O;O
monitoring;O;O
,;O;O
especially;O;O
when;O;O
anabolic;B-group;B-DDI-DrugBank.d584.s2.e0
steroids;I-group;I-DDI-DrugBank.d584.s2.e0
are;O;O
started;O;O
or;O;O
stopped;O;O
.;O;O
DDI-DrugBank.d584.s3;;
Warfarin;B-drug;B-DDI-DrugBank.d584.s3.e0
:;O;O
A;O;O
multidose;O;O
study;O;O
of;O;O
oxandrolone;B-drug;B-DDI-DrugBank.d584.s3.e1
,;O;O
given;O;O
as;O;O
5;O;O
or;O;O
10;O;O
mg;O;O
BID;O;O
in;O;O
15;O;O
healthy;O;O
subjects;O;O
concurrently;O;O
treated;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d584.s3.e2
,;O;O
resulted;O;O
in;O;O
a;O;O
mean;O;O
increase;O;O
in;O;O
S;B-drug;B-DDI-DrugBank.d584.s3.e3
-;I-drug;I-DDI-DrugBank.d584.s3.e3
warfarin;I-drug;I-DDI-DrugBank.d584.s3.e3
half;O;O
-;O;O
life;O;O
from;O;O
26;O;O
to;O;O
48;O;O
hours;O;O
and;O;O
AUC;O;O
from;O;O
4.55;O;O
to;O;O
12.08;O;O
ng;O;O
*;O;O
hr;O;O
/;O;O
mL;O;O
:;O;O
similar;O;O
increases;O;O
in;O;O
R;B-drug;B-DDI-DrugBank.d584.s3.e4
-;I-drug;I-DDI-DrugBank.d584.s3.e4
warfarin;I-drug;I-DDI-DrugBank.d584.s3.e4
half;O;O
-;O;O
life;O;O
and;O;O
AUC;O;O
were;O;O
also;O;O
detected;O;O
.;O;O
DDI-DrugBank.d584.s4;;
Microscopic;O;O
hematuria;O;O
(;O;O
9;O;O
/;O;O
15;O;O
);O;O
and;O;O
gingival;O;O
bleeding;O;O
(;O;O
1;O;O
/;O;O
15;O;O
);O;O
were;O;O
also;O;O
observed;O;O
.;O;O
DDI-DrugBank.d584.s5;;
A;O;O
5.5;O;O
-;O;O
fold;O;O
decrease;O;O
in;O;O
the;O;O
mean;O;O
warfarin;B-drug;B-DDI-DrugBank.d584.s5.e0
dose;O;O
from;O;O
6.13;O;O
mg;O;O
/;O;O
day;O;O
to;O;O
1.13;O;O
mg;O;O
/;O;O
day;O;O
(;O;O
approximately;O;O
80;O;O
-;O;O
85;O;O
%;O;O
reduction;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d584.s5.e1
dose;O;O
);O;O
,;O;O
was;O;O
necessary;O;O
to;O;O
maintain;O;O
a;O;O
target;O;O
INR;O;O
of;O;O
1.5;O;O
.;O;O
DDI-DrugBank.d584.s6;;
When;O;O
oxandrolone;B-drug;B-DDI-DrugBank.d584.s6.e0
therapy;O;O
is;O;O
initiated;O;O
in;O;O
a;O;O
patient;O;O
already;O;O
receiving;O;O
treatment;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d584.s6.e1
,;O;O
the;O;O
INR;O;O
or;O;O
prothrombin;O;O
time;O;O
(;O;O
PT;O;O
);O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
and;O;O
the;O;O
dose;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d584.s6.e2
adjusted;O;O
as;O;O
necessary;O;O
until;O;O
a;O;O
stable;O;O
target;O;O
INR;O;O
or;O;O
PT;O;O
has;O;O
been;O;O
achieved;O;O
.;O;O
DDI-DrugBank.d584.s7;;
Furthermore;O;O
,;O;O
in;O;O
patients;O;O
receiving;O;O
both;O;O
drugs;O;O
,;O;O
careful;O;O
monitoring;O;O
of;O;O
the;O;O
INR;O;O
or;O;O
PT;O;O
,;O;O
and;O;O
adjustment;O;O
of;O;O
the;O;O
warfarin;B-drug;B-DDI-DrugBank.d584.s7.e0
dosage;O;O
if;O;O
indicated;O;O
are;O;O
recommended;O;O
when;O;O
the;O;O
oxandrolone;B-drug;B-DDI-DrugBank.d584.s7.e1
dose;O;O
is;O;O
changed;O;O
or;O;O
discontinued;O;O
.;O;O
DDI-DrugBank.d584.s8;;
Patients;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
for;O;O
signs;O;O
and;O;O
symptoms;O;O
of;O;O
occult;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d584.s9;;
Oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d584.s9.e0
agents;I-group;I-DDI-DrugBank.d584.s9.e0
Oxandrolone;I-drug;I-DDI-DrugBank.d584.s9.e1
may;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d584.s9.e2
agents;I-group;I-DDI-DrugBank.d584.s9.e2
.;O;O
DDI-DrugBank.d584.s10;;
Adrenal;B-group;B-DDI-DrugBank.d584.s10.e0
steroids;I-group;I-DDI-DrugBank.d584.s10.e0
or;O;O
ACTH;B-drug;B-DDI-DrugBank.d584.s10.e1
In;O;O
patients;O;O
with;O;O
edema;O;O
,;O;O
concomitant;O;O
administration;O;O
with;O;O
adrenal;B-group;B-DDI-DrugBank.d584.s10.e2
cortical;I-group;I-DDI-DrugBank.d584.s10.e2
steroids;I-group;I-DDI-DrugBank.d584.s10.e2
or;O;O
ACTH;B-drug;B-DDI-DrugBank.d584.s10.e3
may;O;O
increase;O;O
the;O;O
edema;O;O
.;O;O
DDI-DrugBank.d584.s11;;
Drug;O;O
/;O;O
Laboratory;O;O
test;O;O
interactions;O;O
Anabolic;B-drug;B-DDI-DrugBank.d584.s11.e0
steroids;I-drug;I-DDI-DrugBank.d584.s11.e0
may;O;O
decrease;O;O
levels;O;O
of;O;O
thyroxine;O;O
-;O;O
binding;O;O
globulin;O;O
,;O;O
resulting;O;O
in;O;O
decreased;O;O
total;O;O
T4;O;O
serum;O;O
levels;O;O
and;O;O
increased;O;O
resin;O;O
uptake;O;O
of;O;O
T3;O;O
and;O;O
T4;O;O
.;O;O
DDI-DrugBank.d584.s12;;
Free;O;O
thyroid;O;O
hormone;O;O
levels;O;O
remain;O;O
unchanged;O;O
.;O;O
DDI-DrugBank.d584.s13;;
In;O;O
addition;O;O
,;O;O
a;O;O
decrease;O;O
in;O;O
PBI;O;O
and;O;O
radioactive;O;O
iodine;O;O
uptake;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d784.s0;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
oxybutynin;B-drug;B-DDI-DrugBank.d784.s0.e0
with;O;O
other;O;O
anticholinergic;B-group;B-DDI-DrugBank.d784.s0.e1
drugs;I-group;I-DDI-DrugBank.d784.s0.e1
or;O;O
with;O;O
other;O;O
agents;O;O
which;O;O
produce;O;O
dry;O;O
mouth;O;O
,;O;O
constipation;O;O
,;O;O
somnolence;O;O
(;O;O
drowsiness;O;O
);O;O
,;O;O
and/or;O;O
other;O;O
anticholinergic;O;O
-;O;O
like;O;O
effects;O;O
may;O;O
increase;O;O
the;O;O
frequency;O;O
and/or;O;O
severity;O;O
of;O;O
such;O;O
effects;O;O
.;O;O
DDI-DrugBank.d784.s1;;
Anticholinergic;B-group;B-DDI-DrugBank.d784.s1.e0
agents;I-group;I-DDI-DrugBank.d784.s1.e0
may;O;O
potentially;O;O
alter;O;O
the;O;O
absorption;O;O
of;O;O
some;O;O
concomitantly;O;O
administered;O;O
drugs;O;O
due;O;O
to;O;O
anticholinergic;O;O
effects;O;O
on;O;O
gastrointestinal;O;O
motility;O;O
.;O;O
DDI-DrugBank.d784.s2;;
This;O;O
may;O;O
be;O;O
of;O;O
concern;O;O
for;O;O
drugs;O;O
with;O;O
a;O;O
narrow;O;O
therapeutic;O;O
index;O;O
.;O;O
DDI-DrugBank.d784.s3;;
Mean;O;O
oxybutynin;B-drug;B-DDI-DrugBank.d784.s3.e0
chloride;I-drug;I-DDI-DrugBank.d784.s3.e0
plasma;O;O
concentrations;O;O
were;O;O
approximately;O;O
2;O;O
fold;O;O
higher;O;O
when;O;O
DITROPAN;B-brand;B-DDI-DrugBank.d784.s3.e1
XL;I-brand;I-DDI-DrugBank.d784.s3.e1
was;O;O
administered;O;O
with;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d784.s3.e2
,;O;O
a;O;O
potent;O;O
CYP3A4;O;O
inhibitor;O;O
.;O;O
DDI-DrugBank.d784.s4;;
Other;O;O
inhibitors;O;O
of;O;O
the;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
enzyme;O;O
system;O;O
,;O;O
such;O;O
as;O;O
antimycotic;B-group;B-DDI-DrugBank.d784.s4.e0
agents;I-group;I-DDI-DrugBank.d784.s4.e0
(;O;O
e.g.;O;O
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d784.s4.e1
and;O;O
miconazole;B-drug;B-DDI-DrugBank.d784.s4.e2
);O;O
or;O;O
macrolide;B-group;B-DDI-DrugBank.d784.s4.e3
antibiotics;I-group;I-DDI-DrugBank.d784.s4.e3
(;O;O
e.g.;O;O
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d784.s4.e4
and;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d784.s4.e5
);O;O
,;O;O
may;O;O
alter;O;O
oxybutynin;B-drug;B-DDI-DrugBank.d784.s4.e6
mean;O;O
pharmacokinetic;O;O
parameters;O;O
(;O;O
i.e.;O;O
,;O;O
Cmax;O;O
and;O;O
AUC;O;O
);O;O
.;O;O
DDI-DrugBank.d784.s5;;
The;O;O
clinical;O;O
relevance;O;O
of;O;O
such;O;O
potential;O;O
interactions;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d784.s6;;
Caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
such;O;O
drugs;O;O
are;O;O
co;O;O
-;O;O
administered;O;O
.;O;O
DDI-DrugBank.d784.s7;;
Concurrent;O;O
ingestion;O;O
of;O;O
antacid;B-group;B-DDI-DrugBank.d784.s7.e0
(;O;O
20;O;O
mL;O;O
of;O;O
antacid;B-group;B-DDI-DrugBank.d784.s7.e1
containing;O;O
aluminum;B-drug;B-DDI-DrugBank.d784.s7.e2
hydroxide;I-drug;I-DDI-DrugBank.d784.s7.e2
,;O;O
magnesium;B-drug;B-DDI-DrugBank.d784.s7.e3
hydroxide;I-drug;I-DDI-DrugBank.d784.s7.e3
,;O;O
and;O;O
simethicone;B-drug;B-DDI-DrugBank.d784.s7.e4
);O;O
did;O;O
not;O;O
significantly;O;O
affect;O;O
the;O;O
exposure;O;O
of;O;O
oxybutynin;B-drug;B-DDI-DrugBank.d784.s7.e5
or;O;O
desethyloxybutynin;B-drug_n;B-DDI-DrugBank.d784.s7.e6
.;O;O
DDI-DrugBank.d758.s0;;
The;O;O
CNS;O;O
depressant;O;O
effects;O;O
of;O;O
oxycodone;B-drug;B-DDI-DrugBank.d758.s0.e0
hydrochloride;I-drug;I-DDI-DrugBank.d758.s0.e0
may;O;O
be;O;O
additive;O;O
with;O;O
that;O;O
of;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d758.s0.e1
depressants;I-group;I-DDI-DrugBank.d758.s0.e1
..;O;O
DDI-DrugBank.d753.s0;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d753.s0.e0
depressants;I-group;I-DDI-DrugBank.d753.s0.e0
including;O;O
sedatives;B-group;B-DDI-DrugBank.d753.s0.e1
,;O;O
hypnotics;B-group;B-DDI-DrugBank.d753.s0.e2
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d753.s0.e3
,;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d753.s0.e4
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d753.s0.e5
,;O;O
other;O;O
opioids;B-group;B-DDI-DrugBank.d753.s0.e6
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d753.s0.e7
antidepressants;I-group;I-DDI-DrugBank.d753.s0.e7
,;O;O
monoamine;B-group;B-DDI-DrugBank.d753.s0.e8
oxidase;I-group;I-DDI-DrugBank.d753.s0.e8
(;I-group;I-DDI-DrugBank.d753.s0.e8
MAO;I-group;I-DDI-DrugBank.d753.s0.e8
);I-group;I-DDI-DrugBank.d753.s0.e8
inhibitors;I-group;I-DDI-DrugBank.d753.s0.e8
,;O;O
and;O;O
alcohol;B-drug;B-DDI-DrugBank.d753.s0.e9
may;O;O
produce;O;O
additive;O;O
CNS;O;O
depressant;O;O
effects;O;O
.;O;O
DDI-DrugBank.d753.s1;;
When;O;O
such;O;O
combined;O;O
therapy;O;O
is;O;O
contemplated;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
one;O;O
or;O;O
both;O;O
agents;O;O
should;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d753.s2;;
Anticholinergics;B-group;B-DDI-DrugBank.d753.s2.e0
or;O;O
other;O;O
medications;O;O
with;O;O
anticholinergic;O;O
activity;O;O
when;O;O
used;O;O
concurrently;O;O
with;O;O
opioid;B-group;B-DDI-DrugBank.d753.s2.e1
analgesics;I-group;I-DDI-DrugBank.d753.s2.e1
may;O;O
result;O;O
in;O;O
increased;O;O
risk;O;O
of;O;O
urinary;O;O
retention;O;O
and/or;O;O
severe;O;O
constipation;O;O
,;O;O
which;O;O
may;O;O
lead;O;O
to;O;O
paralytic;O;O
ileus;O;O
.;O;O
DDI-DrugBank.d753.s3;;
It;O;O
has;O;O
been;O;O
reported;O;O
that;O;O
the;O;O
incidence;O;O
of;O;O
bradycardia;O;O
was;O;O
increased;O;O
when;O;O
oxymorphone;B-drug;B-DDI-DrugBank.d753.s3.e0
was;O;O
combined;O;O
with;O;O
propofol;B-drug;B-DDI-DrugBank.d753.s3.e1
for;O;O
induction;O;O
of;O;O
anesthesia;O;O
.;O;O
DDI-DrugBank.d753.s4;;
In;O;O
addition;O;O
,;O;O
CNS;O;O
toxicity;O;O
has;O;O
been;O;O
reported;O;O
(;O;O
confusion;O;O
,;O;O
disorientation;O;O
,;O;O
respiratory;O;O
depression;O;O
,;O;O
apnea;O;O
,;O;O
seizures;O;O
);O;O
following;O;O
coadministration;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d753.s4.e0
with;O;O
opioid;B-group;B-DDI-DrugBank.d753.s4.e1
analgesics;I-group;I-DDI-DrugBank.d753.s4.e1
;;O;O
DDI-DrugBank.d753.s5;;
no;O;O
clear;O;O
-;O;O
cut;O;O
cause;O;O
and;O;O
effect;O;O
relationship;O;O
was;O;O
established;O;O
.;O;O
DDI-DrugBank.d670.s0;;
Potential;O;O
for;O;O
INVEGA;B-brand;B-DDI-DrugBank.d670.s0.e0
to;O;O
Affect;O;O
Other;O;O
Drugs;O;O
Paliperidone;B-drug;B-DDI-DrugBank.d670.s0.e1
is;O;O
not;O;O
expected;O;O
to;O;O
cause;O;O
clinically;O;O
important;O;O
pharmacokinetic;O;O
interactions;O;O
with;O;O
drugs;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
cytochrome;O;O
P450;O;O
isozymes;O;O
.;O;O
DDI-DrugBank.d670.s1;;
In;O;O
vitro;O;O
studies;O;O
in;O;O
human;O;O
liver;O;O
microsomes;O;O
showed;O;O
that;O;O
paliperidone;B-drug;B-DDI-DrugBank.d670.s1.e0
does;O;O
not;O;O
substantially;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
drugs;O;O
metabolized;O;O
by;O;O
cytochrome;O;O
P450;O;O
isozymes;O;O
,;O;O
including;O;O
CYP1A2;O;O
,;O;O
CYP2A6;O;O
,;O;O
CYP2C8;O;O
/;O;O
9;O;O
/;O;O
10;O;O
,;O;O
CYP2D6;O;O
,;O;O
CYP2E1;O;O
,;O;O
CYP3A4;O;O
,;O;O
and;O;O
CYP3A5;O;O
.;O;O
DDI-DrugBank.d670.s2;;
Therefore;O;O
,;O;O
paliperidone;B-drug;B-DDI-DrugBank.d670.s2.e0
is;O;O
not;O;O
expected;O;O
to;O;O
inhibit;O;O
clearance;O;O
of;O;O
drugs;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
these;O;O
metabolic;O;O
pathways;O;O
in;O;O
a;O;O
clinically;O;O
relevant;O;O
manner;O;O
.;O;O
DDI-DrugBank.d670.s3;;
Paliperidone;B-drug;B-DDI-DrugBank.d670.s3.e0
is;O;O
also;O;O
not;O;O
expected;O;O
to;O;O
have;O;O
enzyme;O;O
inducing;O;O
properties;O;O
.;O;O
DDI-DrugBank.d670.s4;;
At;O;O
therapeutic;O;O
concentrations;O;O
,;O;O
paliperidone;B-drug;B-DDI-DrugBank.d670.s4.e0
did;O;O
not;O;O
inhibit;O;O
P;O;O
-;O;O
glycoprotein;O;O
.;O;O
DDI-DrugBank.d670.s5;;
Paliperidone;B-drug;B-DDI-DrugBank.d670.s5.e0
is;O;O
therefore;O;O
not;O;O
expected;O;O
to;O;O
inhibit;O;O
P;O;O
-;O;O
glycoprotein;O;O
-;O;O
mediated;O;O
transport;O;O
of;O;O
other;O;O
drugs;O;O
in;O;O
a;O;O
clinically;O;O
relevant;O;O
manner;O;O
.;O;O
DDI-DrugBank.d670.s6;;
Given;O;O
the;O;O
primary;O;O
CNS;O;O
effects;O;O
of;O;O
paliperidone;B-drug;B-DDI-DrugBank.d670.s6.e0
,;O;O
INVEGA;B-brand;B-DDI-DrugBank.d670.s6.e1
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
centrally;B-group;B-DDI-DrugBank.d670.s6.e2
acting;I-group;I-DDI-DrugBank.d670.s6.e2
drugs;I-group;I-DDI-DrugBank.d670.s6.e2
and;O;O
alcohol;B-drug;B-DDI-DrugBank.d670.s6.e3
.;O;O
DDI-DrugBank.d670.s7;;
Paliperidone;B-drug;B-DDI-DrugBank.d670.s7.e0
may;O;O
antagonize;O;O
the;O;O
effect;O;O
of;O;O
levodopa;B-drug;B-DDI-DrugBank.d670.s7.e1
and;O;O
other;O;O
dopamine;B-group;B-DDI-DrugBank.d670.s7.e2
agonists;I-group;I-DDI-DrugBank.d670.s7.e2
.;O;O
DDI-DrugBank.d670.s8;;
Because;O;O
of;O;O
its;O;O
potential;O;O
for;O;O
inducing;O;O
orthostatic;O;O
hypotension;O;O
,;O;O
an;O;O
additive;O;O
effect;O;O
may;O;O
be;O;O
observed;O;O
when;O;O
INVEGA;B-brand;B-DDI-DrugBank.d670.s8.e0
is;O;O
administered;O;O
with;O;O
other;O;O
therapeutic;O;O
agents;O;O
that;O;O
have;O;O
this;O;O
potential;O;O
.;O;O
DDI-DrugBank.d670.s9;;
Potential;O;O
for;O;O
Other;O;O
Drugs;O;O
to;O;O
Affect;O;O
INVEGA;B-brand;B-DDI-DrugBank.d670.s9.e0
Paliperidone;I-drug;I-DDI-DrugBank.d670.s9.e1
is;O;O
not;O;O
a;O;O
substrate;O;O
of;O;O
CYP1A2;O;O
,;O;O
CYP2A6;O;O
,;O;O
CYP2C9;O;O
,;O;O
and;O;O
CYP2C19;O;O
,;O;O
so;O;O
that;O;O
an;O;O
interaction;O;O
with;O;O
inhibitors;O;O
or;O;O
inducers;O;O
of;O;O
these;O;O
isozymes;O;O
is;O;O
unlikely;O;O
.;O;O
DDI-DrugBank.d670.s10;;
While;O;O
in;O;O
vitro;O;O
studies;O;O
indicate;O;O
that;O;O
CYP2D6;O;O
and;O;O
CYP3A4;O;O
may;O;O
be;O;O
minimally;O;O
involved;O;O
in;O;O
paliperidone;B-drug;B-DDI-DrugBank.d670.s10.e0
metabolism;O;O
,;O;O
in;O;O
vivo;O;O
studies;O;O
do;O;O
not;O;O
show;O;O
decreased;O;O
elimination;O;O
by;O;O
these;O;O
isozymes;O;O
and;O;O
they;O;O
contribute;O;O
to;O;O
only;O;O
a;O;O
small;O;O
fraction;O;O
of;O;O
total;O;O
body;O;O
clearance;O;O
.;O;O
DDI-DrugBank.d680.s0;;
Pantoprazole;B-drug;B-DDI-DrugBank.d680.s0.e0
is;O;O
metabolized;O;O
through;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
,;O;O
primarily;O;O
the;O;O
CYP2C19;O;O
and;O;O
CYP3A4;O;O
isozymes;O;O
,;O;O
and;O;O
subsequently;O;O
undergoes;O;O
Phase;O;O
II;O;O
conjugation;O;O
.;O;O
DDI-DrugBank.d680.s1;;
Based;O;O
on;O;O
studies;O;O
evaluating;O;O
possible;O;O
interactions;O;O
of;O;O
pantoprazole;B-drug;B-DDI-DrugBank.d680.s1.e0
with;O;O
other;O;O
drugs;O;O
,;O;O
no;O;O
dosage;O;O
adjustment;O;O
is;O;O
needed;O;O
with;O;O
concomitant;O;O
use;O;O
of;O;O
the;O;O
following;O;O
:;O;O
theophylline;B-drug;B-DDI-DrugBank.d680.s1.e1
,;O;O
cisapride;B-drug;B-DDI-DrugBank.d680.s1.e2
,;O;O
antipyrine;B-drug;B-DDI-DrugBank.d680.s1.e3
,;O;O
caffeine;B-drug;B-DDI-DrugBank.d680.s1.e4
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d680.s1.e5
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d680.s1.e6
(;O;O
and;O;O
its;O;O
active;O;O
metabolite;O;O
,;O;O
desmethyldiazepam;B-drug_n;B-DDI-DrugBank.d680.s1.e7
);O;O
,;O;O
diclofenac;B-drug;B-DDI-DrugBank.d680.s1.e8
,;O;O
naproxen;B-drug;B-DDI-DrugBank.d680.s1.e9
,;O;O
piroxicam;B-drug;B-DDI-DrugBank.d680.s1.e10
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d680.s1.e11
,;O;O
ethanol;B-drug;B-DDI-DrugBank.d680.s1.e12
,;O;O
glyburide;B-drug;B-DDI-DrugBank.d680.s1.e13
,;O;O
an;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d680.s1.e14
(;O;O
levonorgestrel;B-drug;B-DDI-DrugBank.d680.s1.e15
/;O;O
ethinyl;B-drug;B-DDI-DrugBank.d680.s1.e16
estradiol;I-drug;I-DDI-DrugBank.d680.s1.e16
);O;O
,;O;O
metoprolol;B-drug;B-DDI-DrugBank.d680.s1.e17
,;O;O
nifedipine;B-drug;B-DDI-DrugBank.d680.s1.e18
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d680.s1.e19
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d680.s1.e20
,;O;O
midazolam;B-drug;B-DDI-DrugBank.d680.s1.e21
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d680.s1.e22
,;O;O
metronidazole;B-drug;B-DDI-DrugBank.d680.s1.e23
,;O;O
or;O;O
amoxicillin;B-drug;B-DDI-DrugBank.d680.s1.e24
.;O;O
DDI-DrugBank.d680.s2;;
Clinically;O;O
relevant;O;O
interactions;O;O
of;O;O
pantoprazole;B-drug;B-DDI-DrugBank.d680.s2.e0
with;O;O
other;O;O
drugs;O;O
with;O;O
the;O;O
same;O;O
metabolic;O;O
pathways;O;O
are;O;O
not;O;O
expected;O;O
.;O;O
DDI-DrugBank.d680.s3;;
Therefore;O;O
,;O;O
when;O;O
coadministered;O;O
with;O;O
pantoprazole;B-drug;B-DDI-DrugBank.d680.s3.e0
,;O;O
adjustment;O;O
of;O;O
the;O;O
dosage;O;O
of;O;O
pantoprazole;B-drug;B-DDI-DrugBank.d680.s3.e1
or;O;O
of;O;O
such;O;O
drugs;O;O
may;O;O
not;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d680.s4;;
There;O;O
was;O;O
also;O;O
no;O;O
interaction;O;O
with;O;O
concomitantly;O;O
administered;O;O
antacids;B-group;B-DDI-DrugBank.d680.s4.e0
.;O;O
DDI-DrugBank.d680.s5;;
There;O;O
have;O;O
been;O;O
postmarketing;O;O
reports;O;O
of;O;O
increased;O;O
INR;O;O
and;O;O
prothrombin;O;O
time;O;O
in;O;O
patients;O;O
receiving;O;O
proton;B-group;B-DDI-DrugBank.d680.s5.e0
pump;I-group;I-DDI-DrugBank.d680.s5.e0
inhibitors;I-group;I-DDI-DrugBank.d680.s5.e0
,;O;O
including;O;O
pantoprazole;B-drug;B-DDI-DrugBank.d680.s5.e1
,;O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d680.s5.e2
concomitantly;O;O
.;O;O
DDI-DrugBank.d680.s6;;
Increases;O;O
in;O;O
INR;O;O
and;O;O
prothrombin;O;O
time;O;O
may;O;O
lead;O;O
to;O;O
abnormal;O;O
bleeding;O;O
and;O;O
even;O;O
death;O;O
.;O;O
DDI-DrugBank.d680.s7;;
Patients;O;O
treated;O;O
with;O;O
proton;B-group;B-DDI-DrugBank.d680.s7.e0
pump;I-group;I-DDI-DrugBank.d680.s7.e0
inhibitors;I-group;I-DDI-DrugBank.d680.s7.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d680.s7.e1
concomitantly;O;O
should;O;O
be;O;O
monitored;O;O
for;O;O
increases;O;O
in;O;O
INR;O;O
and;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d680.s8;;
Because;O;O
of;O;O
profound;O;O
and;O;O
long;O;O
lasting;O;O
inhibition;O;O
of;O;O
gastric;O;O
acid;O;O
secretion;O;O
,;O;O
pantoprazole;B-drug;B-DDI-DrugBank.d680.s8.e0
may;O;O
interfere;O;O
with;O;O
absorption;O;O
of;O;O
drugs;O;O
where;O;O
gastric;O;O
pH;O;O
is;O;O
an;O;O
important;O;O
determinant;O;O
of;O;O
their;O;O
bioavailability;O;O
(;O;O
eg;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d680.s8.e1
,;O;O
ampicillin;B-drug;B-DDI-DrugBank.d680.s8.e2
esters;O;O
,;O;O
and;O;O
iron;B-drug;B-DDI-DrugBank.d680.s8.e3
salts;O;O
);O;O
.;O;O
DDI-DrugBank.d680.s9;;
Laboratory;O;O
Tests;O;O
There;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
false;O;O
-;O;O
positive;O;O
urine;O;O
screening;O;O
tests;O;O
for;O;O
tetrahydrocannabinol;B-drug;B-DDI-DrugBank.d680.s9.e0
(;O;O
THC;B-drug;B-DDI-DrugBank.d680.s9.e1
);O;O
in;O;O
patients;O;O
receiving;O;O
most;O;O
proton;B-group;B-DDI-DrugBank.d680.s9.e2
pump;I-group;I-DDI-DrugBank.d680.s9.e2
inhibitors;I-group;I-DDI-DrugBank.d680.s9.e2
,;O;O
including;O;O
pantoprazole;B-drug;B-DDI-DrugBank.d680.s9.e3
.;O;O
DDI-DrugBank.d680.s10;;
An;O;O
alternative;O;O
confirmatory;O;O
method;O;O
should;O;O
be;O;O
considered;O;O
to;O;O
verify;O;O
positive;O;O
results;O;O
.;O;O
DDI-DrugBank.d726.s0;;
Paricalcitol;B-drug_n;B-DDI-DrugBank.d726.s0.e0
is;O;O
not;O;O
expected;O;O
to;O;O
inhibit;O;O
the;O;O
clearance;O;O
of;O;O
drugs;O;O
metabolized;O;O
by;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
CYP1A2;O;O
,;O;O
CYP2A6;O;O
,;O;O
CYP2B6;O;O
,;O;O
CYP2C8;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2C19;O;O
,;O;O
CYP2D6;O;O
CYP2E1;O;O
or;O;O
CYP3A;O;O
nor;O;O
induce;O;O
the;O;O
clearance;O;O
of;O;O
drugs;O;O
metabolized;O;O
by;O;O
CYP2B6;O;O
,;O;O
CYP2C9;O;O
or;O;O
CYP3A.;O;O
DDI-DrugBank.d726.s1;;
A;O;O
multiple;O;O
dose;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
study;O;O
demonstrated;O;O
that;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d726.s1.e0
approximately;O;O
doubled;O;O
paricalcitol;B-drug;B-DDI-DrugBank.d726.s1.e1
AUC0;O;O
-;O;O
.;O;O
Since;O;O
paricalcitol;B-drug;B-DDI-DrugBank.d726.s1.e2
is;O;O
partially;O;O
metabolized;O;O
by;O;O
CYP3A;O;O
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d726.s1.e3
le;O;O
is;O;O
known;O;O
to;O;O
be;O;O
a;O;O
strong;O;O
inhibitor;O;O
of;O;O
cytochrome;O;O
P450;O;O
3A;O;O
enzyme;O;O
,;O;O
care;O;O
should;O;O
be;O;O
taken;O;O
while;O;O
dosing;O;O
paricalcitol;B-drug;B-DDI-DrugBank.d726.s1.e4
with;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d726.s1.e5
and;O;O
other;O;O
strong;O;O
P450;O;O
3A;O;O
inhibitors;O;O
including;O;O
atazanavir;B-drug;B-DDI-DrugBank.d726.s1.e6
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d726.s1.e7
,;O;O
indinavir;B-drug;B-DDI-DrugBank.d726.s1.e8
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d726.s1.e9
,;O;O
nefazodone;B-drug;B-DDI-DrugBank.d726.s1.e10
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d726.s1.e11
,;O;O
ritonavir;B-drug;B-DDI-DrugBank.d726.s1.e12
,;O;O
saquinavir;B-drug;B-DDI-DrugBank.d726.s1.e13
,;O;O
telithromycin;B-drug;B-DDI-DrugBank.d726.s1.e14
or;O;O
voriconazole;B-drug;B-DDI-DrugBank.d726.s1.e15
.;O;O
DDI-DrugBank.d726.s2;;
Dose;O;O
adjustment;O;O
of;O;O
Zemplar;B-brand;B-DDI-DrugBank.d726.s2.e0
Capsules;O;O
may;O;O
be;O;O
required;O;O
,;O;O
and;O;O
iPTH;O;O
and;O;O
serum;O;O
calcium;O;O
concentrations;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
if;O;O
a;O;O
patient;O;O
initiates;O;O
or;O;O
discontinues;O;O
therapy;O;O
with;O;O
a;O;O
strong;O;O
CYP3A4;O;O
inhibitor;O;O
such;O;O
as;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d726.s2.e1
.;O;O
DDI-DrugBank.d726.s3;;
Drugs;O;O
that;O;O
impair;O;O
intestinal;O;O
absorption;O;O
of;O;O
fat;B-group;B-DDI-DrugBank.d726.s3.e0
-;I-group;I-DDI-DrugBank.d726.s3.e0
soluble;I-group;I-DDI-DrugBank.d726.s3.e0
vitamins;I-group;I-DDI-DrugBank.d726.s3.e0
,;O;O
such;O;O
as;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d726.s3.e1
,;O;O
may;O;O
interfere;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
Zemplar;B-brand;B-DDI-DrugBank.d726.s3.e2
Capsules;O;O
.;O;O
DDI-DrugBank.d581.s0;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
between;O;O
Neulasta;B-brand;B-DDI-DrugBank.d581.s0.e0
and;O;O
other;O;O
drugs;O;O
have;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d581.s1;;
Drugs;O;O
such;O;O
as;O;O
lithium;B-drug;B-DDI-DrugBank.d581.s1.e0
may;O;O
potentiate;O;O
the;O;O
release;O;O
of;O;O
neutrophils;O;O
;;O;O
DDI-DrugBank.d581.s2;;
patients;O;O
receiving;O;O
lithium;B-drug;B-DDI-DrugBank.d581.s2.e0
and;O;O
Neulasta;B-brand;B-DDI-DrugBank.d581.s2.e1
should;O;O
have;O;O
more;O;O
frequent;O;O
monitoring;O;O
of;O;O
neutrophil;O;O
counts;O;O
.;O;O
DDI-DrugBank.d741.s0;;
In;O;O
a;O;O
pharmacokinetic;O;O
study;O;O
of;O;O
18;O;O
chronic;O;O
hepatitis;O;O
C;O;O
patients;O;O
concomitantly;O;O
receiving;O;O
methadone;B-drug;B-DDI-DrugBank.d741.s0.e0
,;O;O
treatment;O;O
with;O;O
PEG;B-brand;B-DDI-DrugBank.d741.s0.e1
-;I-brand;I-DDI-DrugBank.d741.s0.e1
Intron;I-brand;I-DDI-DrugBank.d741.s0.e1
once;O;O
weekly;O;O
for;O;O
4;O;O
weeks;O;O
was;O;O
associated;O;O
with;O;O
a;O;O
mean;O;O
increase;O;O
of;O;O
16;O;O
%;O;O
in;O;O
methadone;B-drug;B-DDI-DrugBank.d741.s0.e2
AUC;O;O
;;O;O
DDI-DrugBank.d741.s1;;
in;O;O
2;O;O
out;O;O
of;O;O
18;O;O
patients;O;O
,;O;O
methadone;B-drug;B-DDI-DrugBank.d741.s1.e0
AUC;O;O
doubled;O;O
.;O;O
DDI-DrugBank.d741.s2;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
finding;O;O
is;O;O
unknown;O;O
;;O;O
DDI-DrugBank.d741.s3;;
however;O;O
,;O;O
patients;O;O
should;O;O
be;O;O
monitored;O;O
for;O;O
the;O;O
signs;O;O
and;O;O
symptoms;O;O
of;O;O
increased;O;O
narcotic;O;O
effect;O;O
.;O;O
DDI-DrugBank.d744.s0;;
Acromegalic;O;O
patients;O;O
with;O;O
diabetes;O;O
mellitus;O;O
being;O;O
treated;O;O
with;O;O
insulin;B-drug;B-DDI-DrugBank.d744.s0.e0
and/or;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d744.s0.e1
agents;O;O
may;O;O
require;O;O
dose;O;O
reductions;O;O
of;O;O
these;O;O
therapeutic;O;O
agents;O;O
after;O;O
the;O;O
initiation;O;O
of;O;O
therapy;O;O
with;O;O
SOMAVERT;B-brand;B-DDI-DrugBank.d744.s0.e2
.;O;O
DDI-DrugBank.d744.s1;;
In;O;O
clinical;O;O
studies;O;O
,;O;O
patients;O;O
on;O;O
opioids;B-group;B-DDI-DrugBank.d744.s1.e0
often;O;O
needed;O;O
higher;O;O
serum;O;O
pegvisomant;B-drug;B-DDI-DrugBank.d744.s1.e1
concentrations;O;O
to;O;O
achieve;O;O
appropriate;O;O
IGF;O;O
-;O;O
I;O;O
suppression;O;O
compared;O;O
with;O;O
patients;O;O
not;O;O
receiving;O;O
opioids;B-group;B-DDI-DrugBank.d744.s1.e2
.;O;O
DDI-DrugBank.d744.s2;;
The;O;O
mechanism;O;O
of;O;O
this;O;O
interaction;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d641.s0;;
ALIMTA;B-brand;B-DDI-DrugBank.d641.s0.e0
is;O;O
primarily;O;O
eliminated;O;O
unchanged;O;O
renally;O;O
as;O;O
a;O;O
result;O;O
of;O;O
glomerular;O;O
filtration;O;O
and;O;O
tubular;O;O
secretion;O;O
.;O;O
DDI-DrugBank.d641.s1;;
Concomitant;O;O
administration;O;O
of;O;O
nephrotoxic;O;O
drugs;O;O
could;O;O
result;O;O
in;O;O
delayed;O;O
clearance;O;O
of;O;O
ALIMTA;B-brand;B-DDI-DrugBank.d641.s1.e0
.;O;O
DDI-DrugBank.d641.s2;;
Concomitant;O;O
administration;O;O
of;O;O
substances;O;O
that;O;O
are;O;O
also;O;O
tubularly;O;O
secreted;O;O
(;O;O
e.g.;O;O
,;O;O
probenecid;B-drug;B-DDI-DrugBank.d641.s2.e0
);O;O
could;O;O
potentially;O;O
result;O;O
in;O;O
delayed;O;O
clearance;O;O
of;O;O
ALIMTA;B-brand;B-DDI-DrugBank.d641.s2.e1
.;O;O
DDI-DrugBank.d641.s3;;
Although;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d641.s3.e0
(;O;O
400;O;O
mg;O;O
qid;O;O
);O;O
can;O;O
be;O;O
administered;O;O
with;O;O
ALIMTA;B-brand;B-DDI-DrugBank.d641.s3.e1
in;O;O
patients;O;O
with;O;O
normal;O;O
renal;O;O
function;O;O
(;O;O
creatinine;O;O
clearance;O;O
80;O;O
mL;O;O
/;O;O
min;O;O
);O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
administering;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d641.s3.e2
concurrently;O;O
with;O;O
ALIMTA;B-brand;B-DDI-DrugBank.d641.s3.e3
to;O;O
patients;O;O
with;O;O
mild;O;O
to;O;O
moderate;O;O
renal;O;O
insufficiency;O;O
(;O;O
creatinine;O;O
clearance;O;O
from;O;O
45;O;O
to;O;O
79;O;O
mL;O;O
/;O;O
min;O;O
);O;O
.;O;O
DDI-DrugBank.d641.s4;;
Patients;O;O
with;O;O
mild;O;O
to;O;O
moderate;O;O
renal;O;O
insufficiency;O;O
should;O;O
avoid;O;O
taking;O;O
NSAIDs;B-group;B-DDI-DrugBank.d641.s4.e0
with;O;O
short;O;O
elimination;O;O
half;O;O
-;O;O
lives;O;O
for;O;O
a;O;O
period;O;O
of;O;O
2;O;O
days;O;O
before;O;O
,;O;O
the;O;O
day;O;O
of;O;O
,;O;O
and;O;O
2;O;O
days;O;O
following;O;O
administration;O;O
of;O;O
ALIMTA;B-brand;B-DDI-DrugBank.d641.s4.e1
.;O;O
DDI-DrugBank.d641.s5;;
In;O;O
the;O;O
absence;O;O
of;O;O
data;O;O
regarding;O;O
potential;O;O
interaction;O;O
between;O;O
ALIMTA;B-brand;B-DDI-DrugBank.d641.s5.e0
and;O;O
NSAIDs;B-group;B-DDI-DrugBank.d641.s5.e1
with;O;O
longer;O;O
half;O;O
-;O;O
lives;O;O
,;O;O
all;O;O
patients;O;O
taking;O;O
these;O;O
NSAIDs;B-group;B-DDI-DrugBank.d641.s5.e2
should;O;O
interrupt;O;O
dosing;O;O
for;O;O
at;O;O
least;O;O
5;O;O
days;O;O
before;O;O
,;O;O
the;O;O
day;O;O
of;O;O
,;O;O
and;O;O
2;O;O
days;O;O
following;O;O
ALIMTA;B-brand;B-DDI-DrugBank.d641.s5.e3
administration;O;O
.;O;O
DDI-DrugBank.d641.s6;;
If;O;O
concomitant;O;O
administration;O;O
of;O;O
an;O;O
NSAID;B-group;B-DDI-DrugBank.d641.s6.e0
is;O;O
necessary;O;O
,;O;O
patients;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
for;O;O
toxicity;O;O
,;O;O
especially;O;O
myelosuppression;O;O
,;O;O
renal;O;O
,;O;O
and;O;O
gastrointestinal;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d641.s7;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
None;O;O
known;O;O
.;O;O
DDI-DrugBank.d671.s0;;
The;O;O
interaction;O;O
of;O;O
CYLERT;B-brand;B-DDI-DrugBank.d671.s0.e0
(;O;O
pemoline;B-drug;B-DDI-DrugBank.d671.s0.e1
);O;O
with;O;O
other;O;O
drugs;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
in;O;O
humans;O;O
.;O;O
DDI-DrugBank.d671.s1;;
Patients;O;O
who;O;O
are;O;O
receiving;O;O
CYLERT;B-brand;B-DDI-DrugBank.d671.s1.e0
concurrently;O;O
with;O;O
other;O;O
drugs;O;O
,;O;O
especially;O;O
drugs;O;O
with;O;O
CNS;O;O
activity;O;O
,;O;O
should;O;O
be;O;O
monitored;O;O
carefully;O;O
.;O;O
DDI-DrugBank.d671.s2;;
Decreased;O;O
seizure;O;O
threshold;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
CYLERT;B-brand;B-DDI-DrugBank.d671.s2.e0
concomitantly;O;O
with;O;O
antiepileptic;B-group;B-DDI-DrugBank.d671.s2.e1
medications;I-group;I-DDI-DrugBank.d671.s2.e1
.;O;O
DDI-DrugBank.d665.s0;;
Concurrent;O;O
administration;O;O
of;O;O
bacteriostatic;B-group;B-DDI-DrugBank.d665.s0.e0
antibiotics;I-group;I-DDI-DrugBank.d665.s0.e0
(;O;O
e.g.;O;O
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d665.s0.e1
,;O;O
tetracycline;B-drug;B-DDI-DrugBank.d665.s0.e2
);O;O
may;O;O
diminish;O;O
the;O;O
bactericidal;O;O
effects;O;O
of;O;O
penicillins;B-group;B-DDI-DrugBank.d665.s0.e3
by;O;O
slowing;O;O
the;O;O
rate;O;O
of;O;O
bacterial;O;O
growth;O;O
.;O;O
DDI-DrugBank.d665.s1;;
Bactericidal;O;O
agents;O;O
work;O;O
most;O;O
effectively;O;O
against;O;O
the;O;O
immature;O;O
cell;O;O
wall;O;O
of;O;O
rapidly;O;O
proliferating;O;O
microorganisms;O;O
.;O;O
DDI-DrugBank.d665.s2;;
This;O;O
has;O;O
been;O;O
demonstrated;O;O
in;O;O
vitro;O;O
;;O;O
DDI-DrugBank.d665.s3;;
however;O;O
,;O;O
the;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
interaction;O;O
is;O;O
not;O;O
well;O;O
documented;O;O
.;O;O
DDI-DrugBank.d665.s4;;
There;O;O
are;O;O
few;O;O
clinical;O;O
situations;O;O
in;O;O
which;O;O
the;O;O
concurrent;O;O
use;O;O
of;O;O
';O;O
';O;O
static;O;O
';O;O
';O;O
and;O;O
';O;O
';O;O
cidal;O;O
'';O;O
antibiotics;B-group;B-DDI-DrugBank.d665.s4.e0
are;O;O
indicated;O;O
.;O;O
DDI-DrugBank.d665.s5;;
However;O;O
,;O;O
in;O;O
selected;O;O
circumstances;O;O
in;O;O
which;O;O
such;O;O
therapy;O;O
is;O;O
appropriate;O;O
,;O;O
using;O;O
adequate;O;O
doses;O;O
of;O;O
antibacterial;B-group;B-DDI-DrugBank.d665.s5.e0
agents;O;O
and;O;O
beginning;O;O
penicillin;O;O
therapy;O;O
first;O;O
,;O;O
should;O;O
minimize;O;O
the;O;O
potential;O;O
for;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d665.s6;;
Penicillin;B-group;B-DDI-DrugBank.d665.s6.e0
blood;O;O
levels;O;O
may;O;O
be;O;O
prolonged;O;O
by;O;O
concurrent;O;O
administration;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d665.s6.e1
which;O;O
blocks;O;O
the;O;O
renal;O;O
tubular;O;O
secretion;O;O
of;O;O
penicillins;B-group;B-DDI-DrugBank.d665.s6.e2
.;O;O
DDI-DrugBank.d665.s7;;
Displacement;O;O
of;O;O
penicillin;B-group;B-DDI-DrugBank.d665.s7.e0
from;O;O
plasma;O;O
protein;O;O
binding;O;O
sites;O;O
will;O;O
elevate;O;O
the;O;O
level;O;O
of;O;O
free;O;O
penicillin;B-group;B-DDI-DrugBank.d665.s7.e1
in;O;O
the;O;O
serum;O;O
.;O;O
DDI-DrugBank.d757.s0;;
Usage;O;O
with;O;O
Alcohol;B-drug;B-DDI-DrugBank.d757.s0.e0
:;O;O
Due;O;O
to;O;O
the;O;O
potential;O;O
for;O;O
increased;O;O
CNS;O;O
depressants;O;O
effects;O;O
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d757.s0.e1
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
who;O;O
are;O;O
currently;O;O
receiving;O;O
pentazocine;B-drug;B-DDI-DrugBank.d757.s0.e2
.;O;O
DDI-DrugBank.d659.s0;;
Although;O;O
a;O;O
causal;O;O
relationship;O;O
has;O;O
not;O;O
been;O;O
established;O;O
,;O;O
there;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
bleeding;O;O
and/or;O;O
prolonged;O;O
prothrombin;O;O
time;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
TRENTAL;B-brand;B-DDI-DrugBank.d659.s0.e0
with;O;O
and;O;O
without;O;O
anticoagulants;B-group;B-DDI-DrugBank.d659.s0.e1
or;O;O
platelet;B-group;B-DDI-DrugBank.d659.s0.e2
aggregation;I-group;I-DDI-DrugBank.d659.s0.e2
inhibitors;I-group;I-DDI-DrugBank.d659.s0.e2
.;O;O
DDI-DrugBank.d659.s1;;
Patients;O;O
on;O;O
Warfarin;B-drug;B-DDI-DrugBank.d659.s1.e0
should;O;O
have;O;O
more;O;O
frequent;O;O
monitoring;O;O
of;O;O
prothrombin;O;O
times;O;O
,;O;O
while;O;O
patients;O;O
with;O;O
other;O;O
risk;O;O
factors;O;O
complicated;O;O
by;O;O
hemorrhage;O;O
(;O;O
e.g.;O;O
,;O;O
recent;O;O
surgery;O;O
,;O;O
peptic;O;O
ulceration;O;O
);O;O
should;O;O
have;O;O
periodic;O;O
examinations;O;O
for;O;O
bleeding;O;O
including;O;O
hematocrit;O;O
and/or;O;O
hemoglobin;O;O
.;O;O
DDI-DrugBank.d659.s2;;
Concomitant;O;O
administration;O;O
of;O;O
TRENTAL;B-brand;B-DDI-DrugBank.d659.s2.e0
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d659.s2.e1
-;O;O
containing;O;O
drugs;O;O
leads;O;O
to;O;O
increased;O;O
theophylline;B-drug;B-DDI-DrugBank.d659.s2.e2
levels;O;O
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d659.s2.e3
toxicity;O;O
in;O;O
some;O;O
individuals;O;O
.;O;O
DDI-DrugBank.d659.s3;;
Such;O;O
patients;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
for;O;O
signs;O;O
of;O;O
toxicity;O;O
and;O;O
have;O;O
their;O;O
theophylline;B-drug;B-DDI-DrugBank.d659.s3.e0
dosage;O;O
adjusted;O;O
as;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d659.s4;;
TRENTAL;B-brand;B-DDI-DrugBank.d659.s4.e0
has;O;O
been;O;O
used;O;O
concurrently;O;O
with;O;O
antihypertensive;B-group;B-DDI-DrugBank.d659.s4.e1
drugs;I-group;I-DDI-DrugBank.d659.s4.e1
,;O;O
beta;B-group;B-DDI-DrugBank.d659.s4.e2
blockers;I-group;I-DDI-DrugBank.d659.s4.e2
,;O;O
digitalis;B-group;B-DDI-DrugBank.d659.s4.e3
,;O;O
diuretics;B-group;B-DDI-DrugBank.d659.s4.e4
,;O;O
antidiabetic;B-group;B-DDI-DrugBank.d659.s4.e5
agents;I-group;I-DDI-DrugBank.d659.s4.e5
,;O;O
and;O;O
antiarrhythmics;B-group;B-DDI-DrugBank.d659.s4.e6
,;O;O
without;O;O
observed;O;O
problems;O;O
.;O;O
DDI-DrugBank.d659.s5;;
Small;O;O
decreases;O;O
in;O;O
blood;O;O
pressure;O;O
have;O;O
been;O;O
observed;O;O
in;O;O
some;O;O
patients;O;O
treated;O;O
with;O;O
TRENTAL;B-brand;B-DDI-DrugBank.d659.s5.e0
;;O;O
DDI-DrugBank.d659.s6;;
periodic;O;O
systemic;O;O
blood;O;O
pressure;O;O
monitoring;O;O
is;O;O
recommended;O;O
for;O;O
patients;O;O
receiving;O;O
concomitant;O;O
antihypertensive;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d659.s7;;
If;O;O
indicated;O;O
,;O;O
dosage;O;O
of;O;O
the;O;O
antihypertensive;B-group;B-DDI-DrugBank.d659.s7.e0
agents;I-group;I-DDI-DrugBank.d659.s7.e0
should;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d650.s0;;
Dopamine;B-group;B-DDI-DrugBank.d650.s0.e0
antagonists;I-group;I-DDI-DrugBank.d650.s0.e0
,;O;O
such;O;O
as;O;O
the;O;O
neuroleptics;B-group;B-DDI-DrugBank.d650.s0.e1
(;O;O
phenothiazines;B-group;B-DDI-DrugBank.d650.s0.e2
,;O;O
butyrophenones;B-group;B-DDI-DrugBank.d650.s0.e3
,;O;O
thioxanthines;B-group;B-DDI-DrugBank.d650.s0.e4
);O;O
or;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d650.s0.e5
,;O;O
ordinarily;O;O
should;O;O
not;O;O
be;O;O
administered;O;O
concurrently;O;O
with;O;O
Permax;B-brand;B-DDI-DrugBank.d650.s0.e6
(;O;O
a;O;O
dopamine;B-group;B-DDI-DrugBank.d650.s0.e7
agonist;I-group;I-DDI-DrugBank.d650.s0.e7
);O;O
;;O;O
DDI-DrugBank.d650.s1;;
these;O;O
agents;O;O
may;O;O
diminish;O;O
the;O;O
effectiveness;O;O
of;O;O
Permax;B-brand;B-DDI-DrugBank.d650.s1.e0
.;O;O
DDI-DrugBank.d650.s2;;
Because;O;O
pergolide;B-drug;B-DDI-DrugBank.d650.s2.e0
mesylate;I-drug;I-DDI-DrugBank.d650.s2.e0
is;O;O
approximately;O;O
90;O;O
%;O;O
bound;O;O
to;O;O
plasma;O;O
proteins;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
if;O;O
pergolide;B-drug;B-DDI-DrugBank.d650.s2.e1
mesylate;I-drug;I-DDI-DrugBank.d650.s2.e1
is;O;O
coadministered;O;O
with;O;O
other;O;O
drugs;O;O
known;O;O
to;O;O
affect;O;O
protein;O;O
binding;O;O
.;O;O
DDI-DrugBank.d781.s0;;
Diuretics;B-group;B-DDI-DrugBank.d781.s0.e0
:;O;O
Patients;O;O
on;O;O
diuretics;B-group;B-DDI-DrugBank.d781.s0.e1
,;O;O
and;O;O
especially;O;O
those;O;O
started;O;O
recently;O;O
,;O;O
may;O;O
occasionally;O;O
experience;O;O
an;O;O
excessive;O;O
reduction;O;O
of;O;O
blood;O;O
pressure;O;O
after;O;O
initiation;O;O
of;O;O
ACEON;B-brand;B-DDI-DrugBank.d781.s0.e2
Tablets;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d781.s1;;
The;O;O
possibility;O;O
of;O;O
hypotensive;O;O
effects;O;O
can;O;O
be;O;O
minimized;O;O
by;O;O
either;O;O
discontinuing;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d781.s1.e0
or;O;O
increasing;O;O
the;O;O
salt;O;O
intake;O;O
prior;O;O
to;O;O
initiation;O;O
of;O;O
treatment;O;O
with;O;O
perindopril;B-drug;B-DDI-DrugBank.d781.s1.e1
.;O;O
DDI-DrugBank.d781.s2;;
If;O;O
diuretics;B-group;B-DDI-DrugBank.d781.s2.e0
can;O;O
not;O;O
be;O;O
interrupted;O;O
,;O;O
close;O;O
medical;O;O
supervision;O;O
should;O;O
be;O;O
provided;O;O
with;O;O
the;O;O
first;O;O
dose;O;O
of;O;O
ACEON;B-brand;B-DDI-DrugBank.d781.s2.e1
Tablets;O;O
,;O;O
for;O;O
at;O;O
least;O;O
two;O;O
hours;O;O
and;O;O
until;O;O
blood;O;O
pressure;O;O
has;O;O
stabilized;O;O
for;O;O
another;O;O
hour;O;O
.;O;O
DDI-DrugBank.d781.s3;;
The;O;O
rate;O;O
and;O;O
extent;O;O
of;O;O
perindopril;B-drug;B-DDI-DrugBank.d781.s3.e0
absorption;O;O
and;O;O
elimination;O;O
are;O;O
not;O;O
affected;O;O
by;O;O
concomitant;O;O
diuretics;B-group;B-DDI-DrugBank.d781.s3.e1
.;O;O
DDI-DrugBank.d781.s4;;
The;O;O
bioavailability;O;O
of;O;O
perindoprilat;B-drug_n;B-DDI-DrugBank.d781.s4.e0
was;O;O
reduced;O;O
by;O;O
diuretics;B-group;B-DDI-DrugBank.d781.s4.e1
,;O;O
however;O;O
,;O;O
and;O;O
this;O;O
was;O;O
associated;O;O
with;O;O
a;O;O
decrease;O;O
in;O;O
plasma;O;O
ACE;O;O
inhibition;O;O
.;O;O
DDI-DrugBank.d781.s5;;
Potassium;B-drug;B-DDI-DrugBank.d781.s5.e0
Supplements;O;O
and;O;O
Potassium;B-group;B-DDI-DrugBank.d781.s5.e1
-;I-group;I-DDI-DrugBank.d781.s5.e1
Sparing;I-group;I-DDI-DrugBank.d781.s5.e1
Diuretics;I-group;I-DDI-DrugBank.d781.s5.e1
:;O;O
ACEON;B-brand;B-DDI-DrugBank.d781.s5.e2
Tablets;O;O
may;O;O
increase;O;O
serum;O;O
potassium;O;O
because;O;O
of;O;O
its;O;O
potential;O;O
to;O;O
decrease;O;O
aldosterone;O;O
production;O;O
.;O;O
DDI-DrugBank.d781.s6;;
Use;O;O
of;O;O
potassium;B-group;B-DDI-DrugBank.d781.s6.e0
-;I-group;I-DDI-DrugBank.d781.s6.e0
sparing;I-group;I-DDI-DrugBank.d781.s6.e0
diuretics;I-group;I-DDI-DrugBank.d781.s6.e0
(;O;O
spironolactone;B-drug;B-DDI-DrugBank.d781.s6.e1
,;O;O
amiloride;B-drug;B-DDI-DrugBank.d781.s6.e2
,;O;O
triamterene;B-drug;B-DDI-DrugBank.d781.s6.e3
and;O;O
others;O;O
);O;O
,;O;O
potassium;B-drug;B-DDI-DrugBank.d781.s6.e4
supplements;O;O
or;O;O
other;O;O
drugs;O;O
capable;O;O
of;O;O
increasing;O;O
serum;O;O
potassium;O;O
(;O;O
indomethacin;B-drug;B-DDI-DrugBank.d781.s6.e5
,;O;O
heparin;B-drug;B-DDI-DrugBank.d781.s6.e6
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d781.s6.e7
and;O;O
others;O;O
);O;O
can;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
hyperkalemia;O;O
.;O;O
DDI-DrugBank.d781.s7;;
Therefore;O;O
,;O;O
if;O;O
concomitant;O;O
use;O;O
of;O;O
such;O;O
agents;O;O
is;O;O
indicated;O;O
,;O;O
they;O;O
should;O;O
be;O;O
given;O;O
with;O;O
caution;O;O
and;O;O
the;O;O
patient;O;O
's;O;O
serum;O;O
potassium;O;O
should;O;O
be;O;O
monitored;O;O
frequently;O;O
.;O;O
DDI-DrugBank.d781.s8;;
Lithium;B-drug;B-DDI-DrugBank.d781.s8.e0
:;O;O
Increased;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d781.s8.e1
and;O;O
symptoms;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d781.s8.e2
toxicity;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
concomitant;O;O
lithium;B-drug;B-DDI-DrugBank.d781.s8.e3
and;O;O
ACE;O;O
inhibitor;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d781.s9;;
These;O;O
drugs;O;O
should;O;O
be;O;O
coadministered;O;O
with;O;O
caution;O;O
and;O;O
frequent;O;O
monitoring;O;O
of;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d781.s9.e0
concentration;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d781.s10;;
Use;O;O
of;O;O
a;O;O
diuretic;B-group;B-DDI-DrugBank.d781.s10.e0
may;O;O
further;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d781.s10.e1
toxicity;O;O
.;O;O
DDI-DrugBank.d781.s11;;
Digoxin;B-drug;B-DDI-DrugBank.d781.s11.e0
:;O;O
A;O;O
controlled;O;O
pharmacokinetic;O;O
study;O;O
has;O;O
shown;O;O
no;O;O
effect;O;O
on;O;O
plasma;O;O
digoxin;B-drug;B-DDI-DrugBank.d781.s11.e1
concentrations;O;O
when;O;O
coadministered;O;O
with;O;O
ACEON;B-brand;B-DDI-DrugBank.d781.s11.e2
Tablets;O;O
,;O;O
but;O;O
an;O;O
effect;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d781.s11.e3
on;O;O
the;O;O
plasma;O;O
concentration;O;O
of;O;O
perindopril;B-drug;B-DDI-DrugBank.d781.s11.e4
/;O;O
perindoprilat;B-drug_n;B-DDI-DrugBank.d781.s11.e5
has;O;O
not;O;O
been;O;O
excluded;O;O
.;O;O
DDI-DrugBank.d781.s12;;
Gentamicin;B-drug;B-DDI-DrugBank.d781.s12.e0
:;O;O
Animal;O;O
data;O;O
have;O;O
suggested;O;O
the;O;O
possibility;O;O
of;O;O
interaction;O;O
between;O;O
perindopril;B-drug;B-DDI-DrugBank.d781.s12.e1
and;O;O
gentamicin;B-drug;B-DDI-DrugBank.d781.s12.e2
.;O;O
DDI-DrugBank.d781.s13;;
However;O;O
,;O;O
this;O;O
has;O;O
not;O;O
been;O;O
investigated;O;O
in;O;O
human;O;O
studies;O;O
.;O;O
DDI-DrugBank.d781.s14;;
Coadministration;O;O
of;O;O
both;O;O
drugs;O;O
should;O;O
proceed;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d781.s15;;
Food;O;O
Interaction;O;O
:;O;O
Oral;O;O
administration;O;O
of;O;O
ACEON;B-brand;B-DDI-DrugBank.d781.s15.e0
Tablets;O;O
with;O;O
food;O;O
does;O;O
not;O;O
significantly;O;O
lower;O;O
the;O;O
rate;O;O
or;O;O
extent;O;O
of;O;O
perindopril;B-drug;B-DDI-DrugBank.d781.s15.e1
absorption;O;O
relative;O;O
to;O;O
the;O;O
fasted;O;O
state;O;O
.;O;O
DDI-DrugBank.d781.s16;;
However;O;O
,;O;O
the;O;O
extent;O;O
of;O;O
biotransformation;O;O
of;O;O
perindopril;B-drug;B-DDI-DrugBank.d781.s16.e0
to;O;O
the;O;O
active;O;O
metabolite;O;O
,;O;O
perindoprilat;B-drug_n;B-DDI-DrugBank.d781.s16.e1
,;O;O
is;O;O
reduced;O;O
approximately;O;O
43;O;O
%;O;O
,;O;O
resulting;O;O
in;O;O
a;O;O
reduction;O;O
in;O;O
the;O;O
plasma;O;O
ACE;O;O
inhibition;O;O
curve;O;O
of;O;O
approximately;O;O
20;O;O
%;O;O
,;O;O
probably;O;O
clinically;O;O
insignificant;O;O
.;O;O
DDI-DrugBank.d781.s17;;
In;O;O
clinical;O;O
trials;O;O
,;O;O
perindopril;B-drug;B-DDI-DrugBank.d781.s17.e0
was;O;O
generally;O;O
administered;O;O
in;O;O
a;O;O
non;O;O
-;O;O
fasting;O;O
state;O;O
.;O;O
DDI-DrugBank.d750.s0;;
Concomitant;O;O
use;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d750.s0.e0
with;O;O
phentermine;B-drug;B-DDI-DrugBank.d750.s0.e1
hydrochloride;I-drug;I-DDI-DrugBank.d750.s0.e1
may;O;O
result;O;O
in;O;O
an;O;O
adverse;O;O
drug;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d725.s0;;
Vasopressors;B-group;B-DDI-DrugBank.d725.s0.e0
,;O;O
particularly;O;O
metaraminol;B-drug;B-DDI-DrugBank.d725.s0.e1
,;O;O
may;O;O
cause;O;O
serious;O;O
cardiac;O;O
arrhythmias;O;O
during;O;O
halothane;B-drug;B-DDI-DrugBank.d725.s0.e2
anesthesia;O;O
and;O;O
therefore;O;O
should;O;O
be;O;O
used;O;O
only;O;O
with;O;O
great;O;O
caution;O;O
or;O;O
not;O;O
at;O;O
all;O;O
.;O;O
DDI-DrugBank.d725.s1;;
MAO;B-group;B-DDI-DrugBank.d725.s1.e0
Inhibitors;I-group;I-DDI-DrugBank.d725.s1.e0
:;O;O
The;O;O
pressor;O;O
effect;O;O
of;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d725.s1.e1
pressor;I-group;I-DDI-DrugBank.d725.s1.e1
amines;I-group;I-DDI-DrugBank.d725.s1.e1
is;O;O
markedly;O;O
potentiated;O;O
in;O;O
patients;O;O
receiving;O;O
monoamine;B-group;B-DDI-DrugBank.d725.s1.e2
oxidase;I-group;I-DDI-DrugBank.d725.s1.e2
inhibitors;I-group;I-DDI-DrugBank.d725.s1.e2
(;O;O
MAOI;B-group;B-DDI-DrugBank.d725.s1.e3
);O;O
.;O;O
DDI-DrugBank.d725.s2;;
Therefore;O;O
,;O;O
when;O;O
initiating;O;O
pressor;O;O
therapy;O;O
in;O;O
these;O;O
patients;O;O
,;O;O
the;O;O
initial;O;O
dose;O;O
should;O;O
be;O;O
small;O;O
and;O;O
used;O;O
with;O;O
due;O;O
caution;O;O
.;O;O
DDI-DrugBank.d725.s3;;
The;O;O
pressor;O;O
response;O;O
of;O;O
adrenergic;B-group;B-DDI-DrugBank.d725.s3.e0
agents;I-group;I-DDI-DrugBank.d725.s3.e0
may;O;O
also;O;O
be;O;O
potentiated;O;O
by;O;O
tricyclic;B-group;B-DDI-DrugBank.d725.s3.e1
antidepressants;I-group;I-DDI-DrugBank.d725.s3.e1
.;O;O
DDI-DrugBank.d689.s0;;
Vasopressors;B-group;B-DDI-DrugBank.d689.s0.e0
,;O;O
particularly;O;O
metaraminol;B-drug;B-DDI-DrugBank.d689.s0.e1
,;O;O
may;O;O
cause;O;O
serious;O;O
cardiac;O;O
arrhythmias;O;O
during;O;O
halothane;B-drug;B-DDI-DrugBank.d689.s0.e2
anesthesia;O;O
and;O;O
therefore;O;O
should;O;O
be;O;O
used;O;O
only;O;O
with;O;O
great;O;O
caution;O;O
or;O;O
not;O;O
at;O;O
all;O;O
.;O;O
DDI-DrugBank.d689.s1;;
MAO;B-group;B-DDI-DrugBank.d689.s1.e0
Inhibitors;I-group;I-DDI-DrugBank.d689.s1.e0
-;O;O
The;O;O
pressor;O;O
effect;O;O
of;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d689.s1.e1
pressor;I-group;I-DDI-DrugBank.d689.s1.e1
amines;I-group;I-DDI-DrugBank.d689.s1.e1
is;O;O
markedly;O;O
potentiated;O;O
in;O;O
patients;O;O
receiving;O;O
monoamine;B-group;B-DDI-DrugBank.d689.s1.e2
oxidase;I-group;I-DDI-DrugBank.d689.s1.e2
inhibitors;I-group;I-DDI-DrugBank.d689.s1.e2
(;O;O
MAOI;B-group;B-DDI-DrugBank.d689.s1.e3
);O;O
.;O;O
DDI-DrugBank.d689.s2;;
Therefore;O;O
,;O;O
when;O;O
initiating;O;O
pressor;O;O
therapy;O;O
in;O;O
these;O;O
patients;O;O
,;O;O
the;O;O
initial;O;O
dose;O;O
should;O;O
be;O;O
small;O;O
and;O;O
used;O;O
with;O;O
due;O;O
caution;O;O
.;O;O
DDI-DrugBank.d689.s3;;
The;O;O
pressor;O;O
response;O;O
of;O;O
adrenergic;B-group;B-DDI-DrugBank.d689.s3.e0
agents;I-group;I-DDI-DrugBank.d689.s3.e0
may;O;O
also;O;O
be;O;O
potentiated;O;O
by;O;O
tricyclic;B-group;B-DDI-DrugBank.d689.s3.e1
antidepressants;I-group;I-DDI-DrugBank.d689.s3.e1
.;O;O
DDI-DrugBank.d627.s0;;
Pilocarpine;B-drug;B-DDI-DrugBank.d627.s0.e0
should;O;O
be;O;O
administered;O;O
with;O;O
caution;O;O
to;O;O
patients;O;O
taking;O;O
beta;B-group;B-DDI-DrugBank.d627.s0.e1
adrenergic;I-group;I-DDI-DrugBank.d627.s0.e1
antagonists;I-group;I-DDI-DrugBank.d627.s0.e1
because;O;O
of;O;O
the;O;O
possibility;O;O
of;O;O
conduction;O;O
disturbances;O;O
.;O;O
DDI-DrugBank.d627.s1;;
Drugs;O;O
with;O;O
parasympathomimetic;O;O
effects;O;O
administered;O;O
concurrently;O;O
with;O;O
pilocarpine;B-drug;B-DDI-DrugBank.d627.s1.e0
would;O;O
be;O;O
expected;O;O
to;O;O
result;O;O
in;O;O
additive;O;O
pharmacologic;O;O
effects;O;O
.;O;O
DDI-DrugBank.d627.s2;;
Pilocarpine;B-drug;B-DDI-DrugBank.d627.s2.e0
might;O;O
antagonize;O;O
the;O;O
anticholinergic;O;O
effects;O;O
of;O;O
drugs;O;O
used;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d627.s3;;
These;O;O
effects;O;O
should;O;O
be;O;O
considered;O;O
when;O;O
anticholinergic;O;O
properties;O;O
may;O;O
be;O;O
contributing;O;O
to;O;O
the;O;O
therapeutic;O;O
effect;O;O
of;O;O
concomitant;O;O
medication;O;O
(;O;O
e.g.;O;O
,;O;O
atropine;B-drug;B-DDI-DrugBank.d627.s3.e0
,;O;O
inhaled;O;O
ipratropium;B-drug;B-DDI-DrugBank.d627.s3.e1
);O;O
.;O;O
DDI-DrugBank.d627.s4;;
While;O;O
no;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
,;O;O
the;O;O
following;O;O
concomitant;O;O
drugs;O;O
were;O;O
used;O;O
in;O;O
at;O;O
least;O;O
10;O;O
%;O;O
of;O;O
patients;O;O
in;O;O
either;O;O
or;O;O
both;O;O
Sj;O;O
grens;O;O
efficacy;O;O
studies;O;O
:;O;O
acetylsalicylic;B-drug;B-DDI-DrugBank.d627.s4.e0
acid;I-drug;I-DDI-DrugBank.d627.s4.e0
,;O;O
artificial;O;O
tears;O;O
,;O;O
calcium;B-drug;B-DDI-DrugBank.d627.s4.e1
,;O;O
conjugated;B-drug;B-DDI-DrugBank.d627.s4.e2
estrogens;I-drug;I-DDI-DrugBank.d627.s4.e2
,;O;O
hydroxychloroquine;B-drug;B-DDI-DrugBank.d627.s4.e3
sulfate;I-drug;I-DDI-DrugBank.d627.s4.e3
,;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d627.s4.e4
,;O;O
levothyroxine;B-drug;B-DDI-DrugBank.d627.s4.e5
sodium;I-drug;I-DDI-DrugBank.d627.s4.e5
,;O;O
medroxyprogesterone;B-drug;B-DDI-DrugBank.d627.s4.e6
acetate;I-drug;I-DDI-DrugBank.d627.s4.e6
,;O;O
methotrexate;B-drug;B-DDI-DrugBank.d627.s4.e7
,;O;O
multivitamins;B-group;B-DDI-DrugBank.d627.s4.e8
,;O;O
naproxen;B-drug;B-DDI-DrugBank.d627.s4.e9
,;O;O
omeprazole;B-drug;B-DDI-DrugBank.d627.s4.e10
,;O;O
paracetamol;B-drug;B-DDI-DrugBank.d627.s4.e11
,;O;O
and;O;O
prednisone;B-drug;B-DDI-DrugBank.d627.s4.e12
.;O;O
DDI-DrugBank.d666.s0;;
Catecholamine;O;O
-;O;O
depleting;O;O
drugs;O;O
(;O;O
e.g.;O;O
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d666.s0.e0
);O;O
may;O;O
have;O;O
an;O;O
additive;O;O
effect;O;O
when;O;O
given;O;O
with;O;O
beta;B-group;B-DDI-DrugBank.d666.s0.e1
-;I-group;I-DDI-DrugBank.d666.s0.e1
blocking;I-group;I-DDI-DrugBank.d666.s0.e1
agents;I-group;I-DDI-DrugBank.d666.s0.e1
.;O;O
DDI-DrugBank.d666.s1;;
Patients;O;O
receiving;O;O
pindolol;B-drug;B-DDI-DrugBank.d666.s1.e0
plus;O;O
a;O;O
catecholamine;O;O
-;O;O
depleting;O;O
agent;O;O
should;O;O
,;O;O
therefore;O;O
,;O;O
be;O;O
closely;O;O
observed;O;O
for;O;O
evidence;O;O
of;O;O
hypotension;O;O
and/or;O;O
marked;O;O
bradycardia;O;O
which;O;O
may;O;O
produce;O;O
vertigo;O;O
,;O;O
syncope;O;O
,;O;O
or;O;O
postural;O;O
hypotension;O;O
.;O;O
DDI-DrugBank.d666.s2;;
Pindolol;B-drug;B-DDI-DrugBank.d666.s2.e0
has;O;O
been;O;O
used;O;O
with;O;O
a;O;O
variety;O;O
of;O;O
antihypertensive;B-group;B-DDI-DrugBank.d666.s2.e1
agents;I-group;I-DDI-DrugBank.d666.s2.e1
,;O;O
including;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d666.s2.e2
,;O;O
hydralazine;B-drug;B-DDI-DrugBank.d666.s2.e3
,;O;O
and;O;O
guanethidine;B-drug;B-DDI-DrugBank.d666.s2.e4
without;O;O
unexpected;O;O
adverse;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d666.s3;;
Pindolol;B-drug;B-DDI-DrugBank.d666.s3.e0
has;O;O
been;O;O
shown;O;O
to;O;O
increase;O;O
serum;O;O
thioridazine;B-drug;B-DDI-DrugBank.d666.s3.e1
levels;O;O
when;O;O
both;O;O
drugs;O;O
are;O;O
co;O;O
-;O;O
administered;O;O
.;O;O
DDI-DrugBank.d666.s4;;
Pindolol;B-drug;B-DDI-DrugBank.d666.s4.e0
levels;O;O
may;O;O
also;O;O
be;O;O
increased;O;O
with;O;O
this;O;O
combination;O;O
.;O;O
DDI-DrugBank.d666.s5;;
Risk;O;O
of;O;O
anaphylactic;O;O
reaction;O;O
:;O;O
While;O;O
taking;O;O
beta;B-group;B-DDI-DrugBank.d666.s5.e0
blockers;I-group;I-DDI-DrugBank.d666.s5.e0
,;O;O
patients;O;O
with;O;O
a;O;O
history;O;O
of;O;O
severe;O;O
anaphylactic;O;O
reaction;O;O
to;O;O
a;O;O
variety;O;O
of;O;O
allergens;O;O
may;O;O
be;O;O
more;O;O
reactive;O;O
to;O;O
repeated;O;O
challenge;O;O
,;O;O
either;O;O
accidental;O;O
,;O;O
diagnostic;O;O
,;O;O
or;O;O
therapeutic;O;O
.;O;O
DDI-DrugBank.d666.s6;;
Such;O;O
patients;O;O
may;O;O
be;O;O
unresponsive;O;O
to;O;O
the;O;O
usual;O;O
doses;O;O
of;O;O
epinephrine;B-drug;B-DDI-DrugBank.d666.s6.e0
used;O;O
to;O;O
treat;O;O
allergic;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d635.s0;;
Other;O;O
short;B-group;B-DDI-DrugBank.d635.s0.e0
-;I-group;I-DDI-DrugBank.d635.s0.e0
acting;I-group;I-DDI-DrugBank.d635.s0.e0
beta;I-group;I-DDI-DrugBank.d635.s0.e0
adrenergic;I-group;I-DDI-DrugBank.d635.s0.e0
aerosol;I-group;I-DDI-DrugBank.d635.s0.e0
bronchodilators;I-group;I-DDI-DrugBank.d635.s0.e0
should;O;O
not;O;O
be;O;O
used;O;O
concomitantly;O;O
with;O;O
MAXAIR;B-brand;B-DDI-DrugBank.d635.s0.e1
AUTOHALER;I-brand;I-DDI-DrugBank.d635.s0.e1
because;O;O
they;O;O
may;O;O
have;O;O
additive;O;O
effects;O;O
.;O;O
DDI-DrugBank.d656.s0;;
FELDENE;B-brand;B-DDI-DrugBank.d656.s0.e0
is;O;O
highly;O;O
protein;O;O
bound;O;O
,;O;O
and;O;O
therefore;O;O
,;O;O
might;O;O
be;O;O
expected;O;O
to;O;O
displace;O;O
other;O;O
protein;O;O
-;O;O
bound;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d656.s1;;
Although;O;O
this;O;O
has;O;O
not;O;O
occurred;O;O
in;O;O
in;O;O
vitro;O;O
studies;O;O
with;O;O
coumarin;B-group;B-DDI-DrugBank.d656.s1.e0
-;I-group;I-DDI-DrugBank.d656.s1.e0
type;I-group;I-DDI-DrugBank.d656.s1.e0
anticoagulants;I-group;I-DDI-DrugBank.d656.s1.e0
,;O;O
interactions;O;O
with;O;O
coumarin;B-group;B-DDI-DrugBank.d656.s1.e1
-;I-group;I-DDI-DrugBank.d656.s1.e1
type;I-group;I-DDI-DrugBank.d656.s1.e1
anticoagulants;I-group;I-DDI-DrugBank.d656.s1.e1
have;O;O
been;O;O
reported;O;O
with;O;O
FELDENE;B-brand;B-DDI-DrugBank.d656.s1.e2
since;O;O
marketing;O;O
,;O;O
therefore;O;O
,;O;O
physicians;O;O
should;O;O
closely;O;O
monitor;O;O
patients;O;O
for;O;O
a;O;O
change;O;O
in;O;O
dosage;O;O
requirements;O;O
when;O;O
administering;O;O
FELDENE;B-brand;B-DDI-DrugBank.d656.s1.e3
to;O;O
patients;O;O
on;O;O
coumarin;B-group;B-DDI-DrugBank.d656.s1.e4
-;I-group;I-DDI-DrugBank.d656.s1.e4
type;I-group;I-DDI-DrugBank.d656.s1.e4
anticoagulants;I-group;I-DDI-DrugBank.d656.s1.e4
and;O;O
other;O;O
highly;O;O
protein;O;O
-;O;O
bound;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d656.s2;;
Plasma;O;O
levels;O;O
of;O;O
piroxicam;B-drug;B-DDI-DrugBank.d656.s2.e0
are;O;O
depressed;O;O
to;O;O
approximately;O;O
80;O;O
%;O;O
of;O;O
their;O;O
normal;O;O
values;O;O
when;O;O
FELDENE;B-brand;B-DDI-DrugBank.d656.s2.e1
is;O;O
administered;O;O
in;O;O
conjunction;O;O
with;O;O
aspirin;B-brand;B-DDI-DrugBank.d656.s2.e2
(;O;O
3900;O;O
mg;O;O
/;O;O
day;O;O
);O;O
,;O;O
but;O;O
concomitant;O;O
administration;O;O
of;O;O
antacids;B-group;B-DDI-DrugBank.d656.s2.e3
has;O;O
no;O;O
effect;O;O
on;O;O
piroxicam;B-drug;B-DDI-DrugBank.d656.s2.e4
plasma;O;O
levels;O;O
.;O;O
Nonsteroidal;B-group;B-DDI-DrugBank.d656.s2.e5
anti;I-group;I-DDI-DrugBank.d656.s2.e5
-;I-group;I-DDI-DrugBank.d656.s2.e5
inflammatory;I-group;I-DDI-DrugBank.d656.s2.e5
agents;I-group;I-DDI-DrugBank.d656.s2.e5
,;O;O
including;O;O
FELDENE;B-brand;B-DDI-DrugBank.d656.s2.e6
,;O;O
have;O;O
been;O;O
reported;O;O
to;O;O
increase;O;O
steady;O;O
state;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d656.s2.e7
levels;O;O
.;O;O
DDI-DrugBank.d656.s3;;
It;O;O
is;O;O
recommended;O;O
that;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d656.s3.e0
levels;O;O
be;O;O
monitored;O;O
when;O;O
initiating;O;O
,;O;O
adjusting;O;O
and;O;O
discontinuing;O;O
FELDENE;B-brand;B-DDI-DrugBank.d656.s3.e1
.;O;O
DDI-DrugBank.d622.s0;;
When;O;O
atropine;B-drug;B-DDI-DrugBank.d622.s0.e0
and;O;O
pralidoxime;B-drug;B-DDI-DrugBank.d622.s0.e1
are;O;O
used;O;O
together;O;O
,;O;O
the;O;O
signs;O;O
of;O;O
atropinization;O;O
(;O;O
flushing;O;O
,;O;O
mydriasis;O;O
,;O;O
tachycardia;O;O
,;O;O
dryness;O;O
of;O;O
the;O;O
mouth;O;O
and;O;O
nose;O;O
);O;O
may;O;O
occur;O;O
earlier;O;O
than;O;O
might;O;O
be;O;O
expected;O;O
when;O;O
atropine;B-drug;B-DDI-DrugBank.d622.s0.e2
is;O;O
used;O;O
alone;O;O
.;O;O
DDI-DrugBank.d622.s1;;
This;O;O
is;O;O
especially;O;O
true;O;O
if;O;O
the;O;O
total;O;O
dose;O;O
of;O;O
atropine;B-drug;B-DDI-DrugBank.d622.s1.e0
has;O;O
been;O;O
large;O;O
and;O;O
the;O;O
administration;O;O
of;O;O
pralidoxime;B-drug;B-DDI-DrugBank.d622.s1.e1
has;O;O
been;O;O
delayed;O;O
.;O;O
DDI-DrugBank.d622.s2;;
2;O;O
-;O;O
4;O;O
The;O;O
following;O;O
precautions;O;O
should;O;O
be;O;O
kept;O;O
in;O;O
mind;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
anticholinesterase;O;O
poisoning;O;O
,;O;O
although;O;O
they;O;O
do;O;O
not;O;O
bear;O;O
directly;O;O
on;O;O
the;O;O
use;O;O
of;O;O
pralidoxime;B-drug;B-DDI-DrugBank.d622.s2.e0
:;O;O
since;O;O
barbiturates;B-group;B-DDI-DrugBank.d622.s2.e1
are;O;O
potentiated;O;O
by;O;O
the;O;O
anticholinesterases;B-group;B-DDI-DrugBank.d622.s2.e2
,;O;O
they;O;O
should;O;O
be;O;O
used;O;O
cautiously;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
convulsions;O;O
;;O;O
DDI-DrugBank.d622.s3;;
morphine;B-drug;B-DDI-DrugBank.d622.s3.e0
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d622.s3.e1
,;O;O
aminophylline;B-drug;B-DDI-DrugBank.d622.s3.e2
,;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d622.s3.e3
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d622.s3.e4
,;O;O
and;O;O
phenothiazine;B-group;B-DDI-DrugBank.d622.s3.e5
-;I-group;I-DDI-DrugBank.d622.s3.e5
type;I-group;I-DDI-DrugBank.d622.s3.e5
tranquilizers;I-group;I-DDI-DrugBank.d622.s3.e5
should;O;O
be;O;O
avoided;O;O
in;O;O
patients;O;O
with;O;O
organophosphate;O;O
poisoning;O;O
.;O;O
DDI-DrugBank.d737.s0;;
Carbidopa;B-drug;B-DDI-DrugBank.d737.s0.e0
/;O;O
Levodopa;B-drug;B-DDI-DrugBank.d737.s0.e1
:;O;O
Carbidopa;B-drug;B-DDI-DrugBank.d737.s0.e2
/;O;O
Levodopa;B-drug;B-DDI-DrugBank.d737.s0.e3
does;O;O
not;O;O
influence;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
pramipexole;B-drug;B-DDI-DrugBank.d737.s0.e4
in;O;O
healthy;O;O
volunteers;O;O
(;O;O
N=;O;O
10;O;O
);O;O
.;O;O
DDI-DrugBank.d737.s1;;
5;O;O
hours;O;O
.;O;O
DDI-DrugBank.d737.s2;;
Selegiline;B-drug;B-DDI-DrugBank.d737.s2.e0
:;O;O
In;O;O
healthy;O;O
volunteers;O;O
(;O;O
N=;O;O
11;O;O
);O;O
,;O;O
selegiline;B-drug;B-DDI-DrugBank.d737.s2.e1
did;O;O
not;O;O
influence;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
pramipexole;B-drug;B-DDI-DrugBank.d737.s2.e2
.;O;O
DDI-DrugBank.d737.s3;;
Amantadine;B-drug;B-DDI-DrugBank.d737.s3.e0
:;O;O
Population;O;O
pharmacokinetic;O;O
analysis;O;O
suggests;O;O
that;O;O
amantadine;B-drug;B-DDI-DrugBank.d737.s3.e1
is;O;O
unlikely;O;O
to;O;O
alter;O;O
the;O;O
oral;O;O
clearance;O;O
of;O;O
pramipexole;B-drug;B-DDI-DrugBank.d737.s3.e2
(;O;O
N=;O;O
54;O;O
);O;O
.;O;O
DDI-DrugBank.d737.s4;;
Cimetidine;B-drug;B-DDI-DrugBank.d737.s4.e0
:;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d737.s4.e1
,;O;O
a;O;O
known;O;O
inhibitor;O;O
of;O;O
renal;O;O
tubular;O;O
secretion;O;O
of;O;O
organic;O;O
bases;O;O
via;O;O
the;O;O
cationic;O;O
transport;O;O
system;O;O
,;O;O
caused;O;O
a;O;O
50;O;O
%;O;O
increase;O;O
in;O;O
pramipexole;B-drug;B-DDI-DrugBank.d737.s4.e2
AUC;O;O
and;O;O
a;O;O
40;O;O
%;O;O
increase;O;O
in;O;O
half;O;O
-;O;O
life;O;O
(;O;O
N=;O;O
12;O;O
);O;O
.;O;O
DDI-DrugBank.d737.s5;;
Probenecid;B-drug;B-DDI-DrugBank.d737.s5.e0
:;O;O
Probenecid;B-drug;B-DDI-DrugBank.d737.s5.e1
,;O;O
a;O;O
known;O;O
inhibitor;O;O
of;O;O
renal;O;O
tubular;O;O
secretion;O;O
of;O;O
organic;O;O
acids;O;O
via;O;O
the;O;O
aruonic;O;O
transporter;O;O
,;O;O
did;O;O
not;O;O
noticeably;O;O
influence;O;O
pramipexole;B-drug;B-DDI-DrugBank.d737.s5.e2
pharmacokinetics;O;O
(;O;O
N=;O;O
12;O;O
);O;O
.;O;O
DDI-DrugBank.d737.s6;;
Other;O;O
drugs;O;O
eliminated;O;O
via;O;O
renal;O;O
secretion;O;O
:;O;O
Population;O;O
pharmacokinetic;O;O
analysis;O;O
suggests;O;O
that;O;O
coadministration;O;O
of;O;O
drugs;O;O
that;O;O
are;O;O
secreted;O;O
by;O;O
the;O;O
cationic;O;O
transport;O;O
system;O;O
(;O;O
e.g.;O;O
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d737.s6.e0
,;O;O
ranitidine;B-drug;B-DDI-DrugBank.d737.s6.e1
,;O;O
diltiazem;B-drug;B-DDI-DrugBank.d737.s6.e2
,;O;O
triamterene;B-drug;B-DDI-DrugBank.d737.s6.e3
,;O;O
verapamil;B-drug;B-DDI-DrugBank.d737.s6.e4
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d737.s6.e5
,;O;O
and;O;O
quinine;B-drug;B-DDI-DrugBank.d737.s6.e6
);O;O
decreases;O;O
the;O;O
oral;O;O
clearance;O;O
of;O;O
pramipexole;B-drug;B-DDI-DrugBank.d737.s6.e7
by;O;O
about;O;O
20;O;O
%;O;O
,;O;O
while;O;O
those;O;O
secreted;O;O
by;O;O
the;O;O
anionic;O;O
transport;O;O
system;O;O
(;O;O
e.g.;O;O
,;O;O
cephalosporins;B-group;B-DDI-DrugBank.d737.s6.e8
,;O;O
penicillins;B-group;B-DDI-DrugBank.d737.s6.e9
,;O;O
indomethacin;B-drug;B-DDI-DrugBank.d737.s6.e10
,;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d737.s6.e11
,;O;O
and;O;O
chlorpropamide;B-drug;B-DDI-DrugBank.d737.s6.e12
);O;O
are;O;O
likely;O;O
to;O;O
have;O;O
little;O;O
effect;O;O
on;O;O
the;O;O
oral;O;O
clearance;O;O
of;O;O
pramipexole;B-drug;B-DDI-DrugBank.d737.s6.e13
.;O;O
DDI-DrugBank.d737.s7;;
CYP;O;O
interactions;O;O
:;O;O
Inhibitors;O;O
of;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
would;O;O
not;O;O
be;O;O
expected;O;O
to;O;O
affect;O;O
pramipexole;B-drug;B-DDI-DrugBank.d737.s7.e0
elimination;O;O
because;O;O
pramipexole;B-drug;B-DDI-DrugBank.d737.s7.e1
is;O;O
not;O;O
appreciably;O;O
metabolized;O;O
by;O;O
these;O;O
enzymes;O;O
in;O;O
vivo;O;O
or;O;O
in;O;O
vitro;O;O
.;O;O
DDI-DrugBank.d737.s8;;
Pramipexole;B-drug;B-DDI-DrugBank.d737.s8.e0
does;O;O
not;O;O
inhibit;O;O
CYP;O;O
enzymes;O;O
CYPIA2;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2CI9;O;O
,;O;O
CYP2EI;O;O
,;O;O
and;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d737.s9;;
Inhibition;O;O
of;O;O
CYP2D6;O;O
was;O;O
observed;O;O
with;O;O
an;O;O
apparent;O;O
Ki;O;O
of;O;O
30;O;O
uM;O;O
,;O;O
indicating;O;O
that;O;O
pramipexole;B-drug;B-DDI-DrugBank.d737.s9.e0
will;O;O
not;O;O
inhibit;O;O
CYP;O;O
enzymes;O;O
at;O;O
plasma;O;O
concentrations;O;O
observed;O;O
following;O;O
the;O;O
highest;O;O
recommended;O;O
clinical;O;O
dose;O;O
(;O;O
1.5;O;O
mg;O;O
tid;O;O
);O;O
.;O;O
DDI-DrugBank.d737.s10;;
Dopamine;B-group;B-DDI-DrugBank.d737.s10.e0
antagonists;I-group;I-DDI-DrugBank.d737.s10.e0
:;O;O
Since;O;O
pramipexole;B-drug;B-DDI-DrugBank.d737.s10.e1
is;O;O
a;O;O
dopamine;B-group;B-DDI-DrugBank.d737.s10.e2
agonist;I-group;I-DDI-DrugBank.d737.s10.e2
,;O;O
it;O;O
is;O;O
possible;O;O
that;O;O
dopamine;B-group;B-DDI-DrugBank.d737.s10.e3
antagonists;I-group;I-DDI-DrugBank.d737.s10.e3
,;O;O
such;O;O
as;O;O
the;O;O
neuroleptics;B-group;B-DDI-DrugBank.d737.s10.e4
(;O;O
phenothiazines;B-group;B-DDI-DrugBank.d737.s10.e5
,;O;O
butyrophenones;B-group;B-DDI-DrugBank.d737.s10.e6
,;O;O
thioxanthenes;B-group;B-DDI-DrugBank.d737.s10.e7
);O;O
or;O;O
metoclopramide;B-group;B-DDI-DrugBank.d737.s10.e8
,;O;O
may;O;O
diminish;O;O
the;O;O
effectiveness;O;O
of;O;O
MIRAPEX;B-brand;B-DDI-DrugBank.d737.s10.e9
.;O;O
DDI-DrugBank.d737.s11;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
There;O;O
are;O;O
no;O;O
known;O;O
interactions;O;O
between;O;O
MIRAPEX;B-brand;B-DDI-DrugBank.d737.s11.e0
and;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-DrugBank.d632.s0;;
Due;O;O
to;O;O
its;O;O
effects;O;O
on;O;O
gastric;O;O
emptying;O;O
,;O;O
SYMLIN;B-brand;B-DDI-DrugBank.d632.s0.e0
therapy;O;O
should;O;O
not;O;O
be;O;O
considered;O;O
for;O;O
patients;O;O
taking;O;O
drugs;O;O
that;O;O
alter;O;O
gastrointestinal;O;O
motility;O;O
(;O;O
e.g.;O;O
,;O;O
anticholinergic;B-group;B-DDI-DrugBank.d632.s0.e1
agents;I-group;I-DDI-DrugBank.d632.s0.e1
such;O;O
as;O;O
atropine;B-drug;B-DDI-DrugBank.d632.s0.e2
);O;O
and;O;O
agents;O;O
that;O;O
slow;O;O
the;O;O
intestinal;O;O
absorption;O;O
of;O;O
nutrients;O;O
(;O;O
e.g.;O;O
,;O;O
alpha;B-group;B-DDI-DrugBank.d632.s0.e3
glucosidase;I-group;I-DDI-DrugBank.d632.s0.e3
inhibitors;I-group;I-DDI-DrugBank.d632.s0.e3
);O;O
.;O;O
DDI-DrugBank.d632.s1;;
Patients;O;O
using;O;O
these;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
studied;O;O
in;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d632.s2;;
SYMLIN;B-brand;B-DDI-DrugBank.d632.s2.e0
has;O;O
the;O;O
potential;O;O
to;O;O
delay;O;O
the;O;O
absorption;O;O
of;O;O
concomitantly;O;O
administered;O;O
oral;O;O
medications;O;O
.;O;O
DDI-DrugBank.d632.s3;;
When;O;O
the;O;O
rapid;O;O
onset;O;O
of;O;O
a;O;O
concomitant;O;O
orally;O;O
administered;O;O
agent;O;O
is;O;O
a;O;O
critical;O;O
determinant;O;O
of;O;O
effectiveness;O;O
(;O;O
such;O;O
as;O;O
analgesics;B-group;B-DDI-DrugBank.d632.s3.e0
);O;O
,;O;O
the;O;O
agent;O;O
should;O;O
be;O;O
administered;O;O
at;O;O
least;O;O
1;O;O
hour;O;O
prior;O;O
to;O;O
or;O;O
2;O;O
hours;O;O
after;O;O
SYMLIN;B-brand;B-DDI-DrugBank.d632.s3.e1
injection;O;O
.;O;O
DDI-DrugBank.d632.s4;;
In;O;O
clinical;O;O
trials;O;O
,;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
sulfonylureas;B-group;B-DDI-DrugBank.d632.s4.e0
or;O;O
biguanides;B-group;B-DDI-DrugBank.d632.s4.e1
did;O;O
not;O;O
alter;O;O
the;O;O
adverse;O;O
event;O;O
profile;O;O
of;O;O
SYMLIN;B-brand;B-DDI-DrugBank.d632.s4.e2
.;O;O
DDI-DrugBank.d632.s5;;
No;O;O
formal;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
to;O;O
assess;O;O
the;O;O
effect;O;O
of;O;O
SYMLIN;B-brand;B-DDI-DrugBank.d632.s5.e0
on;O;O
the;O;O
kinetics;O;O
of;O;O
oral;O;O
antidiabetic;B-group;B-DDI-DrugBank.d632.s5.e1
agents;I-group;I-DDI-DrugBank.d632.s5.e1
.;O;O
DDI-DrugBank.d632.s6;;
Mixing;O;O
SYMLIN;B-brand;B-DDI-DrugBank.d632.s6.e0
and;O;O
Insulin;B-drug;B-DDI-DrugBank.d632.s6.e1
The;O;O
pharmacokinetic;O;O
parameters;O;O
of;O;O
SYMLIN;B-brand;B-DDI-DrugBank.d632.s6.e2
were;O;O
altered;O;O
when;O;O
mixed;O;O
with;O;O
regular;O;O
,;O;O
NPH;O;O
,;O;O
and;O;O
70;O;O
/;O;O
30;O;O
premixed;O;O
formulations;O;O
of;O;O
recombinant;O;O
human;B-drug;B-DDI-DrugBank.d632.s6.e3
insulin;I-drug;I-DDI-DrugBank.d632.s6.e3
immediately;O;O
prior;O;O
to;O;O
injection;O;O
.;O;O
DDI-DrugBank.d632.s7;;
Thus;O;O
,;O;O
SYMLIN;B-brand;B-DDI-DrugBank.d632.s7.e0
and;O;O
insulin;B-drug;B-DDI-DrugBank.d632.s7.e1
should;O;O
not;O;O
be;O;O
mixed;O;O
and;O;O
must;O;O
be;O;O
administered;O;O
separately;O;O
.;O;O
DDI-DrugBank.d653.s0;;
The;O;O
pharmacokinetic;O;O
interactions;O;O
listed;O;O
below;O;O
are;O;O
potentially;O;O
clinically;O;O
important;O;O
.;O;O
DDI-DrugBank.d653.s1;;
Drugs;O;O
that;O;O
induce;O;O
hepatic;O;O
enzymes;O;O
such;O;O
as;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d653.s1.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d653.s1.e1
and;O;O
rifampin;B-drug;B-DDI-DrugBank.d653.s1.e2
may;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d653.s1.e3
and;O;O
may;O;O
require;O;O
increases;O;O
in;O;O
corticosteroid;B-group;B-DDI-DrugBank.d653.s1.e4
dose;O;O
to;O;O
achieve;O;O
the;O;O
desired;O;O
response;O;O
.;O;O
DDI-DrugBank.d653.s2;;
Drugs;O;O
such;O;O
as;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d653.s2.e0
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d653.s2.e1
may;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d653.s2.e2
and;O;O
thus;O;O
decrease;O;O
their;O;O
clearance;O;O
.;O;O
DDI-DrugBank.d653.s3;;
Therefore;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
corticosteroid;B-group;B-DDI-DrugBank.d653.s3.e0
should;O;O
be;O;O
titrated;O;O
to;O;O
avoid;O;O
steroid;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d653.s4;;
Corticosteroids;B-group;B-DDI-DrugBank.d653.s4.e0
may;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
chronic;O;O
high;O;O
dose;O;O
aspirin;B-brand;B-DDI-DrugBank.d653.s4.e1
.;O;O
DDI-DrugBank.d653.s5;;
This;O;O
could;O;O
lead;O;O
to;O;O
decreased;O;O
salicylate;B-group;B-DDI-DrugBank.d653.s5.e0
serum;O;O
levels;O;O
or;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
salicylate;B-group;B-DDI-DrugBank.d653.s5.e1
toxicity;O;O
when;O;O
corticosteroid;B-group;B-DDI-DrugBank.d653.s5.e2
is;O;O
withdrawn;O;O
.;O;O
DDI-DrugBank.d653.s6;;
Aspirin;B-brand;B-DDI-DrugBank.d653.s6.e0
should;O;O
be;O;O
used;O;O
cautiously;O;O
in;O;O
conjunction;O;O
with;O;O
corticosteroids;B-group;B-DDI-DrugBank.d653.s6.e1
in;O;O
patients;O;O
suffering;O;O
from;O;O
hypoprothrombinemia;O;O
.;O;O
DDI-DrugBank.d653.s7;;
The;O;O
effect;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d653.s7.e0
on;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d653.s7.e1
is;O;O
variable;O;O
.;O;O
DDI-DrugBank.d653.s8;;
There;O;O
are;O;O
reports;O;O
of;O;O
enhanced;O;O
as;O;O
well;O;O
as;O;O
diminished;O;O
effects;O;O
of;O;O
anticoagulants;B-group;B-DDI-DrugBank.d653.s8.e0
when;O;O
given;O;O
concurrently;O;O
with;O;O
corticosteroids;B-group;B-DDI-DrugBank.d653.s8.e1
.;O;O
DDI-DrugBank.d653.s9;;
Therefore;O;O
,;O;O
coagulation;O;O
indices;O;O
should;O;O
be;O;O
monitored;O;O
to;O;O
maintain;O;O
the;O;O
desired;O;O
anticoagulant;O;O
effect;O;O
.;O;O
DDI-DrugBank.d780.s0;;
Anticholinesterases;B-group;B-DDI-DrugBank.d780.s0.e0
:;O;O
Concurrent;O;O
use;O;O
of;O;O
procaine;B-drug;B-DDI-DrugBank.d780.s0.e1
hydrochloride;I-drug;I-DDI-DrugBank.d780.s0.e1
and;O;O
anticholinesterase;B-group;B-DDI-DrugBank.d780.s0.e2
agents;I-group;I-DDI-DrugBank.d780.s0.e2
may;O;O
result;O;O
in;O;O
increased;O;O
systemic;O;O
toxicity;O;O
since;O;O
anticholinesterases;B-group;B-DDI-DrugBank.d780.s0.e3
inhibit;O;O
the;O;O
breakdown;O;O
of;O;O
procaine;B-drug;B-DDI-DrugBank.d780.s0.e4
hydrochloride;I-drug;I-DDI-DrugBank.d780.s0.e4
.;O;O
DDI-DrugBank.d780.s1;;
Antimyasthenics;O;O
Concurrent;O;O
use;O;O
of;O;O
procaine;B-drug;B-DDI-DrugBank.d780.s1.e0
hydrochloride;I-drug;I-DDI-DrugBank.d780.s1.e0
and;O;O
antimyasthenics;O;O
may;O;O
result;O;O
in;O;O
loss;O;O
of;O;O
control;O;O
of;O;O
symptoms;O;O
of;O;O
myasthenia;O;O
gravis;O;O
due;O;O
to;O;O
antagonism;O;O
of;O;O
the;O;O
effects;O;O
of;O;O
antimyasthenics;O;O
on;O;O
skeletal;O;O
muscle;O;O
.;O;O
DDI-DrugBank.d780.s2;;
Temporary;O;O
dosage;O;O
adjustment;O;O
of;O;O
antimyasthenics;O;O
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d780.s3;;
Also;O;O
antimyasthenics;O;O
may;O;O
have;O;O
anticholinesterase;O;O
activity;O;O
.;O;O
DDI-DrugBank.d780.s4;;
CNS;B-group;B-DDI-DrugBank.d780.s4.e0
depressant;I-group;I-DDI-DrugBank.d780.s4.e0
medications;O;O
:;O;O
Concurrent;O;O
use;O;O
of;O;O
procaine;B-drug;B-DDI-DrugBank.d780.s4.e1
hydrochloride;I-drug;I-DDI-DrugBank.d780.s4.e1
and;O;O
CNS;B-group;B-DDI-DrugBank.d780.s4.e2
depressant;I-group;I-DDI-DrugBank.d780.s4.e2
medications;I-group;I-DDI-DrugBank.d780.s4.e2
may;O;O
result;O;O
in;O;O
additive;O;O
depressant;O;O
effects;O;O
.;O;O
DDI-DrugBank.d780.s5;;
Hyaluronidase;B-drug;B-DDI-DrugBank.d780.s5.e0
:;O;O
Hyaluronidase;B-drug;B-DDI-DrugBank.d780.s5.e1
may;O;O
increase;O;O
the;O;O
diffusion;O;O
rate;O;O
of;O;O
procaine;B-drug;B-DDI-DrugBank.d780.s5.e2
hydrochloride;I-drug;I-DDI-DrugBank.d780.s5.e2
,;O;O
resulting;O;O
in;O;O
a;O;O
decreased;O;O
time;O;O
of;O;O
onset;O;O
,;O;O
but;O;O
an;O;O
increase;O;O
in;O;O
systemic;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d780.s6;;
Neuromuscular;B-group;B-DDI-DrugBank.d780.s6.e0
blocking;I-group;I-DDI-DrugBank.d780.s6.e0
agents;I-group;I-DDI-DrugBank.d780.s6.e0
(;O;O
such;O;O
as;O;O
suxamethonium;B-drug;B-DDI-DrugBank.d780.s6.e1
chloride;I-drug;I-DDI-DrugBank.d780.s6.e1
);O;O
:;O;O
Concurrent;O;O
use;O;O
of;O;O
procaine;B-drug;B-DDI-DrugBank.d780.s6.e2
hydrochloride;I-drug;I-DDI-DrugBank.d780.s6.e2
and;O;O
neuromuscular;B-group;B-DDI-DrugBank.d780.s6.e3
blocking;I-group;I-DDI-DrugBank.d780.s6.e3
agents;I-group;I-DDI-DrugBank.d780.s6.e3
may;O;O
result;O;O
in;O;O
prolongation;O;O
or;O;O
enhancement;O;O
of;O;O
the;O;O
neuromuscular;O;O
blockade;O;O
.;O;O
DDI-DrugBank.d780.s7;;
Sulfonamides;B-group;B-DDI-DrugBank.d780.s7.e0
:;O;O
Concurrent;O;O
use;O;O
of;O;O
procaine;B-drug;B-DDI-DrugBank.d780.s7.e1
hydrochloride;I-drug;I-DDI-DrugBank.d780.s7.e1
and;O;O
sulfonamides;B-group;B-DDI-DrugBank.d780.s7.e2
may;O;O
result;O;O
in;O;O
a;O;O
reduction;O;O
of;O;O
the;O;O
antibacterial;O;O
action;O;O
of;O;O
the;O;O
sulfonamide;B-group;B-DDI-DrugBank.d780.s7.e3
.;O;O
DDI-DrugBank.d780.s8;;
Acetazolamide;B-drug;B-DDI-DrugBank.d780.s8.e0
:;O;O
Concurrent;O;O
use;O;O
of;O;O
acetazolamide;B-drug;B-DDI-DrugBank.d780.s8.e1
and;O;O
procaine;B-drug;B-DDI-DrugBank.d780.s8.e2
hydrochloride;I-drug;I-DDI-DrugBank.d780.s8.e2
may;O;O
extend;O;O
the;O;O
plasma;O;O
half;O;O
-;O;O
life;O;O
of;O;O
procaine;B-drug;B-DDI-DrugBank.d780.s8.e3
.;O;O
DDI-DrugBank.d676.s0;;
To;O;O
minimize;O;O
CNS;O;O
depression;O;O
and;O;O
possible;O;O
potentiation;O;O
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d676.s0.e0
,;O;O
antihistamines;B-group;B-DDI-DrugBank.d676.s0.e1
,;O;O
narcotics;B-group;B-DDI-DrugBank.d676.s0.e2
,;O;O
hypotensive;B-group;B-DDI-DrugBank.d676.s0.e3
agents;I-group;I-DDI-DrugBank.d676.s0.e3
or;O;O
phenothiazines;B-group;B-DDI-DrugBank.d676.s0.e4
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d676.s1;;
Ethyl;B-drug;B-DDI-DrugBank.d676.s1.e0
alcohol;I-drug;I-DDI-DrugBank.d676.s1.e0
should;O;O
not;O;O
be;O;O
used;O;O
since;O;O
there;O;O
may;O;O
be;O;O
an;O;O
Antabuse;O;O
(;O;O
disulfiram);O;O
-;O;O
like;O;O
reaction;O;O
.;O;O
DDI-DrugBank.d676.s2;;
Because;O;O
Matulane;B-brand;B-DDI-DrugBank.d676.s2.e0
exhibits;O;O
some;O;O
monoamine;O;O
oxidase;O;O
inhibitory;O;O
activity;O;O
,;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d676.s2.e1
drugs;I-group;I-DDI-DrugBank.d676.s2.e1
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d676.s2.e2
antidepressant;I-group;I-DDI-DrugBank.d676.s2.e2
drugs;O;O
(;O;O
e.g.;O;O
,;O;O
amitriptyline;B-drug;B-DDI-DrugBank.d676.s2.e3
HCl;I-drug;I-DDI-DrugBank.d676.s2.e3
,;O;O
imipramine;B-drug;B-DDI-DrugBank.d676.s2.e4
HCl;I-drug;I-DDI-DrugBank.d676.s2.e4
);O;O
and;O;O
other;O;O
drugs;O;O
and;O;O
foods;O;O
with;O;O
known;O;O
high;O;O
tyramine;B-drug_n;B-DDI-DrugBank.d676.s2.e5
content;O;O
,;O;O
such;O;O
as;O;O
wine;O;O
,;O;O
yogurt;O;O
,;O;O
ripe;O;O
cheese;O;O
and;O;O
bananas;O;O
,;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d676.s3;;
A;O;O
further;O;O
phenomenon;O;O
of;O;O
toxicity;O;O
common;O;O
to;O;O
many;O;O
hydrazine;B-group;B-DDI-DrugBank.d676.s3.e0
derivatives;I-group;I-DDI-DrugBank.d676.s3.e0
is;O;O
hemolysis;O;O
and;O;O
the;O;O
appearance;O;O
of;O;O
Heinz;O;O
-;O;O
Ehrlich;O;O
inclusion;O;O
bodies;O;O
in;O;O
erythrocytes;O;O
.;O;O
DDI-DrugBank.d676.s4;;
No;O;O
cross;O;O
-;O;O
resistance;O;O
with;O;O
other;O;O
chemotherapeutic;B-group;B-DDI-DrugBank.d676.s4.e0
agents;I-group;I-DDI-DrugBank.d676.s4.e0
,;O;O
radiotherapy;O;O
or;O;O
steroids;B-group;B-DDI-DrugBank.d676.s4.e1
has;O;O
been;O;O
demonstrated;O;O
.;O;O
DDI-DrugBank.d734.s0;;
Thiazide;B-group;B-DDI-DrugBank.d734.s0.e0
diuretics;I-group;I-DDI-DrugBank.d734.s0.e0
may;O;O
accentuate;O;O
the;O;O
orthostatic;O;O
hypotension;O;O
that;O;O
may;O;O
occur;O;O
with;O;O
phenothiazines;B-group;B-DDI-DrugBank.d734.s0.e1
.;O;O
DDI-DrugBank.d734.s1;;
Antihypertensive;O;O
effects;O;O
of;O;O
guanethidine;B-drug;B-DDI-DrugBank.d734.s1.e0
and;O;O
related;O;O
compounds;O;O
may;O;O
be;O;O
counteracted;O;O
when;O;O
phenothiazines;B-group;B-DDI-DrugBank.d734.s1.e1
are;O;O
used;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d734.s2;;
Concomitant;O;O
administration;O;O
of;O;O
propranolol;B-drug;B-DDI-DrugBank.d734.s2.e0
with;O;O
phenothiazines;B-group;B-DDI-DrugBank.d734.s2.e1
results;O;O
in;O;O
increased;O;O
plasma;O;O
levels;O;O
of;O;O
both;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d628.s0;;
The;O;O
induction;O;O
dose;O;O
requirements;O;O
of;O;O
DIPRIVAN;B-brand;B-DDI-DrugBank.d628.s0.e0
Injectable;O;O
Emulsion;O;O
may;O;O
be;O;O
reduced;O;O
in;O;O
patients;O;O
with;O;O
intramuscular;O;O
or;O;O
intravenous;O;O
premedication;O;O
,;O;O
particularly;O;O
with;O;O
narcotics;B-group;B-DDI-DrugBank.d628.s0.e1
(;O;O
eg;O;O
,;O;O
morphine;B-drug;B-DDI-DrugBank.d628.s0.e2
,;O;O
meperidine;B-drug;B-DDI-DrugBank.d628.s0.e3
,;O;O
and;O;O
fentanyl;B-drug;B-DDI-DrugBank.d628.s0.e4
,;O;O
etc;O;O
.;O;O
);O;O
DDI-DrugBank.d628.s1;;
and;O;O
combinations;O;O
of;O;O
opioids;B-group;B-DDI-DrugBank.d628.s1.e0
and;O;O
sedatives;B-group;B-DDI-DrugBank.d628.s1.e1
(;O;O
eg;O;O
,;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d628.s1.e2
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d628.s1.e3
,;O;O
chloral;B-drug;B-DDI-DrugBank.d628.s1.e4
hydrate;I-drug;I-DDI-DrugBank.d628.s1.e4
,;O;O
droperidol;B-drug;B-DDI-DrugBank.d628.s1.e5
,;O;O
etc;O;O
.;O;O
);O;O
.;O;O
DDI-DrugBank.d628.s2;;
These;O;O
agents;O;O
may;O;O
increase;O;O
the;O;O
anesthetic;O;O
or;O;O
sedative;O;O
effects;O;O
of;O;O
DIPRIVAN;B-brand;B-DDI-DrugBank.d628.s2.e0
Injectable;O;O
Emulsion;O;O
and;O;O
may;O;O
also;O;O
result;O;O
in;O;O
more;O;O
pronounced;O;O
decreases;O;O
in;O;O
systolic;O;O
,;O;O
diastolic;O;O
,;O;O
and;O;O
mean;O;O
arterial;O;O
pressures;O;O
and;O;O
cardiac;O;O
output;O;O
.;O;O
DDI-DrugBank.d628.s3;;
During;O;O
maintenance;O;O
of;O;O
anesthesia;O;O
or;O;O
sedation;O;O
,;O;O
the;O;O
rate;O;O
of;O;O
DIPRIVAN;B-brand;B-DDI-DrugBank.d628.s3.e0
Injectable;O;O
Emulsion;O;O
administration;O;O
should;O;O
be;O;O
adjusted;O;O
according;O;O
to;O;O
the;O;O
desired;O;O
level;O;O
of;O;O
anesthesia;O;O
or;O;O
sedation;O;O
and;O;O
may;O;O
be;O;O
reduced;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
supplemental;O;O
analgesic;B-group;B-DDI-DrugBank.d628.s3.e1
agents;I-group;I-DDI-DrugBank.d628.s3.e1
(;O;O
eg;O;O
,;O;O
nitrous;B-drug;B-DDI-DrugBank.d628.s3.e2
oxide;I-drug;I-DDI-DrugBank.d628.s3.e2
or;O;O
opioids;B-group;B-DDI-DrugBank.d628.s3.e3
);O;O
.;O;O
DDI-DrugBank.d628.s4;;
The;O;O
concurrent;O;O
administration;O;O
of;O;O
potent;O;O
inhalational;O;O
agents;O;O
(;O;O
eg;O;O
,;O;O
isoflurane;B-drug;B-DDI-DrugBank.d628.s4.e0
,;O;O
enflurane;B-drug;B-DDI-DrugBank.d628.s4.e1
,;O;O
and;O;O
halothane;B-drug;B-DDI-DrugBank.d628.s4.e2
);O;O
during;O;O
maintenance;O;O
with;O;O
DIPRIVAN;B-brand;B-DDI-DrugBank.d628.s4.e3
Injectable;O;O
Emulsion;O;O
has;O;O
not;O;O
been;O;O
extensively;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d628.s5;;
These;O;O
inhalational;O;O
agents;O;O
can;O;O
also;O;O
be;O;O
expected;O;O
to;O;O
increase;O;O
the;O;O
anesthetic;O;O
or;O;O
sedative;O;O
and;O;O
cardiorespiratory;O;O
effects;O;O
of;O;O
DIPRIVAN;B-brand;B-DDI-DrugBank.d628.s5.e0
Injectable;O;O
Emulsion;O;O
.;O;O
DDI-DrugBank.d628.s6;;
DIPRIVAN;B-brand;B-DDI-DrugBank.d628.s6.e0
Injectable;O;O
Emulsion;O;O
does;O;O
not;O;O
cause;O;O
a;O;O
clinically;O;O
significant;O;O
change;O;O
in;O;O
onset;O;O
,;O;O
intensity;O;O
,;O;O
or;O;O
duration;O;O
of;O;O
action;O;O
of;O;O
the;O;O
commonly;O;O
used;O;O
neuromuscular;B-group;B-DDI-DrugBank.d628.s6.e1
blocking;I-group;I-DDI-DrugBank.d628.s6.e1
agents;I-group;I-DDI-DrugBank.d628.s6.e1
(;O;O
eg;O;O
,;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d628.s6.e2
and;O;O
nondepolarizing;B-group;B-DDI-DrugBank.d628.s6.e3
muscle;I-group;I-DDI-DrugBank.d628.s6.e3
relaxants;I-group;I-DDI-DrugBank.d628.s6.e3
);O;O
.;O;O
DDI-DrugBank.d628.s7;;
No;O;O
significant;O;O
adverse;O;O
interactions;O;O
with;O;O
commonly;O;O
used;O;O
premedications;O;O
or;O;O
drugs;O;O
used;O;O
during;O;O
anesthesia;O;O
or;O;O
sedation;O;O
(;O;O
including;O;O
a;O;O
range;O;O
of;O;O
muscle;B-group;B-DDI-DrugBank.d628.s7.e0
relaxants;I-group;I-DDI-DrugBank.d628.s7.e0
,;O;O
inhalational;O;O
agents;O;O
,;O;O
analgesic;B-group;B-DDI-DrugBank.d628.s7.e1
agents;I-group;I-DDI-DrugBank.d628.s7.e1
,;O;O
and;O;O
local;O;O
anesthetic;B-group;B-DDI-DrugBank.d628.s7.e2
agents;I-group;I-DDI-DrugBank.d628.s7.e2
);O;O
have;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d690.s0;;
The;O;O
CNS;O;O
-;O;O
depressant;O;O
effect;O;O
of;O;O
propoxyphene;B-drug;B-DDI-DrugBank.d690.s0.e0
is;O;O
additive;O;O
with;O;O
that;O;O
of;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d690.s0.e1
depressants;I-group;I-DDI-DrugBank.d690.s0.e1
,;O;O
including;O;O
alcohol;B-drug;B-DDI-DrugBank.d690.s0.e2
.;O;O
DDI-DrugBank.d690.s1;;
As;O;O
is;O;O
the;O;O
case;O;O
with;O;O
many;O;O
medicinal;O;O
agents;O;O
,;O;O
propoxyphene;B-drug;B-DDI-DrugBank.d690.s1.e0
may;O;O
slow;O;O
the;O;O
metabolism;O;O
of;O;O
a;O;O
concomitantly;O;O
administered;O;O
drug;O;O
.;O;O
DDI-DrugBank.d690.s2;;
Should;O;O
this;O;O
occur;O;O
,;O;O
the;O;O
higher;O;O
serum;O;O
concentrations;O;O
of;O;O
that;O;O
drug;O;O
may;O;O
result;O;O
in;O;O
increased;O;O
pharmacologic;O;O
or;O;O
adverse;O;O
effects;O;O
of;O;O
that;O;O
drug;O;O
.;O;O
DDI-DrugBank.d690.s3;;
Such;O;O
occurrences;O;O
have;O;O
been;O;O
reported;O;O
when;O;O
propoxyphene;B-drug;B-DDI-DrugBank.d690.s3.e0
was;O;O
administered;O;O
to;O;O
patients;O;O
on;O;O
antidepressants;B-group;B-DDI-DrugBank.d690.s3.e1
,;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d690.s3.e2
,;O;O
or;O;O
warfarin;B-drug;B-DDI-DrugBank.d690.s3.e3
-;O;O
like;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d690.s4;;
Sever;O;O
neurologic;O;O
signs;O;O
,;O;O
including;O;O
coma;O;O
,;O;O
have;O;O
occurred;O;O
with;O;O
concurrent;O;O
use;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d690.s4.e0
.;O;O
DDI-DrugBank.d606.s0;;
MAO;B-group;B-DDI-DrugBank.d606.s0.e0
inhibitors;I-group;I-DDI-DrugBank.d606.s0.e0
and;O;O
beta;B-group;B-DDI-DrugBank.d606.s0.e1
adrenergic;I-group;I-DDI-DrugBank.d606.s0.e1
blockers;I-group;I-DDI-DrugBank.d606.s0.e1
increase;O;O
the;O;O
effects;O;O
of;O;O
pseudoephedrine;B-drug;B-DDI-DrugBank.d606.s0.e2
.;O;O
DDI-DrugBank.d606.s1;;
Sympathomimetics;B-group;B-DDI-DrugBank.d606.s1.e0
may;O;O
reduce;O;O
the;O;O
antihypertensive;O;O
effects;O;O
of;O;O
methyldopa;B-drug;B-DDI-DrugBank.d606.s1.e1
,;O;O
mecamylamine;B-drug;B-DDI-DrugBank.d606.s1.e2
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d606.s1.e3
and;O;O
veratrum;B-group;B-DDI-DrugBank.d606.s1.e4
alkaloids;I-group;I-DDI-DrugBank.d606.s1.e4
.;O;O
DDI-DrugBank.d631.s0;;
Pyrimethamine;B-drug;B-DDI-DrugBank.d631.s0.e0
may;O;O
be;O;O
used;O;O
with;O;O
sulfonamides;B-group;B-DDI-DrugBank.d631.s0.e1
,;O;O
quinine;B-drug;B-DDI-DrugBank.d631.s0.e2
and;O;O
other;O;O
antimalarials;B-group;B-DDI-DrugBank.d631.s0.e3
,;O;O
and;O;O
with;O;O
other;O;O
antibiotics;B-group;B-DDI-DrugBank.d631.s0.e4
.;O;O
DDI-DrugBank.d631.s1;;
If;O;O
signs;O;O
of;O;O
folate;O;O
deficiency;O;O
develop;O;O
,;O;O
pyrimethamine;B-drug;B-DDI-DrugBank.d631.s1.e0
should;O;O
be;O;O
discontinued;O;O
.;O;O
DDI-DrugBank.d631.s2;;
Folinic;B-drug;B-DDI-DrugBank.d631.s2.e0
acid;I-drug;I-DDI-DrugBank.d631.s2.e0
(;O;O
leucovorin;B-drug;B-DDI-DrugBank.d631.s2.e1
);O;O
should;O;O
be;O;O
administered;O;O
until;O;O
normal;O;O
hematopoiesis;O;O
is;O;O
restored;O;O
.;O;O
DDI-DrugBank.d631.s3;;
Mild;O;O
hepatotoxicity;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
some;O;O
patients;O;O
when;O;O
lorazepam;B-drug;B-DDI-DrugBank.d631.s3.e0
and;O;O
pyrimethamine;B-drug;B-DDI-DrugBank.d631.s3.e1
were;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d648.s0;;
Cholestyramine;B-drug;B-DDI-DrugBank.d648.s0.e0
:;O;O
Cholestyramine;B-drug;B-DDI-DrugBank.d648.s0.e1
causes;O;O
a;O;O
60;O;O
%;O;O
reduction;O;O
in;O;O
the;O;O
absorption;O;O
and;O;O
enterohepatic;O;O
cycling;O;O
of;O;O
raloxifene;B-drug;B-DDI-DrugBank.d648.s0.e2
and;O;O
should;O;O
not;O;O
be;O;O
coadministered;O;O
with;O;O
EVISTA;B-brand;B-DDI-DrugBank.d648.s0.e3
.;O;O
DDI-DrugBank.d648.s1;;
Warfarin;B-drug;B-DDI-DrugBank.d648.s1.e0
:;O;O
The;O;O
coadministration;O;O
of;O;O
EVISTA;B-brand;B-DDI-DrugBank.d648.s1.e1
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d648.s1.e2
has;O;O
not;O;O
been;O;O
assessed;O;O
under;O;O
chronic;O;O
conditions;O;O
.;O;O
DDI-DrugBank.d648.s2;;
However;O;O
,;O;O
10;O;O
%;O;O
decreases;O;O
in;O;O
prothrombin;O;O
time;O;O
have;O;O
been;O;O
observed;O;O
in;O;O
single;O;O
-;O;O
dose;O;O
studies;O;O
.;O;O
DDI-DrugBank.d648.s3;;
If;O;O
EVISTA;B-brand;B-DDI-DrugBank.d648.s3.e0
is;O;O
given;O;O
concurrently;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d648.s3.e1
,;O;O
prothrombin;O;O
time;O;O
should;O;O
be;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d648.s4;;
Other;O;O
Highly;O;O
Protein;O;O
-;O;O
Bound;O;O
Drugs;O;O
:;O;O
Raloxifene;B-drug;B-DDI-DrugBank.d648.s4.e0
is;O;O
more;O;O
than;O;O
95;O;O
%;O;O
bound;O;O
to;O;O
plasma;O;O
proteins;O;O
.;O;O
DDI-DrugBank.d648.s5;;
In;O;O
vitro;O;O
,;O;O
raloxifene;B-drug;B-DDI-DrugBank.d648.s5.e0
did;O;O
not;O;O
affect;O;O
the;O;O
binding;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d648.s5.e1
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d648.s5.e2
,;O;O
or;O;O
tamoxifen;B-drug;B-DDI-DrugBank.d648.s5.e3
.;O;O
DDI-DrugBank.d648.s6;;
Caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
EVISTA;B-brand;B-DDI-DrugBank.d648.s6.e0
is;O;O
coadministered;O;O
with;O;O
other;O;O
highly;O;O
protein;O;O
-;O;O
bound;O;O
drugs;O;O
,;O;O
such;O;O
as;O;O
clofibrate;B-drug;B-DDI-DrugBank.d648.s6.e1
,;O;O
indomethacin;B-drug;B-DDI-DrugBank.d648.s6.e2
,;O;O
naproxen;B-drug;B-DDI-DrugBank.d648.s6.e3
,;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d648.s6.e4
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d648.s6.e5
,;O;O
and;O;O
diazoxide;B-drug;B-DDI-DrugBank.d648.s6.e6
.;O;O
DDI-DrugBank.d648.s7;;
See;O;O
also;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
,;O;O
Drug;O;O
-;O;O
Drug;O;O
Interactions;O;O
DDI-DrugBank.d590.s0;;
Coadministration;O;O
of;O;O
TRITEC;B-brand;B-DDI-DrugBank.d590.s0.e0
with;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d590.s0.e1
resulted;O;O
in;O;O
increased;O;O
plasma;O;O
ranitidine;B-drug;B-DDI-DrugBank.d590.s0.e2
concentrations;O;O
(;O;O
57;O;O
%;O;O
);O;O
,;O;O
increased;O;O
plasma;O;O
bismuth;O;O
trough;O;O
concentrations;O;O
(;O;O
48;O;O
%;O;O
);O;O
,;O;O
and;O;O
increased;O;O
14;B-drug_n;B-DDI-DrugBank.d590.s0.e3
-;I-drug_n;I-DDI-DrugBank.d590.s0.e3
hydroxy;I-drug_n;I-DDI-DrugBank.d590.s0.e3
-;I-drug_n;I-DDI-DrugBank.d590.s0.e3
clarithromycin;I-drug_n;I-DDI-DrugBank.d590.s0.e3
plasma;O;O
concentrations;O;O
(;O;O
31;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d590.s1;;
Coadministration;O;O
with;O;O
aspirin;B-brand;B-DDI-DrugBank.d590.s1.e0
results;O;O
in;O;O
a;O;O
slight;O;O
decrease;O;O
in;O;O
the;O;O
rate;O;O
of;O;O
salicylate;B-group;B-DDI-DrugBank.d590.s1.e1
absorption;O;O
that;O;O
is;O;O
clinically;O;O
unimportant;O;O
.;O;O
DDI-DrugBank.d590.s2;;
Coadministration;O;O
with;O;O
a;O;O
high;O;O
dose;O;O
of;O;O
antacid;B-group;B-DDI-DrugBank.d590.s2.e0
(;O;O
170;O;O
mEq;O;O
);O;O
results;O;O
in;O;O
a;O;O
28;O;O
%;O;O
decrease;O;O
in;O;O
plasma;O;O
concentrations;O;O
of;O;O
ranitidine;B-drug;B-DDI-DrugBank.d590.s2.e1
and;O;O
may;O;O
decrease;O;O
plasma;O;O
concentrations;O;O
of;O;O
bismuth;O;O
from;O;O
TRITEC;B-brand;B-DDI-DrugBank.d590.s2.e2
.;O;O
DDI-DrugBank.d590.s3;;
These;O;O
effects;O;O
are;O;O
clinically;O;O
insignificant;O;O
.;O;O
DDI-DrugBank.d590.s4;;
For;O;O
information;O;O
on;O;O
drug;O;O
interactions;O;O
associated;O;O
with;O;O
ranitidine;B-drug;B-DDI-DrugBank.d590.s4.e0
,;O;O
refer;O;O
to;O;O
the;O;O
ZANTAC;B-brand;B-DDI-DrugBank.d590.s4.e1
package;O;O
insert;O;O
.;O;O
DDI-DrugBank.d654.s0;;
Co;O;O
-;O;O
administration;O;O
of;O;O
oral;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d654.s0.e0
200;O;O
mg;O;O
twice;O;O
daily;O;O
increased;O;O
retapamulin;B-drug;B-DDI-DrugBank.d654.s0.e1
geometric;O;O
mean;O;O
AUC(0;O;O
-;O;O
24;O;O
);O;O
and;O;O
Cmax;O;O
by;O;O
81;O;O
%;O;O
after;O;O
topical;O;O
application;O;O
of;O;O
retapamulin;B-drug;B-DDI-DrugBank.d654.s0.e2
ointment;O;O
,;O;O
1;O;O
%;O;O
on;O;O
the;O;O
abraded;O;O
skin;O;O
of;O;O
healthy;O;O
adult;O;O
males;O;O
.;O;O
DDI-DrugBank.d654.s1;;
Due;O;O
to;O;O
low;O;O
systemic;O;O
exposure;O;O
to;O;O
retapamulin;B-drug;B-DDI-DrugBank.d654.s1.e0
following;O;O
topical;O;O
application;O;O
in;O;O
patients;O;O
,;O;O
dosage;O;O
adjustments;O;O
for;O;O
retapamulin;B-drug;B-DDI-DrugBank.d654.s1.e1
are;O;O
unnecessary;O;O
when;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
CYP3A4;O;O
inhibitors;O;O
,;O;O
such;O;O
as;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d654.s1.e2
.;O;O
DDI-DrugBank.d654.s2;;
Based;O;O
on;O;O
in;O;O
vitro;O;O
P450;O;O
inhibition;O;O
studies;O;O
and;O;O
the;O;O
low;O;O
systemic;O;O
exposure;O;O
observed;O;O
following;O;O
topical;O;O
application;O;O
of;O;O
ALTABAX;B-brand;B-DDI-DrugBank.d654.s2.e0
,;O;O
retapamulin;B-drug;B-DDI-DrugBank.d654.s2.e1
is;O;O
unlikely;O;O
to;O;O
affect;O;O
the;O;O
metabolism;O;O
of;O;O
other;O;O
P450;O;O
substrates;O;O
.;O;O
DDI-DrugBank.d654.s3;;
The;O;O
effect;O;O
of;O;O
concurrent;O;O
application;O;O
of;O;O
ALTABAX;B-brand;B-DDI-DrugBank.d654.s3.e0
and;O;O
other;O;O
topical;O;O
products;O;O
to;O;O
the;O;O
same;O;O
area;O;O
of;O;O
skin;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d618.s0;;
The;O;O
interaction;O;O
of;O;O
Retavase;B-brand;B-DDI-DrugBank.d618.s0.e0
with;O;O
other;O;O
cardioactive;O;O
drugs;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d618.s1;;
In;O;O
addition;O;O
to;O;O
bleeding;O;O
associated;O;O
with;O;O
heparin;B-drug;B-DDI-DrugBank.d618.s1.e0
and;O;O
vitamin;B-group;B-DDI-DrugBank.d618.s1.e1
K;I-group;I-DDI-DrugBank.d618.s1.e1
antagonists;I-group;I-DDI-DrugBank.d618.s1.e1
,;O;O
drugs;O;O
that;O;O
alter;O;O
platelet;O;O
function;O;O
(;O;O
such;O;O
as;O;O
aspirin;B-brand;B-DDI-DrugBank.d618.s1.e2
,;O;O
dipyridamole;B-drug;B-DDI-DrugBank.d618.s1.e3
,;O;O
and;O;O
abciximab;B-drug;B-DDI-DrugBank.d618.s1.e4
);O;O
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
bleeding;O;O
if;O;O
administered;O;O
prior;O;O
to;O;O
or;O;O
after;O;O
Retavase;B-brand;B-DDI-DrugBank.d618.s1.e5
therapy;O;O
.;O;O
DDI-DrugBank.d698.s0;;
Interactions;O;O
for;O;O
Vitamin;B-drug;B-DDI-DrugBank.d698.s0.e0
B2;I-drug;I-DDI-DrugBank.d698.s0.e0
(;O;O
Riboflavin;B-drug;B-DDI-DrugBank.d698.s0.e1
);O;O
:;O;O
Alcohol;B-drug;B-DDI-DrugBank.d698.s0.e2
-;O;O
impairs;O;O
the;O;O
intestinal;O;O
absorption;O;O
of;O;O
riboflavin;B-drug;B-DDI-DrugBank.d698.s0.e3
DDI-DrugBank.d698.s1;;
Probenecid;I-drug;I-DDI-DrugBank.d698.s1.e0
-;O;O
concurrent;O;O
use;O;O
decreases;O;O
gastrointestinal;O;O
absorption;O;O
of;O;O
riboflavin;B-drug;B-DDI-DrugBank.d698.s1.e1
;;O;O
DDI-DrugBank.d698.s2;;
requirements;O;O
for;O;O
riboflavin;B-drug;B-DDI-DrugBank.d698.s2.e0
may;O;O
be;O;O
increased;O;O
in;O;O
patients;O;O
receiving;O;O
probenecid;B-drug;B-DDI-DrugBank.d698.s2.e1
.;O;O
DDI-DrugBank.d710.s0;;
Cimetidine;B-drug;B-DDI-DrugBank.d710.s0.e0
:;O;O
The;O;O
effects;O;O
of;O;O
chronic;O;O
cimetidine;B-drug;B-DDI-DrugBank.d710.s0.e1
use;O;O
on;O;O
the;O;O
metabolism;O;O
of;O;O
rimantadine;B-drug;B-DDI-DrugBank.d710.s0.e2
are;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d710.s1;;
When;O;O
a;O;O
single;O;O
100;O;O
mg;O;O
dose;O;O
of;O;O
rimantadine;B-drug;B-DDI-DrugBank.d710.s1.e0
HCl;I-drug;I-DDI-DrugBank.d710.s1.e0
was;O;O
administered;O;O
one;O;O
hour;O;O
after;O;O
the;O;O
initiation;O;O
of;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d710.s1.e1
(;O;O
300;O;O
mg;O;O
four;O;O
times;O;O
a;O;O
day;O;O
);O;O
,;O;O
the;O;O
apparent;O;O
total;O;O
rimantadine;B-drug;B-DDI-DrugBank.d710.s1.e2
clearance;O;O
of;O;O
this;O;O
single;O;O
dose;O;O
in;O;O
normal;O;O
healthy;O;O
adults;O;O
was;O;O
reduced;O;O
by;O;O
18;O;O
%;O;O
(;O;O
compared;O;O
to;O;O
the;O;O
apparent;O;O
total;O;O
rimantadine;B-drug;B-DDI-DrugBank.d710.s1.e3
clearance;O;O
in;O;O
the;O;O
same;O;O
subjects;O;O
in;O;O
the;O;O
absence;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d710.s1.e4
);O;O
.;O;O
DDI-DrugBank.d710.s2;;
Acetaminophen;B-drug;B-DDI-DrugBank.d710.s2.e0
:;O;O
Rimantadine;B-drug;B-DDI-DrugBank.d710.s2.e1
HCl;I-drug;I-DDI-DrugBank.d710.s2.e1
,;O;O
100;O;O
mg;O;O
,;O;O
was;O;O
given;O;O
twice;O;O
daily;O;O
for;O;O
13;O;O
days;O;O
to;O;O
12;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d710.s3;;
On;O;O
day;O;O
11;O;O
,;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d710.s3.e0
(;O;O
650;O;O
mg;O;O
four;O;O
times;O;O
daily;O;O
);O;O
was;O;O
started;O;O
and;O;O
continued;O;O
for;O;O
8;O;O
days;O;O
.;O;O
DDI-DrugBank.d710.s4;;
The;O;O
pharmacokinetics;O;O
of;O;O
rimantadine;B-drug;B-DDI-DrugBank.d710.s4.e0
were;O;O
assessed;O;O
on;O;O
days;O;O
11;O;O
and;O;O
13;O;O
.;O;O
DDI-DrugBank.d710.s5;;
Coadministration;O;O
with;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d710.s5.e0
reduced;O;O
the;O;O
peak;O;O
concentration;O;O
and;O;O
AUC;O;O
values;O;O
for;O;O
rimantadine;B-drug;B-DDI-DrugBank.d710.s5.e1
by;O;O
approximately;O;O
11;O;O
%;O;O
.;O;O
DDI-DrugBank.d710.s6;;
Aspirin;B-brand;B-DDI-DrugBank.d710.s6.e0
:;O;O
Rimantadine;B-drug;B-DDI-DrugBank.d710.s6.e1
HCl;I-drug;I-DDI-DrugBank.d710.s6.e1
,;O;O
100;O;O
mg;O;O
,;O;O
was;O;O
given;O;O
twice;O;O
daily;O;O
fro;O;O
13;O;O
days;O;O
to;O;O
12;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d710.s7;;
On;O;O
day;O;O
11;O;O
,;O;O
aspirin;B-brand;B-DDI-DrugBank.d710.s7.e0
(;O;O
650;O;O
mg;O;O
,;O;O
four;O;O
times;O;O
daily;O;O
);O;O
was;O;O
started;O;O
and;O;O
continued;O;O
for;O;O
8;O;O
days;O;O
.;O;O
DDI-DrugBank.d710.s8;;
The;O;O
pharmacokinetics;O;O
of;O;O
rimantadine;B-drug;B-DDI-DrugBank.d710.s8.e0
were;O;O
assessed;O;O
on;O;O
days;O;O
11;O;O
and;O;O
13;O;O
.;O;O
DDI-DrugBank.d710.s9;;
Peak;O;O
plasma;O;O
concentrations;O;O
and;O;O
AUC;O;O
of;O;O
rimantadine;B-drug;B-DDI-DrugBank.d710.s9.e0
were;O;O
reduced;O;O
approximately;O;O
10;O;O
%;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d710.s9.e1
.;O;O
DDI-DrugBank.d596.s0;;
Drug;O;O
-;O;O
Drug;O;O
Interactions;O;O
Effect;O;O
of;O;O
Exelon;B-brand;B-DDI-DrugBank.d596.s0.e0
(;O;O
rivastigmine;B-drug;B-DDI-DrugBank.d596.s0.e1
tartrate;I-drug;I-DDI-DrugBank.d596.s0.e1
);O;O
on;O;O
the;O;O
Metabolism;O;O
of;O;O
Other;O;O
Drugs;O;O
:;O;O
Rivastigmine;B-drug;B-DDI-DrugBank.d596.s0.e2
is;O;O
primarily;O;O
metabolized;O;O
through;O;O
hydrolysis;O;O
by;O;O
esterases;O;O
.;O;O
DDI-DrugBank.d596.s1;;
Minimal;O;O
metabolism;O;O
occurs;O;O
via;O;O
the;O;O
major;O;O
cytochrome;O;O
P450;O;O
isoenzymes;O;O
.;O;O
DDI-DrugBank.d596.s2;;
Based;O;O
on;O;O
in;O;O
vitro;O;O
studies;O;O
,;O;O
no;O;O
pharmacokinetic;O;O
drug;O;O
interactions;O;O
with;O;O
drugs;O;O
metabolized;O;O
by;O;O
the;O;O
following;O;O
isoenzyme;O;O
systems;O;O
are;O;O
expected;O;O
:;O;O
CYP1A2;O;O
,;O;O
CYP2D6;O;O
,;O;O
CYP3A4;O;O
/;O;O
5;O;O
,;O;O
CYP2E1;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2C8;O;O
,;O;O
or;O;O
CYP2C19;O;O
.;O;O
DDI-DrugBank.d596.s3;;
No;O;O
pharmacokinetic;O;O
interaction;O;O
was;O;O
observed;O;O
between;O;O
rivastigmine;B-drug;B-DDI-DrugBank.d596.s3.e0
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d596.s3.e1
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d596.s3.e2
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d596.s3.e3
,;O;O
or;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d596.s3.e4
in;O;O
studies;O;O
in;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d596.s4;;
The;O;O
elevation;O;O
of;O;O
prothrombin;O;O
time;O;O
induced;O;O
by;O;O
warfarin;B-drug;B-DDI-DrugBank.d596.s4.e0
is;O;O
not;O;O
affected;O;O
by;O;O
administration;O;O
of;O;O
Exelon;B-brand;B-DDI-DrugBank.d596.s4.e1
.;O;O
DDI-DrugBank.d596.s5;;
Effect;O;O
of;O;O
Other;O;O
Drugs;O;O
on;O;O
the;O;O
Metabolism;O;O
of;O;O
Exelon;B-brand;B-DDI-DrugBank.d596.s5.e0
:;O;O
Drugs;O;O
that;O;O
induce;O;O
or;O;O
inhibit;O;O
CYP450;O;O
metabolism;O;O
are;O;O
not;O;O
expected;O;O
to;O;O
alter;O;O
the;O;O
metabolism;O;O
of;O;O
rivastigmine;B-drug;B-DDI-DrugBank.d596.s5.e1
.;O;O
DDI-DrugBank.d596.s6;;
Single;O;O
dose;O;O
pharmacokinetic;O;O
studies;O;O
demonstrated;O;O
that;O;O
the;O;O
metabolism;O;O
of;O;O
rivastigmine;B-drug;B-DDI-DrugBank.d596.s6.e0
is;O;O
not;O;O
significantly;O;O
affected;O;O
by;O;O
concurrent;O;O
administration;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d596.s6.e1
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d596.s6.e2
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d596.s6.e3
,;O;O
or;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d596.s6.e4
.;O;O
DDI-DrugBank.d596.s7;;
Population;O;O
PK;O;O
analysis;O;O
with;O;O
a;O;O
database;O;O
of;O;O
625;O;O
patients;O;O
showed;O;O
that;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
rivastigmine;B-drug;B-DDI-DrugBank.d596.s7.e0
were;O;O
not;O;O
influenced;O;O
by;O;O
commonly;O;O
prescribed;O;O
medications;O;O
such;O;O
as;O;O
antacids;B-group;B-DDI-DrugBank.d596.s7.e1
(;O;O
n=77;O;O
);O;O
,;O;O
antihypertensives;B-group;B-DDI-DrugBank.d596.s7.e2
(;O;O
n=72;O;O
);O;O
,;O;O
calcium;B-group;B-DDI-DrugBank.d596.s7.e3
channel;I-group;I-DDI-DrugBank.d596.s7.e3
blockers;I-group;I-DDI-DrugBank.d596.s7.e3
(;O;O
n=75;O;O
);O;O
,;O;O
antidiabetics;B-group;B-DDI-DrugBank.d596.s7.e4
(;O;O
n=21;O;O
);O;O
,;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d596.s7.e5
anti;I-group;I-DDI-DrugBank.d596.s7.e5
-;I-group;I-DDI-DrugBank.d596.s7.e5
inflammatory;I-group;I-DDI-DrugBank.d596.s7.e5
drugs;I-group;I-DDI-DrugBank.d596.s7.e5
(;O;O
n=79;O;O
);O;O
,;O;O
estrogens;B-group;B-DDI-DrugBank.d596.s7.e6
(;O;O
n=70;O;O
);O;O
,;O;O
salicylate;B-group;B-DDI-DrugBank.d596.s7.e7
analgesics;I-group;I-DDI-DrugBank.d596.s7.e7
(;O;O
n=177;O;O
);O;O
,;O;O
antianginals;B-group;B-DDI-DrugBank.d596.s7.e8
(;O;O
n=35;O;O
);O;O
,;O;O
and;O;O
antihistamines;B-group;B-DDI-DrugBank.d596.s7.e9
(;O;O
n=15;O;O
);O;O
.;O;O
DDI-DrugBank.d596.s8;;
Use;O;O
with;O;O
Anticholinergics;B-group;B-DDI-DrugBank.d596.s8.e0
:;O;O
Because;O;O
of;O;O
their;O;O
mechanism;O;O
of;O;O
action;O;O
,;O;O
cholinesterase;B-group;B-DDI-DrugBank.d596.s8.e1
inhibitors;I-group;I-DDI-DrugBank.d596.s8.e1
have;O;O
the;O;O
potential;O;O
to;O;O
interfere;O;O
with;O;O
the;O;O
activity;O;O
of;O;O
anticholinergic;B-group;B-DDI-DrugBank.d596.s8.e2
medications;I-group;I-DDI-DrugBank.d596.s8.e2
.;O;O
DDI-DrugBank.d596.s9;;
Use;O;O
with;O;O
Cholinomimetics;B-group;B-DDI-DrugBank.d596.s9.e0
and;O;O
Other;O;O
Cholinesterase;B-group;B-DDI-DrugBank.d596.s9.e1
Inhibitors;I-group;I-DDI-DrugBank.d596.s9.e1
:;O;O
A;O;O
synergistic;O;O
effect;O;O
may;O;O
be;O;O
expected;O;O
when;O;O
cholinesterase;B-group;B-DDI-DrugBank.d596.s9.e2
inhibitors;I-group;I-DDI-DrugBank.d596.s9.e2
are;O;O
given;O;O
concurrently;O;O
with;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d596.s9.e3
,;O;O
similar;O;O
neuromuscular;B-group;B-DDI-DrugBank.d596.s9.e4
blocking;I-group;I-DDI-DrugBank.d596.s9.e4
agents;I-group;I-DDI-DrugBank.d596.s9.e4
or;O;O
cholinergic;B-group;B-DDI-DrugBank.d596.s9.e5
agonists;I-group;I-DDI-DrugBank.d596.s9.e5
such;O;O
as;O;O
bethanechol;B-drug;B-DDI-DrugBank.d596.s9.e6
.;O;O
DDI-DrugBank.d661.s0;;
Drug;O;O
Interactions;O;O
:;O;O
The;O;O
use;O;O
of;O;O
ZEMURON;B-brand;B-DDI-DrugBank.d661.s0.e0
(;O;O
rocuronium;B-drug;B-DDI-DrugBank.d661.s0.e1
bromide;I-drug;I-DDI-DrugBank.d661.s0.e1
);O;O
Injection;O;O
before;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d661.s0.e2
,;O;O
for;O;O
the;O;O
purpose;O;O
of;O;O
attenuating;O;O
some;O;O
of;O;O
the;O;O
side;O;O
effects;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d661.s0.e3
,;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d661.s1;;
If;O;O
ZEMURON;B-brand;B-DDI-DrugBank.d661.s1.e0
is;O;O
administered;O;O
following;O;O
administration;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d661.s1.e1
,;O;O
it;O;O
should;O;O
not;O;O
be;O;O
given;O;O
until;O;O
recovery;O;O
from;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d661.s1.e2
has;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d661.s2;;
The;O;O
median;O;O
duration;O;O
of;O;O
action;O;O
of;O;O
ZEMURON;B-brand;B-DDI-DrugBank.d661.s2.e0
0.6;O;O
mg;O;O
/;O;O
kg;O;O
administered;O;O
after;O;O
a;O;O
1;O;O
mg;O;O
/;O;O
kg;O;O
dose;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d661.s2.e1
when;O;O
T;O;O
1;O;O
returned;O;O
to;O;O
75;O;O
%;O;O
of;O;O
control;O;O
was;O;O
36;O;O
minutes;O;O
(;O;O
range;O;O
14;O;O
-;O;O
57;O;O
,;O;O
n=12;O;O
);O;O
vs.;O;O
DDI-DrugBank.d661.s3;;
28;O;O
minutes;O;O
(;O;O
17;O;O
-;O;O
51;O;O
,;O;O
n=12;O;O
);O;O
without;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d661.s3.e0
.;O;O
DDI-DrugBank.d661.s4;;
There;O;O
are;O;O
no;O;O
controlled;O;O
studies;O;O
documenting;O;O
the;O;O
use;O;O
of;O;O
ZEMURON;B-brand;B-DDI-DrugBank.d661.s4.e0
before;O;O
or;O;O
after;O;O
other;O;O
nondepolarizing;B-group;B-DDI-DrugBank.d661.s4.e1
muscle;I-group;I-DDI-DrugBank.d661.s4.e1
relaxants;I-group;I-DDI-DrugBank.d661.s4.e1
.;O;O
DDI-DrugBank.d661.s5;;
Interactions;O;O
have;O;O
been;O;O
observed;O;O
when;O;O
other;O;O
nondepolarizing;B-group;B-DDI-DrugBank.d661.s5.e0
muscle;I-group;I-DDI-DrugBank.d661.s5.e0
relaxants;I-group;I-DDI-DrugBank.d661.s5.e0
have;O;O
been;O;O
administered;O;O
in;O;O
succession;O;O
.;O;O
DDI-DrugBank.d661.s6;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
None;O;O
known;O;O
.;O;O
DDI-DrugBank.d591.s0;;
Ropivacaine;B-drug;B-DDI-DrugBank.d591.s0.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
receiving;O;O
other;O;O
local;O;O
anesthetics;B-group;B-DDI-DrugBank.d591.s0.e1
or;O;O
agents;O;O
structurally;O;O
related;O;O
to;O;O
amide;B-group;B-DDI-DrugBank.d591.s0.e2
-;I-group;I-DDI-DrugBank.d591.s0.e2
type;I-group;I-DDI-DrugBank.d591.s0.e2
local;I-group;I-DDI-DrugBank.d591.s0.e2
anesthetics;I-group;I-DDI-DrugBank.d591.s0.e2
,;O;O
since;O;O
the;O;O
toxic;O;O
effects;O;O
of;O;O
these;O;O
drugs;O;O
are;O;O
additive;O;O
.;O;O
DDI-DrugBank.d591.s1;;
Cytochrome;O;O
P4501A2;O;O
is;O;O
involved;O;O
in;O;O
the;O;O
formation;O;O
of;O;O
3;B-drug_n;B-DDI-DrugBank.d591.s1.e0
-;I-drug_n;I-DDI-DrugBank.d591.s1.e0
hydroxy;I-drug_n;I-DDI-DrugBank.d591.s1.e0
ropivacaine;I-drug_n;I-DDI-DrugBank.d591.s1.e0
,;O;O
the;O;O
major;O;O
metabolite;O;O
.;O;O
DDI-DrugBank.d591.s2;;
In;O;O
vivo;O;O
,;O;O
the;O;O
plasma;O;O
clearance;O;O
of;O;O
ropivacaine;B-drug;B-DDI-DrugBank.d591.s2.e0
was;O;O
reduced;O;O
by;O;O
70;O;O
%;O;O
during;O;O
coadministration;O;O
of;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d591.s2.e1
(;O;O
25;O;O
mg;O;O
bid;O;O
for;O;O
2;O;O
days;O;O
);O;O
,;O;O
a;O;O
selective;O;O
and;O;O
potent;O;O
CYP1A2;O;O
inhibitor;O;O
.;O;O
DDI-DrugBank.d591.s3;;
Thus;O;O
strong;O;O
inhibitors;O;O
of;O;O
cytochrome;O;O
P4501A2;O;O
,;O;O
such;O;O
as;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d591.s3.e0
,;O;O
given;O;O
concomitantly;O;O
during;O;O
administration;O;O
of;O;O
Ropivacaine;B-drug;B-DDI-DrugBank.d591.s3.e1
,;O;O
can;O;O
interact;O;O
with;O;O
Ropivacaine;B-drug;B-DDI-DrugBank.d591.s3.e2
leading;O;O
to;O;O
increased;O;O
ropivacaine;B-drug;B-DDI-DrugBank.d591.s3.e3
plasma;O;O
levels;O;O
.;O;O
DDI-DrugBank.d591.s4;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
CYP1A2;O;O
inhibitors;O;O
are;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d591.s5;;
Possible;O;O
interactions;O;O
with;O;O
drugs;O;O
known;O;O
to;O;O
be;O;O
metabolized;O;O
by;O;O
CYP1A2;O;O
via;O;O
competitive;O;O
inhibition;O;O
such;O;O
as;O;O
theophylline;B-drug;B-DDI-DrugBank.d591.s5.e0
and;O;O
imipramine;B-drug;B-DDI-DrugBank.d591.s5.e1
may;O;O
also;O;O
occur;O;O
.;O;O
DDI-DrugBank.d591.s6;;
Coadministration;O;O
of;O;O
a;O;O
selective;O;O
and;O;O
potent;O;O
inhibitor;O;O
of;O;O
CYP3A4;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d591.s6.e0
(;O;O
100;O;O
mg;O;O
bid;O;O
for;O;O
2;O;O
days;O;O
with;O;O
ropivacaine;B-drug;B-DDI-DrugBank.d591.s6.e1
infusion;O;O
administered;O;O
1;O;O
hour;O;O
after;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d591.s6.e2
);O;O
caused;O;O
a;O;O
15;O;O
%;O;O
reduction;O;O
in;O;O
in;O;O
-;O;O
vivo;O;O
plasma;O;O
clearance;O;O
of;O;O
ropivacaine;B-drug;B-DDI-DrugBank.d591.s6.e3
.;O;O
DDI-DrugBank.d609.s0;;
An;O;O
inhibitor;O;O
of;O;O
CYP2C8;O;O
(;O;O
such;O;O
as;O;O
gemfibrozil;B-drug;B-DDI-DrugBank.d609.s0.e0
);O;O
may;O;O
increase;O;O
the;O;O
AUC;O;O
of;O;O
rosiglitazone;B-drug;B-DDI-DrugBank.d609.s0.e1
and;O;O
an;O;O
inducer;O;O
of;O;O
CYP2C8;O;O
(;O;O
such;O;O
as;O;O
rifampin;B-drug;B-DDI-DrugBank.d609.s0.e2
);O;O
may;O;O
decrease;O;O
the;O;O
AUC;O;O
of;O;O
rosiglitazone;B-drug;B-DDI-DrugBank.d609.s0.e3
.;O;O
DDI-DrugBank.d609.s1;;
Therefore;O;O
,;O;O
if;O;O
an;O;O
inhibitor;O;O
or;O;O
an;O;O
inducer;O;O
of;O;O
CYP2C8;O;O
is;O;O
started;O;O
or;O;O
stopped;O;O
during;O;O
treatment;O;O
with;O;O
rosiglitazone;B-drug;B-DDI-DrugBank.d609.s1.e0
,;O;O
changes;O;O
in;O;O
diabetes;O;O
treatment;O;O
may;O;O
be;O;O
needed;O;O
based;O;O
upon;O;O
clinical;O;O
response;O;O
.;O;O
DDI-DrugBank.d709.s0;;
Concomitant;O;O
administration;O;O
contra;O;O
-;O;O
indicated;O;O
:;O;O
-;O;O
Vasoconstrictive;O;O
ergot;B-group;B-DDI-DrugBank.d709.s0.e0
alkaloids;I-group;I-DDI-DrugBank.d709.s0.e0
.;O;O
DDI-DrugBank.d709.s1;;
Concomitant;O;O
administrations;O;O
not;O;O
recommended;O;O
:;O;O
-;O;O
Terfenadine;B-drug;B-DDI-DrugBank.d709.s1.e0
and;O;O
astemizole;B-drug;B-DDI-DrugBank.d709.s1.e1
:;O;O
Certain;O;O
macrolides;B-group;B-DDI-DrugBank.d709.s1.e2
interact;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d709.s1.e3
and;O;O
astemizole;B-drug;B-DDI-DrugBank.d709.s1.e4
leading;O;O
to;O;O
increased;O;O
serum;O;O
concentrations;O;O
of;O;O
the;O;O
latter;O;O
.;O;O
DDI-DrugBank.d709.s2;;
This;O;O
may;O;O
result;O;O
in;O;O
severe;O;O
ventricular;O;O
arrhythmia;O;O
,;O;O
typically;O;O
torsades;O;O
de;O;O
pointe;O;O
.;O;O
DDI-DrugBank.d709.s3;;
Although;O;O
such;O;O
a;O;O
reaction;O;O
has;O;O
not;O;O
been;O;O
demonstrated;O;O
with;O;O
roxithromycin;B-drug;B-DDI-DrugBank.d709.s3.e0
,;O;O
concomitant;O;O
administration;O;O
of;O;O
roxithromycin;B-drug;B-DDI-DrugBank.d709.s3.e1
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d709.s3.e2
or;O;O
astemizole;B-drug;B-DDI-DrugBank.d709.s3.e3
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d709.s4;;
-;O;O
Cisapride;B-drug;B-DDI-DrugBank.d709.s4.e0
,;O;O
pimozide;B-drug;B-DDI-DrugBank.d709.s4.e1
:;O;O
Other;O;O
drugs;O;O
such;O;O
as;O;O
cisapride;B-drug;B-DDI-DrugBank.d709.s4.e2
or;O;O
pimozide;B-drug;B-DDI-DrugBank.d709.s4.e3
,;O;O
which;O;O
are;O;O
metabolised;O;O
by;O;O
hepatic;O;O
CYP3A;O;O
isozymes;O;O
have;O;O
been;O;O
associated;O;O
with;O;O
QT;O;O
interval;O;O
prolongation;O;O
and/or;O;O
cardiac;O;O
arrythmias;O;O
(;O;O
typically;O;O
torsades;O;O
de;O;O
pointe;O;O
);O;O
as;O;O
a;O;O
result;O;O
of;O;O
increase;O;O
in;O;O
their;O;O
serum;O;O
level;O;O
subsequent;O;O
to;O;O
interaction;O;O
with;O;O
significant;O;O
inhibitors;O;O
of;O;O
the;O;O
isozyme;O;O
,;O;O
including;O;O
some;O;O
macrolide;B-group;B-DDI-DrugBank.d709.s4.e4
antibacterials;I-group;I-DDI-DrugBank.d709.s4.e4
.;O;O
DDI-DrugBank.d709.s5;;
Although;O;O
such;O;O
a;O;O
risk;O;O
is;O;O
not;O;O
verified;O;O
for;O;O
roxithromycin;B-drug;B-DDI-DrugBank.d709.s5.e0
,;O;O
combination;O;O
of;O;O
roxithromycin;B-drug;B-DDI-DrugBank.d709.s5.e1
with;O;O
such;O;O
drugs;O;O
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d770.s0;;
Nasal;O;O
Spray;O;O
:;O;O
Formal;O;O
studies;O;O
designed;O;O
to;O;O
evaluate;O;O
drug;O;O
interactions;O;O
with;O;O
Calcitonin;O;O
(;O;O
salmon;O;O
);O;O
have;O;O
not;O;O
been;O;O
done;O;O
.;O;O
DDI-DrugBank.d770.s1;;
No;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
with;O;O
Calcitonin;O;O
(;O;O
salmon;O;O
);O;O
nasal;O;O
spray;O;O
ingredients;O;O
.;O;O
DDI-DrugBank.d770.s2;;
Currently;O;O
,;O;O
no;O;O
drug;O;O
interactions;O;O
with;O;O
Calcitonin;O;O
(;O;O
salmon;O;O
);O;O
have;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d770.s3;;
The;O;O
effects;O;O
of;O;O
prior;O;O
use;O;O
of;O;O
diphosphonates;B-group;B-DDI-DrugBank.d770.s3.e0
in;O;O
postmenopausal;O;O
osteoporosis;O;O
patients;O;O
have;O;O
not;O;O
been;O;O
assessed;O;O
;;O;O
DDI-DrugBank.d770.s4;;
however;O;O
,;O;O
in;O;O
patients;O;O
with;O;O
Paget;O;O
's;O;O
Disease;O;O
prior;O;O
diphosphonate;B-group;B-DDI-DrugBank.d770.s4.e0
use;O;O
appears;O;O
to;O;O
reduce;O;O
the;O;O
anti;O;O
-;O;O
resorptive;O;O
response;O;O
to;O;O
Calcitonin;O;O
(;O;O
salmon;O;O
);O;O
nasal;O;O
spray;O;O
.;O;O
DDI-DrugBank.d576.s0;;
Salicylates;B-group;B-DDI-DrugBank.d576.s0.e0
antagonize;O;O
the;O;O
uricosuric;O;O
action;O;O
of;O;O
.;O;O
drugs;O;O
used;O;O
to;O;O
treat;O;O
gout;O;O
.;O;O
DDI-DrugBank.d576.s1;;
ASPIRIN;B-brand;B-DDI-DrugBank.d576.s1.e0
AND;O;O
OTHER;O;O
SALICYLATE;B-group;B-DDI-DrugBank.d576.s1.e1
DRUGS;I-group;I-DDI-DrugBank.d576.s1.e1
WILL;O;O
BE;O;O
ADDITIVE;O;O
TO;O;O
DISALCID;B-brand;B-DDI-DrugBank.d576.s1.e2
AND;O;O
MAY;O;O
INCREASE;O;O
PLASMA;O;O
CONCENTRATIONS;O;O
OF;O;O
SALICYLIC;B-drug;B-DDI-DrugBank.d576.s1.e3
ACID;I-drug;I-DDI-DrugBank.d576.s1.e3
TO;O;O
TOXIC;O;O
LEVELS;O;O
.;O;O
DDI-DrugBank.d576.s2;;
Drugs;O;O
and;O;O
foods;O;O
that;O;O
raise;O;O
urine;O;O
pH;O;O
will;O;O
increase;O;O
renal;O;O
clearance;O;O
and;O;O
urinary;O;O
excretion;O;O
of;O;O
salicylic;B-drug;B-DDI-DrugBank.d576.s2.e0
acid;I-drug;I-DDI-DrugBank.d576.s2.e0
,;O;O
thus;O;O
lowering;O;O
plasma;O;O
levels;O;O
;;O;O
DDI-DrugBank.d576.s3;;
acidifying;O;O
drugs;O;O
or;O;O
foods;O;O
will;O;O
decrease;O;O
urinary;O;O
excretion;O;O
and;O;O
increase;O;O
plasma;O;O
levels;O;O
.;O;O
DDI-DrugBank.d576.s4;;
Salicylates;B-group;B-DDI-DrugBank.d576.s4.e0
given;O;O
concomitantly;O;O
with;O;O
anticoagulant;B-group;B-DDI-DrugBank.d576.s4.e1
drugs;I-group;I-DDI-DrugBank.d576.s4.e1
may;O;O
predispose;O;O
to;O;O
systemic;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d576.s5;;
Salicylates;B-group;B-DDI-DrugBank.d576.s5.e0
may;O;O
enhance;O;O
the;O;O
hypoglycemic;O;O
effect;O;O
of;O;O
oral;O;O
antidiabetic;B-group;B-DDI-DrugBank.d576.s5.e1
drugs;I-group;I-DDI-DrugBank.d576.s5.e1
of;O;O
the;O;O
sulfonylurea;O;O
class;O;O
.;O;O
DDI-DrugBank.d576.s6;;
Salicylate;B-group;B-DDI-DrugBank.d576.s6.e0
competes;O;O
with;O;O
a;O;O
number;O;O
of;O;O
drugs;O;O
for;O;O
protein;O;O
binding;O;O
sites;O;O
,;O;O
notably;O;O
penicillin;B-drug;B-DDI-DrugBank.d576.s6.e1
,;O;O
thiopental;B-drug;B-DDI-DrugBank.d576.s6.e2
,;O;O
thyroxine;B-drug;B-DDI-DrugBank.d576.s6.e3
,;O;O
triiodothyronine;B-drug;B-DDI-DrugBank.d576.s6.e4
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d576.s6.e5
,;O;O
sulfinpyrazone;B-drug;B-DDI-DrugBank.d576.s6.e6
,;O;O
naproxen;B-drug;B-DDI-DrugBank.d576.s6.e7
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d576.s6.e8
,;O;O
methotrexate;B-drug;B-DDI-DrugBank.d576.s6.e9
,;O;O
and;O;O
possibly;O;O
corticosteroids;B-group;B-DDI-DrugBank.d576.s6.e10
.;O;O
DDI-DrugBank.d576.s7;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Salicylate;B-group;B-DDI-DrugBank.d576.s7.e0
competes;O;O
with;O;O
thyroid;O;O
hormone;O;O
for;O;O
binding;O;O
to;O;O
plasma;O;O
proteins;O;O
,;O;O
which;O;O
may;O;O
be;O;O
reflected;O;O
in;O;O
a;O;O
depressed;O;O
plasma;O;O
T4;O;O
value;O;O
in;O;O
some;O;O
patients;O;O
;;O;O
DDI-DrugBank.d576.s8;;
thyroid;O;O
function;O;O
and;O;O
basal;O;O
metabolism;O;O
are;O;O
unaffected;O;O
.;O;O
DDI-DrugBank.d607.s0;;
Interactions;O;O
between;O;O
Leukine;B-brand;B-DDI-DrugBank.d607.s0.e0
and;O;O
other;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
fully;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d607.s1;;
Drugs;O;O
which;O;O
may;O;O
potentiate;O;O
the;O;O
myeloproliferative;O;O
effects;O;O
of;O;O
Leukine;B-brand;B-DDI-DrugBank.d607.s1.e0
,;O;O
such;O;O
as;O;O
lithium;B-drug;B-DDI-DrugBank.d607.s1.e1
and;O;O
corticosteroids;B-group;B-DDI-DrugBank.d607.s1.e2
,;O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d771.s0;;
The;O;O
absorption;O;O
of;O;O
oral;O;O
medications;O;O
may;O;O
be;O;O
decreased;O;O
during;O;O
the;O;O
concurrent;O;O
use;O;O
of;O;O
scopolamine;B-drug;B-DDI-DrugBank.d771.s0.e0
because;O;O
of;O;O
decreased;O;O
gastric;O;O
motility;O;O
and;O;O
delayed;O;O
gastric;O;O
emptying;O;O
.;O;O
DDI-DrugBank.d771.s1;;
Scopolamine;B-drug;B-DDI-DrugBank.d771.s1.e0
should;O;O
be;O;O
used;O;O
with;O;O
care;O;O
in;O;O
patients;O;O
taking;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
capable;O;O
of;O;O
causing;O;O
CNS;O;O
effects;O;O
such;O;O
as;O;O
sedatives;B-group;B-DDI-DrugBank.d771.s1.e1
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d771.s1.e2
,;O;O
or;O;O
alcohol;B-drug;B-DDI-DrugBank.d771.s1.e3
.;O;O
DDI-DrugBank.d771.s2;;
Special;O;O
attention;O;O
should;O;O
be;O;O
paid;O;O
to;O;O
potential;O;O
interactions;O;O
with;O;O
drugs;O;O
having;O;O
anticholinergic;O;O
properties;O;O
;;O;O
DDI-DrugBank.d771.s3;;
e.g.;O;O
,;O;O
other;O;O
belladonna;B-group;B-DDI-DrugBank.d771.s3.e0
alkaloids;I-group;I-DDI-DrugBank.d771.s3.e0
,;O;O
antihistamines;B-group;B-DDI-DrugBank.d771.s3.e1
(;O;O
including;O;O
meclizine;B-drug;B-DDI-DrugBank.d771.s3.e2
);O;O
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d771.s3.e3
antidepressants;I-group;I-DDI-DrugBank.d771.s3.e3
,;O;O
and;O;O
muscle;B-group;B-DDI-DrugBank.d771.s3.e4
relaxants;I-group;I-DDI-DrugBank.d771.s3.e4
.;O;O
DDI-DrugBank.d771.s4;;
Laboratory;O;O
Test;O;O
Interactions;O;O
Scopolamine;B-drug;B-DDI-DrugBank.d771.s4.e0
will;O;O
interfere;O;O
with;O;O
the;O;O
gastric;O;O
secretion;O;O
test;O;O
.;O;O
DDI-DrugBank.d601.s0;;
Barbiturates;B-group;B-DDI-DrugBank.d601.s0.e0
may;O;O
decrease;O;O
the;O;O
effectiveness;O;O
of;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d601.s0.e1
,;O;O
certain;O;O
antibiotics;B-group;B-DDI-DrugBank.d601.s0.e2
,;O;O
quinidine;B-group;B-DDI-DrugBank.d601.s0.e3
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d601.s0.e4
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d601.s0.e5
,;O;O
anticoagulants;B-group;B-DDI-DrugBank.d601.s0.e6
,;O;O
and;O;O
beta;B-group;B-DDI-DrugBank.d601.s0.e7
blockers;I-group;I-DDI-DrugBank.d601.s0.e7
.;O;O
DDI-DrugBank.d619.s0;;
The;O;O
occurrence;O;O
of;O;O
stupor;O;O
,;O;O
muscular;O;O
rigidity;O;O
,;O;O
severe;O;O
agitation;O;O
,;O;O
and;O;O
elevated;O;O
temperature;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
some;O;O
patients;O;O
receiving;O;O
the;O;O
combination;O;O
of;O;O
selegiline;B-drug;B-DDI-DrugBank.d619.s0.e0
and;O;O
meperidine;B-drug;B-DDI-DrugBank.d619.s0.e1
.;O;O
DDI-DrugBank.d619.s1;;
Symptoms;O;O
usually;O;O
resolve;O;O
over;O;O
days;O;O
when;O;O
the;O;O
combination;O;O
is;O;O
discontinued;O;O
.;O;O
DDI-DrugBank.d619.s2;;
This;O;O
is;O;O
typical;O;O
of;O;O
the;O;O
interaction;O;O
of;O;O
meperidine;B-drug;B-DDI-DrugBank.d619.s2.e0
and;O;O
MAOIs;B-group;B-DDI-DrugBank.d619.s2.e1
.;O;O
DDI-DrugBank.d619.s3;;
Other;O;O
serious;O;O
reactions;O;O
(;O;O
including;O;O
severe;O;O
agitation;O;O
,;O;O
hallucinations;O;O
,;O;O
and;O;O
death;O;O
);O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
this;O;O
combination;O;O
.;O;O
DDI-DrugBank.d619.s4;;
Severe;O;O
toxicity;O;O
has;O;O
also;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
the;O;O
combination;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d619.s4.e0
antidepressants;I-group;I-DDI-DrugBank.d619.s4.e0
and;O;O
ELDEPRYL;B-brand;B-DDI-DrugBank.d619.s4.e1
and;O;O
selective;B-group;B-DDI-DrugBank.d619.s4.e2
serotonin;I-group;I-DDI-DrugBank.d619.s4.e2
reuptake;I-group;I-DDI-DrugBank.d619.s4.e2
inhibitors;I-group;I-DDI-DrugBank.d619.s4.e2
and;O;O
ELDEPRYL;B-brand;B-DDI-DrugBank.d619.s4.e3
.;O;O
DDI-DrugBank.d619.s5;;
One;O;O
case;O;O
of;O;O
hypertensive;O;O
crisis;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
a;O;O
patient;O;O
taking;O;O
the;O;O
recommended;O;O
doses;O;O
of;O;O
selegiline;B-drug;B-DDI-DrugBank.d619.s5.e0
and;O;O
a;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d619.s5.e1
medication;I-group;I-DDI-DrugBank.d619.s5.e1
(;O;O
ephedrine;B-drug;B-DDI-DrugBank.d619.s5.e2
);O;O
.;O;O
DDI-DrugBank.d694.s0;;
Digoxin;B-drug;B-DDI-DrugBank.d694.s0.e0
:;O;O
There;O;O
was;O;O
a;O;O
slight;O;O
increase;O;O
in;O;O
the;O;O
area;O;O
under;O;O
the;O;O
curve;O;O
(;O;O
AUC;O;O
,;O;O
11;O;O
%;O;O
);O;O
and;O;O
mean;O;O
peak;O;O
drug;O;O
concentration;O;O
(;O;O
Cmax;O;O
,;O;O
18;O;O
%;O;O
);O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d694.s0.e1
with;O;O
the;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
100;O;O
mg;O;O
sitagliptin;B-drug;B-DDI-DrugBank.d694.s0.e2
for;O;O
10;O;O
days;O;O
.;O;O
DDI-DrugBank.d694.s1;;
Patients;O;O
receiving;O;O
digoxin;B-drug;B-DDI-DrugBank.d694.s1.e0
should;O;O
be;O;O
monitored;O;O
appropriately;O;O
.;O;O
DDI-DrugBank.d694.s2;;
No;O;O
dosage;O;O
adjustment;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d694.s2.e0
or;O;O
JANUVIA;B-brand;B-DDI-DrugBank.d694.s2.e1
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d595.s0;;
Additives;O;O
may;O;O
be;O;O
incompatible;O;O
;;O;O
DDI-DrugBank.d595.s1;;
norepinephrine;B-drug;B-DDI-DrugBank.d595.s1.e0
and;O;O
dobutamine;B-drug;B-DDI-DrugBank.d595.s1.e1
are;O;O
incompatible;O;O
with;O;O
sodium;B-drug;B-DDI-DrugBank.d595.s1.e2
bicarbonate;I-drug;I-DDI-DrugBank.d595.s1.e2
solution;O;O
.;O;O
DDI-DrugBank.d595.s2;;
The;O;O
addition;O;O
of;O;O
sodium;B-drug;B-DDI-DrugBank.d595.s2.e0
bicarbonate;I-drug;I-DDI-DrugBank.d595.s2.e0
to;O;O
parenteral;O;O
solutions;O;O
containing;O;O
calcium;B-drug;B-DDI-DrugBank.d595.s2.e1
should;O;O
be;O;O
avoided;O;O
,;O;O
except;O;O
where;O;O
compatibility;O;O
has;O;O
been;O;O
previously;O;O
established;O;O
.;O;O
DDI-DrugBank.d595.s3;;
Precipitation;O;O
or;O;O
haze;O;O
may;O;O
result;O;O
from;O;O
sodium;O;O
bicarbonate;O;O
-;O;O
calcium;O;O
admixtures;O;O
.;O;O
DDI-DrugBank.d595.s4;;
NOTE;O;O
:;O;O
Do;O;O
not;O;O
use;O;O
the;O;O
injection;O;O
if;O;O
it;O;O
contains;O;O
precipitate;O;O
.;O;O
DDI-DrugBank.d595.s5;;
Additives;O;O
may;O;O
be;O;O
incompatible;O;O
.;O;O
DDI-DrugBank.d595.s6;;
Consult;O;O
with;O;O
pharmacist;O;O
,;O;O
if;O;O
available;O;O
.;O;O
DDI-DrugBank.d595.s7;;
When;O;O
introducing;O;O
additives;O;O
,;O;O
use;O;O
aseptic;O;O
technique;O;O
,;O;O
mix;O;O
thoroughly;O;O
and;O;O
do;O;O
not;O;O
store;O;O
.;O;O
DDI-DrugBank.d738.s0;;
Do;O;O
not;O;O
exceed;O;O
a;O;O
5;O;O
mg;O;O
daily;O;O
dose;O;O
of;O;O
VESIcare;B-brand;B-DDI-DrugBank.d738.s0.e0
when;O;O
administered;O;O
with;O;O
therapeutic;O;O
doses;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d738.s0.e1
or;O;O
other;O;O
potent;O;O
CYP3A4;O;O
inhibitors;O;O
.;O;O
DDI-DrugBank.d738.s1;;
Patients;O;O
with;O;O
Congenital;O;O
or;O;O
Acquired;O;O
QT;O;O
Prolongation;O;O
In;O;O
a;O;O
study;O;O
of;O;O
the;O;O
effect;O;O
of;O;O
solifenacin;B-drug;B-DDI-DrugBank.d738.s1.e0
on;O;O
the;O;O
QT;O;O
interval;O;O
in;O;O
76;O;O
healthy;O;O
women;O;O
,;O;O
the;O;O
QT;O;O
prolonging;O;O
effect;O;O
appeared;O;O
less;O;O
with;O;O
solifenacin;B-drug;B-DDI-DrugBank.d738.s1.e1
10;O;O
mg;O;O
than;O;O
with;O;O
30;O;O
mg;O;O
(;O;O
three;O;O
times;O;O
the;O;O
maximum;O;O
recommended;O;O
dose;O;O
);O;O
,;O;O
and;O;O
the;O;O
effect;O;O
of;O;O
solifenacin;B-drug;B-DDI-DrugBank.d738.s1.e2
30;O;O
mg;O;O
did;O;O
not;O;O
appear;O;O
as;O;O
large;O;O
as;O;O
that;O;O
of;O;O
the;O;O
positive;O;O
control;O;O
moxifloxacin;B-drug;B-DDI-DrugBank.d738.s1.e3
at;O;O
its;O;O
therapeutic;O;O
dose;O;O
.;O;O
DDI-DrugBank.d738.s2;;
This;O;O
observation;O;O
should;O;O
be;O;O
considered;O;O
in;O;O
clinical;O;O
decisions;O;O
to;O;O
prescribe;O;O
VESIcare;B-brand;B-DDI-DrugBank.d738.s2.e0
for;O;O
patients;O;O
with;O;O
a;O;O
known;O;O
history;O;O
of;O;O
QT;O;O
prolongation;O;O
or;O;O
patients;O;O
who;O;O
are;O;O
taking;O;O
medications;O;O
known;O;O
to;O;O
prolong;O;O
the;O;O
QT;O;O
interval;O;O
.;O;O
DDI-DrugBank.d599.s0;;
Excessive;O;O
glucocorticoid;O;O
therapy;O;O
will;O;O
inhibit;O;O
the;O;O
growth;O;O
-;O;O
promoting;O;O
effect;O;O
of;O;O
human;B-drug;B-DDI-DrugBank.d599.s0.e0
GH;I-drug;I-DDI-DrugBank.d599.s0.e0
.;O;O
DDI-DrugBank.d599.s1;;
Patients;O;O
with;O;O
ACTH;O;O
deficiency;O;O
should;O;O
have;O;O
their;O;O
glucocorticoid;B-group;B-DDI-DrugBank.d599.s1.e0
-;O;O
replacement;O;O
dose;O;O
carefully;O;O
adjusted;O;O
to;O;O
avoid;O;O
an;O;O
inhibitory;O;O
effect;O;O
on;O;O
growth;O;O
.;O;O
DDI-DrugBank.d599.s2;;
The;O;O
use;O;O
of;O;O
Nutropin;B-brand;B-DDI-DrugBank.d599.s2.e0
in;O;O
patients;O;O
with;O;O
chronic;O;O
renal;O;O
insufficiency;O;O
receiving;O;O
glucocorticoid;O;O
therapy;O;O
has;O;O
not;O;O
been;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d599.s3;;
Concomitant;O;O
glucocorticoid;O;O
therapy;O;O
may;O;O
inhibit;O;O
the;O;O
growth;O;O
-;O;O
promoting;O;O
effect;O;O
of;O;O
Nutropin;B-brand;B-DDI-DrugBank.d599.s3.e0
.;O;O
DDI-DrugBank.d599.s4;;
If;O;O
glucocorticoid;B-group;B-DDI-DrugBank.d599.s4.e0
replacement;O;O
is;O;O
required;O;O
,;O;O
the;O;O
glucocorticoid;B-group;B-DDI-DrugBank.d599.s4.e1
dose;O;O
should;O;O
be;O;O
carefully;O;O
adjusted;O;O
.;O;O
DDI-DrugBank.d599.s5;;
There;O;O
was;O;O
no;O;O
evidence;O;O
in;O;O
the;O;O
controlled;O;O
studies;O;O
of;O;O
Nutropin;B-brand;B-DDI-DrugBank.d599.s5.e0
s;O;O
interaction;O;O
with;O;O
drugs;O;O
commonly;O;O
used;O;O
in;O;O
chronic;O;O
renal;O;O
insufficiency;O;O
patients;O;O
.;O;O
DDI-DrugBank.d599.s6;;
Limited;O;O
published;O;O
data;O;O
indicate;O;O
that;O;O
GH;B-drug;B-DDI-DrugBank.d599.s6.e0
treatment;O;O
increases;O;O
cytochrome;O;O
P450;O;O
(;O;O
CP450;O;O
);O;O
mediated;O;O
antipyrine;B-drug;B-DDI-DrugBank.d599.s6.e1
clearance;O;O
in;O;O
man;O;O
.;O;O
DDI-DrugBank.d599.s7;;
These;O;O
data;O;O
suggest;O;O
that;O;O
GH;B-drug;B-DDI-DrugBank.d599.s7.e0
administration;O;O
may;O;O
alter;O;O
the;O;O
clearance;O;O
of;O;O
compounds;O;O
known;O;O
to;O;O
be;O;O
metabolized;O;O
by;O;O
CP450;O;O
liver;O;O
enzymes;O;O
(;O;O
e.g.;O;O
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d599.s7.e1
,;O;O
sex;B-group;B-DDI-DrugBank.d599.s7.e2
steroids;I-group;I-DDI-DrugBank.d599.s7.e2
,;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d599.s7.e3
,;O;O
cyclosporin;B-drug;B-DDI-DrugBank.d599.s7.e4
);O;O
.;O;O
DDI-DrugBank.d599.s8;;
Careful;O;O
monitoring;O;O
is;O;O
advisable;O;O
when;O;O
GH;B-drug;B-DDI-DrugBank.d599.s8.e0
is;O;O
administered;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
drugs;O;O
known;O;O
to;O;O
be;O;O
metabolized;O;O
by;O;O
CP450;O;O
liver;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d602.s0;;
Caution;O;O
is;O;O
recommended;O;O
when;O;O
administering;O;O
NEXAVAR;B-brand;B-DDI-DrugBank.d602.s0.e0
with;O;O
compounds;O;O
that;O;O
are;O;O
metabolized;O;O
/;O;O
eliminated;O;O
predominantly;O;O
by;O;O
the;O;O
UGT1A1;O;O
pathway;O;O
(;O;O
e.g.;O;O
irinotecan;B-drug;B-DDI-DrugBank.d602.s0.e1
);O;O
.;O;O
DDI-DrugBank.d602.s1;;
Concomitant;O;O
treatment;O;O
with;O;O
NEXAVAR;B-brand;B-DDI-DrugBank.d602.s1.e0
resulted;O;O
in;O;O
a;O;O
21;O;O
%;O;O
increase;O;O
in;O;O
the;O;O
AUC;O;O
of;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d602.s1.e1
.;O;O
DDI-DrugBank.d602.s2;;
Caution;O;O
is;O;O
recommended;O;O
when;O;O
administering;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d602.s2.e0
with;O;O
NEXAVAR;B-brand;B-DDI-DrugBank.d602.s2.e1
.;O;O
DDI-DrugBank.d602.s3;;
Sorafenib;B-drug;B-DDI-DrugBank.d602.s3.e0
inhibits;O;O
CYP2B6;O;O
and;O;O
CYP2C8;O;O
in;O;O
vitro;O;O
with;O;O
Ki;O;O
values;O;O
of;O;O
6;O;O
and;O;O
1;O;O
-;O;O
2;O;O
?;O;O
M;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d602.s4;;
Systemic;O;O
exposure;O;O
to;O;O
substrates;O;O
of;O;O
CYP2B6;O;O
and;O;O
CYP2C8;O;O
is;O;O
expected;O;O
to;O;O
increase;O;O
when;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
NEXAVAR;B-brand;B-DDI-DrugBank.d602.s4.e0
.;O;O
DDI-DrugBank.d602.s5;;
Caution;O;O
is;O;O
recommended;O;O
when;O;O
administering;O;O
substrates;O;O
of;O;O
CYP2B6;O;O
and;O;O
CYP2C8;O;O
with;O;O
NEXAVAR;B-brand;B-DDI-DrugBank.d602.s5.e0
.;O;O
DDI-DrugBank.d727.s0;;
Zidovudine;B-drug;B-DDI-DrugBank.d727.s0.e0
competitively;O;O
inhibits;O;O
the;O;O
intracellular;O;O
phosphorylation;O;O
of;O;O
stavudine;B-drug;B-DDI-DrugBank.d727.s0.e1
.;O;O
DDI-DrugBank.d727.s1;;
Therefore;O;O
,;O;O
use;O;O
of;O;O
zidovudine;B-drug;B-DDI-DrugBank.d727.s1.e0
in;O;O
combination;O;O
with;O;O
ZERIT;B-brand;B-DDI-DrugBank.d727.s1.e1
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d727.s2;;
In;O;O
vitro;O;O
data;O;O
indicate;O;O
that;O;O
the;O;O
phosphorylation;O;O
of;O;O
stavudine;B-drug;B-DDI-DrugBank.d727.s2.e0
is;O;O
also;O;O
inhibited;O;O
at;O;O
relevant;O;O
concentrations;O;O
by;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d727.s2.e1
and;O;O
ribavirin;B-drug;B-DDI-DrugBank.d727.s2.e2
.;O;O
DDI-DrugBank.d727.s3;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
these;O;O
in;O;O
vitro;O;O
interactions;O;O
is;O;O
unknown;O;O
;;O;O
DDI-DrugBank.d727.s4;;
therefore;O;O
,;O;O
concomitant;O;O
use;O;O
of;O;O
stavudine;B-drug;B-DDI-DrugBank.d727.s4.e0
with;O;O
either;O;O
of;O;O
these;O;O
drugs;O;O
should;O;O
be;O;O
undertaken;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d777.s0;;
The;O;O
interaction;O;O
of;O;O
Streptase;B-brand;B-DDI-DrugBank.d777.s0.e0
,;O;O
Streptokinase;B-drug;B-DDI-DrugBank.d777.s0.e1
,;O;O
with;O;O
other;O;O
drugs;O;O
has;O;O
not;O;O
been;O;O
well;O;O
studied;O;O
.;O;O
DDI-DrugBank.d777.s1;;
Use;O;O
of;O;O
Anticoagulants;B-group;B-DDI-DrugBank.d777.s1.e0
and;O;O
Antiplatelet;B-group;B-DDI-DrugBank.d777.s1.e1
Agents;I-group;I-DDI-DrugBank.d777.s1.e1
-;O;O
-;O;O
Streptase;B-brand;B-DDI-DrugBank.d777.s1.e2
,;O;O
Streptokinase;B-drug;B-DDI-DrugBank.d777.s1.e3
,;O;O
alone;O;O
or;O;O
in;O;O
combination;O;O
with;O;O
antiplatelet;B-group;B-DDI-DrugBank.d777.s1.e4
agents;I-group;I-DDI-DrugBank.d777.s1.e4
and;O;O
anticoagulants;B-group;B-DDI-DrugBank.d777.s1.e5
,;O;O
may;O;O
cause;O;O
bleeding;O;O
complications;O;O
.;O;O
DDI-DrugBank.d777.s2;;
Therefore;O;O
,;O;O
careful;O;O
monitoring;O;O
is;O;O
advised;O;O
.;O;O
DDI-DrugBank.d777.s3;;
In;O;O
the;O;O
treatment;O;O
of;O;O
acute;O;O
MI;O;O
,;O;O
aspirin;B-brand;B-DDI-DrugBank.d777.s3.e0
,;O;O
when;O;O
not;O;O
otherwise;O;O
contraindicated;O;O
,;O;O
should;O;O
be;O;O
administered;O;O
with;O;O
Streptokinase;B-drug;B-DDI-DrugBank.d777.s3.e1
(;O;O
see;O;O
below;O;O
);O;O
.;O;O
DDI-DrugBank.d777.s4;;
Anticoagulation;O;O
and;O;O
Antiplatelets;B-group;B-DDI-DrugBank.d777.s4.e0
After;O;O
Treatment;O;O
for;O;O
Myocardial;O;O
Infarction;O;O
-;O;O
-;O;O
In;O;O
the;O;O
treatment;O;O
of;O;O
acute;O;O
myocardial;O;O
infarction;O;O
,;O;O
the;O;O
use;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d777.s4.e1
has;O;O
been;O;O
shown;O;O
to;O;O
reduce;O;O
the;O;O
incidence;O;O
of;O;O
reinfarction;O;O
and;O;O
stroke;O;O
.;O;O
DDI-DrugBank.d777.s5;;
The;O;O
addition;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d777.s5.e0
to;O;O
Streptokinase;B-drug;B-DDI-DrugBank.d777.s5.e1
causes;O;O
a;O;O
minimal;O;O
increase;O;O
in;O;O
the;O;O
risk;O;O
of;O;O
minor;O;O
bleeding;O;O
(;O;O
3.9;O;O
%;O;O
vs.;O;O
3.1;O;O
%;O;O
);O;O
,;O;O
but;O;O
does;O;O
not;O;O
appear;O;O
to;O;O
increase;O;O
the;O;O
incidence;O;O
of;O;O
major;O;O
bleeding;O;O
(;O;O
see;O;O
DDI-DrugBank.d647.s0;;
ZANOSAR;B-brand;B-DDI-DrugBank.d647.s0.e0
may;O;O
demonstrate;O;O
additive;O;O
toxicity;O;O
when;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
cytotoxic;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d647.s1;;
Streptozocin;B-drug;B-DDI-DrugBank.d647.s1.e0
has;O;O
been;O;O
reported;O;O
to;O;O
prolong;O;O
the;O;O
elimination;O;O
half;O;O
-;O;O
life;O;O
of;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d647.s1.e1
and;O;O
may;O;O
lead;O;O
to;O;O
severe;O;O
bone;O;O
marrow;O;O
suppression;O;O
;;O;O
DDI-DrugBank.d647.s2;;
a;O;O
reduction;O;O
of;O;O
the;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d647.s2.e0
dosage;O;O
should;O;O
be;O;O
considered;O;O
in;O;O
patients;O;O
receiving;O;O
ZANOSAR;B-brand;B-DDI-DrugBank.d647.s2.e1
concurrently;O;O
.;O;O
DDI-DrugBank.d647.s3;;
The;O;O
concurrent;O;O
use;O;O
of;O;O
streptozocin;B-drug;B-DDI-DrugBank.d647.s3.e0
and;O;O
phenytoin;B-drug;B-DDI-DrugBank.d647.s3.e1
has;O;O
been;O;O
reported;O;O
in;O;O
one;O;O
case;O;O
to;O;O
result;O;O
in;O;O
reduced;O;O
streptozocin;B-drug;B-DDI-DrugBank.d647.s3.e2
cytotoxicity;O;O
.;O;O
DDI-DrugBank.d732.s0;;
CHEMET;B-brand;B-DDI-DrugBank.d732.s0.e0
is;O;O
not;O;O
known;O;O
to;O;O
interact;O;O
with;O;O
other;O;O
drugs;O;O
including;O;O
iron;B-drug;B-DDI-DrugBank.d732.s0.e1
supplements;O;O
;;O;O
DDI-DrugBank.d732.s1;;
interactions;O;O
have;O;O
not;O;O
been;O;O
systematically;O;O
studied;O;O
.;O;O
DDI-DrugBank.d732.s2;;
Concomitant;O;O
administration;O;O
of;O;O
CHEMET;B-brand;B-DDI-DrugBank.d732.s2.e0
with;O;O
other;O;O
chelation;O;O
therapy;O;O
,;O;O
such;O;O
as;O;O
CaNa;B-drug;B-DDI-DrugBank.d732.s2.e1
2;I-drug;I-DDI-DrugBank.d732.s2.e1
EDTA;I-drug;I-DDI-DrugBank.d732.s2.e1
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d732.s3;;
Drug;O;O
/;O;O
Laboratory;O;O
Tests;O;O
Interaction;O;O
:;O;O
Succimer;B-drug;B-DDI-DrugBank.d732.s3.e0
may;O;O
interfere;O;O
with;O;O
serum;O;O
and;O;O
urinary;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-DrugBank.d732.s4;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
shown;O;O
succimer;B-drug;B-DDI-DrugBank.d732.s4.e0
to;O;O
cause;O;O
false;O;O
positive;O;O
results;O;O
for;O;O
ketones;O;O
in;O;O
urine;O;O
using;O;O
nitroprusside;O;O
reagents;O;O
such;O;O
as;O;O
Ketostix;O;O
and;O;O
falsely;O;O
decreased;O;O
measurements;O;O
of;O;O
serum;O;O
uric;O;O
acid;O;O
and;O;O
CPK;O;O
.;O;O
DDI-DrugBank.d649.s0;;
Sulfamethizole;B-drug;B-DDI-DrugBank.d649.s0.e0
may;O;O
increase;O;O
the;O;O
effects;O;O
of;O;O
barbiturates;B-group;B-DDI-DrugBank.d649.s0.e1
,;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d649.s0.e2
,;O;O
and;O;O
uricosurics;B-group;B-DDI-DrugBank.d649.s0.e3
.;O;O
DDI-DrugBank.d649.s1;;
It;O;O
may;O;O
also;O;O
interact;O;O
with;O;O
thiazides;B-group;B-DDI-DrugBank.d649.s1.e0
(;O;O
increased;O;O
thrombocytopenia;O;O
);O;O
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d649.s1.e1
(;O;O
increased;O;O
nephrotoxicity;O;O
);O;O
,;O;O
sulfonylurea;B-group;B-DDI-DrugBank.d649.s1.e2
agents;I-group;I-DDI-DrugBank.d649.s1.e2
(;O;O
increased;O;O
hypoglycemic;O;O
response;O;O
);O;O
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d649.s1.e3
(;O;O
increased;O;O
anticoagulant;O;O
effect;O;O
);O;O
,;O;O
methotrexate;B-drug;B-DDI-DrugBank.d649.s1.e4
(;O;O
decreased;O;O
renal;O;O
excretion;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d649.s1.e5
);O;O
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d649.s1.e6
(;O;O
decreased;O;O
hepatic;O;O
clearance;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d649.s1.e7
);O;O
.;O;O
DDI-DrugBank.d577.s0;;
In;O;O
elderly;O;O
patients;O;O
concurrently;O;O
receiving;O;O
certain;O;O
diuretics;B-group;B-DDI-DrugBank.d577.s0.e0
,;O;O
primarily;O;O
thiazides;B-group;B-DDI-DrugBank.d577.s0.e1
,;O;O
an;O;O
increased;O;O
incidence;O;O
of;O;O
thrombopenia;O;O
with;O;O
purpura;O;O
has;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d577.s1;;
It;O;O
has;O;O
been;O;O
reported;O;O
that;O;O
sulfamethoxazole;B-drug;B-DDI-DrugBank.d577.s1.e0
may;O;O
prolong;O;O
the;O;O
prothrombin;O;O
time;O;O
in;O;O
patients;O;O
who;O;O
are;O;O
receiving;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d577.s1.e1
warfarin;I-drug;I-DDI-DrugBank.d577.s1.e2
.;O;O
DDI-DrugBank.d577.s2;;
This;O;O
interaction;O;O
should;O;O
be;O;O
kept;O;O
in;O;O
mind;O;O
when;O;O
Gantanol;B-brand;B-DDI-DrugBank.d577.s2.e0
is;O;O
given;O;O
to;O;O
patients;O;O
already;O;O
on;O;O
anticoagulant;O;O
therapy;O;O
,;O;O
and;O;O
the;O;O
coagulation;O;O
time;O;O
should;O;O
be;O;O
reassessed;O;O
.;O;O
DDI-DrugBank.d577.s3;;
Sulfamethoxazole;B-drug;B-DDI-DrugBank.d577.s3.e0
may;O;O
inhibit;O;O
the;O;O
hepatic;O;O
metabolism;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d577.s3.e1
.;O;O
DDI-DrugBank.d577.s4;;
At;O;O
a;O;O
1.6;O;O
-;O;O
g;O;O
dose;O;O
,;O;O
sulfamethoxazole;B-drug;B-DDI-DrugBank.d577.s4.e0
produced;O;O
a;O;O
slight;O;O
but;O;O
significant;O;O
increase;O;O
in;O;O
the;O;O
half;O;O
-;O;O
life;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d577.s4.e1
but;O;O
did;O;O
not;O;O
produce;O;O
a;O;O
corresponding;O;O
decrease;O;O
in;O;O
the;O;O
metabolic;O;O
clearance;O;O
rate;O;O
.;O;O
DDI-DrugBank.d577.s5;;
When;O;O
administering;O;O
these;O;O
drugs;O;O
concurrently;O;O
,;O;O
one;O;O
should;O;O
be;O;O
alert;O;O
for;O;O
possible;O;O
excessive;O;O
phenytoin;B-drug;B-DDI-DrugBank.d577.s5.e0
effect;O;O
.;O;O
DDI-DrugBank.d577.s6;;
Sulfonamides;B-group;B-DDI-DrugBank.d577.s6.e0
can;O;O
also;O;O
displace;O;O
methotrexate;B-drug;B-DDI-DrugBank.d577.s6.e1
from;O;O
plasma;O;O
protein;O;O
-;O;O
binding;O;O
sites;O;O
,;O;O
thus;O;O
increasing;O;O
free;O;O
methotrexate;B-drug;B-DDI-DrugBank.d577.s6.e2
concentrations;O;O
.;O;O
DDI-DrugBank.d577.s7;;
The;O;O
presence;O;O
of;O;O
sulfamethoxazole;B-drug;B-DDI-DrugBank.d577.s7.e0
may;O;O
interfere;O;O
with;O;O
the;O;O
Jaff;O;O
alkaline;O;O
picrate;O;O
reaction;O;O
assay;O;O
for;O;O
creatinine;O;O
,;O;O
resulting;O;O
in;O;O
overestimations;O;O
of;O;O
about;O;O
10;O;O
%;O;O
in;O;O
the;O;O
range;O;O
of;O;O
normal;O;O
values;O;O
.;O;O
DDI-DrugBank.d693.s0;;
Reduced;O;O
absorption;O;O
of;O;O
folic;B-drug;B-DDI-DrugBank.d693.s0.e0
acid;I-drug;I-DDI-DrugBank.d693.s0.e0
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d693.s0.e1
have;O;O
been;O;O
reported;O;O
when;O;O
those;O;O
agents;O;O
were;O;O
administered;O;O
concomitantly;O;O
with;O;O
sulfasalazine;B-drug;B-DDI-DrugBank.d693.s0.e2
.;O;O
DDI-DrugBank.d693.s1;;
When;O;O
daily;O;O
doses;O;O
of;O;O
sulfasalazine;B-drug;B-DDI-DrugBank.d693.s1.e0
2;O;O
g;O;O
and;O;O
weekly;O;O
doses;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d693.s1.e1
7.5;O;O
mg;O;O
were;O;O
coadministered;O;O
to;O;O
15;O;O
rheumatoid;O;O
arthritis;O;O
patients;O;O
in;O;O
a;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
study;O;O
,;O;O
the;O;O
pharmacokinetic;O;O
disposition;O;O
of;O;O
the;O;O
drugs;O;O
was;O;O
not;O;O
altered;O;O
.;O;O
DDI-DrugBank.d693.s2;;
Daily;O;O
doses;O;O
of;O;O
sulfasalazine;B-drug;B-DDI-DrugBank.d693.s2.e0
2;O;O
g;O;O
(;O;O
maximum;O;O
3;O;O
g;O;O
);O;O
and;O;O
weekly;O;O
doses;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d693.s2.e1
7.5;O;O
mg;O;O
(;O;O
maximum;O;O
15;O;O
mg;O;O
);O;O
were;O;O
administered;O;O
alone;O;O
or;O;O
in;O;O
combination;O;O
to;O;O
310;O;O
rheumatoid;O;O
arthritis;O;O
patients;O;O
in;O;O
two;O;O
controlled;O;O
52;O;O
-;O;O
week;O;O
clinical;O;O
studies;O;O
.;O;O
DDI-DrugBank.d693.s3;;
The;O;O
overall;O;O
toxicity;O;O
profile;O;O
of;O;O
the;O;O
combination;O;O
revealed;O;O
an;O;O
increased;O;O
incidence;O;O
of;O;O
gastrointestinal;O;O
adverse;O;O
events;O;O
,;O;O
especially;O;O
nausea;O;O
,;O;O
when;O;O
compared;O;O
to;O;O
the;O;O
incidence;O;O
associated;O;O
with;O;O
either;O;O
drug;O;O
administered;O;O
alone;O;O
.;O;O
DDI-DrugBank.d693.s4;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
The;O;O
presence;O;O
of;O;O
sulfasalazine;B-drug;B-DDI-DrugBank.d693.s4.e0
or;O;O
its;O;O
metabolites;O;O
in;O;O
body;O;O
fluids;O;O
has;O;O
not;O;O
been;O;O
reported;O;O
to;O;O
interfere;O;O
with;O;O
laboratory;O;O
test;O;O
procedures;O;O
.;O;O
DDI-DrugBank.d693.s5;;
REFERENCES;O;O
7.Farr;O;O
M;O;O
,;O;O
et;O;O
al;O;O
.;O;O
DDI-DrugBank.d693.s6;;
Immunodeficiencies;O;O
associated;O;O
with;O;O
sulphasalazine;B-drug;B-DDI-DrugBank.d693.s6.e0
therapy;O;O
in;O;O
inflammatory;O;O
arthritis;O;O
.;O;O
DDI-DrugBank.d693.s7;;
British;O;O
Jnl;O;O
Rheum;O;O
1991;O;O
;;O;O
30:413;O;O
-;O;O
417;O;O
.;O;O
DDI-DrugBank.d682.s0;;
Sulfoxone;B-drug;B-DDI-DrugBank.d682.s0.e0
may;O;O
increase;O;O
the;O;O
effects;O;O
of;O;O
barbiturates;B-group;B-DDI-DrugBank.d682.s0.e1
,;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d682.s0.e2
,;O;O
and;O;O
uricosurics;B-group;B-DDI-DrugBank.d682.s0.e3
.;O;O
DDI-DrugBank.d682.s1;;
It;O;O
may;O;O
also;O;O
interact;O;O
with;O;O
thiazides;B-group;B-DDI-DrugBank.d682.s1.e0
(;O;O
increased;O;O
thrombocytopenia;O;O
);O;O
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d682.s1.e1
(;O;O
increased;O;O
nephrotoxicity;O;O
);O;O
,;O;O
sulfonylurea;B-group;B-DDI-DrugBank.d682.s1.e2
agents;I-group;I-DDI-DrugBank.d682.s1.e2
(;O;O
increased;O;O
hypoglycemic;O;O
response;O;O
);O;O
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d682.s1.e3
(;O;O
increased;O;O
anticoagulant;O;O
effect;O;O
);O;O
,;O;O
methotrexate;B-drug;B-DDI-DrugBank.d682.s1.e4
(;O;O
decreased;O;O
renal;O;O
excretion;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d682.s1.e5
);O;O
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d682.s1.e6
(;O;O
decreased;O;O
hepatic;O;O
clearance;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d682.s1.e7
);O;O
.;O;O
DDI-DrugBank.d720.s0;;
Ergot;B-group;B-DDI-DrugBank.d720.s0.e0
-;O;O
containing;O;O
drugs;O;O
have;O;O
been;O;O
reported;O;O
to;O;O
cause;O;O
prolonged;O;O
vasospastic;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d720.s1;;
Because;O;O
there;O;O
is;O;O
a;O;O
theoretical;O;O
basis;O;O
that;O;O
these;O;O
effects;O;O
may;O;O
be;O;O
additive;O;O
,;O;O
use;O;O
of;O;O
ergotamine;B-drug;B-DDI-DrugBank.d720.s1.e0
-;O;O
containing;O;O
or;O;O
ergot;B-group;B-DDI-DrugBank.d720.s1.e1
-;I-group;I-DDI-DrugBank.d720.s1.e1
type;I-group;I-DDI-DrugBank.d720.s1.e1
medications;I-group;I-DDI-DrugBank.d720.s1.e1
(;O;O
like;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d720.s1.e2
or;O;O
methysergide;B-drug;B-DDI-DrugBank.d720.s1.e3
);O;O
and;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d720.s1.e4
within;O;O
24;O;O
hours;O;O
of;O;O
each;O;O
other;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d720.s2;;
MAO;B-group;B-DDI-DrugBank.d720.s2.e0
-;I-group;I-DDI-DrugBank.d720.s2.e0
A;I-group;I-DDI-DrugBank.d720.s2.e0
inhibitors;I-group;I-DDI-DrugBank.d720.s2.e0
reduce;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d720.s2.e1
clearance;O;O
,;O;O
significantly;O;O
increasing;O;O
systemic;O;O
exposure;O;O
.;O;O
DDI-DrugBank.d720.s3;;
Therefore;O;O
,;O;O
the;O;O
use;O;O
of;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d720.s3.e0
succinate;I-drug;I-DDI-DrugBank.d720.s3.e0
tablets;O;O
in;O;O
patients;O;O
receiving;O;O
MAO;B-group;B-DDI-DrugBank.d720.s3.e1
-;I-group;I-DDI-DrugBank.d720.s3.e1
A;I-group;I-DDI-DrugBank.d720.s3.e1
inhibitors;I-group;I-DDI-DrugBank.d720.s3.e1
is;O;O
contraindicated;O;O
.;O;O
Selective;B-group;B-DDI-DrugBank.d720.s3.e2
serotonin;I-group;I-DDI-DrugBank.d720.s3.e2
reuptake;I-group;I-DDI-DrugBank.d720.s3.e2
inhibitors;I-group;I-DDI-DrugBank.d720.s3.e2
(;O;O
SSRIs;B-group;B-DDI-DrugBank.d720.s3.e3
);O;O
(;O;O
e.g.;O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d720.s3.e4
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d720.s3.e5
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d720.s3.e6
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d720.s3.e7
);O;O
have;O;O
been;O;O
reported;O;O
,;O;O
rarely;O;O
,;O;O
to;O;O
cause;O;O
weakness;O;O
,;O;O
hyperreflexia;O;O
,;O;O
and;O;O
incoordination;O;O
when;O;O
coadministered;O;O
with;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d720.s3.e8
.;O;O
DDI-DrugBank.d720.s4;;
If;O;O
concomitant;O;O
treatment;O;O
with;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d720.s4.e0
and;O;O
an;O;O
SSRI;B-group;B-DDI-DrugBank.d720.s4.e1
is;O;O
clinically;O;O
warranted;O;O
,;O;O
appropriate;O;O
observation;O;O
of;O;O
the;O;O
patient;O;O
is;O;O
advised;O;O
.;O;O
DDI-DrugBank.d639.s0;;
Co;O;O
-;O;O
administration;O;O
of;O;O
SUTENT;B-brand;B-DDI-DrugBank.d639.s0.e0
with;O;O
strong;O;O
inhibitors;O;O
of;O;O
the;O;O
CYP3A4;O;O
family;O;O
(;O;O
e.g.;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d639.s0.e1
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d639.s0.e2
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d639.s0.e3
,;O;O
atazanavir;B-drug;B-DDI-DrugBank.d639.s0.e4
,;O;O
indinavir;B-drug;B-DDI-DrugBank.d639.s0.e5
,;O;O
nefazodone;B-drug;B-DDI-DrugBank.d639.s0.e6
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d639.s0.e7
,;O;O
ritonavir;B-drug;B-DDI-DrugBank.d639.s0.e8
,;O;O
saquinavir;B-drug;B-DDI-DrugBank.d639.s0.e9
,;O;O
telithromycin;B-drug;B-DDI-DrugBank.d639.s0.e10
,;O;O
voriconizole;B-drug;B-DDI-DrugBank.d639.s0.e11
);O;O
may;O;O
increases;O;O
sunitinib;B-drug;B-DDI-DrugBank.d639.s0.e12
concentrations;O;O
.;O;O
DDI-DrugBank.d639.s1;;
Grapefruit;O;O
may;O;O
also;O;O
increase;O;O
plasma;O;O
concentrations;O;O
of;O;O
SUTENT;B-brand;B-DDI-DrugBank.d639.s1.e0
.;O;O
DDI-DrugBank.d639.s2;;
Co;O;O
-;O;O
administration;O;O
of;O;O
SUTENT;B-brand;B-DDI-DrugBank.d639.s2.e0
with;O;O
inducers;O;O
of;O;O
the;O;O
CYP3A4;O;O
family;O;O
(;O;O
e.g.;O;O
,;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d639.s2.e1
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d639.s2.e2
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d639.s2.e3
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d639.s2.e4
,;O;O
rifabutin;B-drug;B-DDI-DrugBank.d639.s2.e5
,;O;O
rifapentin;B-drug;B-DDI-DrugBank.d639.s2.e6
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d639.s2.e7
,;O;O
St.;O;O
Johns;O;O
Wort;O;O
);O;O
may;O;O
decrease;O;O
sunitinib;B-drug;B-DDI-DrugBank.d639.s2.e8
concentrations;O;O
.;O;O
DDI-DrugBank.d639.s3;;
St.;O;O
DDI-DrugBank.d639.s4;;
Johns;O;O
Wort;O;O
may;O;O
decrease;O;O
SUTENT;B-brand;B-DDI-DrugBank.d639.s4.e0
plasma;O;O
concentrations;O;O
unpredictably;O;O
.;O;O
DDI-DrugBank.d639.s5;;
Patients;O;O
receiving;O;O
SUTENT;B-brand;B-DDI-DrugBank.d639.s5.e0
should;O;O
not;O;O
take;O;O
St.;O;O
DDI-DrugBank.d639.s6;;
Johns;O;O
Wort;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d639.s7;;
SUTENT;B-brand;B-DDI-DrugBank.d639.s7.e0
dose;O;O
modification;O;O
is;O;O
recommended;O;O
in;O;O
patients;O;O
using;O;O
concomitant;O;O
CYP3A4;O;O
inhibitors;O;O
or;O;O
inducers;O;O
.;O;O
DDI-DrugBank.d723.s0;;
Other;O;O
eye;O;O
drops;O;O
or;O;O
medications;O;O
such;O;O
as;O;O
acetylcholine;B-drug;B-DDI-DrugBank.d723.s0.e0
chloride;I-drug;I-DDI-DrugBank.d723.s0.e0
(;O;O
Miochol;B-brand;B-DDI-DrugBank.d723.s0.e1
);O;O
and;O;O
carbachol;B-drug;B-DDI-DrugBank.d723.s0.e2
(;O;O
Carboptic;B-brand;B-DDI-DrugBank.d723.s0.e3
,;O;O
Isopto;B-brand;B-DDI-DrugBank.d723.s0.e4
Carbachol;I-brand;I-DDI-DrugBank.d723.s0.e4
);O;O
may;O;O
decrease;O;O
the;O;O
effects;O;O
of;O;O
suprofen;B-drug;B-DDI-DrugBank.d723.s0.e5
ophthalmic;O;O
.;O;O
DDI-DrugBank.d704.s0;;
Drug;O;O
-;O;O
Drug;O;O
Interactions;O;O
:;O;O
The;O;O
pharmacokinetic;O;O
and;O;O
pharmacodynamic;O;O
interactions;O;O
between;O;O
FLOMAX;B-brand;B-DDI-DrugBank.d704.s0.e0
capsules;O;O
and;O;O
other;O;O
alpha;B-group;B-DDI-DrugBank.d704.s0.e1
-;I-group;I-DDI-DrugBank.d704.s0.e1
adrenergic;I-group;I-DDI-DrugBank.d704.s0.e1
blocking;I-group;I-DDI-DrugBank.d704.s0.e1
agents;I-group;I-DDI-DrugBank.d704.s0.e1
have;O;O
not;O;O
been;O;O
determined;O;O
.;O;O
DDI-DrugBank.d704.s1;;
However;O;O
,;O;O
interactions;O;O
may;O;O
be;O;O
expected;O;O
and;O;O
FLOMAX;B-brand;B-DDI-DrugBank.d704.s1.e0
capsules;O;O
should;O;O
NOT;O;O
be;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
alpha;B-group;B-DDI-DrugBank.d704.s1.e1
-;I-group;I-DDI-DrugBank.d704.s1.e1
adrenergic;I-group;I-DDI-DrugBank.d704.s1.e1
blocking;I-group;I-DDI-DrugBank.d704.s1.e1
agents;I-group;I-DDI-DrugBank.d704.s1.e1
.;O;O
DDI-DrugBank.d704.s2;;
The;O;O
pharmacokinetic;O;O
interaction;O;O
between;O;O
cimetidine;B-drug;B-DDI-DrugBank.d704.s2.e0
and;O;O
FLOMAX;B-brand;B-DDI-DrugBank.d704.s2.e1
capsules;O;O
was;O;O
investigated;O;O
.;O;O
DDI-DrugBank.d704.s3;;
The;O;O
results;O;O
indicate;O;O
significant;O;O
changes;O;O
in;O;O
tamsulosin;B-drug;B-DDI-DrugBank.d704.s3.e0
HCI;I-drug;I-DDI-DrugBank.d704.s3.e0
clearance;O;O
(;O;O
26;O;O
%;O;O
decrease;O;O
);O;O
and;O;O
AUC;O;O
(;O;O
44;O;O
%;O;O
increase;O;O
);O;O
.;O;O
DDI-DrugBank.d704.s4;;
Therefore;O;O
,;O;O
FLOMAX;B-brand;B-DDI-DrugBank.d704.s4.e0
capsules;O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
combination;O;O
with;O;O
cimetidine;B-drug;B-DDI-DrugBank.d704.s4.e1
,;O;O
particularly;O;O
at;O;O
doses;O;O
higher;O;O
than;O;O
0.4;O;O
mg;O;O
.;O;O
DDI-DrugBank.d704.s5;;
Results;O;O
from;O;O
limited;O;O
in;O;O
vitro;O;O
and;O;O
in;O;O
vivo;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
between;O;O
tamsulosin;B-drug;B-DDI-DrugBank.d704.s5.e0
HCI;I-drug;I-DDI-DrugBank.d704.s5.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d704.s5.e1
are;O;O
inconclusive;O;O
.;O;O
DDI-DrugBank.d704.s6;;
Therefore;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
with;O;O
concomitant;O;O
administration;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d704.s6.e0
and;O;O
FLOMAX;B-brand;B-DDI-DrugBank.d704.s6.e1
capsules;O;O
.;O;O
DDI-DrugBank.d687.s0;;
Administration;O;O
of;O;O
valproic;B-drug;B-DDI-DrugBank.d687.s0.e0
acid;I-drug;I-DDI-DrugBank.d687.s0.e0
decreases;O;O
oral;O;O
clearance;O;O
of;O;O
temozolomide;B-drug;B-DDI-DrugBank.d687.s0.e1
by;O;O
about;O;O
5;O;O
%;O;O
.;O;O
DDI-DrugBank.d687.s1;;
The;O;O
clinical;O;O
implication;O;O
of;O;O
this;O;O
effect;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d687.s2;;
Patients;O;O
with;O;O
Severe;O;O
Hepatic;O;O
or;O;O
Renal;O;O
Impairment;O;O
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
TEMODAR;B-brand;B-DDI-DrugBank.d687.s2.e0
Capsules;O;O
are;O;O
administered;O;O
to;O;O
patients;O;O
with;O;O
severe;O;O
hepatic;O;O
or;O;O
renal;O;O
impairment;O;O
.;O;O
DDI-DrugBank.d773.s0;;
Formal;O;O
interaction;O;O
studies;O;O
of;O;O
TNKase;B-brand;B-DDI-DrugBank.d773.s0.e0
with;O;O
other;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d773.s1;;
Patients;O;O
studied;O;O
in;O;O
clinical;O;O
trials;O;O
of;O;O
TNKase;B-brand;B-DDI-DrugBank.d773.s1.e0
were;O;O
routinely;O;O
treated;O;O
with;O;O
heparin;B-drug;B-DDI-DrugBank.d773.s1.e1
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d773.s1.e2
.;O;O
DDI-DrugBank.d773.s2;;
Anticoagulants;B-group;B-DDI-DrugBank.d773.s2.e0
(;O;O
such;O;O
as;O;O
heparin;B-drug;B-DDI-DrugBank.d773.s2.e1
and;O;O
vitamin;B-group;B-DDI-DrugBank.d773.s2.e2
K;I-group;I-DDI-DrugBank.d773.s2.e2
antagonists;I-group;I-DDI-DrugBank.d773.s2.e2
);O;O
and;O;O
drugs;O;O
that;O;O
alter;O;O
platelet;O;O
function;O;O
(;O;O
such;O;O
as;O;O
acetylsalicylic;B-drug;B-DDI-DrugBank.d773.s2.e3
acid;I-drug;I-DDI-DrugBank.d773.s2.e3
,;O;O
dipyridamole;B-drug;B-DDI-DrugBank.d773.s2.e4
,;O;O
and;O;O
GP;O;O
IIb;O;O
/;O;O
IIIa;O;O
inhibitors;O;O
);O;O
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
bleeding;O;O
if;O;O
administered;O;O
prior;O;O
to;O;O
,;O;O
during;O;O
,;O;O
or;O;O
after;O;O
TNKase;B-brand;B-DDI-DrugBank.d773.s2.e5
therapy;O;O
.;O;O
DDI-DrugBank.d773.s3;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
During;O;O
TNKase;B-brand;B-DDI-DrugBank.d773.s3.e0
therapy;O;O
,;O;O
results;O;O
of;O;O
coagulation;O;O
tests;O;O
and/or;O;O
measures;O;O
of;O;O
fibrinolytic;O;O
activity;O;O
may;O;O
be;O;O
unreliable;O;O
unless;O;O
specific;O;O
precautions;O;O
are;O;O
taken;O;O
to;O;O
prevent;O;O
in;O;O
vitro;O;O
artifacts;O;O
.;O;O
DDI-DrugBank.d773.s4;;
Tenecteplase;B-drug;B-DDI-DrugBank.d773.s4.e0
is;O;O
an;O;O
enzyme;O;O
that;O;O
,;O;O
when;O;O
present;O;O
in;O;O
blood;O;O
in;O;O
pharmacologic;O;O
concentrations;O;O
,;O;O
remains;O;O
active;O;O
under;O;O
in;O;O
vitro;O;O
conditions;O;O
.;O;O
DDI-DrugBank.d773.s5;;
This;O;O
can;O;O
lead;O;O
to;O;O
degradation;O;O
of;O;O
fibrinogen;O;O
in;O;O
blood;O;O
samples;O;O
removed;O;O
for;O;O
analysis;O;O
.;O;O
DDI-DrugBank.d575.s0;;
In;O;O
a;O;O
study;O;O
in;O;O
which;O;O
34;O;O
different;O;O
drugs;O;O
were;O;O
tested;O;O
,;O;O
therapeutically;O;O
relevant;O;O
concentrations;O;O
of;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d575.s0.e0
,;O;O
sodium;B-drug;B-DDI-DrugBank.d575.s0.e1
salicylate;I-drug;I-DDI-DrugBank.d575.s0.e1
and;O;O
sulfamethizole;B-drug;B-DDI-DrugBank.d575.s0.e2
displaced;O;O
protein;O;O
-;O;O
bound;O;O
teniposide;B-drug;B-DDI-DrugBank.d575.s0.e3
in;O;O
fresh;O;O
human;O;O
serum;O;O
to;O;O
a;O;O
small;O;O
but;O;O
significant;O;O
extent;O;O
.;O;O
DDI-DrugBank.d575.s1;;
Because;O;O
of;O;O
the;O;O
extremely;O;O
high;O;O
binding;O;O
of;O;O
teniposide;B-drug;B-DDI-DrugBank.d575.s1.e0
to;O;O
plasma;O;O
proteins;O;O
,;O;O
these;O;O
small;O;O
decreases;O;O
in;O;O
binding;O;O
could;O;O
cause;O;O
substantial;O;O
increases;O;O
in;O;O
free;O;O
drug;O;O
levels;O;O
in;O;O
plasma;O;O
which;O;O
could;O;O
result;O;O
in;O;O
potentiation;O;O
of;O;O
drug;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d575.s2;;
Therefore;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
in;O;O
administering;O;O
VUMON;B-brand;B-DDI-DrugBank.d575.s2.e0
(;O;O
teniposide;B-drug;B-DDI-DrugBank.d575.s2.e1
injection;O;O
);O;O
to;O;O
patients;O;O
receiving;O;O
these;O;O
other;O;O
agents;O;O
.;O;O
DDI-DrugBank.d575.s3;;
There;O;O
was;O;O
no;O;O
change;O;O
in;O;O
the;O;O
plasma;O;O
kinetics;O;O
of;O;O
teniposide;B-drug;B-DDI-DrugBank.d575.s3.e0
when;O;O
coadministered;O;O
with;O;O
methotrexate;B-drug;B-DDI-DrugBank.d575.s3.e1
.;O;O
DDI-DrugBank.d575.s4;;
However;O;O
,;O;O
the;O;O
plasma;O;O
clearance;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d575.s4.e0
was;O;O
slightly;O;O
increased;O;O
.;O;O
DDI-DrugBank.d575.s5;;
An;O;O
increase;O;O
in;O;O
intracellular;O;O
levels;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d575.s5.e0
was;O;O
observed;O;O
in;O;O
vitro;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
teniposide;B-drug;B-DDI-DrugBank.d575.s5.e1
.;O;O
DDI-DrugBank.d645.s0;;
In;O;O
vitro;O;O
studies;O;O
with;O;O
human;O;O
liver;O;O
microsomes;O;O
showed;O;O
that;O;O
terbinafine;B-drug;B-DDI-DrugBank.d645.s0.e0
does;O;O
not;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d645.s0.e1
,;O;O
ethinylestradiol;B-drug;B-DDI-DrugBank.d645.s0.e2
,;O;O
ethoxycoumarin;B-drug_n;B-DDI-DrugBank.d645.s0.e3
,;O;O
and;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d645.s0.e4
.;O;O
DDI-DrugBank.d645.s1;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
also;O;O
shown;O;O
that;O;O
terbinafine;B-drug;B-DDI-DrugBank.d645.s1.e0
inhibits;O;O
CYP2D6;O;O
-;O;O
mediated;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d645.s2;;
This;O;O
may;O;O
be;O;O
of;O;O
clinical;O;O
relevance;O;O
for;O;O
compounds;O;O
predominantly;O;O
metabolized;O;O
by;O;O
this;O;O
enzyme;O;O
,;O;O
such;O;O
as;O;O
tricyclic;B-group;B-DDI-DrugBank.d645.s2.e0
antidepressants;I-group;I-DDI-DrugBank.d645.s2.e0
,;O;O
-blockers;O;O
,;O;O
selective;B-group;B-DDI-DrugBank.d645.s2.e1
serotonin;I-group;I-DDI-DrugBank.d645.s2.e1
reuptake;I-group;I-DDI-DrugBank.d645.s2.e1
inhibitors;I-group;I-DDI-DrugBank.d645.s2.e1
(;O;O
SSRIs;B-group;B-DDI-DrugBank.d645.s2.e2
);O;O
,;O;O
and;O;O
monoamine;B-group;B-DDI-DrugBank.d645.s2.e3
oxidase;I-group;I-DDI-DrugBank.d645.s2.e3
inhibitors;I-group;I-DDI-DrugBank.d645.s2.e3
(;I-group;I-DDI-DrugBank.d645.s2.e3
MAO;I-group;I-DDI-DrugBank.d645.s2.e3
-;I-group;I-DDI-DrugBank.d645.s2.e3
Is;I-group;I-DDI-DrugBank.d645.s2.e3
);I-group;I-DDI-DrugBank.d645.s2.e3
Type;I-group;I-DDI-DrugBank.d645.s2.e3
B;I-group;I-DDI-DrugBank.d645.s2.e3
,;O;O
if;O;O
they;O;O
have;O;O
a;O;O
narrow;O;O
therapeutic;O;O
window;O;O
.;O;O
DDI-DrugBank.d645.s3;;
In;O;O
vivo;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
conducted;O;O
in;O;O
normal;O;O
volunteer;O;O
subjects;O;O
showed;O;O
that;O;O
terbinafine;B-drug;B-DDI-DrugBank.d645.s3.e0
does;O;O
not;O;O
affect;O;O
the;O;O
clearance;O;O
of;O;O
antipyrine;B-drug;B-DDI-DrugBank.d645.s3.e1
or;O;O
digoxin;B-drug;B-DDI-DrugBank.d645.s3.e2
.;O;O
DDI-DrugBank.d645.s4;;
Terbinafine;B-drug;B-DDI-DrugBank.d645.s4.e0
decreases;O;O
the;O;O
clearance;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d645.s4.e1
by;O;O
19;O;O
%;O;O
.;O;O
DDI-DrugBank.d645.s5;;
Terbinafine;B-drug;B-DDI-DrugBank.d645.s5.e0
increases;O;O
the;O;O
clearance;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d645.s5.e1
by;O;O
15;O;O
%;O;O
.;O;O
DDI-DrugBank.d645.s6;;
There;O;O
have;O;O
been;O;O
spontaneous;O;O
reports;O;O
of;O;O
increase;O;O
or;O;O
decrease;O;O
in;O;O
prothrombin;O;O
times;O;O
in;O;O
patients;O;O
concomitantly;O;O
taking;O;O
oral;O;O
terbinafine;B-drug;B-DDI-DrugBank.d645.s6.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d645.s6.e1
,;O;O
however;O;O
,;O;O
a;O;O
causal;O;O
relationship;O;O
between;O;O
LAMISIL;B-brand;B-DDI-DrugBank.d645.s6.e2
Tablets;O;O
and;O;O
these;O;O
changes;O;O
has;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d645.s7;;
Terbinafine;B-drug;B-DDI-DrugBank.d645.s7.e0
clearance;O;O
is;O;O
increased;O;O
100;O;O
%;O;O
by;O;O
rifampin;B-drug;B-DDI-DrugBank.d645.s7.e1
,;O;O
a;O;O
CyP450;O;O
enzyme;O;O
inducer;O;O
,;O;O
and;O;O
decreased;O;O
33;O;O
%;O;O
by;O;O
cimetidine;B-drug;B-DDI-DrugBank.d645.s7.e2
,;O;O
a;O;O
CyP450;O;O
enzyme;O;O
inhibitor;O;O
.;O;O
DDI-DrugBank.d645.s8;;
Terbinafine;B-drug;B-DDI-DrugBank.d645.s8.e0
clearance;O;O
is;O;O
unaffected;O;O
by;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d645.s8.e1
.;O;O
DDI-DrugBank.d645.s9;;
There;O;O
is;O;O
no;O;O
information;O;O
available;O;O
from;O;O
adequate;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
with;O;O
the;O;O
following;O;O
classes;O;O
of;O;O
drugs;O;O
:;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d645.s9.e0
,;O;O
hormone;O;O
replacement;O;O
therapies;O;O
,;O;O
hypoglycemics;B-group;B-DDI-DrugBank.d645.s9.e1
,;O;O
theophyllines;B-drug;B-DDI-DrugBank.d645.s9.e2
,;O;O
phenytoins;B-drug;B-DDI-DrugBank.d645.s9.e3
,;O;O
thiazide;B-group;B-DDI-DrugBank.d645.s9.e4
diuretics;I-group;I-DDI-DrugBank.d645.s9.e4
,;O;O
beta;B-group;B-DDI-DrugBank.d645.s9.e5
blockers;I-group;I-DDI-DrugBank.d645.s9.e5
,;O;O
and;O;O
calcium;B-group;B-DDI-DrugBank.d645.s9.e6
channel;I-group;I-DDI-DrugBank.d645.s9.e6
blockers;I-group;I-DDI-DrugBank.d645.s9.e6
.;O;O
DDI-DrugBank.d743.s0;;
Ketoconazole;B-drug;B-DDI-DrugBank.d743.s0.e0
:;O;O
Spontaneous;O;O
adverse;O;O
reaction;O;O
reports;O;O
of;O;O
patients;O;O
taking;O;O
concomitant;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d743.s0.e1
with;O;O
recommended;O;O
doses;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s0.e2
demonstrate;O;O
QT;O;O
interval;O;O
prolongation;O;O
and;O;O
rare;O;O
serious;O;O
cardiac;O;O
events;O;O
,;O;O
e.g.;O;O
DDI-DrugBank.d743.s1;;
death;O;O
,;O;O
cardiac;O;O
arrest;O;O
,;O;O
and;O;O
ventricular;O;O
arrhythmia;O;O
including;O;O
torsades;O;O
de;O;O
pointes;O;O
.;O;O
DDI-DrugBank.d743.s2;;
Pharmacokinetic;O;O
data;O;O
indicate;O;O
that;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d743.s2.e0
markedly;O;O
inhibits;O;O
the;O;O
metabolism;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s2.e1
,;O;O
resulting;O;O
in;O;O
elevated;O;O
plasma;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s2.e2
levels;O;O
.;O;O
DDI-DrugBank.d743.s3;;
Presence;O;O
of;O;O
unchanged;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s3.e0
is;O;O
associated;O;O
with;O;O
statistically;O;O
significant;O;O
prolongation;O;O
of;O;O
the;O;O
QT;O;O
and;O;O
QTc;O;O
intervals;O;O
.;O;O
DDI-DrugBank.d743.s4;;
Concomitant;O;O
administration;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d743.s4.e0
and;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s4.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d743.s5;;
Itraconazole;B-drug;B-DDI-DrugBank.d743.s5.e0
:;O;O
Torsades;O;O
de;O;O
pointes;O;O
and;O;O
elevated;O;O
parent;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s5.e1
levels;O;O
have;O;O
been;O;O
reported;O;O
during;O;O
concomitant;O;O
use;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s5.e2
and;O;O
itraconazole;B-drug;B-DDI-DrugBank.d743.s5.e3
in;O;O
clinical;O;O
trials;O;O
of;O;O
itraconazole;B-drug;B-DDI-DrugBank.d743.s5.e4
and;O;O
from;O;O
foreign;O;O
post;O;O
-;O;O
marketing;O;O
sources;O;O
.;O;O
DDI-DrugBank.d743.s6;;
One;O;O
death;O;O
has;O;O
also;O;O
been;O;O
reported;O;O
from;O;O
foreign;O;O
post;O;O
-;O;O
marketing;O;O
sources;O;O
.;O;O
DDI-DrugBank.d743.s7;;
Concomitant;O;O
administration;O;O
of;O;O
itraconazole;B-drug;B-DDI-DrugBank.d743.s7.e0
and;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s7.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d743.s8;;
Due;O;O
to;O;O
the;O;O
chemical;O;O
similarity;O;O
of;O;O
other;O;O
azole;B-group;B-DDI-DrugBank.d743.s8.e0
-;I-group;I-DDI-DrugBank.d743.s8.e0
type;I-group;I-DDI-DrugBank.d743.s8.e0
antifungal;I-group;I-DDI-DrugBank.d743.s8.e0
agents;I-group;I-DDI-DrugBank.d743.s8.e0
(;O;O
including;O;O
fluconazole;B-drug;B-DDI-DrugBank.d743.s8.e1
,;O;O
metronidazole;B-drug;B-DDI-DrugBank.d743.s8.e2
,;O;O
and;O;O
miconazole;B-drug;B-DDI-DrugBank.d743.s8.e3
);O;O
to;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d743.s8.e4
,;O;O
and;O;O
itraconazole;B-drug;B-DDI-DrugBank.d743.s8.e5
,;O;O
concomitant;O;O
use;O;O
of;O;O
these;O;O
products;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s8.e6
is;O;O
not;O;O
recommended;O;O
pending;O;O
full;O;O
examination;O;O
of;O;O
potential;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d743.s9;;
Macrolides;B-group;B-DDI-DrugBank.d743.s9.e0
:;O;O
Clinical;O;O
drug;O;O
interaction;O;O
studies;O;O
indicate;O;O
that;O;O
erythromycin;B-drug;B-DDI-DrugBank.d743.s9.e1
and;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d743.s9.e2
can;O;O
exert;O;O
an;O;O
effect;O;O
on;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s9.e3
metabolism;O;O
by;O;O
a;O;O
mechanism;O;O
which;O;O
may;O;O
be;O;O
similar;O;O
to;O;O
that;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d743.s9.e4
,;O;O
but;O;O
to;O;O
a;O;O
lesser;O;O
extent;O;O
.;O;O
DDI-DrugBank.d743.s10;;
Although;O;O
erythromycin;O;O
measurably;O;O
decreases;O;O
the;O;O
clearance;O;O
of;O;O
the;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s10.e0
acid;O;O
metabolite;O;O
,;O;O
its;O;O
influence;O;O
on;O;O
terfenadine;O;O
plasma;O;O
levels;O;O
is;O;O
still;O;O
under;O;O
investigation;O;O
.;O;O
DDI-DrugBank.d743.s11;;
A;O;O
few;O;O
spontaneous;O;O
accounts;O;O
of;O;O
QT;O;O
interval;O;O
prolongation;O;O
with;O;O
ventricular;O;O
arrhythmia;O;O
including;O;O
torsades;O;O
de;O;O
pointes;O;O
,;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
erythromycin;B-drug;B-DDI-DrugBank.d743.s11.e0
or;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d743.s11.e1
.;O;O
DDI-DrugBank.d743.s12;;
Concomitant;O;O
administration;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s12.e0
with;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d743.s12.e1
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d743.s12.e2
,;O;O
or;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d743.s12.e3
is;O;O
contraindicated;O;O
:;O;O
Pending;O;O
full;O;O
characterization;O;O
of;O;O
potential;O;O
interactions;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s12.e4
with;O;O
other;O;O
macrolide;B-group;B-DDI-DrugBank.d743.s12.e5
antibiotics;I-group;I-DDI-DrugBank.d743.s12.e5
,;O;O
including;O;O
azithromycin;B-drug;B-DDI-DrugBank.d743.s12.e6
,;O;O
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d743.s13;;
Studies;O;O
to;O;O
evaluate;O;O
potential;O;O
interactions;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d743.s13.e0
with;O;O
azithromycin;B-drug;B-DDI-DrugBank.d743.s13.e1
are;O;O
in;O;O
progress;O;O
.;O;O
DDI-DrugBank.d658.s0;;
When;O;O
administered;O;O
concurrently;O;O
,;O;O
testolactone;B-drug;B-DDI-DrugBank.d658.s0.e0
may;O;O
increase;O;O
the;O;O
effects;O;O
of;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d658.s0.e1
;;O;O
DDI-DrugBank.d658.s1;;
monitor;O;O
and;O;O
adjust;O;O
anticoagulant;B-group;B-DDI-DrugBank.d658.s1.e0
dosage;O;O
accordingly;O;O
.;O;O
DDI-DrugBank.d658.s2;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
Physiologic;O;O
effects;O;O
of;O;O
testolactone;B-drug;B-DDI-DrugBank.d658.s2.e0
may;O;O
result;O;O
in;O;O
decreased;O;O
estradiol;O;O
concentrations;O;O
with;O;O
radioimmunoassays;O;O
for;O;O
estradiol;O;O
,;O;O
increased;O;O
plasma;O;O
calcium;O;O
concentrations;O;O
,;O;O
and;O;O
increased;O;O
24;O;O
-;O;O
hour;O;O
urinary;O;O
excretion;O;O
of;O;O
creatine;O;O
and;O;O
17;O;O
-;O;O
ketosteroids;O;O
.;O;O
DDI-DrugBank.d604.s0;;
Thalidomide;B-drug;B-DDI-DrugBank.d604.s0.e0
has;O;O
been;O;O
reported;O;O
to;O;O
enhance;O;O
the;O;O
sedative;O;O
activity;O;O
of;O;O
barbiturates;B-group;B-DDI-DrugBank.d604.s0.e1
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d604.s0.e2
,;O;O
chlorpromazine;B-drug;B-DDI-DrugBank.d604.s0.e3
,;O;O
and;O;O
reserpine;B-drug;B-DDI-DrugBank.d604.s0.e4
.;O;O
DDI-DrugBank.d604.s1;;
Peripheral;O;O
Neuropathy;O;O
:;O;O
Medications;O;O
known;O;O
to;O;O
be;O;O
associated;O;O
with;O;O
peripheral;O;O
neuropathy;O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
receiving;O;O
thalidomide;B-drug;B-DDI-DrugBank.d604.s1.e0
.;O;O
DDI-DrugBank.d604.s2;;
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d604.s2.e0
:;O;O
In;O;O
10;O;O
healthy;O;O
women;O;O
,;O;O
the;O;O
pharmacokinetic;O;O
profiles;O;O
of;O;O
norethindrone;B-drug;B-DDI-DrugBank.d604.s2.e1
and;O;O
ethinyl;B-drug;B-DDI-DrugBank.d604.s2.e2
estradiol;I-drug;I-DDI-DrugBank.d604.s2.e2
following;O;O
administration;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
containing;O;O
1.0;O;O
mg;O;O
of;O;O
norethindrone;B-drug;B-DDI-DrugBank.d604.s2.e3
acetate;I-drug;I-DDI-DrugBank.d604.s2.e3
and;O;O
75;O;O
g;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d604.s2.e4
estradiol;I-drug;I-DDI-DrugBank.d604.s2.e4
were;O;O
studied;O;O
.;O;O
DDI-DrugBank.d604.s3;;
The;O;O
results;O;O
were;O;O
similar;O;O
with;O;O
and;O;O
without;O;O
coadministration;O;O
of;O;O
thalidomide;B-drug;B-DDI-DrugBank.d604.s3.e0
200;O;O
mg;O;O
/;O;O
day;O;O
to;O;O
steady;O;O
-;O;O
state;O;O
levels;O;O
.;O;O
DDI-DrugBank.d604.s4;;
Important;O;O
Non;O;O
-;O;O
Thalidomide;B-drug;B-DDI-DrugBank.d604.s4.e0
Drug;O;O
Interactions;O;O
Drugs;O;O
That;O;O
Interfere;O;O
with;O;O
Hormonal;B-group;B-DDI-DrugBank.d604.s4.e1
Contraceptives;I-group;I-DDI-DrugBank.d604.s4.e1
:;O;O
Concomitant;O;O
use;O;O
of;O;O
HIV;B-group;B-DDI-DrugBank.d604.s4.e2
-;I-group;I-DDI-DrugBank.d604.s4.e2
protease;I-group;I-DDI-DrugBank.d604.s4.e2
inhibitors;I-group;I-DDI-DrugBank.d604.s4.e2
,;O;O
griseofulvin;B-drug;B-DDI-DrugBank.d604.s4.e3
,;O;O
modafinil;B-drug;B-DDI-DrugBank.d604.s4.e4
,;O;O
penicillins;B-group;B-DDI-DrugBank.d604.s4.e5
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d604.s4.e6
,;O;O
rifabutin;B-drug;B-DDI-DrugBank.d604.s4.e7
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d604.s4.e8
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d604.s4.e9
,;O;O
or;O;O
certain;O;O
herbal;O;O
supplements;O;O
such;O;O
as;O;O
St.;O;O
DDI-DrugBank.d604.s5;;
John;B-drug_n;B-DDI-DrugBank.d604.s5.e0
's;I-drug_n;I-DDI-DrugBank.d604.s5.e0
Wort;I-drug_n;I-DDI-DrugBank.d604.s5.e0
with;O;O
hormonal;B-group;B-DDI-DrugBank.d604.s5.e1
contraceptive;I-group;I-DDI-DrugBank.d604.s5.e1
agents;I-group;I-DDI-DrugBank.d604.s5.e1
may;O;O
reduce;O;O
the;O;O
effectiveness;O;O
of;O;O
the;O;O
contraception;O;O
and;O;O
up;O;O
to;O;O
one;O;O
month;O;O
after;O;O
discontinuation;O;O
of;O;O
these;O;O
concomitant;O;O
therapies;O;O
.;O;O
DDI-DrugBank.d604.s6;;
Therefore;O;O
,;O;O
women;O;O
requiring;O;O
treatment;O;O
with;O;O
one;O;O
or;O;O
more;O;O
of;O;O
these;O;O
drugs;O;O
must;O;O
use;O;O
two;O;O
OTHER;O;O
effective;O;O
or;O;O
highly;O;O
effective;O;O
methods;O;O
of;O;O
contraception;O;O
or;O;O
abstain;O;O
from;O;O
heterosexual;O;O
sexual;O;O
contact;O;O
while;O;O
taking;O;O
thalidomide;B-drug;B-DDI-DrugBank.d604.s6.e0
.;O;O
DDI-DrugBank.d686.s0;;
Thiabendazole;B-drug;B-DDI-DrugBank.d686.s0.e0
may;O;O
compete;O;O
with;O;O
other;O;O
drugs;O;O
,;O;O
such;O;O
as;O;O
theophylline;B-drug;B-DDI-DrugBank.d686.s0.e1
,;O;O
for;O;O
sites;O;O
of;O;O
metabolism;O;O
in;O;O
the;O;O
liver;O;O
,;O;O
thus;O;O
elevating;O;O
the;O;O
serum;O;O
levels;O;O
of;O;O
such;O;O
compounds;O;O
to;O;O
potentially;O;O
toxic;O;O
levels;O;O
.;O;O
DDI-DrugBank.d686.s1;;
Therefore;O;O
,;O;O
when;O;O
concomitant;O;O
use;O;O
of;O;O
thiabendazole;B-drug;B-DDI-DrugBank.d686.s1.e0
and;O;O
xanthine;B-group;B-DDI-DrugBank.d686.s1.e1
derivatives;I-group;I-DDI-DrugBank.d686.s1.e1
is;O;O
anticipated;O;O
,;O;O
it;O;O
may;O;O
be;O;O
necessary;O;O
to;O;O
monitor;O;O
blood;O;O
levels;O;O
and/or;O;O
reduce;O;O
the;O;O
dosage;O;O
of;O;O
such;O;O
compounds;O;O
.;O;O
DDI-DrugBank.d686.s2;;
Such;O;O
concomitant;O;O
use;O;O
should;O;O
be;O;O
administered;O;O
under;O;O
careful;O;O
medical;O;O
supervision;O;O
.;O;O
DDI-DrugBank.d697.s0;;
Interactions;O;O
for;O;O
Vitamin;B-drug;B-DDI-DrugBank.d697.s0.e0
B1;I-drug;I-DDI-DrugBank.d697.s0.e0
(;O;O
Thiamine;B-drug;B-DDI-DrugBank.d697.s0.e1
);O;O
:;O;O
Loop;B-group;B-DDI-DrugBank.d697.s0.e2
Diuretics;I-group;I-DDI-DrugBank.d697.s0.e2
,;O;O
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d697.s0.e3
,;O;O
Stavudine;B-drug;B-DDI-DrugBank.d697.s0.e4
,;O;O
Tricyclic;B-group;B-DDI-DrugBank.d697.s0.e5
Antidepressants;I-group;I-DDI-DrugBank.d697.s0.e5
DDI-DrugBank.d677.s0;;
Phenothiazines;I-group;I-DDI-DrugBank.d677.s0.e0
are;O;O
capable;O;O
of;O;O
potentiating;O;O
CNS;B-group;B-DDI-DrugBank.d677.s0.e1
depressants;I-group;I-DDI-DrugBank.d677.s0.e1
(;O;O
e.g.;O;O
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d677.s0.e2
,;O;O
anesthetics;B-group;B-DDI-DrugBank.d677.s0.e3
,;O;O
opiates;B-group;B-DDI-DrugBank.d677.s0.e4
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d677.s0.e5
,;O;O
etc;O;O
.;O;O
);O;O
DDI-DrugBank.d677.s1;;
as;O;O
well;O;O
as;O;O
atropine;B-drug;B-DDI-DrugBank.d677.s1.e0
and;O;O
phosphorous;B-drug_n;B-DDI-DrugBank.d677.s1.e1
insecticides;I-drug_n;I-DDI-DrugBank.d677.s1.e1
.;O;O
DDI-DrugBank.d722.s0;;
There;O;O
is;O;O
usually;O;O
complete;O;O
cross;O;O
-;O;O
resistance;O;O
between;O;O
PURINETHOL;B-brand;B-DDI-DrugBank.d722.s0.e0
(;O;O
mercaptopurine;B-drug;B-DDI-DrugBank.d722.s0.e1
);O;O
and;O;O
TABLOID;B-brand;B-DDI-DrugBank.d722.s0.e2
brand;O;O
Thioguanine;B-drug;B-DDI-DrugBank.d722.s0.e3
.;O;O
DDI-DrugBank.d722.s1;;
As;O;O
there;O;O
is;O;O
in;O;O
vitro;O;O
evidence;O;O
that;O;O
aminosalicylate;B-group;B-DDI-DrugBank.d722.s1.e0
derivatives;I-group;I-DDI-DrugBank.d722.s1.e0
(;O;O
e.g.;O;O
,;O;O
olsalazine;B-drug;B-DDI-DrugBank.d722.s1.e1
,;O;O
mesalazine;B-drug;B-DDI-DrugBank.d722.s1.e2
,;O;O
or;O;O
sulphasalazine;B-drug;B-DDI-DrugBank.d722.s1.e3
);O;O
inhibit;O;O
the;O;O
TPMT;O;O
enzyme;O;O
,;O;O
they;O;O
should;O;O
be;O;O
administered;O;O
with;O;O
caution;O;O
to;O;O
patients;O;O
receiving;O;O
concurrent;O;O
thioguanine;B-drug;B-DDI-DrugBank.d722.s1.e4
therapy;O;O
.;O;O
DDI-DrugBank.d616.s0;;
Interactions;O;O
between;O;O
ZADAXIN;B-brand;B-DDI-DrugBank.d616.s0.e0
and;O;O
other;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
fully;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d616.s1;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
administering;O;O
ZADAXIN;B-brand;B-DDI-DrugBank.d616.s1.e0
therapy;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
immunomodulating;B-group;B-DDI-DrugBank.d616.s1.e1
drugs;I-group;I-DDI-DrugBank.d616.s1.e1
.;O;O
DDI-DrugBank.d616.s2;;
ZADAXIN;B-brand;B-DDI-DrugBank.d616.s2.e0
should;O;O
not;O;O
be;O;O
mixed;O;O
with;O;O
any;O;O
other;O;O
drug;O;O
.;O;O
DDI-DrugBank.d642.s0;;
Prothrombin;O;O
time;O;O
or;O;O
other;O;O
suitable;O;O
anticoagulation;O;O
test;O;O
should;O;O
be;O;O
monitored;O;O
if;O;O
tigecycline;B-drug;B-DDI-DrugBank.d642.s0.e0
is;O;O
administered;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d642.s0.e1
.;O;O
DDI-DrugBank.d642.s1;;
Concurrent;O;O
use;O;O
of;O;O
antibacterial;B-group;B-DDI-DrugBank.d642.s1.e0
drugs;I-group;I-DDI-DrugBank.d642.s1.e0
with;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d642.s1.e1
may;O;O
render;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d642.s1.e2
less;O;O
effective;O;O
.;O;O
DDI-DrugBank.d642.s2;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
There;O;O
are;O;O
no;O;O
reported;O;O
drug;O;O
-;O;O
laboratory;O;O
test;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d721.s0;;
The;O;O
bioavailability;O;O
of;O;O
SKELID;B-brand;B-DDI-DrugBank.d721.s0.e0
is;O;O
decreased;O;O
80;O;O
%;O;O
by;O;O
calcium;B-drug;B-DDI-DrugBank.d721.s0.e1
,;O;O
when;O;O
calcium;B-drug;B-DDI-DrugBank.d721.s0.e2
and;O;O
SKELID;B-brand;B-DDI-DrugBank.d721.s0.e3
are;O;O
administered;O;O
at;O;O
the;O;O
same;O;O
time;O;O
,;O;O
and;O;O
60;O;O
%;O;O
by;O;O
some;O;O
aluminum;B-drug;B-DDI-DrugBank.d721.s0.e4
-;O;O
or;O;O
magnesium;B-drug;B-DDI-DrugBank.d721.s0.e5
-;O;O
containing;O;O
antacids;B-drug;B-DDI-DrugBank.d721.s0.e6
,;O;O
when;O;O
administered;O;O
1;O;O
hour;O;O
before;O;O
SKELID;B-brand;B-DDI-DrugBank.d721.s0.e7
.;O;O
DDI-DrugBank.d721.s1;;
Aspirin;B-brand;B-DDI-DrugBank.d721.s1.e0
may;O;O
decrease;O;O
bioavailability;O;O
of;O;O
SKELID;B-brand;B-DDI-DrugBank.d721.s1.e1
by;O;O
up;O;O
to;O;O
50;O;O
%;O;O
when;O;O
taken;O;O
2;O;O
hours;O;O
after;O;O
SKELID;B-brand;B-DDI-DrugBank.d721.s1.e2
.;O;O
DDI-DrugBank.d721.s2;;
The;O;O
bioavailability;O;O
of;O;O
SKELID;B-brand;B-DDI-DrugBank.d721.s2.e0
is;O;O
increased;O;O
2;O;O
-;O;O
4;O;O
fold;O;O
by;O;O
indomethacin;B-drug;B-DDI-DrugBank.d721.s2.e1
but;O;O
is;O;O
not;O;O
significantly;O;O
altered;O;O
by;O;O
coadministration;O;O
of;O;O
diclofenac;B-drug;B-DDI-DrugBank.d721.s2.e2
.;O;O
DDI-DrugBank.d721.s3;;
The;O;O
pharmacokinetic;O;O
parameters;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d721.s3.e0
are;O;O
not;O;O
significantly;O;O
modified;O;O
by;O;O
SKELID;B-brand;B-DDI-DrugBank.d721.s3.e1
coadministration;O;O
.;O;O
DDI-DrugBank.d721.s4;;
In;O;O
vitro;O;O
studies;O;O
show;O;O
that;O;O
tiludronate;B-drug;B-DDI-DrugBank.d721.s4.e0
does;O;O
not;O;O
displace;O;O
warfarin;B-drug;B-DDI-DrugBank.d721.s4.e1
from;O;O
its;O;O
binding;O;O
site;O;O
on;O;O
protein;O;O
.;O;O
DDI-DrugBank.d702.s0;;
SPIRIVA;B-brand;B-DDI-DrugBank.d702.s0.e0
has;O;O
been;O;O
used;O;O
concomitantly;O;O
with;O;O
other;O;O
drugs;O;O
commonly;O;O
used;O;O
in;O;O
COPD;O;O
without;O;O
increases;O;O
in;O;O
adverse;O;O
drug;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d702.s1;;
These;O;O
include;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d702.s1.e0
bronchodilators;I-group;I-DDI-DrugBank.d702.s1.e0
,;O;O
methylxanthines;B-group;B-DDI-DrugBank.d702.s1.e1
,;O;O
and;O;O
oral;O;O
and;O;O
inhaled;O;O
steroids;B-group;B-DDI-DrugBank.d702.s1.e2
.;O;O
DDI-DrugBank.d702.s2;;
However;O;O
,;O;O
the;O;O
co;O;O
administration;O;O
of;O;O
SPIRIVA;B-brand;B-DDI-DrugBank.d702.s2.e0
with;O;O
other;O;O
anticholinergic;B-group;B-DDI-DrugBank.d702.s2.e1
containing;O;O
drugs;O;O
(;O;O
e.g.;O;O
,;O;O
ipratropium;B-drug;B-DDI-DrugBank.d702.s2.e2
);O;O
has;O;O
not;O;O
been;O;O
studied;O;O
and;O;O
is;O;O
therefore;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d751.s0;;
AGGRASTAT;B-brand;B-DDI-DrugBank.d751.s0.e0
has;O;O
been;O;O
studied;O;O
on;O;O
a;O;O
background;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d751.s0.e1
and;O;O
heparin;B-drug;B-DDI-DrugBank.d751.s0.e2
.;O;O
DDI-DrugBank.d751.s1;;
The;O;O
use;O;O
of;O;O
AGGRASTAT;B-brand;B-DDI-DrugBank.d751.s1.e0
,;O;O
in;O;O
combination;O;O
with;O;O
heparin;B-drug;B-DDI-DrugBank.d751.s1.e1
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d751.s1.e2
,;O;O
has;O;O
been;O;O
associated;O;O
with;O;O
an;O;O
increase;O;O
in;O;O
bleeding;O;O
compared;O;O
to;O;O
heparin;B-drug;B-DDI-DrugBank.d751.s1.e3
and;O;O
aspirin;B-drug;B-DDI-DrugBank.d751.s1.e4
alone;O;O
(;O;O
see;O;O
DDI-DrugBank.d624.s0;;
In;O;O
clinical;O;O
studies;O;O
of;O;O
TOBI;B-brand;B-DDI-DrugBank.d624.s0.e0
,;O;O
patients;O;O
taking;O;O
TOBI;B-brand;B-DDI-DrugBank.d624.s0.e1
concomitantly;O;O
with;O;O
dornase;B-drug;B-DDI-DrugBank.d624.s0.e2
alfa;I-drug;I-DDI-DrugBank.d624.s0.e2
(;O;O
PULMOZYME;B-brand;B-DDI-DrugBank.d624.s0.e3
,;O;O
Genentech;O;O
);O;O
,;O;O
(;B-group;B-DDI-DrugBank.d624.s0.e4
beta);I-group;I-DDI-DrugBank.d624.s0.e4
-;I-group;I-DDI-DrugBank.d624.s0.e4
agonists;I-group;I-DDI-DrugBank.d624.s0.e4
,;O;O
inhaled;O;O
corticosteroids;B-group;B-DDI-DrugBank.d624.s0.e5
,;O;O
other;O;O
anti;B-group;B-DDI-DrugBank.d624.s0.e6
-;I-group;I-DDI-DrugBank.d624.s0.e6
pseudomonal;I-group;I-DDI-DrugBank.d624.s0.e6
antibiotics;I-group;I-DDI-DrugBank.d624.s0.e6
,;O;O
or;O;O
parenteral;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d624.s0.e7
demonstrated;O;O
adverse;O;O
experience;O;O
profiles;O;O
similar;O;O
to;O;O
the;O;O
study;O;O
population;O;O
as;O;O
a;O;O
whole;O;O
.;O;O
DDI-DrugBank.d624.s1;;
Concurrent;O;O
and/or;O;O
sequential;O;O
use;O;O
of;O;O
TOBI;B-brand;B-DDI-DrugBank.d624.s1.e0
with;O;O
other;O;O
drugs;O;O
with;O;O
neurotoxic;O;O
or;O;O
ototoxic;O;O
potential;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d624.s2;;
Some;O;O
diuretics;B-group;B-DDI-DrugBank.d624.s2.e0
can;O;O
enhance;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d624.s2.e1
toxicity;O;O
by;O;O
altering;O;O
antibiotic;B-group;B-DDI-DrugBank.d624.s2.e2
concentrations;O;O
in;O;O
serum;O;O
and;O;O
tissue;O;O
.;O;O
DDI-DrugBank.d624.s3;;
TOBI;B-brand;B-DDI-DrugBank.d624.s3.e0
should;O;O
not;O;O
be;O;O
administered;O;O
concomitantly;O;O
with;O;O
ethacrynic;B-drug;B-DDI-DrugBank.d624.s3.e1
acid;I-drug;I-DDI-DrugBank.d624.s3.e1
,;O;O
furosemide;B-drug;B-DDI-DrugBank.d624.s3.e2
,;O;O
urea;B-drug;B-DDI-DrugBank.d624.s3.e3
,;O;O
or;O;O
mannitol;B-drug;B-DDI-DrugBank.d624.s3.e4
.;O;O
DDI-DrugBank.d608.s0;;
The;O;O
in;O;O
vitro;O;O
binding;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d608.s0.e0
to;O;O
human;O;O
plasma;O;O
proteins;O;O
is;O;O
unaffected;O;O
by;O;O
tolmetin;B-drug;B-DDI-DrugBank.d608.s0.e1
,;O;O
and;O;O
tolmetin;B-drug;B-DDI-DrugBank.d608.s0.e2
does;O;O
not;O;O
alter;O;O
the;O;O
prothrombin;O;O
time;O;O
of;O;O
normal;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d608.s1;;
However;O;O
,;O;O
increased;O;O
prothrombin;O;O
time;O;O
and;O;O
bleeding;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
on;O;O
concomitant;O;O
TOLECTIN;B-brand;B-DDI-DrugBank.d608.s1.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d608.s1.e1
therapy;O;O
.;O;O
DDI-DrugBank.d608.s2;;
Therefore;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
administering;O;O
TOLECTIN;B-brand;B-DDI-DrugBank.d608.s2.e0
to;O;O
patients;O;O
on;O;O
anticoagulants;B-group;B-DDI-DrugBank.d608.s2.e1
.;O;O
DDI-DrugBank.d608.s3;;
In;O;O
adult;O;O
diabetic;O;O
patients;O;O
under;O;O
treatment;O;O
with;O;O
either;O;O
sulfonylureas;B-group;B-DDI-DrugBank.d608.s3.e0
or;O;O
insulin;B-drug;B-DDI-DrugBank.d608.s3.e1
there;O;O
is;O;O
no;O;O
change;O;O
in;O;O
the;O;O
clinical;O;O
effects;O;O
of;O;O
either;O;O
TOLECTIN;B-brand;B-DDI-DrugBank.d608.s3.e2
or;O;O
the;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d608.s3.e3
agents;I-group;I-DDI-DrugBank.d608.s3.e3
.;O;O
DDI-DrugBank.d608.s4;;
Caution;O;O
should;O;O
be;O;O
used;O;O
if;O;O
TOLECTIN;B-brand;B-DDI-DrugBank.d608.s4.e0
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
methotrexate;B-drug;B-DDI-DrugBank.d608.s4.e1
.;O;O
DDI-DrugBank.d608.s5;;
TOLECTIN;B-brand;B-DDI-DrugBank.d608.s5.e0
and;O;O
other;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d608.s5.e1
anti;I-group;I-DDI-DrugBank.d608.s5.e1
-;I-group;I-DDI-DrugBank.d608.s5.e1
inflammatory;I-group;I-DDI-DrugBank.d608.s5.e1
drugs;I-group;I-DDI-DrugBank.d608.s5.e1
have;O;O
been;O;O
reported;O;O
to;O;O
reduce;O;O
the;O;O
tubular;O;O
secretion;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d608.s5.e2
in;O;O
an;O;O
animal;O;O
model;O;O
,;O;O
possibly;O;O
enhancing;O;O
the;O;O
toxicity;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d608.s5.e3
.;O;O
DDI-DrugBank.d608.s6;;
Laboratory;O;O
Tests;O;O
Because;O;O
serious;O;O
GI;O;O
tract;O;O
ulceration;O;O
and;O;O
bleeding;O;O
can;O;O
occur;O;O
without;O;O
warning;O;O
symptoms;O;O
,;O;O
physicians;O;O
should;O;O
follow;O;O
chronically;O;O
treated;O;O
patients;O;O
for;O;O
the;O;O
signs;O;O
and;O;O
symptoms;O;O
of;O;O
ulceration;O;O
and;O;O
bleeding;O;O
and;O;O
should;O;O
inform;O;O
them;O;O
of;O;O
the;O;O
importance;O;O
of;O;O
this;O;O
follow;O;O
-;O;O
up;O;O
.;O;O
DDI-DrugBank.d765.s0;;
CYP3A4;O;O
Inhibitors;O;O
:;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d765.s0.e0
,;O;O
an;O;O
inhibitor;O;O
of;O;O
the;O;O
drug;O;O
metabolizing;O;O
enzyme;O;O
CYP3A4;O;O
,;O;O
significantly;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
tolterodine;B-drug;B-DDI-DrugBank.d765.s0.e1
when;O;O
coadministered;O;O
to;O;O
subjects;O;O
who;O;O
were;O;O
poor;O;O
metabolizers;O;O
(;O;O
see;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
,;O;O
Variability;O;O
in;O;O
Metabolism;O;O
and;O;O
Drug;O;O
-;O;O
Drug;O;O
Interactions;O;O
);O;O
.;O;O
DDI-DrugBank.d765.s1;;
For;O;O
patients;O;O
receiving;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d765.s1.e0
or;O;O
other;O;O
potent;O;O
CYP3A4;O;O
inhibitors;O;O
such;O;O
as;O;O
other;O;O
azole;B-group;B-DDI-DrugBank.d765.s1.e1
antifungals;I-group;I-DDI-DrugBank.d765.s1.e1
(;O;O
eg;O;O
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d765.s1.e2
,;O;O
miconazole;B-drug;B-DDI-DrugBank.d765.s1.e3
);O;O
or;O;O
macrolide;B-group;B-DDI-DrugBank.d765.s1.e4
antibiotics;I-group;I-DDI-DrugBank.d765.s1.e4
(;O;O
eg;O;O
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d765.s1.e5
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d765.s1.e6
);O;O
or;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d765.s1.e7
or;O;O
vinblastine;B-drug;B-DDI-DrugBank.d765.s1.e8
,;O;O
the;O;O
recommended;O;O
dose;O;O
of;O;O
DETROL;B-brand;B-DDI-DrugBank.d765.s1.e9
LA;I-brand;I-DDI-DrugBank.d765.s1.e9
is;O;O
2;O;O
mg;O;O
daily;O;O
.;O;O
DDI-DrugBank.d765.s2;;
Drug;O;O
-;O;O
Laboratory;O;O
-;O;O
Test;O;O
Interactions;O;O
Interactions;O;O
between;O;O
tolterodine;B-drug;B-DDI-DrugBank.d765.s2.e0
and;O;O
laboratory;O;O
tests;O;O
have;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d712.s0;;
There;O;O
have;O;O
been;O;O
no;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
performed;O;O
with;O;O
HERCEPTIN;B-brand;B-DDI-DrugBank.d712.s0.e0
in;O;O
humans;O;O
.;O;O
DDI-DrugBank.d712.s1;;
Administration;O;O
of;O;O
paclitaxel;B-drug;B-DDI-DrugBank.d712.s1.e0
in;O;O
combination;O;O
with;O;O
HERCEPTIN;B-brand;B-DDI-DrugBank.d712.s1.e1
resulted;O;O
in;O;O
a;O;O
two;O;O
-;O;O
fold;O;O
decrease;O;O
in;O;O
HERCEPTIN;B-brand;B-DDI-DrugBank.d712.s1.e2
clearance;O;O
in;O;O
a;O;O
non;O;O
-;O;O
human;O;O
primate;O;O
study;O;O
and;O;O
in;O;O
a;O;O
1.5;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
HERCEPTIN;B-brand;B-DDI-DrugBank.d712.s1.e3
serum;O;O
levels;O;O
in;O;O
clinical;O;O
studies;O;O
.;O;O
DDI-DrugBank.d774.s0;;
Trilostane;B-drug;B-DDI-DrugBank.d774.s0.e0
may;O;O
interact;O;O
with;O;O
aminoglutethimide;B-drug;B-DDI-DrugBank.d774.s0.e1
or;O;O
mitotane;B-drug;B-DDI-DrugBank.d774.s0.e2
(;O;O
causing;O;O
too;O;O
great;O;O
a;O;O
decrease;O;O
in;O;O
adrenal;O;O
function;O;O
);O;O
.;O;O
DDI-DrugBank.d598.s0;;
Trimethoprim;B-drug;B-DDI-DrugBank.d598.s0.e0
may;O;O
inhibit;O;O
the;O;O
hepatic;O;O
metabolism;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d598.s0.e1
.;O;O
DDI-DrugBank.d598.s1;;
Trimethoprim;B-drug;B-DDI-DrugBank.d598.s1.e0
,;O;O
given;O;O
at;O;O
a;O;O
common;O;O
clinical;O;O
dosage;O;O
,;O;O
increased;O;O
the;O;O
phenytoin;B-drug;B-DDI-DrugBank.d598.s1.e1
half;O;O
-;O;O
life;O;O
by;O;O
51;O;O
%;O;O
and;O;O
decreased;O;O
the;O;O
phenytoin;B-drug;B-DDI-DrugBank.d598.s1.e2
metabolic;O;O
clearance;O;O
rate;O;O
by;O;O
30;O;O
%;O;O
.;O;O
DDI-DrugBank.d598.s2;;
When;O;O
administering;O;O
these;O;O
drugs;O;O
concurrently;O;O
,;O;O
one;O;O
should;O;O
be;O;O
alert;O;O
for;O;O
possible;O;O
excessive;O;O
phenytoin;B-drug;B-DDI-DrugBank.d598.s2.e0
effect;O;O
.;O;O
DDI-DrugBank.d766.s0;;
Since;O;O
trimetrexate;B-drug;B-DDI-DrugBank.d766.s0.e0
is;O;O
metabolized;O;O
by;O;O
a;O;O
P450;O;O
enzyme;O;O
system;O;O
,;O;O
drugs;O;O
that;O;O
induce;O;O
or;O;O
inhibit;O;O
this;O;O
drug;O;O
metabolizing;O;O
enzyme;O;O
system;O;O
may;O;O
elicit;O;O
important;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
that;O;O
may;O;O
alter;O;O
trimetrexate;B-drug;B-DDI-DrugBank.d766.s0.e1
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d766.s1;;
Agents;O;O
that;O;O
might;O;O
be;O;O
coadministered;O;O
with;O;O
trimetrexate;B-drug;B-DDI-DrugBank.d766.s1.e0
in;O;O
AIDS;O;O
patients;O;O
for;O;O
other;O;O
indications;O;O
that;O;O
could;O;O
elicit;O;O
this;O;O
activity;O;O
include;O;O
erythromycin;B-drug;B-DDI-DrugBank.d766.s1.e1
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d766.s1.e2
,;O;O
rifabutin;B-drug;B-DDI-DrugBank.d766.s1.e3
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d766.s1.e4
,;O;O
and;O;O
fluconazole;B-drug;B-DDI-DrugBank.d766.s1.e5
.;O;O
DDI-DrugBank.d766.s2;;
In;O;O
vitro;O;O
perfusion;O;O
of;O;O
isolated;O;O
rat;O;O
liver;O;O
has;O;O
shown;O;O
that;O;O
cimetidine;B-drug;B-DDI-DrugBank.d766.s2.e0
caused;O;O
a;O;O
significant;O;O
reduction;O;O
in;O;O
trimetrexate;B-drug;B-DDI-DrugBank.d766.s2.e1
metabolism;O;O
and;O;O
that;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d766.s2.e2
altered;O;O
the;O;O
relative;O;O
concentration;O;O
of;O;O
trimetrexate;O;O
metabolites;O;O
possibly;O;O
by;O;O
competing;O;O
for;O;O
sulfate;O;O
metabolites;O;O
.;O;O
DDI-DrugBank.d766.s3;;
Based;O;O
on;O;O
an;O;O
in;O;O
vitro;O;O
rat;O;O
liver;O;O
model;O;O
,;O;O
nitrogen;O;O
substituted;O;O
imidazole;B-group;B-DDI-DrugBank.d766.s3.e0
drugs;I-group;I-DDI-DrugBank.d766.s3.e0
(;O;O
clotrimazole;B-drug;B-DDI-DrugBank.d766.s3.e1
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d766.s3.e2
,;O;O
miconazole;B-drug;B-DDI-DrugBank.d766.s3.e3
);O;O
were;O;O
potent;O;O
,;O;O
non;O;O
-;O;O
competitive;O;O
inhibitors;O;O
of;O;O
trimetrexate;B-drug;B-DDI-DrugBank.d766.s3.e4
metabolism;O;O
.;O;O
DDI-DrugBank.d766.s4;;
Patients;O;O
medicated;O;O
with;O;O
these;O;O
drugs;O;O
and;O;O
trimetrexate;B-drug;B-DDI-DrugBank.d766.s4.e0
should;O;O
be;O;O
carefully;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d615.s0;;
Triprolidine;B-drug;B-DDI-DrugBank.d615.s0.e0
may;O;O
enhance;O;O
the;O;O
sedative;O;O
effects;O;O
of;O;O
central;B-group;B-DDI-DrugBank.d615.s0.e1
nervous;I-group;I-DDI-DrugBank.d615.s0.e1
system;I-group;I-DDI-DrugBank.d615.s0.e1
depressants;I-group;I-DDI-DrugBank.d615.s0.e1
including;O;O
alcohol;B-drug;B-DDI-DrugBank.d615.s0.e2
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d615.s0.e3
,;O;O
hypnotics;B-group;B-DDI-DrugBank.d615.s0.e4
,;O;O
narcotic;B-group;B-DDI-DrugBank.d615.s0.e5
analgesics;I-group;I-DDI-DrugBank.d615.s0.e5
,;O;O
sedatives;B-group;B-DDI-DrugBank.d615.s0.e6
,;O;O
and;O;O
tranquillisers;B-group;B-DDI-DrugBank.d615.s0.e7
.;O;O
DDI-DrugBank.d615.s1;;
The;O;O
effects;O;O
of;O;O
anticholinergic;B-group;B-DDI-DrugBank.d615.s1.e0
drugs;I-group;I-DDI-DrugBank.d615.s1.e0
,;O;O
such;O;O
as;O;O
atropine;B-drug;B-DDI-DrugBank.d615.s1.e1
and;O;O
tricyclic;B-group;B-DDI-DrugBank.d615.s1.e2
antidepressants;I-group;I-DDI-DrugBank.d615.s1.e2
may;O;O
be;O;O
enhanced;O;O
by;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
triprolidine;B-drug;B-DDI-DrugBank.d615.s1.e3
.;O;O
DDI-DrugBank.d615.s2;;
Triprolidine;B-drug;B-DDI-DrugBank.d615.s2.e0
may;O;O
effect;O;O
the;O;O
metabolism;O;O
of;O;O
drugs;O;O
in;O;O
the;O;O
liver;O;O
.;O;O
DDI-DrugBank.d713.s0;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
Sanctura;B-brand;B-DDI-DrugBank.d713.s0.e0
with;O;O
other;O;O
anticholinergic;B-group;B-DDI-DrugBank.d713.s0.e1
agents;I-group;I-DDI-DrugBank.d713.s0.e1
that;O;O
produce;O;O
dry;O;O
mouth;O;O
,;O;O
constipation;O;O
,;O;O
and;O;O
other;O;O
anticholinergic;O;O
pharmacological;O;O
effects;O;O
may;O;O
increase;O;O
the;O;O
frequency;O;O
and/or;O;O
severity;O;O
of;O;O
such;O;O
effects;O;O
.;O;O
DDI-DrugBank.d713.s1;;
Anticholinergic;B-group;B-DDI-DrugBank.d713.s1.e0
agents;I-group;I-DDI-DrugBank.d713.s1.e0
may;O;O
potentially;O;O
alter;O;O
the;O;O
absorption;O;O
of;O;O
some;O;O
concomitantly;O;O
administered;O;O
drugs;O;O
due;O;O
to;O;O
anticholinergic;O;O
effects;O;O
on;O;O
gastrointestinal;O;O
motility;O;O
.;O;O
DDI-DrugBank.d713.s2;;
Drugs;O;O
Eliminated;O;O
by;O;O
Active;O;O
Tubular;O;O
Secretion;O;O
:;O;O
Although;O;O
studies;O;O
to;O;O
assess;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
with;O;O
Sanctura;B-brand;B-DDI-DrugBank.d713.s2.e0
have;O;O
not;O;O
been;O;O
conducted;O;O
,;O;O
Sanctura;B-brand;B-DDI-DrugBank.d713.s2.e1
has;O;O
the;O;O
potential;O;O
for;O;O
pharmacokinetic;O;O
interactions;O;O
with;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
eliminated;O;O
by;O;O
active;O;O
tubular;O;O
secretion;O;O
(;O;O
e.g.;O;O
digoxin;B-drug;B-DDI-DrugBank.d713.s2.e2
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d713.s2.e3
,;O;O
pancuronium;B-drug;B-DDI-DrugBank.d713.s2.e4
,;O;O
morphine;B-drug;B-DDI-DrugBank.d713.s2.e5
,;O;O
vancomycin;B-drug;B-DDI-DrugBank.d713.s2.e6
,;O;O
metformin;B-drug;B-DDI-DrugBank.d713.s2.e7
and;O;O
tenofovir;B-drug;B-DDI-DrugBank.d713.s2.e8
);O;O
.;O;O
DDI-DrugBank.d713.s3;;
Coadministration;O;O
of;O;O
Sanctura;B-brand;B-DDI-DrugBank.d713.s3.e0
with;O;O
drugs;O;O
that;O;O
are;O;O
eliminated;O;O
by;O;O
active;O;O
renal;O;O
tubular;O;O
secretion;O;O
may;O;O
increase;O;O
the;O;O
serum;O;O
concentration;O;O
of;O;O
Sanctura;B-brand;B-DDI-DrugBank.d713.s3.e1
and/or;O;O
the;O;O
coadministered;O;O
drug;O;O
due;O;O
to;O;O
competition;O;O
for;O;O
this;O;O
elimination;O;O
pathway;O;O
.;O;O
DDI-DrugBank.d713.s4;;
Careful;O;O
patient;O;O
monitoring;O;O
is;O;O
recommended;O;O
in;O;O
patients;O;O
receiving;O;O
such;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d713.s5;;
Drug;O;O
-;O;O
Laboratory;O;O
-;O;O
Test;O;O
Interactions;O;O
Interactions;O;O
between;O;O
Sanctura;B-brand;B-DDI-DrugBank.d713.s5.e0
and;O;O
laboratory;O;O
tests;O;O
have;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d669.s0;;
Concomitant;O;O
administration;O;O
of;O;O
vancomycin;B-drug;B-DDI-DrugBank.d669.s0.e0
and;O;O
anesthetic;B-group;B-DDI-DrugBank.d669.s0.e1
agents;I-group;I-DDI-DrugBank.d669.s0.e1
has;O;O
been;O;O
associated;O;O
with;O;O
erythema;O;O
and;O;O
histamine;O;O
-;O;O
like;O;O
flushing;O;O
and;O;O
anaphylactoid;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d669.s1;;
Concurrent;O;O
and/or;O;O
sequential;O;O
systemic;O;O
or;O;O
topical;O;O
use;O;O
of;O;O
other;O;O
potentially;O;O
neurotoxic;O;O
and/or;O;O
nephrotoxic;O;O
drugs;O;O
,;O;O
such;O;O
as;O;O
amphotericin;B-drug;B-DDI-DrugBank.d669.s1.e0
B;I-drug;I-DDI-DrugBank.d669.s1.e0
,;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d669.s1.e1
,;O;O
bacitracin;B-drug;B-DDI-DrugBank.d669.s1.e2
,;O;O
polymyxin;B-drug;B-DDI-DrugBank.d669.s1.e3
B;I-drug;I-DDI-DrugBank.d669.s1.e3
,;O;O
colistin;B-drug;B-DDI-DrugBank.d669.s1.e4
,;O;O
viomycin;B-drug;B-DDI-DrugBank.d669.s1.e5
,;O;O
or;O;O
cisplatin;B-drug;B-DDI-DrugBank.d669.s1.e6
,;O;O
when;O;O
indicated;O;O
,;O;O
requires;O;O
careful;O;O
monitoring;O;O
.;O;O
DDI-DrugBank.d613.s0;;
A;O;O
study;O;O
published;O;O
in;O;O
2002;O;O
found;O;O
that;O;O
vigabatrin;B-drug;B-DDI-DrugBank.d613.s0.e0
causes;O;O
a;O;O
statistically;O;O
significant;O;O
increase;O;O
in;O;O
plasma;O;O
clearance;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d613.s0.e1
.;O;O
DDI-DrugBank.d613.s1;;
In;O;O
1984;O;O
,;O;O
Drs;O;O
Rimmer;O;O
and;O;O
Richens;O;O
at;O;O
the;O;O
University;O;O
of;O;O
Wales;O;O
reported;O;O
that;O;O
administering;O;O
vigabatrin;B-drug;B-DDI-DrugBank.d613.s1.e0
with;O;O
phenytoin;B-drug;B-DDI-DrugBank.d613.s1.e1
lowered;O;O
the;O;O
serum;O;O
phenytoin;B-drug;B-DDI-DrugBank.d613.s1.e2
concentration;O;O
in;O;O
patients;O;O
with;O;O
treatment;O;O
-;O;O
resistant;O;O
epilepsy;O;O
.;O;O
DDI-DrugBank.d613.s2;;
The;O;O
concentration;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d613.s2.e0
falls;O;O
to;O;O
23;O;O
%;O;O
within;O;O
five;O;O
weeks;O;O
,;O;O
according;O;O
to;O;O
an;O;O
experiment;O;O
published;O;O
in;O;O
1989;O;O
by;O;O
the;O;O
same;O;O
two;O;O
scientists;O;O
that;O;O
tried;O;O
and;O;O
failed;O;O
to;O;O
elucidate;O;O
the;O;O
mechanism;O;O
behind;O;O
this;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d782.s0;;
Vindesine;B-drug;B-DDI-DrugBank.d782.s0.e0
can;O;O
interact;O;O
with;O;O
the;O;O
drugs;O;O
of;O;O
the;O;O
following;O;O
categories;O;O
:;O;O
-;O;O
Blood;O;O
dyscrasia;O;O
:;O;O
can;O;O
cause;O;O
unpredictable;O;O
myelotoxicity;O;O
-;O;O
Bone;O;O
marrow;O;O
depressants;O;O
:;O;O
can;O;O
cause;O;O
a;O;O
predictable;O;O
dose;O;O
-;O;O
related;O;O
myelotoxicity;O;O
-;O;O
Radiation;O;O
therapy;O;O
:;O;O
may;O;O
cause;O;O
marrow;O;O
depression;O;O
-;O;O
Neurotoxic;O;O
medications;O;O
:;O;O
can;O;O
cause;O;O
neurologic;O;O
toxicity;O;O
-;O;O
Phenytoin;B-drug;B-DDI-DrugBank.d782.s0.e1
:;O;O
can;O;O
increase;O;O
seizure;O;O
activity;O;O
-;O;O
Live;B-group;B-DDI-DrugBank.d782.s0.e2
virus;I-group;I-DDI-DrugBank.d782.s0.e2
vaccines;I-group;I-DDI-DrugBank.d782.s0.e2
:;O;O
may;O;O
potentiate;O;O
the;O;O
replication;O;O
of;O;O
the;O;O
vaccine;B-drug;B-DDI-DrugBank.d782.s0.e3
virus;O;O
,;O;O
may;O;O
increase;O;O
the;O;O
side;O;O
effects;O;O
of;O;O
the;O;O
vaccination;O;O
,;O;O
and;O;O
decrease;O;O
patient;O;O
's;O;O
response;O;O
to;O;O
the;O;O
vaccine;O;O
-;O;O
Mitomycin;O;O
-;O;O
C;O;O
:;O;O
may;O;O
cause;O;O
shortness;O;O
of;O;O
breath;O;O
and;O;O
bronchospasm;O;O
-;O;O
Killed;B-group;B-DDI-DrugBank.d782.s0.e5
virus;I-group;I-DDI-DrugBank.d782.s0.e5
vaccines;I-group;I-DDI-DrugBank.d782.s0.e5
:;O;O
may;O;O
decrease;O;O
patient;O;O
's;O;O
response;O;O
to;O;O
the;O;O
vaccine;B-group;B-DDI-DrugBank.d782.s0.e6
DDI-DrugBank.d651.s0;;
Drug;O;O
Interactions;O;O
:;O;O
Women;O;O
on;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d651.s0.e0
have;O;O
shown;O;O
a;O;O
significant;O;O
increase;O;O
in;O;O
plasma;O;O
vitamin;B-group;B-DDI-DrugBank.d651.s0.e1
A;I-group;I-DDI-DrugBank.d651.s0.e1
levels;O;O
.;O;O
DDI-DrugBank.d759.s0;;
Limited;O;O
evidence;O;O
suggests;O;O
that;O;O
ascorbic;B-drug;B-DDI-DrugBank.d759.s0.e0
acid;I-drug;I-DDI-DrugBank.d759.s0.e0
may;O;O
influence;O;O
the;O;O
intensity;O;O
and;O;O
duration;O;O
of;O;O
action;O;O
of;O;O
bishydroxycoumarin;B-drug;B-DDI-DrugBank.d759.s0.e1
.;O;O
DDI-DrugBank.d769.s0;;
Coumarin;B-group;B-DDI-DrugBank.d769.s0.e0
-;I-group;I-DDI-DrugBank.d769.s0.e0
Derivative;I-group;I-DDI-DrugBank.d769.s0.e0
Anticoagulants;I-group;I-DDI-DrugBank.d769.s0.e0
:;O;O
Prolongation;O;O
of;O;O
prothrombin;O;O
time;O;O
(;O;O
PT;O;O
);O;O
and;O;O
International;O;O
Normalized;O;O
Ratio;O;O
(;O;O
INR;O;O
);O;O
were;O;O
observed;O;O
in;O;O
patients;O;O
receiving;O;O
ZOLINZA;B-brand;B-DDI-DrugBank.d769.s0.e1
concomitantly;O;O
with;O;O
coumarin;B-group;B-DDI-DrugBank.d769.s0.e2
-;I-group;I-DDI-DrugBank.d769.s0.e2
derivative;I-group;I-DDI-DrugBank.d769.s0.e2
anticoagulants;I-group;I-DDI-DrugBank.d769.s0.e2
.;O;O
DDI-DrugBank.d769.s1;;
Physicians;O;O
should;O;O
carefully;O;O
monitor;O;O
PT;O;O
and;O;O
INR;O;O
in;O;O
patients;O;O
concurrently;O;O
administered;O;O
ZOLINZA;B-brand;B-DDI-DrugBank.d769.s1.e0
and;O;O
coumarin;B-group;B-DDI-DrugBank.d769.s1.e1
derivatives;I-group;I-DDI-DrugBank.d769.s1.e1
.;O;O
DDI-DrugBank.d769.s2;;
Other;O;O
HDAC;B-group;B-DDI-DrugBank.d769.s2.e0
Inhibitors;I-group;I-DDI-DrugBank.d769.s2.e0
Severe;O;O
thrombocytopenia;O;O
and;O;O
gastrointestinal;O;O
bleeding;O;O
have;O;O
been;O;O
reported;O;O
with;O;O
concomitant;O;O
use;O;O
of;O;O
ZOLINZA;B-brand;B-DDI-DrugBank.d769.s2.e1
and;O;O
other;O;O
HDAC;B-group;B-DDI-DrugBank.d769.s2.e2
inhibitors;I-group;I-DDI-DrugBank.d769.s2.e2
(;O;O
e.g.;O;O
,;O;O
valproic;B-drug;B-DDI-DrugBank.d769.s2.e3
acid;I-drug;I-DDI-DrugBank.d769.s2.e3
);O;O
.;O;O
DDI-DrugBank.d769.s3;;
Monitor;O;O
platelet;O;O
count;O;O
every;O;O
2;O;O
weeks;O;O
for;O;O
the;O;O
first;O;O
2;O;O
months;O;O
.;O;O
